The O
present O
study O
was O
designed O
to O
determine O
the O
effect O
of O
a O
new O
( B
25 I
) I
Mg I
( I
2 I
+ I
) I
- O
carrying O
nanoparticle O
( O
( B
25 I
) I
MgPMC16 I
) O
on O
energy O
depletion O
, O
oxidative O
stress O
, O
and O
electrocardiographic O
( O
ECG O
) O
parameters O
on O
heart O
tissue O
of O
the O
rats O
poisoned O
by O
aluminum B
phosphide I
( O
AlP B
) O
. O

In O
the O
germination O
assays O
, O
high O
inhibitory O
allelopathic O
effects O
of O
the O
extracts O
and O
isocorilagin B
were O
observed O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
activity O
of O
isocorilagin B
was O
higher O
than O
those O
of O
the O
standards O
used O
( O
Trolox B
and O
butylated B
hydroxyanisole I
) O
. O

The O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
and O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
are O
the O
most O
abundant O
of O
the O
heterocyclic B
amine I
carcinogens O
present O
in O
cooked O
food O
. O

The O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
and O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
are O
the O
most O
abundant O
of O
the O
heterocyclic B
amine I
carcinogens O
present O
in O
cooked O
food O
. O

The O
host O
molecule O
1 B
, I
1 I
, I
6 I
, I
6 I
- I
tetraphenylhexa I
- I
2 I
, I
4 I
- I
diyne I
- I
1 I
, I
6 I
- I
diol I
( O
A O
) O
was O
used O
to O
selectively O
recognise O
the O
guest O
molecule O
patchouli B
alcohol I
( O
B O
) O
in O
the O
essential O
oil O
of O
Pogostemon O
cablin O
( O
Blanco O
) O
Benth O
through O
two O
strong O
hydrogen B
bonding O
. O

The O
isolated O
compounds O
were O
identified O
by O
spectroscopic O
analyses O
as O
( B
22E I
, I
24R I
) I
- I
6 I
beta I
- I
methoxyergosta I
- I
7 I
, I
22 I
- I
diene I
- I
3 I
beta I
, I
5 I
alpha I
- I
diol I
( O
1 O
) O
, O
2 B
' I
, I
3 I
' I
- I
diacetoxy I
- I
3 I
, I
4 I
, I
5 I
' I
, I
6 I
' I
, I
4 I
' I
' I
- I
pentahydroxy I
- I
p I
- I
terphenyl I
( O
2 O
) O
, O
cerebroside B
B I
( O
3 O
) O
, O
ergosta B
- I
7 I
, I
22 I
- I
dien I
- I
3 I
beta I
- I
ol I
( O
4 O
) O
, O
ergosterol B
peroxide I
( O
5 O

The O
isolated O
compounds O
were O
identified O
by O
spectroscopic O
analyses O
as O
( B
22E I
, I
24R I
) I
- I
6 I
beta I
- I
methoxyergosta I
- I
7 I
, I
22 I
- I
diene I
- I
3 I
beta I
, I
5 I
alpha I
- I
diol I
( O
1 O
) O
, O
2 B
' I
, I
3 I
' I
- I
diacetoxy I
- I
3 I
, I
4 I
, I
5 I
' I
, I
6 I
' I
, I
4 I
' I
' I
- I
pentahydroxy I
- I
p I
- I
terphenyl I
( O
2 O
) O
, O
cerebroside B
B I
( O
3 O
) O
, O
ergosta B
- I
7 I
, I
22 I
- I
dien I
- I
3 I
beta I
- I
ol I
( O
4 O
) O
, O
ergosterol B
peroxide I
( O
5 O

The O
isolated O
compounds O
were O
identified O
by O
spectroscopic O
analyses O
as O
( B
22E I
, I
24R I
) I
- I
6 I
beta I
- I
methoxyergosta I
- I
7 I
, I
22 I
- I
diene I
- I
3 I
beta I
, I
5 I
alpha I
- I
diol I
( O
1 O
) O
, O
2 B
' I
, I
3 I
' I
- I
diacetoxy I
- I
3 I
, I
4 I
, I
5 I
' I
, I
6 I
' I
, I
4 I
' I
' I
- I
pentahydroxy I
- I
p I
- I
terphenyl I
( O
2 O
) O
, O
cerebroside B
B I
( O
3 O
) O
, O
ergosta B
- I
7 I
, I
22 I
- I
dien I
- I
3 I
beta I
- I
ol I
( O
4 O
) O
, O
ergosterol B
peroxide I
( O
5 O

) O
, O
( B
22E I
, I
24R I
) I
- I
3 I
beta I
- I
hydroxy I
- I
ergosta I
- I
5 I
, I
22 I
- I
dien I
- I
7 I
- I
one I
( O
6 O
) O
, O
benzoic B
acid I
( O
7 O
) O
, O
methyl B
p I
- I
hydroxybenzoate I
( O
8 O
) O
and O
3 B
, I
4 I
- I
dihydroxybenzoic I
acid I
( O
9 O
) O
. O

In O
continuation O
of O
our O
search O
for O
bioactive O
secondary O
metabolites O
from O
terrestrial O
Bacillus O
spp O
. O
, O
a O
new O
microbial O
diketopiperazine B
, O
cis B
- I
cyclo I
- I
( I
His I
, I
Leu I
) I
( O
1 O
) O
was O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
a O
strain O
B O
. O
subtilis O
B38 O
, O
together O
with O
cis B
- I
cyclo I
- I
( I
Phe I
, I
Phe I
) I
( O
2 O
) O
, O
tryptophane B
( O
3 O
) O
, O
cis B
- I
cyclo I
- I
( I
Leu I
, I
Tyr I
) I
( O
4 O
) O
, O
cis B
- I
cyclo I
- I
( I

In O
continuation O
of O
our O
search O
for O
bioactive O
secondary O
metabolites O
from O
terrestrial O
Bacillus O
spp O
. O
, O
a O
new O
microbial O
diketopiperazine B
, O
cis B
- I
cyclo I
- I
( I
His I
, I
Leu I
) I
( O
1 O
) O
was O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
a O
strain O
B O
. O
subtilis O
B38 O
, O
together O
with O
cis B
- I
cyclo I
- I
( I
Phe I
, I
Phe I
) I
( O
2 O
) O
, O
tryptophane B
( O
3 O
) O
, O
cis B
- I
cyclo I
- I
( I
Leu I
, I
Tyr I
) I
( O
4 O
) O
, O
cis B
- I
cyclo I
- I
( I

In O
continuation O
of O
our O
search O
for O
bioactive O
secondary O
metabolites O
from O
terrestrial O
Bacillus O
spp O
. O
, O
a O
new O
microbial O
diketopiperazine B
, O
cis B
- I
cyclo I
- I
( I
His I
, I
Leu I
) I
( O
1 O
) O
was O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
a O
strain O
B O
. O
subtilis O
B38 O
, O
together O
with O
cis B
- I
cyclo I
- I
( I
Phe I
, I
Phe I
) I
( O
2 O
) O
, O
tryptophane B
( O
3 O
) O
, O
cis B
- I
cyclo I
- I
( I
Leu I
, I
Tyr I
) I
( O
4 O
) O
, O
cis B
- I
cyclo I
- I
( I

Three O
new O
compounds O
; O
epi B
- I
mukulin I
, O
( B
Z I
) I
- I
Delta I
( I
1 I
, I
2 I
) I
dehydroguggulsterone I
and O
Delta B
( I
6 I
, I
7 I
) I
dehydro I
- I
20 I
- I
hydroxygugglsterone I
were O
isolated O
from O
the O
n B
- I
hexane I
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol B
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin B
, O
( B
+ I
) I
- I
epi I
- I
magnolin I
, O
( B
+ I
) I
- I
diayangambin I
, O

Three O
new O
compounds O
; O
epi B
- I
mukulin I
, O
( B
Z I
) I
- I
Delta I
( I
1 I
, I
2 I
) I
dehydroguggulsterone I
and O
Delta B
( I
6 I
, I
7 I
) I
dehydro I
- I
20 I
- I
hydroxygugglsterone I
were O
isolated O
from O
the O
n B
- I
hexane I
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol B
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin B
, O
( B
+ I
) I
- I
epi I
- I
magnolin I
, O
( B
+ I
) I
- I
diayangambin I
, O

R B
, I
R I
- I
Monatin I
[ O
2R B
, I
4R I
- I
isomer I
of I
2 I
- I
hydroxy I
- I
2 I
- I
( I
indol I
- I
3 I
- I
ylmethyl I
) I
- I
4 I
- I
aminoglutaric I
acid I
] O
is O
one O
of O
four O
natural O
constituent O
isomers O
in O
the O
root O
bark O
of O
Sclerochitin O
ilicifolius O
; O
and O
" O
arruva B
" O
is O
the O
common O
/ O
usual O
name O
that O
is O
proposed O
to O
represent O
R B
, I
R I
- I
monatin I
salt O
forms O
, O
which O
have O
potential O
use O
as O
high O
potency O
sweetener O
food O
ingredients O
. O

The O
structures O
of O
the O
new O
constituents O
have O
been O
elucidated O
by O
spectral O
studies O
including O
1D O
and O
2D O
NMR O
experiments O
( O
HSQC O
, O
HMBC O
, O
COSY O
, O
NOESY O
and O
J O
- O
resolved O
) O
as O
well O
as O
HR O
EI O
- O
MS O
spectroscopic O
data O
analysis O
, O
as O
2S B
* I
- I
( I
3 I
- I
hydroxy I
- I
4 I
- I
methoxyphenyl I
) I
- I
3R I
* I
- I
methyl I
- I
2H I
- I
[ I
1 I
, I
4 I
] I
- I
dioxin I
[ I
2 I
, I
3 I
] I
- I
chromen I
- I
7 I
( I
3H I
) I
- I
one I
( O
1 O
) O
; O
a O

coumarinolignan B
and O
3 B
- I
hydroxy I
- I
1 I
- I
( I
3 I
- I
hydroxy I
- I
4 I
- I
methoxyphenyl I
) I
propan I
- I
1 I
- I
one I
( O
2 O
) O
. O

The O
free O
acid O
derivatives O
as O
they O
are O
good O
candidates O
as O
antiinflammatory O
drugs O
are O
able O
to O
antagonize O
the O
multiple O
neutrophil O
functions O
evoked O
by O
N B
- I
formyl I
- I
L I
- I
methionyl I
- I
L I
- I
leucyl I
- I
Lphenylalanine I
( O
fMLF B
) O
, O
i O
. O
e O
. O
chemotaxis O
, O
superoxide B
anion O
production O
and O
lysozyme O
release O
. O

A O
new O
triterpenoid B
, O
2 B
alpha I
, I
24 I
- I
diacetoxy I
- I
3 I
beta I
- I
hydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
, O
was O
characterised O
from O
the O
rhizomes O
of O
Nelumbo O
nucifera O
Gaertn O
by O
spectroscopic O
and O
chemical O
methods O
along O
with O
four O
known O
compounds O
, O
hyptatic B
acid I
- I
A I
( O
2 B
alpha I
, I
3 I
beta I
, I
24 I
- I
trihydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
( O
2 O
) O
, O
maslinic B
acid I
( O
2 B
alpha I
, I
3 I
beta I
- I

A O
new O
triterpenoid B
, O
2 B
alpha I
, I
24 I
- I
diacetoxy I
- I
3 I
beta I
- I
hydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
, O
was O
characterised O
from O
the O
rhizomes O
of O
Nelumbo O
nucifera O
Gaertn O
by O
spectroscopic O
and O
chemical O
methods O
along O
with O
four O
known O
compounds O
, O
hyptatic B
acid I
- I
A I
( O
2 B
alpha I
, I
3 I
beta I
, I
24 I
- I
trihydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
( O
2 O
) O
, O
maslinic B
acid I
( O
2 B
alpha I
, I
3 I
beta I
- I

Pretreatment O
of O
the O
endothelium O
- O
intact O
aortic O
strips O
with O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
10 O
( O
- O
4 O
) O
M O
) O
, O
1 B
H I
- I
[ I
1 I
, I
2 I
, I
4 I
] I
- I
oxadiazolole I
- I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
10 I
- I
one I
, O
( O
10 O
( O
- O
6 O
) O
M O
) O
and O
methylene B
blue I
( O
10 O
( O
- O
5 O
) O
M O
) O
inhibited O
CA O
- O
induced O
vasorelaxation O
. O

Pretreatment O
of O
the O
endothelium O
- O
intact O
aortic O
strips O
with O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
10 O
( O
- O
4 O
) O
M O
) O
, O
1 B
H I
- I
[ I
1 I
, I
2 I
, I
4 I
] I
- I
oxadiazolole I
- I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
10 I
- I
one I
, O
( O
10 O
( O
- O
6 O
) O
M O
) O
and O
methylene B
blue I
( O
10 O
( O
- O
5 O
) O
M O
) O
inhibited O
CA O
- O
induced O
vasorelaxation O
. O

The O
methanol B
extract O
of O
the O
tubers O
of O
Polygonum O
perfoliatum O
L O
. O
afforded O
a O
new O
lignan B
: O
8 B
- I
oxo I
- I
pinoresinol I
( O
1 O
) O
, O
and O
five O
known O
compounds O
3 B
' I
, I
5 I
- I
dihydroxy I
- I
3 I
, I
4 I
' I
, I
5 I
' I
, I
7 I
- I
tetramethoxy I
- I
flavone I
( O
2 O
) O
, O
catechin B
( O
3 O
) O
, O
quercetin B
( O
4 O
) O
, O
quercetin B
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
glucuronide I
( O
5 O
) O
and O
rutin B
( O
6 O
) O
. O

The O
methanol B
extract O
of O
the O
tubers O
of O
Polygonum O
perfoliatum O
L O
. O
afforded O
a O
new O
lignan B
: O
8 B
- I
oxo I
- I
pinoresinol I
( O
1 O
) O
, O
and O
five O
known O
compounds O
3 B
' I
, I
5 I
- I
dihydroxy I
- I
3 I
, I
4 I
' I
, I
5 I
' I
, I
7 I
- I
tetramethoxy I
- I
flavone I
( O
2 O
) O
, O
catechin B
( O
3 O
) O
, O
quercetin B
( O
4 O
) O
, O
quercetin B
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
glucuronide I
( O
5 O
) O
and O
rutin B
( O
6 O
) O
. O

Chemical O
research O
of O
Plantago O
depressa O
Willd O
. O
led O
to O
one O
new O
phenylethanoid B
glucoside I
with O
alpha B
- I
L I
- I
rhamnosyl I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucose I
structure O
, O
together O
with O
four O
known O
compounds O
. O

1 B
alpha I
- I
acetoxy I
- I
5 I
alpha I
, I
7 I
beta I
- I
dihydroxycassa I
- I
11 I
, I
13 I
( I
15 I
) I
- I
diene I
- I
16 I
, I
12 I
- I
lactone I
, O
a O
new O
cassane B
- O
type O
diterpene B
was O
isolated O
from O
Caesalpinia O
crista O
. O

The O
structure O
of O
the O
new O
saponin B
, O
glinoside B
C I
( O
1 O
) O
, O
was O
established O
as O
16 B
- I
O I
- I
( I
beta I
- I
D I
- I
glucopyranosyl I
) I
- I
3 I
beta I
, I
12 I
beta I
, I
16 I
beta I
, I
21 I
alpha I
, I
22 I
- I
pentahydroxy I
hopane I
by O
extensive O
use O
of O
1 O
- O
D O
, O
2 O
- O
D O
NMR O
and O
mass O
spectral O
techniques O
. O

The O
other O
constituents O
identified O
were O
3 B
- I
O I
- I
( I
beta I
- I
D I
- I
xylopyranosyl I
) I
- I
spergulagenin I
A I
( O
2 O
) O
, O
spergulacin B
( O
3 O
) O
, O
spergulin B
A I
( O
4 O
) O
, O
spergulacin B
A I
( O
5 O
) O
and O
spergulin B
B I
( O
6 O
) O
. O

The O
aim O
of O
this O
work O
was O
to O
prepare O
L B
- I
DOPA I
loaded O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
nanoparticles O
by O
a O
modified O
water O
- O
in O
- O
oil O
- O
in O
- O
water O
( O
W O
( O
1 O
) O
/ O
O O
/ O
W O
( O
2 O
) O
) O
emulsification O
solvent O
evaporation O
method O
. O

A O
new O
flavonol B
triglycoside I
, O
myricetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
xylopyranosyl I
- I
( I
1 I
- I
2 I
) I
- I
alpha I
- I
rhamnopyranoside I
] I
- I
4 I
' I
- I
O I
- I
alpha I
- I
rhamnopyranoside I
, O
named O
as O
bayarin B
( O
1 O
) O
, O
was O
isolated O
from O
the O
aerial O
parts O
of O
Zizyphus O
incurva O
Roxb O
. O

The O
non O
- O
hydrolysable O
NAAG B
analogue O
N B
- I
acetylaspartyl I
- I
beta I
- I
linked I
glutamate I
( O
beta B
- I
NAAG I
) O
antagonized O
NAAG B
and O
LY379268 B
. O

Their O
structures O
were O
defined O
as O
4 B
- I
[ I
( I
6 I
- I
O I
- I
( I
E I
) I
- I
caffeoyl I
) I
- I
beta I
- I
D I
- I
glucopyranosyl I
] I
vanillic I
acid I
( O
1 O
) O
and O
3 B
- I
O I
- I
[ I
beta I
- I
D I
- I
apiofurarnosyl I
- I
( I
1 I
- I
6 I
) I
- I
beta I
- I
D I
- I
glucopyranoxy I
] I
- I
6 I
- I
hydroxy I
- I
p I
- I
cymene I
( O
2 O
) O
on O
the O
basis O
of O
spectral O
analysis O
. O

Their O
structures O
were O
defined O
as O
4 B
- I
[ I
( I
6 I
- I
O I
- I
( I
E I
) I
- I
caffeoyl I
) I
- I
beta I
- I
D I
- I
glucopyranosyl I
] I
vanillic I
acid I
( O
1 O
) O
and O
3 B
- I
O I
- I
[ I
beta I
- I
D I
- I
apiofurarnosyl I
- I
( I
1 I
- I
6 I
) I
- I
beta I
- I
D I
- I
glucopyranoxy I
] I
- I
6 I
- I
hydroxy I
- I
p I
- I
cymene I
( O
2 O
) O
on O
the O
basis O
of O
spectral O
analysis O
. O

A O
comparison O
between O
the O
temperatures O
within O
imploding O
acoustic O
cavitation O
bubbles O
and O
the O
extent O
of O
sonoluminescence O
( O
SL O
) O
quenching O
by O
C O
( O
1 O
) O
- O
C O
( O
5 O
) O
aliphatic B
alcohols I
in O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
ethylsulfate I
( O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
, O
a O
well O
known O
imidazolium B
based O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
) O
, O
has O
been O
made O
at O
an O
ultrasound O
frequency O
of O
213 O
kHz O
. O

A O
comparison O
between O
the O
temperatures O
within O
imploding O
acoustic O
cavitation O
bubbles O
and O
the O
extent O
of O
sonoluminescence O
( O
SL O
) O
quenching O
by O
C O
( O
1 O
) O
- O
C O
( O
5 O
) O
aliphatic B
alcohols I
in O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
ethylsulfate I
( O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
, O
a O
well O
known O
imidazolium B
based O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
) O
, O
has O
been O
made O
at O
an O
ultrasound O
frequency O
of O
213 O
kHz O
. O

The O
temperatures O
obtained O
ranged O
from O
3500 O
+ O
/ O
- O
200K O
, O
in O
neat O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
, O
to O
about O
3200 O
+ O
/ O
- O
200K O
in O
RTIL O
- O
alcohol B
containing O
solutions O
. O

Possible O
reasons O
for O
the O
differences O
in O
the O
observed O
trends O
between O
water O
/ O
alcohol B
and O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
/ O
alcohol B
systems O
under O
sonication O
at O
213 O
kHz O
are O
discussed O
. O

Here O
we O
describe O
effects O
of O
a O
potent O
and O
orally O
bioavailable O
PDE10A O
inhibitor O
[ O
2 B
- I
( I
6 I
- I
chloropyridin I
- I
3 I
- I
yl I
) I
- I
4 I
- I
( I
2 I
- I
methoxyethoxy I
) I
- I
7 I
, I
8 I
- I
dihydropyrido I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
6 I
( I
5H I
) I
- I
yl I
] I
( I
imidazo I
[ I
1 I
, I
5 I
- I
a I
] I
pyridin I
- I
1 I
- I
yl I
) I
methanone I
] O
( O
THPP B
- I
1 I
) O
on O
striatal O
signaling O
pathways O
, O
in O
behavioral O
tests O
that O

THPP B
- I
1 I
significantly O
increased O
phosphorylation O
of O
proteins O
in O
the O
striatum O
involved O
in O
synaptic O
plasticity O
, O
including O
the O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
proprionic I
acid I
receptor O
( O
AMPA B
) O
GluR1 O
subunit O
, O
extracellular O
receptor O
kinase O
( O
ERK O
) O
, O
and O
cAMP B
- O
response O
element O
binding O
protein O
( O
CREB O
) O
. O

The O
new O
natural O
flavonoid B
compounds O
- O
diosmetin B
7 I
- I
O I
- I
beta I
- I
L I
- I
arabinofuranosyl I
( I
1 I
- I
- I
> I
2 I
) I
beta I
- I
D I
- I
apiofuranoside I
( O
1 O
) O
and O
diosmetin B
7 I
- I
O I
- I
beta I
- I
D I
- I
apiofuranoside I
( O
2 O
) O
- O
were O
isolated O
from O
the O
acetone B
extract O
of O
date O
fruits O
epicarp O
belonging O
to O
family O
Arecaceae O
( O
Palmae O
) O
. O

The O
new O
natural O
flavonoid B
compounds O
- O
diosmetin B
7 I
- I
O I
- I
beta I
- I
L I
- I
arabinofuranosyl I
( I
1 I
- I
- I
> I
2 I
) I
beta I
- I
D I
- I
apiofuranoside I
( O
1 O
) O
and O
diosmetin B
7 I
- I
O I
- I
beta I
- I
D I
- I
apiofuranoside I
( O
2 O
) O
- O
were O
isolated O
from O
the O
acetone B
extract O
of O
date O
fruits O
epicarp O
belonging O
to O
family O
Arecaceae O
( O
Palmae O
) O
. O

The O
highest O
RR O
of O
25 O
. O
7 O
was O
determined O
for O
the O
complex O
of O
TDAE B
with O
2 B
- I
nitropyrene I
- I
4 I
, I
5 I
, I
9 I
, I
10 I
- I
tetraone I
at O
0 O
. O
5 O
V O
( O
D1 O
) O
, O
while O
another O
rectifier O
[ O
complex O
of O
TDAE B
with O
2 B
, I
7 I
- I
dimethyl I
nitropyrene I
- I
4 I
, I
5 I
, I
9 I
, I
10 I
- I
tetraone I
( O
D2 O
) O
] O
showed O
a O
maximum O
RR O
of O
only O
2 O
. O
9 O
at O
0 O
. O
3 O
V O
. O

The O
highest O
RR O
of O
25 O
. O
7 O
was O
determined O
for O
the O
complex O
of O
TDAE B
with O
2 B
- I
nitropyrene I
- I
4 I
, I
5 I
, I
9 I
, I
10 I
- I
tetraone I
at O
0 O
. O
5 O
V O
( O
D1 O
) O
, O
while O
another O
rectifier O
[ O
complex O
of O
TDAE B
with O
2 B
, I
7 I
- I
dimethyl I
nitropyrene I
- I
4 I
, I
5 I
, I
9 I
, I
10 I
- I
tetraone I
( O
D2 O
) O
] O
showed O
a O
maximum O
RR O
of O
only O
2 O
. O
9 O
at O
0 O
. O
3 O
V O
. O

Metabolism O
and O
disposition O
of O
[ B
14C I
] I
n I
- I
butyl I
- I
p I
- I
hydroxybenzoate I
in O
male O
and O
female O
Harlan O
Sprague O
Dawley O
rats O
following O
oral O
administration O
and O
dermal O
application O
. O

We O
report O
here O
the O
design O
and O
synthesis O
of O
a O
series O
of O
4 B
- I
anilinoquinazoline I
derivatives O
, O
of O
which O
7 O
compounds O
were O
crystallographically O
characterized O
, O
as O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
inhibitors O
by O
modifications O
on O
the O
aniline B
ring O
or O
at O
the O
6 B
- I
alkoxy I
site O
of O
the O
6 B
, I
7 I
- I
dimethoxy I
- I
4 I
- I
anilinoquinazoline I
pharmacophore O
. O

This O
study O
describes O
two O
novel O
mGlu O
5 O
PAMs O
, O
LSN2463359 B
( O
N B
- I
( I
1 I
- I
methylethyl I
) I
- I
5 I
- I
( I
pyridin I
- I
4 I
- I
ylethynyl I
) I
pyridine I
- I
2 I
- I
carboxamide I
) O
and O
LSN2814617 B
[ O
( B
7S I
) I
- I
3 I
- I
tert I
- I
butyl I
- I
7 I
- I
[ I
3 I
- I
( I
4 I
- I
fluorophenyl I
) I
- I
1 I
, I
2 I
, I
4 I
- I
oxadiazol I
- I
5 I
- I
yl I
] I
- I
5 I
, I
6 I
, I
7 I
, I
8 I
- I
tetrahydro I

Both O
compounds O
are O
potent O
and O
selective O
potentiators O
of O
human O
and O
rat O
mGlu O
5 O
receptors O
in O
vitro O
, O
displaying O
curve O
shift O
ratios O
of O
two O
to O
three O
fold O
in O
the O
concentration O
- O
response O
relationship O
to O
glutamate B
or O
the O
glutamate B
receptor O
agonist O
, O
DHPG B
, O
with O
no O
detectable O
intrinsic O
agonist O
properties O
. O

To O
further O
investigate O
the O
influence O
of O
the O
generation O
of O
hydroxyl B
radicals O
and O
adsorption O
of O
protein O
, O
poly B
( I
ethylene I
- I
alt I
- I
maleic I
anhydride I
) I
( O
PEMA B
) O
and O
chitosan O
were O
used O
to O
coat O
TiO B
( I
2 I
) I
nanoparticles O
. O

Vitamin B
D I
is O
a O
potent O
stimulator O
of O
monocyte O
innate O
immunity O
, O
and O
this O
effect O
is O
mediated O
via O
intracrine O
conversion O
of O
25 B
- I
hydroxyvitamin I
D I
( O
25OHD B
) O
to O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
( O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
) O
. O

In O
the O
kidney O
, O
synthesis O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
is O
suppressed O
by O
fibroblast O
growth O
factor O
23 O
( O
FGF23 O
) O
, O
via O
transcriptional O
suppression O
of O
the O
vitamin B
D I
- O
activating O
enzyme O
1 O
alpha O
- O
hydroxylase O
( O
CYP27B1 O
) O
. O

We O
hypothesized O
that O
FGF23 O
also O
suppresses O
CYP27B1 O
in O
monocytes O
, O
with O
concomitant O
effects O
on O
intracrine O
responses O
to O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

In O
PBMCm O
this O
was O
associated O
with O
downregulation O
of O
25OHD B
to O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
metabolism O
, O
and O
concomitant O
suppression O
of O
intracrine O
induced O
24 O
- O
hydroxylase O
( O
CYP24A1 O
) O
and O
antibacterial O
cathelicidin O
( O
LL37 O
) O
. O

FGF23 O
suppression O
of O
CYP27B1 O
was O
particularly O
pronounced O
in O
PBMCm O
treated O
with O
interleukin O
- O
15 O
to O
stimulate O
synthesis O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

These O
data O
indicate O
that O
FGF23 O
can O
inhibit O
extra O
- O
renal O
expression O
of O
CYP27B1 O
and O
subsequent O
intracrine O
responses O
to O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
in O
two O
different O
human O
monocyte O
models O
. O

Furthermore O
, O
N B
- I
feruloyl I
serotonin I
( O
5 O
) O
and O
N B
- I
isoferuloyl I
serotonin I
( O
6 O
) O
were O
converted O
into O
, O
two O
new O
compounds O
, O
N B
- I
feruloyl I
serotonin I
- I
4 I
' I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
8 O
) O
and O
N B
- I
isoferuloyl I
serotonin I
- I
3 I
' I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
9 O
) O
, O
respectively O
. O

Furthermore O
, O
N B
- I
feruloyl I
serotonin I
( O
5 O
) O
and O
N B
- I
isoferuloyl I
serotonin I
( O
6 O
) O
were O
converted O
into O
, O
two O
new O
compounds O
, O
N B
- I
feruloyl I
serotonin I
- I
4 I
' I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
8 O
) O
and O
N B
- I
isoferuloyl I
serotonin I
- I
3 I
' I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
9 O
) O
, O
respectively O
. O

Electrospray O
ionization O
of O
dilute O
solutions O
of O
phenylpyridines B
( O
phpy B
) O
in O
the O
presence O
of O
nickel B
( I
II I
) I
chloride I
leads O
to O
gaseous O
ions O
of O
the O
type O
[ B
Ni I
( I
phpy I
) I
( I
m I
) I
] I
( I
2 I
+ I
) I
with O
m O
= O
3 O
- O
5 O
and O
[ B
NiCl I
( I
phpy I
) I
( I
n I
) I
] I
( I
+ I
) I
with O
n O
= O
1 O
- O
3 O
, O
which O
are O
characterized O
by O
various O
gas O
- O
phase O
experiments O
in O
combination O
with O
calculations O
using O
density O
functional O
theory O
. O

Electrospray O
ionization O
of O
dilute O
solutions O
of O
phenylpyridines B
( O
phpy B
) O
in O
the O
presence O
of O
nickel B
( I
II I
) I
chloride I
leads O
to O
gaseous O
ions O
of O
the O
type O
[ B
Ni I
( I
phpy I
) I
( I
m I
) I
] I
( I
2 I
+ I
) I
with O
m O
= O
3 O
- O
5 O
and O
[ B
NiCl I
( I
phpy I
) I
( I
n I
) I
] I
( I
+ I
) I
with O
n O
= O
1 O
- O
3 O
, O
which O
are O
characterized O
by O
various O
gas O
- O
phase O
experiments O
in O
combination O
with O
calculations O
using O
density O
functional O
theory O
. O

For O
2 B
- I
phpy I
, O
C B
- I
H I
bond O
activation O
in O
the O
[ B
NiCl I
( I
phpy I
) I
( I
2 I
) I
] I
( I
+ I
) I
complex O
is O
significant O
, O
whereas O
this O
route O
is O
almost O
suppressed O
for O
the O
corresponding O
complexes O
of O
3 B
- I
and I
4 I
- I
phpy I
and O
only O
occurs O
at O
elevated O
energies O
. O

The O
results O
showed O
that O
Pb B
( I
2 I
+ I
) I
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb B
( I
2 I
+ I
) I
addition O
after O
the O
applying O
of O
a O
ryanodine B
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol B
- I
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

Site O
- O
directed O
mutagenesis O
, O
the O
LRG O
assay O
, O
and O
homology O
modeling O
highlighted O
the O
importance O
of O
each O
amino B
acid I
site O
in O
AHR1 O
sensitivity O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
and O
other O
DLCs O
. O

alpha B
- I
Amino I
- I
alpha I
' I
- I
Halomethylketones I
: O
Synthetic O
Methodologies O
and O
Pharmaceutical O
Applications O
as O
Serine B
and O
Cysteine B
Protease O
Inhibitors O
. O

alpha B
- I
Amino I
- I
alpha I
' I
- I
halomethylketones I
are O
interesting O
scaffolds O
bearing O
( O
at O
least O
) O
two O
sequential O
electrophilic O
carbons B
that O
by O
interacting O
with O
the O
nucleophilic O
moieties O
of O
several O
enzymes O
, O
represent O
the O
ideal O
candidates O
for O
in O
vivo O
and O
in O
vitro O
inhibition O
studies O
. O

The O
peptide O
sequence O
synthesized O
was O
in O
the O
reverse O
order O
of O
the O
human O
peptide O
with O
the O
stable O
isotope O
- O
labels O
in O
the O
amino B
acid I
arginine B
( O
( B
13 I
) I
C6 I
( I
15 I
) I
N4 I
) O
resulting O
in O
an O
increase O
in O
the O
mass O
of O
the O
SIL O
peptide O
of O
10 O
amu O
, O
from O
1753 O
to O
1763 O
. O

The O
oxime B
RS150D B
[ O
N B
- I
( I
( I
1 I
- I
( I
3 I
- I
( I
2 I
- I
( I
( I
hydroxyimino I
) I
methyl I
) I
- I
1H I
- I
imidazol I
- I
1 I
- I
yl I
) I
propyl I
) I
- I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazol I
- I
4 I
- I
yl I
) I
methyl I
) I
benzamide I
] O
was O
highlighted O
as O
the O
most O
promising O
reactivator O
of O
the O
tabun B
- O
hAChE O
conjugate O
. O

We O
also O
observed O
that O
oximes B
RS194B B
[ O
N B
- I
( I
2 I
- I
( I
azepan I
- I
1 I
- I
yl I
) I
ethyl I
) I
- I
2 I
- I
( I
hydroxyimino I
) I
acetamide I
] O
and O
RS41A B
[ O
2 B
- I
( I
hydroxyimino I
) I
- I
N I
- I
( I
2 I
- I
( I
pyrrolidin I
- I
1 I
- I
yl I
) I
ethyl I
) I
acetamide I
] O
, O
which O
emerged O
as O
lead O
uncharged O
reactivators O
of O
phosphylated O
hAChE O
with O
other O
OPs O
( O
sarin B
, O
cyclosarin B
and O
VX O
) O
, O
exhibited O
only O
moderate O
reactivation O

We O
also O
observed O
that O
oximes B
RS194B B
[ O
N B
- I
( I
2 I
- I
( I
azepan I
- I
1 I
- I
yl I
) I
ethyl I
) I
- I
2 I
- I
( I
hydroxyimino I
) I
acetamide I
] O
and O
RS41A B
[ O
2 B
- I
( I
hydroxyimino I
) I
- I
N I
- I
( I
2 I
- I
( I
pyrrolidin I
- I
1 I
- I
yl I
) I
ethyl I
) I
acetamide I
] O
, O
which O
emerged O
as O
lead O
uncharged O
reactivators O
of O
phosphylated O
hAChE O
with O
other O
OPs O
( O
sarin B
, O
cyclosarin B
and O
VX O
) O
, O
exhibited O
only O
moderate O
reactivation O

Six O
compounds O
were O
identified O
: O
a O
new O
flavonoid B
, O
3 B
' I
- I
hydroxy I
- I
isoscutellarein I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
; O
three O
iridoid B
glucosides I
: O
harpagide B
, O
acetyl B
harpagide I
and O
for O
the O
first O
time O
in O
this O
species O
, O
8 B
- I
epi I
- I
loganin I
; O
two O
known O
acetylated B
flavonoid I
glycosides I
: O
3 B
' I
- I
hydroxy I
- I
4 I

' I
- I
O I
- I
methylisoscutellarei I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
allopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
6 I
' I
' I
- I
acetyl I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
, O
3 B
' I
- I
hydroxy I
- I
4 I
' I
- I
O I
- I
methylisoscutellarei I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
allopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
. O

This O
includes O
specific O
spin O
traps O
like O
alpha B
- I
phenyl I
- I
N I
- I
tert I
- I
butyl I
nitrone I
, O
a O
catalytic O
antioxidant O
( O
ECSOD O
mimetic O
) O
, O
porphyrins B
( O
AEOL B
10150 I
and O
AEOL B
10113 I
) O
, O
and O
a O
superoxide B
dismutase O
mimetic O
M40419 B
, O
lipid O
peroxidation O
and O
protein O
carbonylation O
blockers O
/ O
inhibitors O
, O
such O
as O
edaravone B
and O
lazaroids B
/ O
tirilazad B
, O
myeloperoxidase O
inhibitors O
, O
as O
well O
as O
specialized O
pro O
- O
resolving O

Peptide O
reactivity O
was O
measured O
by O
monitoring O
unreacted O
peptides O
with O
UV O
- O
Vis O
spectrophotometer O
using O
5 B
, I
5 I
' I
- I
dithiobis I
- I
2 I
- I
nitrobenzoic I
acid I
as O
a O
detection O
reagent O
for O
the O
free O
thiol B
group O
of O
cysteine B
- O
containing O
peptide O
or O
fluorometer O
using O
fluorescamine B
( O
TM O
) O
as O
a O
detection O
reagent O
for O
the O
free O
amine O
group O
of O
lysine B
- O
containing O
peptide O
. O

Acute O
administration O
( O
0 O
. O
63 O
- O
40 O
mg O
/ O
kg O
) O
of O
the O
mGluR5 O
positive O
allosteric O
modulators O
( O
PAMs O
) O
, O
3 B
- I
cyano I
- I
N I
- I
( I
1 I
, I
3 I
- I
diphenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
yl I
) I
benzamide I
( O
CDPPB B
) O
and O
ADX47273 B
, O
reversed O
a O
delay O
- O
induced O
impairment O
in O
social O
novelty O
discrimination O
( O
SND O
) O
in O
adult O
rats O
. O

The O
action O
of O
CDPPB B
was O
blocked O
by O
the O
mGluR5 O
antagonist O
, O
2 B
- I
methyl I
- I
6 I
- I
( I
phenylethynyl I
) I
- I
pyridine I
( O
2 O
. O
5 O
- O
10 O
mg O
/ O
kg O
) O
, O
and O
was O
also O
expressed O
upon O
microinjection O
into O
frontal O
cortex O
( O
0 O
. O
63 O
- O
10 O
mu O
g O
/ O
side O
) O
, O
but O
not O
striatum O
. O

Human O
gastric O
TFF2 O
peptide O
contains O
an O
N B
- I
linked I
fucosylated I
N I
, I
N I
' I
- I
diacetyllactosediami I
( O
LacdiNAc B
) O
oligosaccharide O
. O

Chromatin O
immunoprecipitation O
assays O
were O
used O
to O
identify O
a O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
( O
TPA B
) O
- O
response O
element O
( O
TRE O
- O
III O
) O
responsible O
for O
c O
- O
Jun O
- O
mediated O
transcriptional O
activation O
of O
Gipr O
. O

Phytochemical O
investigation O
of O
the O
n B
- I
butanol I
( O
n B
- I
BuOH I
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 B
, I
6 I
- I
dideoxyhexose I
- I
C I
- I
glycosyl I
flavones I
, O
including O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranosyl I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranoside I
( O
2 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O

Phytochemical O
investigation O
of O
the O
n B
- I
butanol I
( O
n B
- I
BuOH I
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 B
, I
6 I
- I
dideoxyhexose I
- I
C I
- I
glycosyl I
flavones I
, O
including O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranosyl I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranoside I
( O
2 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O

Phytochemical O
investigation O
of O
the O
n B
- I
butanol I
( O
n B
- I
BuOH I
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 B
, I
6 I
- I
dideoxyhexose I
- I
C I
- I
glycosyl I
flavones I
, O
including O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranosyl I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranoside I
( O
2 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O

Phytochemical O
investigation O
of O
the O
n B
- I
butanol I
( O
n B
- I
BuOH I
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 B
, I
6 I
- I
dideoxyhexose I
- I
C I
- I
glycosyl I
flavones I
, O
including O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranosyl I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranoside I
( O
2 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O

3 O
) O
and O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O
4 O
) O
, O
together O
with O
five O
known O
compounds O
( O
5 O
- O
9 O
) O
. O

In O
this O
study O
, O
we O
investigated O
the O
therapeutic O
effects O
of O
ginger O
and O
its O
component O
zingerone B
in O
mice O
with O
2 B
, I
4 I
, I
6 I
- I
trinitrobenzene I
sulphonic I
acid I
( O
TNBS B
) O
- O
induced O
colitis O
. O

Twenty O
four O
hours O
after O
MIPEF O
treatments O
, O
an O
increase O
was O
observed O
in O
hydroxycinnamic B
acids I
and O
flavanones B
, O
whereas O
flavonols B
, O
coumaric B
and I
ferulic I
acid I
- I
O I
- I
glucoside I
were O
not O
affected O
. O

On O
the O
other O
hand O
, O
treatments O
at O
1 O
. O
2kV O
/ O
cm O
and O
5 O
pulses O
led O
to O
maximum O
increases O
of O
alpha B
- I
carotene I
, O
9 B
- I
and I
13 I
- I
cis I
- I
lycopene I
, O
which O
increased O
by O
93 O
% O
, O
94 O
% O
and O
140 O
% O
, O
respectively O
. O

Vitamin B
D I
is O
a O
fat O
- O
soluble O
precursor O
of O
the O
circulating O
25 B
- I
hydroxyvitamin I
D I
3 I
( O
25 B
( I
OH I
) I
D I
3 I
) O
which O
can O
be O
converted O
by O
the O
1 O
alpha O
- O
hydroxylase O
( O
1 O
alpha O
( O
OH O
) O
ase O
) O
enzyme O
into O
the O
bioactive O
hormonal O
metabolite O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
( O
1 B
, I
25 I
( I
OH I
) I
2 I
D I
3 I
) O
, O
generally O
known O
to O
promote O
bone O
mineralization O
through O
its O
ability O
to O
enhance O
calcium B
absorption O
from O
the O
gut O
. O

This O
tutorial O
review O
summarizes O
the O
organometallic O
chemistry O
derived O
from O
the O
half O
- O
sandwich O
complex O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
ZrCl I
( I
tmeda I
) I
] O
, O
which O
was O
used O
as O
an O
efficient O
and O
versatile O
starting O
material O
for O
the O
incorporation O
of O
monoanionic O
ligands O
into O
the O
cycloheptatrienyl B
zirconium I
coordination O
sphere O
by O
conventional O
salt O
metathesis O
reactions O
. O

A O
broad O
variety O
of O
ligands O
was O
employed O
, O
affording O
novel O
and O
previously O
inaccessible O
cycloheptatrienyl B
( O
sandwich O
) O
complexes O
of O
the O
type O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
Zr I
( I
Y I
) I
] O
; O
Y O
comprises O
pentadienyl B
, O
cyclopentadienyl B
, O
allyl B
, O
phospholyl B
, O
boratabenzene B
, O
imidazolin B
- I
2 I
- I
iminato I
and O
amido B
systems O
. O

The O
corresponding O
results O
emphasize O
why O
the O
use O
of O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
ZrCl I
( I
tmeda I
) I
] O
is O
clearly O
an O
advancement O
in O
the O
chemistry O
of O
the O
still O
fairly O
unexplored O
area O
of O
cycloheptatrienyl B
transition I
metal I
complexes I
. O

M1 O
was O
identified O
as O
the O
N B
- O
acetylated O
species O
[ B
( I
2R I
) I
- I
3 I
- I
acetamido I
- I
2 I
- I
fluoropropyl I
] I
- I
phosphinic I
acid I
, O
and O
M6 O
as O
[ B
( I
2R I
) I
- I
3 I
- I
amino I
- I
2 I
- I
fluoropropyl I
] I
- I
phosphonic I
acid I
. O

M1 O
was O
identified O
as O
the O
N B
- O
acetylated O
species O
[ B
( I
2R I
) I
- I
3 I
- I
acetamido I
- I
2 I
- I
fluoropropyl I
] I
- I
phosphinic I
acid I
, O
and O
M6 O
as O
[ B
( I
2R I
) I
- I
3 I
- I
amino I
- I
2 I
- I
fluoropropyl I
] I
- I
phosphonic I
acid I
. O

M3 O
was O
the O
corresponding O
carboxylic B
acid I
species O
retaining O
the O
fluorine B
atom O
, O
( B
2R I
) I
- I
2 I
- I
fluoro I
- I
3 I
- I
hydroxyphosphonoyl I
- I
propanoic I
acid I
. O

Finally O
M4 O
was O
identified O
as O
[ B
( I
2R I
) I
- I
2 I
- I
fluoro I
- I
3 I
- I
guanidino I
- I
propyl I
] I
- I
phosphinic I
acid I
. O

Apoptosis O
induced O
neurotoxicity O
of O
Di B
- I
n I
- I
butyl I
- I
di I
- I
( I
4 I
- I
chlorobenzohydroxama I
) I
Tin I
( I
IV I
) I
via O
mitochondria O
- O
mediated O
pathway O
in O
PC12 O
cells O
. O

Di B
- I
n I
- I
butyl I
- I
di I
- I
( I
4 I
- I
chlorobenzohydroxama I
) I
Tin I
( I
IV I
) I
( O
DBDCT B
) O
, O
an O
antitumor O
agent O
with O
high O
activity O
and O
obvious O
neurotoxicity O
was O
chosen O
as O
a O
typical O
diorganotin B
( I
IV I
) I
compound O
to O
investigate O
its O
neurotoxic O
mechanism O
using O
PC12 O
cells O
and O
comprehensive O
methods O
. O

The O
quinolizidine B
alkaloids I
( O
natural O
products O
) O
such O
as O
oxymatrine B
, O
sophoridine B
, O
sophocarpine B
and O
matrine B
carry O
the O
common O
molecular O
structure O
of O
O B
= I
C I
= I
N I
- I
C I
- I
C I
- I
C I
- I
N I
that O
possessed O
positive O
ionotropic O
effect O
and O
hERG O
blocking O
activity O
. O

In O
this O
study O
, O
an O
analytical O
method O
to O
determine O
enniatins B
A I
, I
A1 I
, I
B I
and I
B1 I
( O
ENs O
) O
, O
beauvericin B
( O
BEA B
) O
and O
fusaproliferin B
( O
FUS B
) O
based O
on O
Ultra O
- O
Turrax O
extraction O
followed O
by O
liquid O
chromatography O
coupled O
to O
triple O
quadrupole O
mass O
spectrometer O
detector O
( O
MS O
/ O
MS O
QqQ O
) O
, O
was O
applied O
for O
the O
analysis O
of O
pasta O
. O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 B
- I
bromo I
- I
2 I
- I
bromomethyl I
glutaronitrile I
, O
cinnamaldehyde B
, O
citral B
, O
diethylmaleate B
, O
dinitrochlorobenzene B
, O
glyoxal B
, O
2 B
- I
mercaptobenzothiazol I
, O
nickel B
sulfate I
, O
4 B
- I
nitrobenzylbromide I
, O
oxazolone B
, O
penicillin B
G I
, O
resorcinol B
, O
tetramethylthiuram B
disulfide I
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

Assay O
of O
vtg O
, O
ERs O
and O
PPARs O
as O
endpoint O
for O
the O
rapid O
in O
vitro O
screening O
of O
the O
harmful O
effect O
of O
Di B
- I
( I
2 I
- I
ethylhexyl I
) I
- I
phthalate I
( O
DEHP B
) O
and O
phthalic B
acid I
( O
PA O
) O
in O
zebrafish O
primary O
hepatocyte O
cultures O
. O

Considering O
that O
, O
at O
date O
data O
available O
dealing O
with O
the O
adverse O
outcome O
of O
Di B
- I
( I
2 I
- I
ethylhexyl I
) I
- I
phthalate I
( O
DEHP B
) O
on O
the O
reproduction O
of O
several O
species O
are O
still O
contrasting O
, O
in O
this O
study O
, O
the O
effects O
induced O
by O
DEHP B
( O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
1 O
, O
10 O
and O
100 O
nM O
) O
and O
its O
active O
metabolite O
, O
phthalic B
acid I
( O
PA O
) O
( O
0 O
. O
01 O
, O
0 O
. O
1 O
, O
1 O
and O
10 O
mu O
M O
) O
, O
were O
analyzed O
in O
zebrafish O
, O
Danio O
rerio O
, O
primary O
hepatocyte O
cultures O
, O
using O
target O
molecules O

Inhibition O
of O
EGF O
/ O
EGFR O
activation O
with O
naphtho B
[ I
1 I
, I
2 I
- I
b I
] I
furan I
- I
4 I
, I
5 I
- I
dione I
blocks O
migration O
and O
invasion O
of O
MDA O
- O
MB O
- O
231 O
cells O
. O

Naphtho B
[ I
1 I
, I
2 I
- I
b I
] I
furan I
- I
4 I
, I
5 I
- I
dione I
( O
NFD B
) O
, O
a O
bioactive O
component O
of O
Avicennia O
marina O
, O
has O
been O
demonstrated O
to O
display O
anti O
- O
cancer O
activity O
. O

Resonance O
Raman O
spectral O
imaging O
of O
intracellular O
uptake O
of O
beta B
- I
carotene I
loaded O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
nanoparticles O
. O

Herein O
, O
we O
employ O
Raman O
microscopy O
as O
a O
non O
- O
invasive O
method O
for O
cellular O
and O
sub O
- O
cellular O
imaging O
, O
to O
monitor O
the O
uptake O
and O
translocation O
patterns O
of O
particles O
based O
on O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
over O
time O
. O

The O
potentiation O
of O
heteromeric O
KARs O
by O
mGlu1 O
activation O
was O
attenuated O
by O
GDP O
beta O
S O
, O
blocked O
by O
an O
inhibitor O
of O
phospholipase O
C O
or O
the O
calcium B
chelator O
1 B
, I
2 I
- I
bis I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
( O
BAPTA B
) O
, O
prolonged O
by O
the O
phosphatase O
inhibitor O
okadaic B
acid I
, O
but O
unaffected O
by O
the O
tyrosine B
kinase O
inhibitor O
lavendustin B
A I
. O

Protein O
kinase O
C O
( O
PKC O
) O
inhibition O
reduced O
the O
potentiation O
by O
mGlu1 O
of O
GluK2 O
/ O
GluK5 O
, O
and O
conversely O
, O
direct O
activation O
of O
PKC O
by O
phorbol B
12 I
- I
myristate I
, I
13 I
- I
acetate I
potentiated O
GluK2 O
/ O
GluK5 O
. O

By O
using O
flow O
cytometry O
and O
Western O
blotting O
, O
we O
demonstrated O
that O
isoproterenol B
, O
S B
- I
propranolol I
, O
CGP B
- I
12177 I
[ O
4 B
- I
[ I
3 I
- I
[ I
( I
1 I
, I
1 I
- I
dimethylethyl I
) I
amino I
] I
2 I
- I
hydroxypropoxy I
] I
- I
1 I
, I
3 I
- I
dihydro I
- I
2H I
- I
benzimidazol I
- I
2 I
- I
one I
] O
, O
pindolol B
, O
and O
timolol B
, O
which O
displayed O
agonistic O
properties O
toward O
the O
beta O
( O
1 O
) O
AR O
in O
either O
the O
adenylyl B
cyclase O
or O

In O
contrast O
, O
metoprolol B
, O
bisoprolol B
, O
and O
CGP B
- I
20712 I
[ O
1 B
- I
[ I
2 I
- I
( I
( I
3 I
- I
carbamoyl I
- I
4 I
- I
hydroxy I
) I
phenoxy I
) I
ethylamino I
] I
- I
3 I
- I
[ I
4 I
- I
( I
1 I
- I
methyl I
- I
4 I
- I
trifluoromethyl I
- I
2 I
- I
imidazolyl I
) I
phenoxy I
] I
- I
2 I
- I
propanol I
] O
, O
which O
showed O
no O
agonistic O
activity O
, O
had O
only O
a O
marginal O
or O
no O
effect O
. O

A O
crucial O
role O
for O
controlling O
ERR O
alpha O
- O
mediated O
target O
gene O
expression O
has O
been O
ascribed O
to O
the O
biarylpyrazole B
compound O
1 B
- I
( I
2 I
, I
4 I
- I
dichlorophenyl I
) I
- I
5 I
- I
( I
4 I
- I
iodophenyl I
) I
- I
4 I
- I
methyl I
- I
N I
- I
1 I
- I
piperidinyl I
- I
1H I
- I
pyrazole I
- I
3 I
- I
carboxamide I
( O
AM251 B
) O
through O
direct O
binding O
to O
and O
destabilization O
of O
ERR O
alpha O
protein O
. O

Furthermore O
, O
the O
AMPK O
activator O
5 B
- I
amino I
- I
1 I
- I
beta I
- I
D I
- I
ribofuranosyl I
- I
imidazole I
- I
4 I
- I
carboxamide I
( O
AICAR B
) O
significantly O
inhibited O
ghrelin O
secretion O
. O

Moreover O
, O
total O
protein O
, O
leukotriene B
( I
LT I
) I
B I
( I
4 I
) I
, O
prostaglandin B
( I
PG I
) I
E I
( I
2 I
) I
and O
pro O
- O
inflammatory O
cytokine O
levels O
were O
increased O
. O

Moreover O
, O
total O
protein O
, O
leukotriene B
( I
LT I
) I
B I
( I
4 I
) I
, O
prostaglandin B
( I
PG I
) I
E I
( I
2 I
) I
and O
pro O
- O
inflammatory O
cytokine O
levels O
were O
increased O
. O

In O
addition O
, O
the O
effect O
of O
a O
new O
polymeric O
excipient O
Soluplus B
( O
R O
) O
( O
polyvinyl B
caprolactam I
- I
polyvinyl I
acetate I
- I
polyethylene I
glycol I
graft I
copolymer I
) O
on O
oral O
bioavailability O
of O
piroxicam B
was O
investigated O
. O

Furthermore O
, O
alpha O
- O
conotoxins O
( O
CTx O
) O
EI O
and O
GI O
were O
used O
to O
antagonize O
the O
actions O
of O
( B
+ I
) I
- I
and I
( I
- I
) I
- I
coniine I
in O
TE O
- O
671 O
cells O
. O

Density O
functional O
conformational O
study O
of O
2 B
- I
O I
- I
sulfated I
3 I
, I
6 I
anhydro I
- I
alpha I
- I
D I
- I
galactose I
and O
of O
neo B
- I
kappa I
- I
and I
iota I
- I
carrabiose I
molecules O
in O
gas O
phase O
and O
water O
. O

Density O
functional O
conformational O
study O
of O
2 B
- I
O I
- I
sulfated I
3 I
, I
6 I
anhydro I
- I
alpha I
- I
D I
- I
galactose I
and O
of O
neo B
- I
kappa I
- I
and I
iota I
- I
carrabiose I
molecules O
in O
gas O
phase O
and O
water O
. O

We O
examined O
the O
conformational O
preferences O
of O
the O
2 B
- I
O I
- I
sulfated I
- I
3 I
, I
6 I
- I
alpha I
- I
D I
- I
anhydrogalactose I
( O
compound O
I O
) O
and O
two O
1 O
, O
3 O
linked O
disaccharides B
constituting O
- O
kappa O
or O
iota O
- O
carrageenans O
using O
density O
functional O
and O
ab O
initio O
methods O
in O
gas O
phase O
and O
aqueous O
solution O
. O

Unlike O
the O
majority O
of O
G O
protein O
- O
coupled O
receptors O
, O
the O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
E B
- I
prostanoid I
3 O
( O
EP3 O
) O
receptor O
binds O
agonist O
with O
high O
affinity O
that O
is O
insensitive O
to O
the O
presence O
of O
guanosine B
5 I
[ I
prime I
] I
- I
O I
- I
( I
3 I
- I
thio I
) I
triphosphate I
( O
GTP B
gamma I
S I
) O
. O

Loss O
of O
agonist O
binding O
was O
observed O
on O
intact O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
W203A O
receptor O
, O
conditions O
where O
high O
GTP B
levels O
are O
present O
; O
however O
, O
high O
affinity O
binding O
[ B
( I
3 I
) I
H I
] I
PGE I
( I
2 I
) I
was O
observed O
in O
broken O
cell O
preparations O
washed O
free O
of O
GTP B
. O

The O
[ B
( I
3 I
) I
H I
] I
PGE I
( I
2 I
) I
binding O
of O
W203A O
in O
broken O
cell O
membrane O
fractions O
was O
inhibited O
by O
addition O
of O
GTP B
gamma I
S I
( O
IC O
( O
50 O
) O
21 O
+ O
/ O
- O
1 O
. O
8 O
nM O
) O
. O

MM B
- I
419447 I
exhibits O
high O
- O
affinity O
binding O
in O
vitro O
to O
T84 O
cells O
, O
resulting O
in O
a O
significant O
, O
concentration O
- O
dependent O
accumulation O
of O
intracellular O
cyclic B
guanosine I
- I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cGMP B
) O
. O

In O
the O
present O
work O
, O
we O
studied O
the O
pharmacokinetics O
of O
this O
short O
therapeutic O
hexapeptide O
( O
His B
- I
( I
D I
- I
Trp I
) I
- I
Ala I
- I
Trp I
- I
( I
D I
- I
Phe I
) I
- I
Lys I
- I
NH I
( I
2 I
, I
) I
MW O
= O
872 O
. O
44 O
Da O
) O
in O
nine O
male O
healthy O
volunteers O
after O
a O
single O
intravenous O
bolus O
administration O
of O
100 O
, O
200 O
and O
400 O
mu O
g O
/ O
kg O
of O
body O
weight O
. O

GHRP B
- I
6 I
was O
quantified O
in O
human O
plasma O
by O
a O
specific O
LC O
- O
MS O
method O
, O
previously O
developed O
and O
validated O
following O
FDA O
guidelines O
, O
using O
( B
13 I
) I
C I
( I
3 I
) I
Ala I
- I
GHRP I
- I
6 I
as O
internal O
standard O
( O
Gil O
et O
al O
. O
, O
2012 O
, O
J O
. O
Pharm O
. O
Biomed O
. O
Anal O
. O
60 O
, O
19 O
- O
25 O
) O
. O

In O
the O
past O
pharmacological O
effects O
of O
BSE O
were O
mainly O
attributed O
to O
11 B
- I
keto I
- I
beta I
- I
boswellic I
acid I
( O
KBA B
) O
and O
3 B
- I
acetyl I
- I
11 I
- I
keto I
- I
beta I
- I
boswellic I
acid I
( O
AKBA B
) O
. O

In O
the O
past O
pharmacological O
effects O
of O
BSE O
were O
mainly O
attributed O
to O
11 B
- I
keto I
- I
beta I
- I
boswellic I
acid I
( O
KBA B
) O
and O
3 B
- I
acetyl I
- I
11 I
- I
keto I
- I
beta I
- I
boswellic I
acid I
( O
AKBA B
) O
. O

Here O
, O
we O
determined O
the O
metabolic O
stability O
, O
permeability O
and O
brain O
availability O
of O
six O
major O
BAs O
, O
that O
is O
, O
KBA B
, O
AKBA B
, O
beta B
BA I
, O
3 B
- I
acetyl I
- I
beta I
- I
boswellic I
acid I
( O
A B
beta I
BA I
) O
, O
alpha B
- I
boswellic I
acid I
( O
alpha B
BA I
) O
, O
and O
3 B
- I
acetyl I
- I
alpha I
- I
boswellic I
acid I
( O
A B
alpha I
BA I
) O
. O

Here O
, O
we O
determined O
the O
metabolic O
stability O
, O
permeability O
and O
brain O
availability O
of O
six O
major O
BAs O
, O
that O
is O
, O
KBA B
, O
AKBA B
, O
beta B
BA I
, O
3 B
- I
acetyl I
- I
beta I
- I
boswellic I
acid I
( O
A B
beta I
BA I
) O
, O
alpha B
- I
boswellic I
acid I
( O
alpha B
BA I
) O
, O
and O
3 B
- I
acetyl I
- I
alpha I
- I
boswellic I
acid I
( O
A B
alpha I
BA I
) O
. O

Arsenic B
trioxide I
( O
As B
( I
2 I
) I
O I
( I
3 I
) I
) O
, O
which O
is O
used O
to O
treat O
acute O
promyelocytic O
leukemia O
, O
can O
cause O
LQTS O
type O
2 O
( O
LQT2 O
) O
by O
reducing O
the O
hERG O
current O
through O
the O
diversion O
of O
hERG O
trafficking O
to O
the O
cytoplasmic O
membrane O
. O

Our O
aim O
was O
to O
develop O
cardioprotective O
agents O
to O
decrease O
As B
( I
2 I
) I
O I
( I
3 I
) I
- O
induced O
cardiotoxicity O
. O

Long O
- O
term O
treatment O
with O
1 O
mu O
M O
matrine B
or O
oxymatrine B
increased O
expression O
of O
the O
hERG O
protein O
and O
rescued O
the O
hERG O
surface O
expression O
disrupted O
by O
As B
( I
2 I
) I
O I
( I
3 I
) I
. O

In O
addition O
, O
Matrine B
and O
oxymatrine B
significantly O
shortened O
action O
potential O
duration O
prolonged O
by O
As B
( I
2 I
) I
O I
( I
3 I
) I
in O
guinea O
pig O
ventricular O
myocytes O
. O

[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
Ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
were O
administered O
intravenously O
and O
the O
incorporation O
of O
( B
15 I
) I
N I
in O
amino B
acids I
as O
well O
as O
the O
content O
of O
the O
amino B
acids I
were O
subsequently O
determined O
in O
plasma O
, O
skeletal O
muscle O
, O
liver O
and O
kidney O
. O

[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
Ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
were O
administered O
intravenously O
and O
the O
incorporation O
of O
( B
15 I
) I
N I
in O
amino B
acids I
as O
well O
as O
the O
content O
of O
the O
amino B
acids I
were O
subsequently O
determined O
in O
plasma O
, O
skeletal O
muscle O
, O
liver O
and O
kidney O
. O

OP O
treatment O
did O
not O
increase O
( B
15 I
) I
N I
labeling O
in O
glutamine B
from O
[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
ornithine I
and O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
in O
skeletal O
muscle O
or O
liver O
. O

OP O
treatment O
did O
not O
increase O
( B
15 I
) I
N I
labeling O
in O
glutamine B
from O
[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
ornithine I
and O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
in O
skeletal O
muscle O
or O
liver O
. O

However O
, O
the O
extent O
of O
glutamine B
labeling O
from O
[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
was O
similar O
in O
arterial O
blood O
and O
liver O
and O
higher O
than O
that O
in O
skeletal O
muscle O
. O

However O
, O
the O
extent O
of O
glutamine B
labeling O
from O
[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
was O
similar O
in O
arterial O
blood O
and O
liver O
and O
higher O
than O
that O
in O
skeletal O
muscle O
. O

Seven O
constituents O
were O
isolated O
from O
the O
stems O
of O
Lawsonia O
alba O
Lam O
. O
, O
following O
an O
activity O
- O
guided O
isolation O
, O
which O
include O
two O
new O
constituents O
, O
namely O
lawsorosemarinol B
( O
1 O
) O
and O
lawsofructose B
( O
2 O
) O
, O
one O
known O
compound O
2 B
- I
( I
beta I
- I
d I
- I
glucopyranosyloxy I
) I
- I
1 I
, I
4 I
- I
naphthoquinone I
( O
3 O
) O
and O
four O
compounds O
, O
4 B
- I
hydroxy I
coumarine I
( O
4 O
) O
, O
3 B
- I
( I
4 I
- I
hyroxyphenyl I
) I
- I
triacontyl I
- I
( I
Z I
) I
- I
propenoate I
( O
5 O
) O
, O

Seven O
constituents O
were O
isolated O
from O
the O
stems O
of O
Lawsonia O
alba O
Lam O
. O
, O
following O
an O
activity O
- O
guided O
isolation O
, O
which O
include O
two O
new O
constituents O
, O
namely O
lawsorosemarinol B
( O
1 O
) O
and O
lawsofructose B
( O
2 O
) O
, O
one O
known O
compound O
2 B
- I
( I
beta I
- I
d I
- I
glucopyranosyloxy I
) I
- I
1 I
, I
4 I
- I
naphthoquinone I
( O
3 O
) O
and O
four O
compounds O
, O
4 B
- I
hydroxy I
coumarine I
( O
4 O
) O
, O
3 B
- I
( I
4 I
- I
hyroxyphenyl I
) I
- I
triacontyl I
- I
( I
Z I
) I
- I
propenoate I
( O
5 O
) O
, O

3 B
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenyl I
) I
- I
triacontyl I
- I
( I
Z I
) I
- I
propenoate I
( O
6 O
) O
and O
7 B
- I
hydroxy I
- I
4 I
- I
methyl I
coumarin I
( O
7 O
) O
first O
time O
isolated O
from O
Lawsonia O
alba O
. O

3 B
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenyl I
) I
- I
triacontyl I
- I
( I
Z I
) I
- I
propenoate I
( O
6 O
) O
and O
7 B
- I
hydroxy I
- I
4 I
- I
methyl I
coumarin I
( O
7 O
) O
first O
time O
isolated O
from O
Lawsonia O
alba O
. O

Herein O
, O
we O
describe O
the O
detailed O
development O
of O
a O
simple O
and O
effective O
method O
to O
microencapsulate O
vaccine O
antigens O
in O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
by O
simple O
mixing O
of O
preformed O
active O
self O
- O
microencapsulating O
( O
SM O
) O
PLGA B
microspheres O
in O
a O
low O
concentration O
aqueous O
antigen O
solution O
at O
modest O
temperature O
( O
10 O
- O
38 O
degrees O
C O
) O
. O

Testing O
type O
I O
[ O
N B
- I
( I
5 I
- I
chloro I
- I
2 I
- I
hydroxyphenyl I
) I
- I
N I
' I
- I
[ I
2 I
- I
chloro I
- I
5 I
- I
( I
trifluoromethyl I
) I
phenyl I
] O
( O
NS1738 B
) O
] O
and O
type O
II O
[ O
1 B
- I
( I
5 I
- I
chloro I
- I
2 I
, I
4 I
- I
dimethoxy I
- I
phenyl I
) I
- I
3 I
- I
( I
5 I
- I
methyl I
- I
isoxazol I
- I
3 I
- I
yl I
) I
( O
PNU B
- I
120596 I
) O
] O
alpha O
7 O
nAChR O
PAMs O
in O
acute O
and O
persistent O
pain O
, O
we O
found O

Testing O
type O
I O
[ O
N B
- I
( I
5 I
- I
chloro I
- I
2 I
- I
hydroxyphenyl I
) I
- I
N I
' I
- I
[ I
2 I
- I
chloro I
- I
5 I
- I
( I
trifluoromethyl I
) I
phenyl I
] O
( O
NS1738 B
) O
] O
and O
type O
II O
[ O
1 B
- I
( I
5 I
- I
chloro I
- I
2 I
, I
4 I
- I
dimethoxy I
- I
phenyl I
) I
- I
3 I
- I
( I
5 I
- I
methyl I
- I
isoxazol I
- I
3 I
- I
yl I
) I
( O
PNU B
- I
120596 I
) O
] O
alpha O
7 O
nAChR O
PAMs O
in O
acute O
and O
persistent O
pain O
, O
we O
found O

Our O
results O
with O
selective O
mitogen O
- O
activated O
protein O
kinase O
kinase O
inhibitor O
1 B
, I
4 I
- I
diamino I
- I
2 I
, I
3 I
- I
dicyano I
- I
1 I
, I
4 I
- I
bis I
( I
o I
- I
aminophenylmercapto I
) I
butadiene I
monoethanolate I
( O
U0126 B
) O
argues O
for O
an O
important O
role O
of O
extracellular O
signal O
- O
regulated O
kinase O
- O
1 O
/ O
2 O
pathways O
activation O
in O
PNU B
- I
120596 I
' O
s O
antinociceptive O
effects O
. O

Antiarrhythmic O
effects O
of O
( B
- I
) I
- I
epicatechin I
- I
3 I
- I
gallate I
, O
a O
novel O
sodium B
channel O
agonist O
in O
cultured O
neonatal O
rat O
ventricular O
myocytes O
. O

( B
- I
) I
- I
Epicatechin I
- I
3 I
- I
gallate I
( O
ECG B
) O
, O
a O
polyphenol B
extracted O
from O
green O
tea O
, O
has O
been O
proposed O
as O
an O
effective O
compound O
for O
improving O
cardiac O
contractility O
. O

In O
this O
work O
, O
phytochemical O
investigation O
of O
litchi O
pericarp O
methanol B
extracts O
led O
to O
the O
isolation O
of O
a O
novel O
phenolic B
, O
2 B
- I
( I
2 I
- I
hydroxyl I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
together O
with O
kaempferol B
, O
isolariciresinol B
, O
stigmasterol B
, O
butylated B
hydroxytoluene I
, O
3 B
, I
4 I
- I
dihydroxyl I
benzoate I
, O
methyl B
shikimate I
and O
ethyl B
shikimate I
. O

Antioxidant O
activities O
of O
the O
eight O
compounds O
were O
determined O
by O
a O
DPPH B
radical O
scavenging O
assay O
and O
the O
results O
showed O
that O
2 B
- I
( I
2 I
- I
hydroxy I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
kaempferol B
, O
isolariciresinol B
, O
butylated B
hydroxytoluene I
and O
3 B
, I
4 I
- I
dihydroxy I
benzoate I
exhibited O
good O
antioxidant O
activities O
. O

Moreover O
, O
the O
herb O
and O
its O
infusion O
are O
a O
source O
of O
phenolic B
compounds O
( O
flavonoids B
such O
as O
flavonols B
and O
flavones B
, O
phenolic B
acids I
and O
derivatives O
) O
and O
organic O
acids O
( O
oxalic B
, I
quinic I
, I
malic I
, I
citric I
and I
fumaric I
acids I
) O
that O
showed O
antioxidant O
and O
antitumour O
activities O
, O
without O
hepatotoxicity O
. O

Besides O
enniatins B
A I
, I
A1 I
, I
B I
and I
B1 I
, O
also O
deoxynivalenol B
and O
its O
conjugated O
form O
( O
deoxynivalenol B
- I
3 I
- I
glucoside I
) O
were O
determined O
in O
almost O
all O
tested O
cereal O
- O
based O
samples O
. O

Antioxidant O
activity O
comparison O
between O
[ B
6S I
] I
- I
5 I
- I
methyltetrahydrofoli I
acid I
calcium I
salt O
and O
the O
related O
racemate O
form O
. O

Folates B
, O
such O
as O
[ B
6S I
] I
- I
5 I
- I
methyltetrahydrofoli I
acid I
, O
have O
been O
introduced O
in O
the O
market O
both O
in O
vitamin O
pills O
and O
in O
fortified O
foods O
. O

In O
this O
study O
, O
a O
comparison O
between O
[ B
6S I
] I
- I
5 I
- I
methyltetrahydrofoli I
acid I
( O
5 B
- I
MTHF I
) O
and O
its O
racemate O
[ O
6R O
, O
S O
] O
form O
was O
made O
by O
TEAC O
assay O
at O
different O
pHs O
, O
FRAP O
assay O
, O
and O
ORAC O
assay O
. O

A O
combination O
of O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Huperzine I
A I
improves O
protection O
against O
soman O
toxicity O
compared O
to O
[ B
+ I
] I
- I
Huperzine I
A I
in O
guinea O
pigs O
. O

We O
investigated O
a O
combination O
of O
[ B
+ I
] I
- I
Hup I
A I
with O
a O
small O
dose O
of O
[ B
- I
] I
- I
Hup I
A I
( O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
) O
against O
soman B
toxicity O
. O

Our O
data O
showed O
that O
pretreatment O
with O
a O
combination O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
significantly O
increased O
the O
survival O
rate O
and O
reduced O
behavioral O
abnormalities O
after O
exposure O
to O
1 O
. O
2 O
x O
LD50 O
soman O
compared O
to O
[ B
+ I
] I
- I
Hup I
A I
in O
guinea O
pigs O
. O

In O
addition O
, O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
pretreatment O
inhibited O
the O
development O
of O
high O
power O
of O
EEG O
better O
than O
[ B
+ I
] I
- I
Hup I
A I
pretreatment O
alone O
. O

These O
data O
suggest O
that O
a O
combination O
of O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
offers O
better O
protection O
than O
[ B
+ I
] I
- I
Hup I
A I
and O
serves O
as O
a O
potent O
medical O
countermeasure O
against O
lethal O
dose O
nerve O
agent O
toxicity O
in O
guinea O
pigs O
. O

The O
general O
formula O
of O
the O
OPCs O
was O
( B
RO I
) I
2P I
( I
O I
) I
X I
, O
where O
R O
= O
alkyl B
, O
X O
= O
- O
SCH B
( I
Hal I
) I
COOEt I
( O
Hal B
= O
Cl B
, O
Br B
) O
, O
- O
SCHCl2 B
, O
- O
SCH2Br B
, O
- O
OCH B
( I
CF3 I
) I
R I
( I
1 I
) I
( O
R O
( O
1 O
) O
= O
C6H5 B
, O
CF3 B
, O
COOEt B
, O
COOMe B
) O
. O

The O
general O
formula O
of O
the O
OPCs O
was O
( B
RO I
) I
2P I
( I
O I
) I
X I
, O
where O
R O
= O
alkyl B
, O
X O
= O
- O
SCH B
( I
Hal I
) I
COOEt I
( O
Hal B
= O
Cl B
, O
Br B
) O
, O
- O
SCHCl2 B
, O
- O
SCH2Br B
, O
- O
OCH B
( I
CF3 I
) I
R I
( I
1 I
) I
( O
R O
( O
1 O
) O
= O
C6H5 B
, O
CF3 B
, O
COOEt B
, O
COOMe B
) O
. O

beta B
- I
Chloroprene I
( O
2 B
- I
chloro I
- I
1 I
, I
3 I
- I
butadiene I
) O
, O
a O
monomer O
used O
in O
the O
production O
of O
neoprene B
elastomers O
, O
is O
of O
regulatory O
interest O
due O
to O
the O
production O
of O
multiorgan O
tumors O
in O
mouse O
and O
rat O
cancer O
bioassays O
. O

Synthesis O
and O
antitumor O
activity O
of O
N B
- I
sulfonyl I
- I
3 I
, I
7 I
- I
dioxo I
- I
5 I
beta I
- I
cholan I
- I
24 I
- I
amides I
, O
ursodeoxycholic B
acid I
derivatives O
. O

A O
series O
of O
N B
- I
sulfonyl I
- I
3 I
, I
7 I
- I
dioxo I
- I
5 I
beta I
- I
cholan I
- I
24 I
- I
amides I
, O
ursodeoxycholic B
acid I
derivatives O
, O
have O
been O
designed O
and O
synthesized O
in O
nine O
steps O
starting O
from O
ursodeoxycholic B
acid I
. O

We O
report O
the O
bindings O
of O
several O
lipids O
cholesterol B
( O
Chol B
) O
, O
1 B
, I
2 I
- I
dioleoyl I
- I
3 I
- I
trimethylammonium I
- I
propane I
( O
DOTAP B
) O
, O
dioctadecyldimethyla B
( O
DDAB B
) O
, O
and O
dioleoylphosphatidyl B
( O
DOPE B
) O
to O
dendrimers O
of O
different O
compositions O
such O
as O
mPEG B
- I
PAMAM I
( O
G3 O
) O
, O
mPEG B
- I
PAMAM I
( O
G4 O
) O
, O
and O
PAMAM B
( O
G4 O
) O
under O
physiological O
conditions O
. O

) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
3 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
9 O
x O
10 O
( O

When O
the O
hollow O
silicate B
nanospheres O
were O
oxidized O
, O
the O
interior O
cavities O
were O
refilled O
with O
a O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
phase O
segregated O
from O
the O
silicate B
phase O
, O
and O
the O
hollow O
structure O
reverted O
to O
the O
initial O
core O
- O
shell O
structure O
. O

More O
interestingly O
, O
when O
catalytically O
active O
Pt B
nanocrystals O
were O
introduced O
into O
the O
manganese B
oxide I
/ O
silica B
system O
, O
the O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
was O
readily O
reduced O
to O
the O
chemically O
reactive O
MnO B
, O
even O
at O
low O
temperature O
, O
which O
enabled O
reconversion O
of O
the O
solid O
nanospheres O
with O
a O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
core O
to O
hollow O
nanostructures O
during O
reductive O
annealing O
. O

More O
interestingly O
, O
when O
catalytically O
active O
Pt B
nanocrystals O
were O
introduced O
into O
the O
manganese B
oxide I
/ O
silica B
system O
, O
the O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
was O
readily O
reduced O
to O
the O
chemically O
reactive O
MnO B
, O
even O
at O
low O
temperature O
, O
which O
enabled O
reconversion O
of O
the O
solid O
nanospheres O
with O
a O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
core O
to O
hollow O
nanostructures O
during O
reductive O
annealing O
. O

Furthermore O
, O
the O
potential O
of O
this O
platform O
is O
demonstrated O
for O
( O
i O
) O
the O
in O
- O
depth O
characterization O
of O
BLMs O
comprising O
both O
synthetic O
and O
natural O
lipids O
( O
1 B
, I
2 I
- I
diphytanoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DPhPC B
) O
and O
L B
- I
alpha I
- I
phosphatidylcholine I
( O
L B
- I
alpha I
- I
PC I
) O
/ O
cholesterol B
, O
respectively O
) O
in O
terms O
of O
seal O
resistance O
, O
capacitance O
, O
surface O
area O
, O
specific O
capacitance O
, O
and O
membrane O
hydrophobic O
thickness O
; O
( O
ii O
) O
confocal O
microscopy O
imaging O

C3 O
' O
/ O
C4 O
' O
- O
Stereochemical O
Effects O
of O
Digitoxigenin B
alpha B
- I
L I
- I
/ I
alpha I
- I
D I
- I
Glycoside I
in O
Cancer O
Cytotoxicity O
. O

4 B
- I
( I
Methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
( O
NNK B
) O
metabolism O
- O
related O
enzymes O
gene O
polymorphisms O
, O
NNK B
metabolites O
levels O
and O
urothelial O
carcinoma O
. O

Gene O
polymorphisms O
of O
the O
4 B
- I
( I
methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
( O
NNK B
) O
metabolism O
- O
related O
enzymes O
- O
cytochrome O
P450 O
( O
CYP O
) O
monooxygenase O
2A13 O
( O
CYP2A13 O
) O
and O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
- O
2B7 O
could O
contribute O
to O
the O
levels O
of O
NNK B
- O
related O
metabolites O
in O
urine O
, O
thereby O
increasing O
the O
susceptibility O
to O
urothelial O

Results O
demonstrate O
that O
these O
distinct O
maturational O
processes O
are O
differentially O
affected O
by O
pharmacological O
compounds O
( O
K252a B
, O
Na B
( I
3 I
) I
VO I
( I
4 I
) I
, O
Bis B
- I
1 I
) O
known O
to O
inhibit O
neurite O
outgrowth O
. O

Fish O
were O
acutely O
exposed O
to O
two O
sub O
- O
lethal O
ammonia B
concentrations O
( O
as O
NH B
( I
4 I
) I
HCO I
( I
3 I
) I
) O
at O
pH O
7 O
. O
9 O
: O
1 O
mM O
for O
a O
period O
of O
12 O
h O
, O
identical O
for O
all O
species O
, O
and O
5 O
mM O
for O
the O
cyprinids O
and O
1 O
. O
4 O
mM O
for O
the O
trout O
for O
3 O
h O
. O

Data O
are O
presented O
showing O
the O
spontaneous O
formation O
of O
electric O
fields O
within O
solid O
films O
of O
the O
chlorofluorocarbons B
( O
CFCs B
) O
CF B
( I
3 I
) I
Cl I
, O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
and O
CFCl B
( I
3 I
) I
as O
a O
function O
of O
film O
deposition O
temperature O
from O
40 O
K O
and O
above O
. O

Maximum O
deposition O
temperatures O
for O
display O
of O
an O
electric O
field O
lie O
at O
~ O
50 O
K O
, O
~ O
65 O
K O
and O
~ O
52 O
K O
for O
CF B
( I
3 I
) I
Cl I
, O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
and O
CFCl B
( I
3 I
) I
respectively O
. O

CF B
( I
3 I
) I
Cl I
and O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
demonstrate O
temperatures O
of O
~ O
65 O
K O
and O
~ O
80 O
K O
at O
which O
the O
electric O
field O
in O
the O
film O
is O
removed O
by O
heating O
, O
so O
- O
called O
Curie O
points O
, O
with O
decay O
of O
the O
field O
spread O
over O
more O
than O
10 O
K O
. O

The O
NaHS B
- O
induced O
NO B
production O
was O
partially O
blocked O
by O
inhibitors O
of O
ryanodine B
receptor O
( O
dantrolene B
) O
or O
inositol B
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
xestospongin B
C I
) O
. O

In O
this O
work O
, O
we O
have O
developed O
and O
evaluated O
a O
new O
targeted O
lipopolyplex O
( O
LPP O
) O
, O
by O
combining O
polyethylenimine B
( O
PEI B
) O
, O
1 B
, I
2 I
- I
dioleoyl I
- I
3 I
- I
( I
trimethylammonium I
) I
propane I
( O
DOTAP B
) O
/ O
Chol O
liposomes O
, O
the O
plasmids O
pCMVLuc O
/ O
pCMVIL O
- O
12 O
, O
and O
the O
ligand O
folic B
acid I
( O
FA O
) O
, O
able O
to O
transfect O
HeLa O
and O
B16 O
- O
F10 O
cells O
in O
the O
presence O
of O
very O
high O
concentration O
of O
serum O
( O
60 O
% O
FBS O
) O
. O

Synthesis O
and O
antitubercular O
activity O
of O
2 B
- I
( I
substituted I
phenyl I
/ I
benzyl I
- I
amino I
) I
- I
6 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
5 I
- I
( I
methoxycarbonyl I
) I
- I
4 I
- I
methyl I
- I
3 I
, I
6 I
- I
dihydropyrimidin I
- I
1 I
- I
ium I
chlorides I
. O

A O
series O
of O
2 B
- I
( I
substituted I
phenyl I
/ I
benzyl I
- I
amino I
) I
- I
6 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
5 I
- I
( I
methoxycarbonyl I
) I
- I
4 I
- I
methyl I
- I
3 I
, I
6 I
- I
dihydropyrimidin I
- I
1 I
- I
ium I
chlorides I
7 O
- O
13 O
and O
15 O
was O
synthesized O
in O
their O
hydrochloride B
salt O
form O
. O

This O
antioxidant O
regenerating O
system O
, O
continuously O
quenched O
in O
situ O
produced O
. B
NO I
, O
O B
( I
2 I
) I
( I
. I
- I
) I
and O
OH B
. I
radicals O
and O
the O
produced O
oxidized O
phenolic B
antioxidants O
were O
regenerated O
back O
to O
their O
original O
parent O
compounds O
by O
CDH O
using O
cellobiose B
as O
electron O
donor O
. O

Interestingly O
, O
this O
study O
also O
challenges O
the O
relevance O
of O
using O
total O
antioxidant O
capacities O
values O
of O
plant O
crude O
extracts O
obtained O
using O
biologically O
none O
relevant O
radical O
species O
like O
( O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
) O
) O
, O
Trolox B
Equivalent O
Antioxidant O
Capacity O
( O
TEAC O
) O
, O
etc O
. O
when O
applied O
as O
medicinal O
remedies O
. O

This O
is O
because O
methoxylated B
phenolic I
antioxidants O
like O
sinapic B
acid I
, O
ferulic B
acid I
; O
2 B
, I
6 I
- I
dimethoxyphenol I
readily O
donate O
their O
electrons O
to O
these O
radicals O
( O
DPPH B
, O
TEAC O
, O
etc O
. O
) O
, O
thereby O
greatly O
influencing O
the O
total O
antioxidant O
values O
although O
this O
study O
showed O
that O
they O
are O
not O
at O
all O
effective O
in O
quenching O
O B
( I
2 I
) I
( I
. I
- I
) I
radicals O
and O
again O
are O
not O
the O
most O
effective O
quenchers O
of O
NO B
and O
OH B
radicals O
as O
demonstrated O
during O
this O
study O
. O

Gamma B
- I
aminobutyric I
- I
acid I
- O
receptors O
and O
glutamtergic O
N B
- I
Methyl I
- I
D I
- I
aspartic I
- I
acid I
- O
receptors O
are O
most O
likely O
to O
be O
involved O
in O
this O
complex O
interplay O
, O
which O
may O
reflect O
a O
disturbed O
signal O
- O
to O
- O
noise O
ratio O
in O
schizophrenia O
patients O
. O

Emergence O
of O
superconductivity O
from O
the O
dynamically O
heterogeneous O
insulating O
state O
in O
La B
( I
2 I
- I
x I
) I
Sr I
( I
x I
) I
CuO4 I
. O

Here O
we O
use O
magnetoresistance O
to O
probe O
both O
the O
insulating O
state O
at O
very O
low O
temperatures O
and O
the O
presence O
of O
superconducting O
fluctuations O
in O
La B
( I
2 I
- I
x I
) I
Sr I
( I
x I
) I
CuO I
( I
4 I
) I
films O
, O
for O
doping O
levels O
that O
range O
from O
the O
insulator O
to O
the O
superconductor O
( O
x O
= O
0 O
. O
03 O
- O
0 O
. O
08 O
) O
. O

The O
results O
indicate O
that O
the O
preferential O
orientations O
of O
H B
( I
2 I
) I
in O
the O
defect O
- O
free O
( O
i O
. O
e O
. O
, O
no O
C B
vacancy O
) O
C B
( I
60 I
) I
TiH I
( I
2 I
) I
complex O
are O
along O
the O
x O
- O
and O
y O
- O
axes O
of O
C B
( I
60 I
) I
( O
with O
adsorption O
energies O
of O
- O
0 O
. O
23 O
and O
- O
0 O
. O
21 O
eV O
, O
respectively O
) O
, O
making O
these O
orientations O
the O
most O
suitable O
ones O
for O
hydrogen B
storage O
, O
in O
contrast O
to O
the O
results O
obtained O
for O
defect O
- O
containing O
fullerenes O
. O

The O
defect O
- O
containing O
( O
i O
. O
e O
. O
, O
containing O
a O
C B
vacancy O
) O
C B
( I
59 I
) I
TiH I
( I
2 I
) I
complex O
do O
not O
exhibit O
adsorption O
energies O
within O
the O
targeted O
energy O
range O
. O

Saturation O
binding O
assays O
showed O
that O
mFpr1 O
and O
mFpr2 O
were O
expressed O
at O
similar O
levels O
on O
the O
cell O
surface O
, O
although O
their O
affinity O
for O
N B
- I
formyl I
- I
Met I
- I
Leu I
- I
Phe I
- I
Ile I
- I
Ile I
- I
Lys I
- I
fluorescein I
isothiocyanate I
varied O
by O
more O
than O
1000 O
- O
fold O
[ O
dissociation O
constant O
( O
K O
( O
d O
) O
) O
values O
of O
2 O
. O
8 O
nM O
for O
mFpr1 O
and O
4 O
. O
8 O
mu O
M O
for O
mFpr2 O
] O
) O
. O

Interspecific O
effects O
of O
4A B
- I
DNT I
( O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
) O
and O
RDX B
( O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
) O
in O
Japanese O
quail O
, O
Northern O
bobwhite O
, O
and O
Zebra O
finch O
. O

Interspecific O
effects O
of O
4A B
- I
DNT I
( O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
) O
and O
RDX B
( O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
) O
in O
Japanese O
quail O
, O
Northern O
bobwhite O
, O
and O
Zebra O
finch O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
toxicological O
effects O
of O
two O
munition O
compounds O
, O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
( O
4A B
- I
DNT I
) O
and O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
( O
RDX B
) O
, O
on O
three O
different O
bird O
species O
: O
two O
common O
toxicological O
model O
species O
- O
the O
Northern O
Bobwhite O
( O
Colinus O
virginianus O
) O
and O
the O
Japanese O
Quail O
( O
Coturnix O
japonica O
) O
, O
and O
a O
representative O
passerine O
- O
the O
Zebra O
Finch O
( O
Taeniopygia O
guttata O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
toxicological O
effects O
of O
two O
munition O
compounds O
, O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
( O
4A B
- I
DNT I
) O
and O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
( O
RDX B
) O
, O
on O
three O
different O
bird O
species O
: O
two O
common O
toxicological O
model O
species O
- O
the O
Northern O
Bobwhite O
( O
Colinus O
virginianus O
) O
and O
the O
Japanese O
Quail O
( O
Coturnix O
japonica O
) O
, O
and O
a O
representative O
passerine O
- O
the O
Zebra O
Finch O
( O
Taeniopygia O
guttata O

Mutation O
of O
Ser B
- O
7 O
and O
nearby O
residues O
strongly O
reduced O
the O
affinity O
of O
rat O
DAT O
for O
the O
cocaine B
analog O
( B
- I
) I
- I
2 I
beta I
- I
carbomethoxy I
- I
3 I
beta I
- I
( I
4 I
- I
fluorophenyl I
) I
tropane I
( O
CFT B
) O
, O
whereas O
in O
rat O
striatal O
tissue O
, O
conditions O
that O
promote O
DAT O
phosphorylation O
caused O
increased O
CFT B
affinity O
. O

Concentrations O
of O
Sigma O
n B
- I
C I
( I
15 I
- I
35 I
) I
( O
n B
- I
alkanes I
with O
15 O
- O
35 O
carbon B
atoms O
) O
, O
Sigma O
LAB B
( O
sum O
of O
C B
( I
10 I
) I
to I
C I
( I
13 I
) I
LABs I
) O
, O
and O
Sigma O
( O
26 O
) O
PAH B
( O
sum O
of O
26 O
PAH B
compounds O
) O
ranged O
from O
110 O
to O
3 O
, O
160 O
, O
11 O
to O
160 O
, O
and O
26 O
to O
600 O
ng O
/ O
g O
, O
with O
medians O
of O
730 O
, O
40 O
, O
and O
230 O
ng O
/ O
g O
, O
respectively O
. O

Concentrations O
of O
Sigma O
n B
- I
C I
( I
15 I
- I
35 I
) I
( O
n B
- I
alkanes I
with O
15 O
- O
35 O
carbon B
atoms O
) O
, O
Sigma O
LAB B
( O
sum O
of O
C B
( I
10 I
) I
to I
C I
( I
13 I
) I
LABs I
) O
, O
and O
Sigma O
( O
26 O
) O
PAH B
( O
sum O
of O
26 O
PAH B
compounds O
) O
ranged O
from O
110 O
to O
3 O
, O
160 O
, O
11 O
to O
160 O
, O
and O
26 O
to O
600 O
ng O
/ O
g O
, O
with O
medians O
of O
730 O
, O
40 O
, O
and O
230 O
ng O
/ O
g O
, O
respectively O
. O

A O
new O
ganoderic B
acid I
( O
GA O
) O
, O
3 B
alpha I
, I
22 I
beta I
- I
diacetoxy I
- I
7 I
alpha I
- I
hydroxyl I
- I
5 I
alpha I
- I
lanost I
- I
8 I
, I
24E I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
together O
with O
four O
known O
compounds O
GA B
- I
Mk I
( O
2 O
) O
, O
- O
Mc O
( O
3 O
) O
, O
- O
S O
( O
4 O
) O
and O
- O
Mf O
( O
5 O
) O
, O
was O
isolated O
and O
characterized O
from O
Ganoderma O
lucidum O
mycelia O
. O

Pretreatment O
of O
the O
resistant O
cells O
with O
a O
potent O
proteasome O
inhibitor O
Z B
- I
Leu I
- I
Leu I
- I
Leu I
- I
al I
augmented O
the O
CDDP B
sensitization O
elicited O
by O
the O
AKR O
inhibitors O
. O

Additionally O
, O
the O
treatment O
of O
the O
cells O
with O
Z B
- I
Leu I
- I
Leu I
- I
Leu I
- I
al I
and O
the O
AKR O
inhibitors O
induced O
the O
expressions O
of O
the O
two O
AKRs O
and O
proteasome O
subunits O
. O

The O
local O
structure O
and O
dynamic O
behaviour O
of O
a O
benzene B
molecular O
assembly O
confined O
within O
the O
nano O
- O
cavities O
of O
a O
zinc B
- O
based O
metal O
- O
organic O
framework O
, O
[ B
Zn I
( I
4 I
) I
O I
( I
CO I
( I
2 I
) I
C I
( I
6 I
) I
H I
( I
4 I
) I
CO I
( I
2 I
) I
) I
( I
3 I
) I
] I
( I
n I
) I
( O
IRMOF B
- I
1 I
) O
, O
were O
investigated O
by O
means O
of O
molecular O
dynamics O
( O
MD O
) O
simulations O
. O

We O
studied O
the O
reaction O
of O
phenyl B
radicals O
( O
C B
( I
6 I
) I
H I
( I
5 I
) I
) O
with O
1 B
, I
3 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCHCHCH I
( I
2 I
) I
) O
exploiting O
a O
high O
temperature O
chemical O
reactor O
under O
combustion O
- O
like O
conditions O
( O
300 O
Torr O
, O
873 O
K O
) O
. O

We O
studied O
the O
reaction O
of O
phenyl B
radicals O
( O
C B
( I
6 I
) I
H I
( I
5 I
) I
) O
with O
1 B
, I
3 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCHCHCH I
( I
2 I
) I
) O
exploiting O
a O
high O
temperature O
chemical O
reactor O
under O
combustion O
- O
like O
conditions O
( O
300 O
Torr O
, O
873 O
K O
) O
. O

The O
reaction O
products O
were O
probed O
in O
a O
supersonic O
beam O
by O
utilizing O
VUV O
radiation O
from O
the O
Advanced O
Light O
Source O
and O
by O
recording O
the O
experimental O
PIE O
curves O
at O
mass O
- O
to O
- O
charge O
ratios O
of O
m O
/ O
z O
= O
130 O
( O
C B
( I
10 I
) I
H I
( I
10 I
) I
( I
+ I
) I
) O
, O
116 O
( O
C B
( I
9 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
, O
and O
104 O
( O
C B
( I
8 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
. O

The O
reaction O
products O
were O
probed O
in O
a O
supersonic O
beam O
by O
utilizing O
VUV O
radiation O
from O
the O
Advanced O
Light O
Source O
and O
by O
recording O
the O
experimental O
PIE O
curves O
at O
mass O
- O
to O
- O
charge O
ratios O
of O
m O
/ O
z O
= O
130 O
( O
C B
( I
10 I
) I
H I
( I
10 I
) I
( I
+ I
) I
) O
, O
116 O
( O
C B
( I
9 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
, O
and O
104 O
( O
C B
( I
8 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
. O

The O
reaction O
products O
were O
probed O
in O
a O
supersonic O
beam O
by O
utilizing O
VUV O
radiation O
from O
the O
Advanced O
Light O
Source O
and O
by O
recording O
the O
experimental O
PIE O
curves O
at O
mass O
- O
to O
- O
charge O
ratios O
of O
m O
/ O
z O
= O
130 O
( O
C B
( I
10 I
) I
H I
( I
10 I
) I
( I
+ I
) I
) O
, O
116 O
( O
C B
( I
9 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
, O
and O
104 O
( O
C B
( I
8 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
. O

Our O
data O
suggest O
that O
the O
atomic O
hydrogen B
( O
H B
) O
, O
methyl B
( O
CH B
( I
3 I
) I
) O
, O
and O
vinyl B
( O
C B
( I
2 I
) I
H I
( I
3 I
) I
) O
losses O
are O
open O
with O
estimated O
branching O
ratios O
of O
about O
86 O
+ O
/ O
- O
4 O
% O
, O
8 O
+ O
/ O
- O
2 O
% O
, O
and O
6 O
+ O
/ O
- O
2 O
% O
, O
respectively O
. O

The O
isomer O
distributions O
were O
probed O
further O
by O
fitting O
the O
experimentally O
recorded O
PIE O
curves O
with O
a O
linear O
combination O
of O
the O
PIE O
curves O
of O
individual O
C B
( I
10 I
) I
H I
( I
10 I
) I
, O
C B
( I
9 I
) I
H I
( I
8 I
) I
, O
and O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomers O
. O

The O
isomer O
distributions O
were O
probed O
further O
by O
fitting O
the O
experimentally O
recorded O
PIE O
curves O
with O
a O
linear O
combination O
of O
the O
PIE O
curves O
of O
individual O
C B
( I
10 I
) I
H I
( I
10 I
) I
, O
C B
( I
9 I
) I
H I
( I
8 I
) I
, O
and O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomers O
. O

The O
isomer O
distributions O
were O
probed O
further O
by O
fitting O
the O
experimentally O
recorded O
PIE O
curves O
with O
a O
linear O
combination O
of O
the O
PIE O
curves O
of O
individual O
C B
( I
10 I
) I
H I
( I
10 I
) I
, O
C B
( I
9 I
) I
H I
( I
8 I
) I
, O
and O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomers O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene B
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene B
) O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene B
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene B
) O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene B
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene B
) O
. O

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

3 I
) I
) O
; O
these O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
can O
be O
formed O
from O
1 B
, I
3 I
- I
butadiene I
via O
hydrogen B
atom O
assisted O
isomerization O
reactions O
or O
via O
thermal O
rearrangements O
of O
1 B
, I
3 I
- I
butadiene I
involving O
hydrogen B
shifts O
in O
the O
high O
temperature O
chemical O
reactor O
. O

In O
contrast O
, O
7 B
- I
hydroxy I
and I
8 I
, I
14 I
- I
hydroxy I
EFV I
were O
only O
detected O
in O
blood O
plasma O
and O
seminal O
plasma O
with O
median O
concentrations O
of O
8 O
. O
84 O
ng O
/ O
ml O
and O
10 O
. O
23 O
ng O
/ O
ml O
, O
and O
5 O
. O
63 O
ng O
/ O
ml O
and O
5 O
. O
43 O
ng O
/ O
ml O
, O
respectively O
. O

New O
calculations O
on O
tert B
- I
butylethane I
- I
1 I
, I
2 I
- I
diol I
, O
phenylethane B
- I
1 I
, I
2 I
- I
diol I
, O
butane B
- I
2 I
, I
3 I
- I
diols I
( O
dl O
and O
meso O
) O
and O
cyclohexane B
- I
1 I
, I
2 I
- I
diols I
( O
cis O
and O
trans O
) O
are O
presented O
. O

One O
process O
yields O
a O
mixture O
of O
tautomers O
, O
i O
. O
e O
. O
, O
cyclopentenyl B
- I
and I
cyclopentadienyl I
- I
acyl I
- I
CoAs I
. O

Discovery O
of O
a O
selective O
M O
4 O
positive O
allosteric O
modulator O
based O
on O
the O
3 B
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
- I
2 I
- I
carboxamide I
scaffold O
: O
development O
of O
ML253 B
, O
a O
potent O
and O
brain O
penetrant O
compound O
that O
is O
active O
in O
a O
preclinical O
model O
of O
schizophrenia O
. O

Boldine B
( O
[ B
s I
] I
- I
2 I
, I
9 I
- I
dihydroxy I
- I
1 I
, I
10 I
- I
dimethoxyaporphine I
) O
is O
a O
major O
alkaloid O
present O
in O
the O
leaves O
and O
bark O
of O
the O
boldo O
tree O
( O
Peumus O
boldus O
Molina O
) O
, O
with O
known O
an O
antioxidant O
activity O
. O

Two O
new O
C B
- I
benzylated I
dihydrochalcone I
derivatives O
, O
4 B
, I
2 I
' I
, I
4 I
' I
- I
trihydroxy I
- I
6 I
' I
- I
methoxy I
- I
3 I
' I
( I
2 I
' I
' I
- I
hydroxybenzyl I
) I
dihydrochalcone I
( O
1 O
) O
and O
2 B
' I
, I
4 I
' I
- I
dihydroxy I
- I
4 I
, I
6 I
' I
- I
dimethoxy I
- I
3 I
' I
( I
2 I
' I
' I
- I
hydroxybenzyl I
) I
dihydrochalcone I
( O
2 O
) O
, O
along O
with O
six O
known O
flavonoid B
derivatives O
( O
3 O
- O
8 O
) O
, O
a O

Two O
new O
C B
- I
benzylated I
dihydrochalcone I
derivatives O
, O
4 B
, I
2 I
' I
, I
4 I
' I
- I
trihydroxy I
- I
6 I
' I
- I
methoxy I
- I
3 I
' I
( I
2 I
' I
' I
- I
hydroxybenzyl I
) I
dihydrochalcone I
( O
1 O
) O
and O
2 B
' I
, I
4 I
' I
- I
dihydroxy I
- I
4 I
, I
6 I
' I
- I
dimethoxy I
- I
3 I
' I
( I
2 I
' I
' I
- I
hydroxybenzyl I
) I
dihydrochalcone I
( O
2 O
) O
, O
along O
with O
six O
known O
flavonoid B
derivatives O
( O
3 O
- O
8 O
) O
, O
a O

Enantioseparation O
of O
four O
organophosphonate B
derivatives O
on O
N B
- I
( I
3 I
, I
5 I
- I
dinitrobenzoyl I
) I
- I
L I
- I
leucine I
- I
n I
- I
propylamide I
stationary O
phase O
by O
molecular O
modeling O
. O

Four O
groups O
of O
organophosphonate B
derivatives O
enantiomers O
were O
separated O
on O
N B
- I
( I
3 I
, I
5 I
- I
dinitrobenzoyl I
) I
- I
S I
- I
leucine I
chiral O
stationary O
phase O
. O

Stochastic O
and O
potentiometric O
microsensors O
based O
on O
porphyrins B
and O
polymeric O
surfactants O
such O
as O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
leucylvanilate I
and O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
vanilate I
were O
developed O
for O
enantioselective O
assay O
of O
pipecolic B
acid I
. O

Stochastic O
and O
potentiometric O
microsensors O
based O
on O
porphyrins B
and O
polymeric O
surfactants O
such O
as O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
leucylvanilate I
and O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
vanilate I
were O
developed O
for O
enantioselective O
assay O
of O
pipecolic B
acid I
. O

By O
employing O
chiral O
high O
- O
performance O
liquid O
chromatography O
, O
it O
was O
possible O
to O
follow O
the O
time O
- O
dependent O
concentrations O
of O
all O
four O
isomeric O
esters B
( O
two O
regioisomeric O
pairs O
of O
enantiomers O
) O
and O
all O
four O
isomeric O
alcohols B
generated O
during O
the O
hydrolysis O
of O
enantiopure O
1 B
- I
( I
4 I
- I
chlorophenyl I
) I
- I
3 I
- I
phenylallyl I
and I
3 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
1 I
- I
phenylallyl I
4 I
- I
nitrobenzoates I
. O

Combination O
of O
these O
results O
with O
the O
directly O
measured O
rate O
constant O
for O
the O
reaction O
of O
the O
laser O
- O
flash O
photolytically O
generated O
1 B
- I
( I
4 I
- I
chlorophenyl I
) I
- I
3 I
- I
phenylallyl I
cation O
with O
water O
provided O
a O
complete O
mechanistic O
scheme O
for O
allyl B
carboxylate I
solvolysis O
. O

Experimental O
results O
showed O
that O
the O
optimum O
conditions O
for O
decolourization O
were O
pH O
3 O
. O
0 O
, O
Fe B
( I
0 I
) I
1g O
/ O
L O
, O
H B
( I
2 I
) I
O I
( I
2 I
) I
5 O
. O
15 O
x O
10 O
( O
- O
3 O
) O
mol O
/ O
L O
with O
ultrasound O
density O
of O
120W O
/ O
L O
at O
60kHz O
. O

Although O
the O
solutions O
containing O
H B
( I
2 I
) I
CO I
( I
3 I
) I
, O
Cl B
( I
- I
) I
, O
ClO B
( I
4 I
) I
( I
- I
) I
, O
NO B
( I
3 I
) I
( I
- I
) I
and O
SO B
( I
4 I
) I
( I
2 I
- I
) I
ions O
did O
not O
have O
a O
significant O
effect O
on O
the O
decolouration O
, O
the O
H B
( I
2 I
) I
PO I
( I
4 I
) I
( I
- I
) I
ion O
did O
decrease O
the O
decolouration O
rate O
. O

Although O
the O
solutions O
containing O
H B
( I
2 I
) I
CO I
( I
3 I
) I
, O
Cl B
( I
- I
) I
, O
ClO B
( I
4 I
) I
( I
- I
) I
, O
NO B
( I
3 I
) I
( I
- I
) I
and O
SO B
( I
4 I
) I
( I
2 I
- I
) I
ions O
did O
not O
have O
a O
significant O
effect O
on O
the O
decolouration O
, O
the O
H B
( I
2 I
) I
PO I
( I
4 I
) I
( I
- I
) I
ion O
did O
decrease O
the O
decolouration O
rate O
. O

Although O
the O
solutions O
containing O
H B
( I
2 I
) I
CO I
( I
3 I
) I
, O
Cl B
( I
- I
) I
, O
ClO B
( I
4 I
) I
( I
- I
) I
, O
NO B
( I
3 I
) I
( I
- I
) I
and O
SO B
( I
4 I
) I
( I
2 I
- I
) I
ions O
did O
not O
have O
a O
significant O
effect O
on O
the O
decolouration O
, O
the O
H B
( I
2 I
) I
PO I
( I
4 I
) I
( I
- I
) I
ion O
did O
decrease O
the O
decolouration O
rate O
. O

N B
, I
N I
- I
dihydroxypyromelliti I
( O
NDHPI B
) O
and O
N B
, I
N I
' I
, I
N I
' I
' I
- I
trihydroxyisocyanuri I
acid I
( O
THICA B
) O
have O
been O
recently O
demonstrated O
to O
act O
as O
better O
carbon B
- O
radical O
- O
producing O
catalysts O
than O
the O
popular O
N B
- I
hydroxyphthalimide I
( O
NHPI B
) O
. O

1 B
, I
3 I
, I
6 I
, I
6 I
' I
- I
tetra I
- I
feruloyl I
sucrose I
named O
taroside O
was O
a O
new O
phenlypropanoid B
glycoside I
, O
together O
with O
3 B
, I
6 I
- I
di I
- I
p I
- I
coumaroyl I
- I
1 I
, I
6 I
' I
- I
di I
- I
feruloyl I
sucrose I
, O
1 B
, I
6 I
, I
6 I
' I
- I
tri I
- I
feruloyl I
- I
3 I
- I
p I
- I
coumaroyl I
sucrose I
, O
N B
- I
trans I
- I
feruloyltyramine I
and O
quercetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
D I
- I
xyloxyl I
- I

1 B
, I
3 I
, I
6 I
, I
6 I
' I
- I
tetra I
- I
feruloyl I
sucrose I
named O
taroside O
was O
a O
new O
phenlypropanoid B
glycoside I
, O
together O
with O
3 B
, I
6 I
- I
di I
- I
p I
- I
coumaroyl I
- I
1 I
, I
6 I
' I
- I
di I
- I
feruloyl I
sucrose I
, O
1 B
, I
6 I
, I
6 I
' I
- I
tri I
- I
feruloyl I
- I
3 I
- I
p I
- I
coumaroyl I
sucrose I
, O
N B
- I
trans I
- I
feruloyltyramine I
and O
quercetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
D I
- I
xyloxyl I
- I

1 B
, I
3 I
, I
6 I
, I
6 I
' I
- I
tetra I
- I
feruloyl I
sucrose I
named O
taroside O
was O
a O
new O
phenlypropanoid B
glycoside I
, O
together O
with O
3 B
, I
6 I
- I
di I
- I
p I
- I
coumaroyl I
- I
1 I
, I
6 I
' I
- I
di I
- I
feruloyl I
sucrose I
, O
1 B
, I
6 I
, I
6 I
' I
- I
tri I
- I
feruloyl I
- I
3 I
- I
p I
- I
coumaroyl I
sucrose I
, O
N B
- I
trans I
- I
feruloyltyramine I
and O
quercetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
D I
- I
xyloxyl I
- I

Identification O
and O
thermal O
stability O
of O
purple O
- O
fleshed O
sweet O
potato O
anthocyanins B
in O
aqueous O
solutions O
with O
various O
pH O
values O
and O
fruit O
juices O
. O

Structure O
- O
effect O
analyses O
of O
various O
phenolic B
and O
bisphenolic B
compounds O
revealed O
that O
1 O
) O
a O
double O
- O
alkylated O
( O
R B
- I
C I
( I
CH I
( I
3 I
) I
) I
( I
2 I
) I
- I
R I
, O
R B
- I
C I
( I
CH I
( I
3 I
) I
) I
( I
CH I
( I
2 I
) I
CH I
( I
3 I
) I
) I
- I
R I
) O
, O
or O
double O
- O
trifluoromethylated O
sp O
( O
3 O
) O
- O
hybridized O
carbon B
atom O
between O
the O
two O
aromatic O
rings O
and O
2 O
) O
the O
two O
aromatic O
moieties O
in O
angulated O
orientation O
are O
optimal O
for O
BPA B
' O
s O
effectiveness O
. O

Structure O
- O
effect O
analyses O
of O
various O
phenolic B
and O
bisphenolic B
compounds O
revealed O
that O
1 O
) O
a O
double O
- O
alkylated O
( O
R B
- I
C I
( I
CH I
( I
3 I
) I
) I
( I
2 I
) I
- I
R I
, O
R B
- I
C I
( I
CH I
( I
3 I
) I
) I
( I
CH I
( I
2 I
) I
CH I
( I
3 I
) I
) I
- I
R I
) O
, O
or O
double O
- O
trifluoromethylated O
sp O
( O
3 O
) O
- O
hybridized O
carbon B
atom O
between O
the O
two O
aromatic O
rings O
and O
2 O
) O
the O
two O
aromatic O
moieties O
in O
angulated O
orientation O
are O
optimal O
for O
BPA B
' O
s O
effectiveness O
. O

In O
this O
study O
, O
the O
analyzed O
product O
was O
bought O
online O
and O
a O
new O
anabolic O
steroid B
known O
as O
methylstenbolone B
( O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
17 I
beta I
- I
hydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
en I
- I
3 I
- I
one I
) O
was O
detected O
, O
as O
described O
on O
label O
. O

Mass O
spectrometric O
data O
allowed O
the O
proposal O
of O
two O
plausible O
metabolites O
: O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
16 I
xi I
, I
17 I
beta I
- I
dihydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
en I
- I
3 I
- I
one I
( O
S1 O
) O
, O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
3 I
alpha I
, I
16 I
xi I
, I
17 I
beta I
- I
trihydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
ene I
( O
S2 O
) O
. O

Mass O
spectrometric O
data O
allowed O
the O
proposal O
of O
two O
plausible O
metabolites O
: O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
16 I
xi I
, I
17 I
beta I
- I
dihydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
en I
- I
3 I
- I
one I
( O
S1 O
) O
, O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
3 I
alpha I
, I
16 I
xi I
, I
17 I
beta I
- I
trihydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
ene I
( O
S2 O
) O
. O

The O
definite O
heterojunction O
interface O
between O
SnS B
( I
2 I
) I
nanosheets O
and O
TiO B
( I
2 I
) I
( I
A I
or I
R I
) I
nanoparticles O
were O
investigated O
by O
high O
resolution O
transmission O
electron O
microscopy O
( O
HRTEM O
) O
and O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
. O

) I
( I
A I
) I
and O
TiO B
( I
2 I
) I
( I
R I
) I
component O
in O
the O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
AR I
) I
heterojunction O
resulting O
in O
the O
high O
separation O
efficiency O
of O
photoinduced O
electron O
- O
hole O
pairs O
, O
as O
evidenced O
by O
photoluminescence O
( O
PL O
) O
and O
surface O
photovoltage O
spectra O
( O
SPS O
) O
. O

3 O
. O
Two O
oxidative O
metabolites O
of O
GA O
( O
15 O
: O
1 O
, O
M0 O
) O
were O
identified O
as O
2 B
- I
hydroxy I
- I
6 I
- I
( I
pentadec I
- I
8 I
- I
enyl I
- I
10 I
- I
hydroxy I
) I
benzoic I
acid I
( O
M1 O
) O
and O
2 B
- I
hydroxy I
- I
6 I
- I
( I
pentadec I
- I
8 I
- I
enyl I
- I
11 I
- I
hydroxy I
- I
13 I
- I
carbonyl I
) I
benzoic I
acid I
( O
M2 O
) O
, O
respectively O
. O

3 O
. O
Two O
oxidative O
metabolites O
of O
GA O
( O
15 O
: O
1 O
, O
M0 O
) O
were O
identified O
as O
2 B
- I
hydroxy I
- I
6 I
- I
( I
pentadec I
- I
8 I
- I
enyl I
- I
10 I
- I
hydroxy I
) I
benzoic I
acid I
( O
M1 O
) O
and O
2 B
- I
hydroxy I
- I
6 I
- I
( I
pentadec I
- I
8 I
- I
enyl I
- I
11 I
- I
hydroxy I
- I
13 I
- I
carbonyl I
) I
benzoic I
acid I
( O
M2 O
) O
, O
respectively O
. O

The O
cytotoxic O
activity O
of O
these O
phenylpropanoids B
against O
HeLa O
cells O
is O
in O
the O
order O
of O
eugenol B
> O
ferulic B
> O
cinnamic B
> O
caffeic B
> O
chlorogenic B
> O
p B
- I
coumaric I
> O
3 B
, I
4 I
- I
dimethoxycinnamic I
> O
2 B
, I
4 I
, I
5 I
- I
trimethoxycinnamic I
acids I
. O

For O
this O
purpose O
, O
the O
combined O
effect O
of O
23 B
- I
methyl I
- I
6 I
- I
O I
- I
desmethylauricepyron I
( O
1 O
) O
, O
quercetin B
( O
2 O
) O
and O
3 B
- I
O I
- I
methylquercetin I
( O
3 O
) O
, O
obtained O
through O
bioguided O
fractionation O
from O
A O
. O
satureioides O
ethanol B
extract O
, O
was O
evaluated O
against O
Staphylococcus O
aureus O
and O
Escherichia O
coli O
. O

Bifunctional O
CA O
- O
PEG B
( O
catechol B
- O
poly B
( I
ethylene I
glycol I
) I
) O
and O
multifunctional O
CA O
- O
PEG B
- O
PGA B
/ O
PEVGE B
( O
poly B
( I
glycidyl I
amine I
) I
/ O
poly B
( I
ethylene I
glycol I
vinyl I
glycidyl I
ether I
) I
) O
ligands O
for O
the O
functionalization O
and O
solubilization O
of O
nanoparticles O
are O
introduced O
. O

The O
functional O
PEG B
ligands O
were O
synthesized O
starting O
from O
the O
acetonide B
- O
protected O
catechol B
initiator O
2 B
, I
2 I
- I
dimethyl I
- I
1 I
, I
3 I
- I
benzodioxole I
- I
5 I
- I
propanol I
( O
CA O
- O
OH B
) O
for O
oxyanionic O
polymerization O
. O

The O
concentration O
- O
response O
was O
markedly O
decreased O
in O
the O
presence O
of O
excess O
GSH B
; O
the O
nitric B
oxide I
scavenger O
2 B
- I
( I
4 I
- I
carboxyphenyl I
) I
- I
4 I
, I
4 I
, I
5 I
, I
5 I
- I
tetramethylimidazoli I
- I
1 I
- I
oxyl I
- I
3 I
- I
oxide I
had O
no O
effect O
. O

NCA B
significantly O
reduced O
contractile O
response O
and O
platelet O
aggregation O
mediated O
by O
the O
thromboxane B
A I
( I
2 I
) I
mimetic O
9 B
, I
11 I
- I
dideoxy I
- I
11 I
alpha I
, I
9 I
alpha I
- I
epoxymethanoprostagl I
F I
( I
2 I
) I
( I
alpha I
) I
in O
a O
cGMP B
- O
dependent O
manner O
. O

In O
addition O
, O
rifampin B
pretreatment O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
formation O
of O
the O
major O
metabolite O
of O
25OHD3 B
, O
4 B
beta I
, I
25 I
( I
OH I
) I
2 I
D3 I
. O

24R B
, I
25 I
( I
OH I
) I
2 I
D3 I
was O
the O
predominant O
monohydroxy B
metabolite O
produced O
from O
25OHD3 B
, O
but O
its O
formation O
was O
unaffected O
by O
the O
inducers O
. O

With O
healthy O
volunteers O
, O
the O
mean O
plasma O
concentration O
of O
4 B
beta I
, I
25 I
( I
OH I
) I
2 I
D3 I
was O
increased O
60 O
% O
( O
p O
< O
0 O
. O
01 O
) O
after O
short O
- O
term O
rifampin B
administration O
. O

This O
was O
accompanied O
by O
a O
statistically O
significant O
reduction O
in O
plasma O
1 B
alpha I
, I
25 I
( I
OH I
) I
2 I
D3 I
( O
- O
10 O
% O
; O
p O
= O
0 O
. O
03 O
) O
, O
and O
a O
nonsignificant O
change O
in O
24R B
, I
25 I
( I
OH I
) I
2 I
D3 I
( O
- O
8 O
% O
; O
p O
= O
0 O
. O
09 O
) O
levels O
. O

This O
was O
accompanied O
by O
a O
statistically O
significant O
reduction O
in O
plasma O
1 B
alpha I
, I
25 I
( I
OH I
) I
2 I
D3 I
( O
- O
10 O
% O
; O
p O
= O
0 O
. O
03 O
) O
, O
and O
a O
nonsignificant O
change O
in O
24R B
, I
25 I
( I
OH I
) I
2 I
D3 I
( O
- O
8 O
% O
; O
p O
= O
0 O
. O
09 O
) O
levels O
. O

Further O
analysis O
revealed O
a O
negative O
correlation O
between O
the O
increase O
in O
4 B
beta I
, I
25 I
( I
OH I
) I
2 I
D3 I
and O
decrease O
in O
1 B
alpha I
, I
25 I
( I
OH I
) I
2 I
D3 I
levels O
. O

Further O
analysis O
revealed O
a O
negative O
correlation O
between O
the O
increase O
in O
4 B
beta I
, I
25 I
( I
OH I
) I
2 I
D3 I
and O
decrease O
in O
1 B
alpha I
, I
25 I
( I
OH I
) I
2 I
D3 I
levels O
. O

Radiosynthesis O
and O
evaluation O
of O
[ O
( B
1 I
) I
( I
1 I
) I
C I
- I
carbonyl I
] O
- O
labeled O
carbamates B
as O
fatty B
acid I
amide B
hydrolase O
radiotracers O
for O
positron O
emission O
tomography O
. O

The O
[ O
( B
1 I
) I
( I
1 I
) I
C I
- I
carbonyl I
] O
- O
radiotracers O
were O
evaluated O
in O
vitro O
and O
ex O
vivo O
in O
rats O
as O
potential O
FAAH O
imaging O
agents O
for O
positron O
emission O
tomography O
( O
PET O
) O
. O

Both O
sets O
of O
[ B
( I
1 I
) I
( I
1 I
) I
C I
] I
O I
- I
arylcarbamates I
showed O
good O
to O
excellent O
brain O
penetration O
and O
an O
appropriate O
regional O
distribution O
. O

We O
explore O
the O
interactions O
between O
a O
fluorescein B
( O
FAM B
) O
- O
labeled O
single O
- O
stranded O
DNA O
( O
P O
) O
, O
graphene B
oxide I
( O
GO O
) O
, O
and O
a O
cationic O
conjugated O
polymer O
, O
poly B
[ I
( I
9 I
, I
9 I
- I
bis I
( I
6 I
' I
- I
N I
, I
N I
, I
N I
- I
trimethylammonium I
) I
hexyl I
) I
- I
fluorenylene I
phenylene I
dibromide I
] I
( O
PFP B
) O
. O

Alpha O
- O
heteroatom O
derivatized O
analogues O
of O
3 B
- I
( I
acetylhydroxyamino I
) I
propyl I
phosphonic I
acid I
( O
FR900098 B
) O
as O
antimalarials O
. O

Native O
cellulose O
nanofibrils O
, O
purified O
from O
wood O
and O
sea O
tunicate O
, O
were O
fully O
dispersed O
in O
water O
via O
a O
topochemical O
modification O
of O
cellulose O
nanofibrils O
using O
2 B
, I
2 I
, I
6 I
, I
6 I
- I
tetramethylpiperidin I
- I
1 I
- I
oxyl I
( O
TEMPO B
) O
as O
a O
catalyst O
. O

Both O
o B
- I
nitrophenyl I
- I
beta I
- I
D I
- I
galactoside I
( O
ONPG B
) O
uptake O
and O
release O
of O
UV O
- O
absorbing O
material O
concentrations O
results O
exhibited O
that O
ceftazidime B
and O
apigenin B
combination O
damaged O
CREC O
cytoplasmic O
membrane O
( O
CM O
) O
and O
caused O
subsequent O
leakage O
of O
intracellular O
constituents O
. O

Fragment O
- O
based O
discovery O
of O
novel O
and O
selective O
mPGES O
- O
1 O
inhibitors O
Part O
1 O
: O
identification O
of O
sulfonamido B
- I
1 I
, I
2 I
, I
3 I
- I
triazole I
- I
4 I
, I
5 I
- I
dicarboxylic I
acid I
. O

Herein O
we O
report O
the O
discovery O
of O
sulfonamido B
- I
1 I
, I
2 I
, I
3 I
- I
triazole I
- I
4 I
, I
5 I
- I
dicarboxylic I
derivatives O
as O
a O
novel O
class O
of O
mPGES O
- O
1 O
inhibitors O
identified O
through O
fragment O
- O
based O
virtual O
screening O
and O
in O
vitro O
assays O
on O
the O
inhibitory O
activity O
of O
the O
actual O
compounds O
. O

1 B
- I
[ I
2 I
- I
( I
N I
- I
Phenylbenzenesulfona I
) I
ethyl I
] I
- I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazole I
- I
4 I
, I
5 I
- I
dicarboxylic I
acid I
( O
6f O
) O
inhibits O
human O
mPGES O
- O
1 O
( O
IC O
( O
50 O
) O
of O
1 O
. O
1 O
mu O
M O
) O
with O
high O
selectivity O
( O
ca O
. O
1000 O
- O
fold O
) O
over O
both O
COX O
- O
1 O
and O
COX O
- O
2 O
in O
a O
cell O
- O
free O
assay O
. O

Mutant O
receptors O
were O
then O
alkylated O
with O
methanethiosulfonate B
- I
ethylammonium I
( O
MTSEA B
) O
, O
and O
binding O
inhibition O
was O
monitored O
using O
the O
CXCR4 O
antagonist O
FC131 B
[ O
cyclo B
( I
- I
D I
- I
Tyr I
( I
1 I
) I
- I
Arg I
( I
2 I
) I
- I
Arg I
( I
3 I
) I
- I
Nal I
( I
4 I
) I
- I
Gly I
( I
5 I
) I
- I
) I
] O
, O
which O
displays O
anti O
- O
HIV O
activity O
. O

Micelles O
of O
zinc B
protoporphyrin I
conjugated O
to O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
for O
imaging O
and O
light O
- O
induced O
antitumor O
effects O
in O
vivo O
. O

We O
synthesized O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
polymer O
conjugated O
with O
zinc B
protoporphyrin I
( O
HPMA B
- O
ZnPP B
) O
and O
evaluated O
its O
application O
for O
tumor O
detection O
by O
imaging O
and O
treatment O
by O
light O
exposure O
using O
in O
mouse O
sarcoma O
model O
. O

This O
first O
in O
vivo O
study O
toward O
the O
biocompatibility O
of O
hexPLA B
implants O
in O
rats O
over O
3 O
months O
in O
comparison O
to O
in O
situ O
forming O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
formulations O
is O
presented O
here O
. O

The O
formation O
of O
Co B
( I
3 I
) I
O I
( I
4 I
) I
nano O
- O
scale O
colloid O
particles O
by O
gamma O
irradiation O
of O
CoSO B
( I
4 I
) I
solutions O
was O
investigated O
. O

The O
resulting O
concentrations O
of O
H B
( I
2 I
) I
, O
H B
( I
2 I
) I
O I
( I
2 I
) I
, O
Co B
( I
II I
) I
and O
Co B
( I
III I
) I
species O
in O
solution O
and O
the O
chemical O
composition O
and O
sizes O
of O
particles O
that O
were O
formed O
were O
measured O
as O
a O
function O
of O
irradiation O
time O
. O

Analysis O
of O
the O
particle O
formation O
as O
a O
function O
of O
irradiation O
time O
shows O
that O
the O
particles O
evolve O
from O
Co B
( I
OH I
) I
( I
2 I
) I
to O
CoOOH B
and O
then O
to O
Co B
( I
3 I
) I
O I
( I
4 I
) I
. O

The O
radiolytic O
oxidation O
of O
Co B
( I
II I
) I
to O
Co B
( I
III I
) I
was O
completed O
in O
100 O
min O
and O
the O
chemical O
composition O
of O
the O
final O
particles O
was O
identified O
as O
Co B
( I
3 I
) I
O I
( I
4 I
) I
by O
XPS O
, O
Raman O
and O
UV O
- O
Vis O
spectroscopy O
. O

We O
identified O
upregulation O
of O
UGT1A9 O
, O
2B10 O
, O
and O
3A1 O
and O
SULT1C4 O
mRNA O
in O
both O
stages O
of O
NASH O
, O
whereas O
UGT2A3 O
, O
2B15 O
, O
and O
2B28 O
and O
SULT1A1 O
, O
2B1 O
, O
and O
4A1 O
as O
well O
as O
3 B
' I
- I
phosphoadenosine I
- I
5 I
' I
- I
phosphosulfate I
synthase O
1 O
were O
increased O
in O
NASH O
( O
not O
fatty O
/ O
cirrhosis O
) O
only O
. O

The O
elongated O
structures O
of O
polyamine B
inverse O
agonists O
such O
as O
1 B
, I
12 I
- I
diaminododecane I
( O
N12N B
) O
and O
5 B
- I
( I
4 I
- I
aminobutyl I
) I
- I
2 I
- I
thiopheneoctanamine I
( O
N4T8N B
) O
lend O
themselves O
to O
a O
combinatorial O
chemistry O
approach O
to O
explore O
a O
potential O
polyamine B
pharmacophore O
at O
the O
NMDA B
receptor O
. O

The O
obtained O
compounds O
were O
tested O
as O
modulators O
of O
[ B
( I
3 I
) I
H I
] I
MK I
- I
801 I
binding O
to O
rat O
brain O
membranes O
and O
of O
NMDA B
- O
induced O
currents O
in O
cultured O
rat O
hippocampal O
neurons O
. O

Incubation O
of O
asiatic B
acid I
with O
P O
. O
lilacinum O
ACCC O
31890 O
and O
F O
. O
equiseti O
CGMCC O
3 O
. O
3658 O
gave O
an O
identical O
product O
: O
2 B
alpha I
, I
3 I
beta I
, I
15 I
alpha I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
2 O
) O
. O

Biotransformation O
of O
asiatic B
acid I
by O
S O
. O
griseus O
CGMCC O
4 O
. O
18 O
resulted O
in O
three O
derivatives O
: O
2 B
alpha I
, I
3 I
beta I
, I
21 I
beta I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
, O
2 B
alpha I
, I
3 I
beta I
, I
23 I
- I
trihydroxyurs I
- I
12 I
- I
en I
- I
28 I
, I
30 I
- I
dioic I
acid I
( O
4 O
) O
, O
and O
2 B
alpha I
, I
3 I
beta I
, I
23 I
, I
30 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
. O

Biotransformation O
of O
asiatic B
acid I
by O
S O
. O
griseus O
CGMCC O
4 O
. O
18 O
resulted O
in O
three O
derivatives O
: O
2 B
alpha I
, I
3 I
beta I
, I
21 I
beta I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
, O
2 B
alpha I
, I
3 I
beta I
, I
23 I
- I
trihydroxyurs I
- I
12 I
- I
en I
- I
28 I
, I
30 I
- I
dioic I
acid I
( O
4 O
) O
, O
and O
2 B
alpha I
, I
3 I
beta I
, I
23 I
, I
30 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
. O

Biotransformation O
of O
asiatic B
acid I
by O
S O
. O
griseus O
CGMCC O
4 O
. O
18 O
resulted O
in O
three O
derivatives O
: O
2 B
alpha I
, I
3 I
beta I
, I
21 I
beta I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
, O
2 B
alpha I
, I
3 I
beta I
, I
23 I
- I
trihydroxyurs I
- I
12 I
- I
en I
- I
28 I
, I
30 I
- I
dioic I
acid I
( O
4 O
) O
, O
and O
2 B
alpha I
, I
3 I
beta I
, I
23 I
, I
30 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
. O

To O
enhance O
PC12 O
cell O
growth O
and O
to O
assist O
in O
controlled O
degradation O
of O
both O
the O
PC12 O
cells O
and O
the O
device O
construct O
, O
small O
PCL B
capsules O
containing O
neural O
growth O
factor O
( O
PCL B
- O
NGF O
) O
and O
a O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
pellet O
containing O
glutamine B
( O
PLGA B
- O
GLN B
) O
were O
also O
placed O
within O
the O
PCL B
chamber O
. O

In O
order O
to O
quantify O
the O
relative O
oral O
bioavailability O
of O
3 B
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
) O
from O
3 B
- I
MCPD I
fatty I
acid I
diesters I
in O
vivo O
, O
1 B
, I
2 I
- I
dipalmitoyl I
- I
3 I
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
diester I
) O
and O
3 B
- I
MCPD I
were O
orally O
applied O
to O
rats O
in O
equimolar O
doses O
. O

In O
order O
to O
quantify O
the O
relative O
oral O
bioavailability O
of O
3 B
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
) O
from O
3 B
- I
MCPD I
fatty I
acid I
diesters I
in O
vivo O
, O
1 B
, I
2 I
- I
dipalmitoyl I
- I
3 I
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
diester I
) O
and O
3 B
- I
MCPD I
were O
orally O
applied O
to O
rats O
in O
equimolar O
doses O
. O

This O
compound O
, O
1 B
- I
( I
3 I
, I
4 I
- I
dichlorophenyl I
) I
- I
3 I
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
4 I
- I
morpholino I
- I
1H I
- I
pyrrole I
- I
2 I
, I
5 I
- I
dione I
, O
named O
RI B
- I
2 I
( O
referred O
to O
as O
compound O
7a O
in O
this O
report O
) O
, O
appears O
to O
bind O
reversibly O
to O
the O
same O
site O
on O
the O
RAD51 O
protein O
as O
does O
compound O
1 O
. O

The O
series O
consisted O
of O
3 B
- I
( I
benzylamino I
) I
- I
5 I
- I
cyanopyrazine I
- I
2 I
- I
carboxamides I
and O
3 B
- I
( I
benzylamino I
) I
pyrazine I
- I
2 I
, I
5 I
- I
dicarbonitriles I
with O
various O
substituents O
on O
the O
phenyl B
ring O
. O

The O
series O
consisted O
of O
3 B
- I
( I
benzylamino I
) I
- I
5 I
- I
cyanopyrazine I
- I
2 I
- I
carboxamides I
and O
3 B
- I
( I
benzylamino I
) I
pyrazine I
- I
2 I
, I
5 I
- I
dicarbonitriles I
with O
various O
substituents O
on O
the O
phenyl B
ring O
. O

3 B
- I
( I
Benzylamino I
) I
pyrazine I
- I
2 I
, I
5 I
- I
dicarbonitrile I
inhibited O
all O
of O
the O
tested O
mycobacterial O
strains O
with O
MIC O
within O
the O
range O
12 O
. O
5 O
- O
25 O
mu O
g O
/ O
mL O
. O

2 B
' I
- I
Fluoro I
- I
6 I
' I
- I
methylene I
- I
carbocyclic I
adenosine I
phosphoramidate I
( O
FMCAP B
) O
prodrug O
: O
in O
vitro O
anti O
- O
HBV O
activity O
against O
the O
lamivudine B
- O
entecavir B
resistant O
triple O
mutant O
and O
its O
mechanism O
of O
action O
. O

Novel O
2 B
' I
- I
fluoro I
- I
6 I
' I
- I
methylene I
- I
carbocyclic I
adenosine I
( O
FMCA B
) O
monophosphate B
prodrug O
( O
FMCAP B
) O
was O
synthesized O
and O
evaluated O
for O
its O
in O
vitro O
anti O
- O
HBV O
potency O
against O
a O
lamivudine B
- O
entecavir B
resistant O
clone O
( O
L180M O
+ O
M204V O
+ O
S202G O
) O
. O

Threshold O
collision O
- O
induced O
dissociation O
of O
hydrated B
magnesium I
: O
experimental O
and O
theoretical O
investigation O
of O
the O
binding O
energies O
for O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
( O
x O
= O
2 O
- O
10 O
) O
. O

The O
sequential O
bond O
energies O
of O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
, O
in O
which O
x O
= O
2 O
- O
10 O
, O
are O
measured O
by O
threshold O
collision O
- O
induced O
dissociation O
in O
a O
guided O
ion O
beam O
tandem O
mass O
spectrometer O
. O

From O
an O
electrospray O
ionization O
source O
that O
produces O
an O
initial O
distribution O
of O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
in O
which O
x O
= O
7 O
- O
10 O
, O
complexes O
down O
to O
x O
= O
3 O
are O
formed O
by O
using O
an O
in O
- O
source O
fragmentation O
technique O
. O

Complexes O
smaller O
than O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
cannot O
be O
formed O
in O
this O
source O
because O
charge O
separation O
into O
MgOH B
( I
+ I
) I
( I
H2O I
) I
and O
H3O B
( I
+ I
) I
is O
a O
lower O
- O
energy O
pathway O
than O
simple O
water O
loss O
from O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
. O

Complexes O
smaller O
than O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
cannot O
be O
formed O
in O
this O
source O
because O
charge O
separation O
into O
MgOH B
( I
+ I
) I
( I
H2O I
) I
and O
H3O B
( I
+ I
) I
is O
a O
lower O
- O
energy O
pathway O
than O
simple O
water O
loss O
from O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
. O

The O
kinetic O
energy O
dependent O
cross O
sections O
for O
dissociation O
of O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
, O
in O
which O
x O
= O
3 O
- O
10 O
, O
are O
examined O
over O
a O
wide O
energy O
range O
to O
monitor O
all O
dissociation O
products O
and O
are O
modeled O
to O
obtain O
0 O
and O
298 O
K O
binding O
energies O
. O

Additionally O
, O
the O
thermodynamic O
onsets O
leading O
to O
the O
charge O
- O
separation O
products O
from O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
and O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
4 I
are O
determined O
for O
the O
first O
time O
. O

Additionally O
, O
the O
thermodynamic O
onsets O
leading O
to O
the O
charge O
- O
separation O
products O
from O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
and O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
4 I
are O
determined O
for O
the O
first O
time O
. O

The O
effect O
of O
P B
( I
GMA I
) I
backbone O
length O
and O
structure O
of O
oligoamine B
on O
gene O
transfer O
efficiency O
was O
then O
determined O
. O

The O
optimal O
polymer O
, O
P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
, O
provided O
comparable O
transfection O
efficiency O
but O
lower O
cytotoxicity O
than O
PEI B
. O

P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
was O
then O
used O
as O
the O
cationic O
block O
in O
diblock O
copolymers O
containing O
hydrophilic O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
and O
oligo B
( I
ethylene I
glycol I
) I
monomethyl I
ether I
methacrylate I
( O
OEGMA B
) O
. O

P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
was O
then O
used O
as O
the O
cationic O
block O
in O
diblock O
copolymers O
containing O
hydrophilic O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
and O
oligo B
( I
ethylene I
glycol I
) I
monomethyl I
ether I
methacrylate I
( O
OEGMA B
) O
. O

P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
was O
then O
used O
as O
the O
cationic O
block O
in O
diblock O
copolymers O
containing O
hydrophilic O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
and O
oligo B
( I
ethylene I
glycol I
) I
monomethyl I
ether I
methacrylate I
( O
OEGMA B
) O
. O

However O
, O
the O
presence O
of O
the O
HPMA B
/ O
OEGMA B
block O
significantly O
decreased O
the O
transfection O
efficacy O
of O
P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
homopolycation O
. O

To O
compensate O
for O
reduced O
cell O
uptake O
caused O
by O
the O
hydrophilic O
shell O
of O
polyplex O
, O
the O
integrin O
- O
binding O
peptide O
, O
RGD O
, O
was O
conjugated O
to O
the O
hydrophilic O
chain O
end O
of O
P B
( I
OEGMA I
) I
( I
15 I
) I
- I
b I
- I
P I
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
copolymer O
by O
Michael O
- O
type O
addition O
reaction O
. O

Anion O
- O
pi O
interactions O
have O
been O
systematically O
studied O
using O
tetraoxacalix B
[ I
2 I
] I
arene I
[ I
2 I
] I
triazine I
1 O
, O
an O
electron O
- O
deficient O
and O
cavity O
self O
- O
tunable O
macrocyclic O
host O
, O
as O
an O
electron O
- O
neutral O
molecular O
probe O
. O

As O
revealed O
by O
electrospray O
ionization O
mass O
spectrometry O
( O
ESI O
- O
MS O
) O
, O
fluorescence O
titration O
and O
X O
- O
ray O
crystallography O
, O
tetraoxacalix B
[ I
2 I
] I
arene I
[ I
2 I
] I
triazine I
has O
been O
found O
to O
form O
1 O
: O
1 O
complexes O
with O
four O
typical O
polyatomic O
anions O
of O
different O
geometries O
and O
shapes O
in O
the O
gaseous O
phase O
, O
in O
solution O
, O
and O
in O
the O
solid O
state O
. O

X O
- O
ray O
molecular O
structures O
of O
the O
complexes O
showed O
that O
two O
opposing O
triazine B
rings O
of O
tetraoxacalix B
[ I
2 I
] I
arene I
[ I
2 I
] I
triazine I
act O
as O
a O
pair O
of O
tweezers O
to O
interact O
with O
the O
included O
anions O
through O
cooperative O
anion O
- O
pi O
and O
lone O
- O
pair O
electron O
- O
pi O
interactions O
. O

The O
desired O
3 B
- I
( I
arylsulfonyl I
) I
spiroimidazolidine I
- I
2 I
, I
4 I
- I
diones I
were O
synthesized O
by O
reacting O
spiroiminoimidazolid B
- I
2 I
, I
4 I
- I
dione I
with O
arylsulfonyl B
chlorides I
. O

Poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
epsilon I
- I
caprolactone I
) I
micelles O
for O
combination O
drug O
delivery O
: O
evaluation O
of O
paclitaxel B
, O
cyclopamine B
and O
gossypol B
in O
intraperitoneal O
xenograft O
models O
of O
ovarian O
cancer O
. O

Poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
epsilon I
- I
caprolactone I
) I
( O
PEG B
- I
b I
- I
PCL I
) O
micelles O
were O
loaded O
with O
paclitaxel B
( O
cytotoxic O
agent O
) O
, O
cyclopamine B
( O
hedgehog O
inhibitor O
) O
, O
and O
gossypol B
( O
Bcl O
- O
2 O
inhibitor O
) O
. O

In O
ES O
- O
2 O
and O
SKOV3 O
xenograft O
models O
, O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
had O
significantly O
less O
tumor O
burden O
than O
paclitaxel B
based O
on O
bioluminescence O
imaging O
, O
3 B
' I
- I
deoxy I
- I
3 I
' I
- I
( I
18 I
) I
F I
- I
fluorothymidine I
( O
( B
18 I
) I
F I
- I
FLT I
) O
PET O
imaging O
, O
and O
overall O
survival O
. O

This O
work O
elucidates O
the O
possible O
reasons O
for O
the O
outstanding O
, O
but O
never O
reproduced O
thermoelectric O
properties O
of O
the O
doped O
Ti B
( I
0 I
. I
5 I
) I
Zr I
( I
0 I
. I
25 I
) I
Hf I
( I
0 I
. I
25 I
) I
NiSn I
Heusler O
compounds O
. O

The O
IC O
( O
50 O
) O
values O
for O
inhibition O
of O
E B
( I
2 I
) I
17 I
beta I
- I
G I
uptake O
were O
similar O
between O
OATP1B1 O
and O
OATP1B1 O
* O
15 O
. O

An O
oxycodone B
hapten O
containing O
a O
tetraglycine B
linker O
at O
the O
C6 O
position O
( O
6OXY B
( I
Gly I
) I
( I
4 I
) I
OH I
) O
conjugated O
to O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
has O
shown O
early O
proof O
- O
of O
- O
efficacy O
in O
rodents O
as O
a O
candidate O
immunogen O
( O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
) O
for O
the O
treatment O
of O
oxycodone B
abuse O
. O

In O
order O
to O
define O
the O
transcriptional O
network O
associated O
with O
oxidative O
stress O
, O
we O
utilized O
the O
MEME O
and O
MAST O
programs O
to O
analyze O
the O
promoter O
regions O
of O
57 O
amoebic O
genes O
that O
had O
increased O
expression O
specifically O
in O
response O
to O
H B
( I
2 I
) I
O I
( I
2 I
) I
exposure O
. O

We O
functionally O
characterized O
an O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
regulatory O
motif O
( O
HRM O
) O
( O
( O
1 O
) O
AAACCTCAATGAAGA O
( O
15 O
) O
) O
, O
which O
was O
enriched O
in O
these O
promoters O
and O
specifically O
bound O
amoebic O
nuclear O
protein O
( O
s O
) O
. O

Assays O
with O
promoter O
- O
luciferase O
fusions O
established O
the O
importance O
of O
key O
residues O
and O
that O
the O
HRM O
motif O
directly O
impacted O
the O
ability O
of O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
responsive O
promoters O
to O
drive O
gene O
expression O
. O

Overexpression O
and O
down O
- O
regulation O
of O
EHI O
_ O
108720 O
demonstrated O
the O
specificity O
of O
EHI O
_ O
108720 O
protein O
binding O
to O
the O
HRM O
, O
and O
overexpression O
increased O
basal O
expression O
from O
an O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
responsive O
wild O
- O
type O
promoter O
but O
not O
from O
its O
mutant O
counterpart O
. O

When O
ether B
vapor O
was O
allowed O
to O
diffuse O
into O
a O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solution O
of O
an O
enantiomer O
of O
a O
hexa B
- I
peri I
- I
hexabenzocoronene I
( O
HBC B
) O
derivative O
carrying O
a O
chiral O
( B
BINAP I
) I
Pt I
( I
II I
) I
- O
appended O
coordination O
metallacycle O
( O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) O
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
) O
, O
screw O
- O
sense O
- O
selective O
assembly O
took O
place O
to O
give O
optically O
active O
nanotubes O
( O
NT O
( O

When O
ether B
vapor O
was O
allowed O
to O
diffuse O
into O
a O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solution O
of O
an O
enantiomer O
of O
a O
hexa B
- I
peri I
- I
hexabenzocoronene I
( O
HBC B
) O
derivative O
carrying O
a O
chiral O
( B
BINAP I
) I
Pt I
( I
II I
) I
- O
appended O
coordination O
metallacycle O
( O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) O
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
) O
, O
screw O
- O
sense O
- O
selective O
assembly O
took O
place O
to O
give O
optically O
active O
nanotubes O
( O
NT O
( O

When O
ether B
vapor O
was O
allowed O
to O
diffuse O
into O
a O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solution O
of O
an O
enantiomer O
of O
a O
hexa B
- I
peri I
- I
hexabenzocoronene I
( O
HBC B
) O
derivative O
carrying O
a O
chiral O
( B
BINAP I
) I
Pt I
( I
II I
) I
- O
appended O
coordination O
metallacycle O
( O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) O
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
) O
, O
screw O
- O
sense O
- O
selective O
assembly O
took O
place O
to O
give O
optically O
active O
nanotubes O
( O
NT O
( O

No O
helical O
inversion O
took O
place O
when O
NT O
( O
Py B
) O
derived O
from O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) I
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
was O
allowed O
to O
complex O
with O
( B
BINAP I
) I
Pt I
( I
II I
) I
with O
an O
absolute O
configuration O
opposite O
to O
the O
original O
one O
. O

No O
helical O
inversion O
took O
place O
when O
NT O
( O
Py B
) O
derived O
from O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) I
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
was O
allowed O
to O
complex O
with O
( B
BINAP I
) I
Pt I
( I
II I
) I
with O
an O
absolute O
configuration O
opposite O
to O
the O
original O
one O
. O

Chemical O
and O
structural O
alterations O
to O
lysozyme O
( O
LYSO O
) O
, O
glucose B
6 I
- I
phosphate I
dehydrogenase O
( O
G6PD O
) O
, O
and O
bovine O
eye O
lens O
proteins O
( O
BLP O
) O
promoted O
by O
peroxyl B
radicals O
generated O
by O
the O
thermal O
decomposition O
of O
2 B
, I
2 I
' I
- I
azobis I
( I
2 I
- I
amidinopropane I
) I
hydrochloride I
( O
AAPH B
) O
under O
aerobic O
conditions O
were O
investigated O
. O

Comparative O
structural O
and O
functional O
studies O
of O
4 B
- I
( I
thiazol I
- I
5 I
- I
yl I
) I
- I
2 I
- I
( I
phenylamino I
) I
pyrimidine I
- I
5 I
- I
carbonitrile I
CDK9 O
inhibitors O
suggest O
the O
basis O
for O
isotype O
selectivity O
. O

In O
order O
to O
aid O
inhibitor O
design O
and O
rationalize O
the O
basis O
for O
CDK9 O
selectivity O
, O
we O
have O
studied O
the O
CDK O
- O
binding O
properties O
of O
six O
different O
members O
of O
a O
4 B
- I
( I
thiazol I
- I
5 I
- I
yl I
) I
- I
2 I
- I
( I
phenylamino I
) I
pyrimidine I
- I
5 I
- I
carbonitrile I
series O
that O
bind O
to O
both O
CDK9 O
/ O
cyclin O
T O
and O
CDK2 O
/ O
cyclin O
A O
. O

We O
have O
used O
DSF O
to O
demonstrate O
that O
the O
binding O
of O
these O
compounds O
is O
independent O
of O
the O
presence O
or O
absence O
of O
the O
C B
- O
terminal O
tail O
region O
of O
CDK9 O
, O
unlike O
the O
binding O
of O
the O
CDK9 O
- O
selective O
inhibitor O
5 B
, I
6 I
- I
dichlorobenzimidazon I
- I
1 I
- I
beta I
- I
d I
- I
ribofuranoside I
( O
DRB B
) O
. O

Finally O
, O
on O
the O
basis O
of O
11 O
cocrystal O
structures O
bound O
to O
CDK9 O
/ O
cyclin O
T O
or O
CDK2 O
/ O
cyclin O
A O
, O
we O
conclude O
that O
selective O
inhibition O
of O
CDK9 O
/ O
cyclin O
T O
by O
members O
of O
the O
4 B
- I
( I
thiazol I
- I
5 I
- I
yl I
) I
- I
2 I
- I
( I
phenylamino I
) I
pyrimidine I
- I
5 I
- I
carbonitrile I
series O
results O
from O
the O
relative O
malleability O
of O
the O
CDK9 O
active O
site O
rather O
than O
from O
the O
formation O
of O
specific O
polar O
contacts O
. O

Protonated B
naphthalene I
( O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
) O
and O
its O
neutral O
counterparts O
( O
hydronaphthyl B
radicals O
, O
C B
( I
10 I
) I
H I
( I
9 I
) I
) O
are O
important O
intermediates O
in O
the O
reactions O
of O
aromatic O
compounds O
and O
in O
understanding O
the O
unidentified O
infrared O
( O
IR O
) O
emissions O
from O
interstellar O
media O
. O

Protonated B
naphthalene I
( O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
) O
and O
its O
neutral O
counterparts O
( O
hydronaphthyl B
radicals O
, O
C B
( I
10 I
) I
H I
( I
9 I
) I
) O
are O
important O
intermediates O
in O
the O
reactions O
of O
aromatic O
compounds O
and O
in O
understanding O
the O
unidentified O
infrared O
( O
IR O
) O
emissions O
from O
interstellar O
media O
. O

We O
report O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
trapped O
in O
solid O
para B
- I
hydrogen I
( O
p B
- I
H I
( I
2 I
) I
) O
; O
the O
latter O
three O
are O
new O
. O

We O
report O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
trapped O
in O
solid O
para B
- I
hydrogen I
( O
p B
- I
H I
( I
2 I
) I
) O
; O
the O
latter O
three O
are O
new O
. O

We O
report O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
trapped O
in O
solid O
para B
- I
hydrogen I
( O
p B
- I
H I
( I
2 I
) I
) O
; O
the O
latter O
three O
are O
new O
. O

We O
report O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
trapped O
in O
solid O
para B
- I
hydrogen I
( O
p B
- I
H I
( I
2 I
) I
) O
; O
the O
latter O
three O
are O
new O
. O

These O
species O
were O
produced O
upon O
electron O
bombardment O
of O
a O
mixture O
of O
naphthalene B
( O
C B
( I
10 I
) I
H I
( I
8 I
) I
) O
and O
p B
- I
H I
( I
2 I
) I
during O
matrix O
deposition O
. O

The O
intensities O
of O
IR O
features O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
decreased O
after O
the O
matrix O
was O
maintained O
in O
darkness O
for O
19 O
h O
, O
whereas O
those O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
increased O
. O

The O
intensities O
of O
IR O
features O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
decreased O
after O
the O
matrix O
was O
maintained O
in O
darkness O
for O
19 O
h O
, O
whereas O
those O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
increased O
. O

The O
intensities O
of O
IR O
features O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
decreased O
after O
the O
matrix O
was O
maintained O
in O
darkness O
for O
19 O
h O
, O
whereas O
those O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
increased O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Compared O
with O
spectra O
recorded O
previously O
with O
IR O
photodissociation O
of O
Ar B
- O
tagged O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
or O
IR O
multiphoton O
dissociation O
of O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
our O
method O
has O
the O
advantages O
of O
producing O
high O
- O
resolution O
IR O
spectra O
with O
a O
wide O
spectral O
coverage O
, O
true O
IR O
intensity O
and O
excellent O
ratio O
of O
signal O
to O
noise O
; O
both O
protonated O
species O
and O
their O
neutral O
counterparts O
are O
produced O
with O
little O
interference O
from O
other O
fragments O
. O

Compared O
with O
spectra O
recorded O
previously O
with O
IR O
photodissociation O
of O
Ar B
- O
tagged O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
or O
IR O
multiphoton O
dissociation O
of O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
our O
method O
has O
the O
advantages O
of O
producing O
high O
- O
resolution O
IR O
spectra O
with O
a O
wide O
spectral O
coverage O
, O
true O
IR O
intensity O
and O
excellent O
ratio O
of O
signal O
to O
noise O
; O
both O
protonated O
species O
and O
their O
neutral O
counterparts O
are O
produced O
with O
little O
interference O
from O
other O
fragments O
. O

With O
these O
advantages O
, O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
are O
here O
clearly O
characterized O
. O

With O
these O
advantages O
, O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
are O
here O
clearly O
characterized O
. O

With O
these O
advantages O
, O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
are O
here O
clearly O
characterized O
. O

With O
these O
advantages O
, O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
are O
here O
clearly O
characterized O
. O

The O
in O
vitro O
anticancer O
effects O
of O
this O
salt O
were O
evaluated O
in O
HCT O
- O
116 O
human O
colon O
cancer O
cells O
using O
a O
3 B
- I
( I
4 I
, I
5 I
- I
dimethyl I
- I
2 I
- I
thiazolyl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT B
) O
assay O
. O

Structural O
- O
Functional O
Studies O
of O
Burkholderia O
cenocepaciad O
- O
Glycero B
- I
beta I
- I
d I
- I
manno I
- I
heptose I
7 I
- I
Phosphate I
Kinase O
( O
HldA O
) O
and O
Characterization O
of O
Inhibitors O
with O
Antibiotic O
Adjuvant O
and O
Antivirulence O
Properties O
. O

Here O
we O
report O
the O
structural O
- O
functional O
studies O
of O
d B
- I
glycero I
- I
beta I
- I
d I
- I
manno I
- I
heptose I
7 I
- I
phosphate I
kinase O
( O
HldA O
) O
, O
an O
absolutely O
conserved O
enzyme O
in O
this O
pathway O
, O
from O
Burkholderia O
cenocepacia O
. O

Application O
of O
a O
liquid O
chromatography O
- O
electrospray O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
method O
to O
the O
biodistribution O
and O
excretion O
studies O
of O
novel O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
( I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
) I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
in O
tumour O
- O
bearing O
mice O
. O

Novel O
betulinic B
acid I
derivative O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
[ I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
] I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
is O
a O
new O
effective O
lupane B
type O
triterpenes B
with O
greater O
anticancer O
activity O
and O
efficacy O
than O
betulinic B
acid I
and O
currently O
under O
advanced O
preclinical O
investigation O
phase O
. O

Construction O
and O
Characterization O
of O
Molecular O
Nonwoven O
Fabrics O
Consisting O
of O
Cross O
- O
Linked O
Poly B
( I
gamma I
- I
methyl I
- I
l I
- I
glutamate I
) I
. O

Molecular O
nonwoven O
fabrics O
in O
the O
form O
of O
ultrathin O
layer O
- O
by O
- O
layer O
( O
LbL O
) O
helical O
polymer O
films O
with O
covalent O
cross O
- O
linking O
were O
assembled O
on O
substrates O
by O
an O
alternate O
ester B
- O
amide B
exchange O
reaction O
between O
poly B
( I
gamma I
- I
methyl I
l I
- I
glutamate I
) I
( O
PMLG B
) O
and O
cross O
- O
linking O
agent O
ethylene B
diamine I
or O
4 B
, I
4 I
' I
- I
diamino I
azobenzene I
. O

The O
ozonolysis O
of O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
POPC B
) O
adsorbed O
on O
salt O
mixtures O
as O
models O
for O
sea O
- O
salt O
particles O
was O
studied O
in O
real O
time O
using O
diffuse O
reflection O
infrared O
Fourier O
transform O
spectrometry O
( O
DRIFTS O
) O
at O
room O
temperature O
with O
and O
without O
added O
water O
vapor O
. O

The O
salt O
substrates O
were O
a O
mixture O
of O
MgCl B
( I
2 I
) I
. I
6H I
( I
2 I
) I
O I
with O
NaCl B
or O
a O
commercially O
available O
synthetic O
sea O
salt O
. O

Prediction O
of O
( B
TiO2 I
) I
x I
( I
Cu2O I
) I
y I
alloys O
for O
efficient O
photoelectrochemical O
water O
splitting O
. O

The O
formation O
of O
( B
TiO I
( I
2 I
) I
) I
( I
x I
) I
( I
Cu I
( I
2 I
) I
O I
) I
( I
y I
) I
solid O
- O
solutions O
is O
investigated O
using O
a O
global O
optimization O
evolutionary O
algorithm O
. O

We O
find O
that O
: O
( O
i O
) O
Ti B
and O
Cu B
in O
( B
TiO I
( I
2 I
) I
) I
( I
x I
) I
( I
Cu I
( I
2 I
) I
O I
) I
( I
y I
) I
alloys O
have O
similar O
local O
environments O
as O
in O
bulk O
TiO B
( I
2 I
) I
and O
Cu B
( I
2 I
) I
O I
except O
for O
( O
TiO B
( I
2 I
) I
) O
( O
Cu B
( I
2 I
) I
O I
) O
which O
has O
some O
trigonal O
- O
planar O
Cu B
ions O
. O

( O
iii O
) O
( B
TiO I
( I
2 I
) I
) I
( I
2 I
) I
( I
Cu I
( I
2 I
) I
O I
) I
has O
the O
lowest O
formation O
energy O
amongst O
all O
studied O
alloys O
and O
the O
positions O
of O
its O
band O
edges O
are O
found O
to O
be O
suitable O
for O
solar O
- O
driven O
water O
splitting O
applications O
. O

The O
versatility O
of O
this O
hydrogel O
system O
was O
exemplified O
through O
variations O
in O
the O
degree O
of O
HPA B
substitution O
, O
polymer O
concentration O
, O
and O
the O
concentration O
of O
cross O
- O
linking O
reagents O
( O
horseradish O
peroxidase O
and O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
, O
which O
resulted O
in O
a O
range O
of O
mechanical O
properties O
and O
gelation O
kinetics O
for O
these O
gels O
. O

Discovery O
of O
a O
new O
series O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalines I
as O
dual O
phosphodiesterase O
2 O
/ O
phosphodiesterase O
10 O
( O
PDE2 O
/ O
PDE10 O
) O
inhibitors O
. O

The O
synthesis O
, O
preliminary O
evaluation O
and O
structure O
- O
activity O
relationship O
( O
SAR O
) O
of O
a O
series O
of O
1 B
- I
aryl I
- I
4 I
- I
methyl I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalines I
as O
dual O
phosphodiesterase O
2 O
/ O
phosphodiesterase O
10 O
( O
PDE2 O
/ O
PDE10 O
) O
inhibitors O
are O
described O
. O

During O
our O
recent O
search O
for O
AKR1C O
inhibitors O
, O
we O
found O
a O
cyclopentanol B
derivative O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanol I
, O
CBCP B
- I
ol I
) O
and O
its O
respective O
cyclopentanone B
counterpart O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanone I
, O
CBCP B
- I
one I
) O
that O
acted O
as O
AKR1C O
substrates O
. O

During O
our O
recent O
search O
for O
AKR1C O
inhibitors O
, O
we O
found O
a O
cyclopentanol B
derivative O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanol I
, O
CBCP B
- I
ol I
) O
and O
its O
respective O
cyclopentanone B
counterpart O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanone I
, O
CBCP B
- I
one I
) O
that O
acted O
as O
AKR1C O
substrates O
. O

The O
effects O
of O
9 O
- O
min O
OGD O
on O
proliferation O
and O
maturation O
of O
cells O
localized O
in O
the O
subgranular O
zone O
of O
DG O
in O
slices O
prepared O
from O
5 B
- I
bromo I
- I
2 I
' I
- I
deoxyuridine I
( O
BrdU B
) O
treated O
rats O
was O
investigated O
. O

Pretreatment O
with O
the O
nitric B
oxide I
inhibitor O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
l B
- I
NAME I
) O
reduced O
the O
locomotor O
activating O
effects O
of O
paraxanthine B
, O
but O
not O
caffeine B
. O

Two O
new O
trisaccharide B
intermediates O
of O
phenylethanoid B
glycosides I
, O
peiioside B
A I
( I
1 I
) I
/ I
A I
( I
2 I
) I
( O
1a O
/ O
1b O
) O
and O
peiioside B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
n B
- I
BuOH I
fraction O
of O
MeOH B
extract O
of O
the O
stems O
of O
Callicarpa O
peii O
H O
. O
T O
. O

The O
structures O
of O
compounds O
1 O
and O
2 O
were O
elucidated O
by O
extensive O
spectroscopic O
methods O
( O
especially O
2D O
- O
NMR O
techniques O
) O
and O
acid O
- O
catalyzed O
hydrolysis O
as O
O B
- I
alpha I
- I
l I
- I
rhamnopyranosyl I
- I
( I
1 I
' I
' I
- I
- I
> I
3 I
' I
) I
- I
O I
- I
[ I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
' I
' I
' I
- I
- I
> I
6 I
' I
) I
] I
- I
4 I
' I
- I
O I
- I
[ I
( I
E I
) I
- I
caffeoyl I
] I
- I
d I
- I
glucopyranoside I
] I
( O
1a O
/ O
1b O
) O
, O
3 B
, I
4 I
- I

The O
twigs O
of O
Cudrania O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase O
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol B
glucoside I
, O
( B
2S I
, I
3S I
) I
- I
2 I
, I
3 I
- I
trans I
- I
dihydromorin I
- I
7 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
1 O
) O
, O
plus O
twenty O
- O
seven O
known O
compounds O
( O
2 O
- O
28 O
) O
. O

Investigation O
of O
the O
effect O
of O
various O
culture O
conditions O
, O
using O
Bacillus O
subtilis O
DSM704 O
and O
the O
DNJ B
high O
- O
production O
Bacillus O
strains O
, O
provided O
evidence O
for O
the O
importance O
of O
sorbitol B
supplementation O
on O
the O
yield O
of O
the O
DNJ B
precursor O
, O
2 B
- I
amino I
- I
2 I
- I
deoxy I
- I
D I
- I
mannitol I
, O
thereby O
increasing O
DNJ B
production O
. O

Nosokophic B
acid I
was O
found O
to O
be O
3 B
- I
phosphoglycosyl I
- I
2 I
- I
sesquiterpenyl I
dihydroxypropionic I
acid I
, O
a O
predicted O
biosynthetic O
intermediate O
of O
nosokomycin B
- O
related O
moenomycins B
. O

The O
affinity O
of O
these O
new O
compounds O
for O
chicken O
brain O
melatonin B
receptors O
and O
recombinant O
human O
MT O
( O
1 O
) O
and O
MT O
( O
2 O
) O
receptors O
was O
evaluated O
using O
2 B
- I
[ I
( I
125 I
) I
I I
] I
- I
iodomelatonin I
as O
radioligand O
. O

Design O
and O
synthesis O
of O
novel O
2 B
- I
methyl I
- I
4 I
, I
5 I
- I
substitutedbenzo I
[ I
f I
] I
- I
3 I
, I
3a I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
pyrazolo I
[ I
1 I
, I
5 I
- I
d I
] I
[ I
1 I
, I
4 I
] I
oxazepin I
- I
8 I
( I
7H I
) I
- I
one I
derivatives O
as O
telomerase O
inhibitors O
. O

Eight O
novel O
4 B
, I
5 I
- I
tetrahydropyrazolo I
[ I
1 I
, I
5 I
- I
d I
] I
[ I
1 I
, I
4 I
] I
oxazepine I
derivatives O
have O
been O
synthesized O
and O
purified O
to O
be O
screened O
for O
anticancer O
activity O
. O

Anti O
- O
inflammatory O
effects O
of O
trans B
- I
1 I
, I
3 I
- I
diphenyl I
- I
2 I
, I
3 I
- I
epoxypropane I
- I
1 I
- I
one I
mediated O
by O
suppression O
of O
inflammatory O
mediators O
in O
LPS O
- O
stimulated O
RAW O
264 O
. O
7 O
macrophages O
. O

To O
assess O
the O
potential O
therapeutic O
properties O
of O
trans B
- I
1 I
, I
3 I
- I
diphenyl I
- I
2 I
, I
3 I
- I
epoxypropane I
- I
1 I
- I
one I
( O
DPEP B
) O
, O
its O
anti O
- O
inflammatory O
effects O
were O
investigated O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
mouse O
macrophage O
( O
RAW O
264 O
. O
7 O
) O
cells O
. O

Rhein B
naturally O
occurs O
in O
anthraquinone B
( O
1 B
, I
3 I
, I
8 I
- I
trihydroxy I
- I
6 I
- I
methyl I
anthraquinone I
) O
, O
which O
is O
found O
in O
R O
. O
palmatum O
L O
. O
and O
related O
plants O
such O
as O
rhubarb O
. O

A O
major O
base O
lesion O
resulting O
from O
oxidative O
stress O
is O
8 B
- I
oxo I
- I
7 I
, I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxoG I
) O
that O
has O
ambiguous O
coding O
potential O
. O

To O
determine O
how O
pol O
beta O
discriminates O
between O
anti B
- I
and I
syn I
- I
8 I
- I
oxoG I
, O
we O
introduced O
a O
point O
mutation O
( O
R283K O
) O
to O
alter O
insertion O
specificity O
. O

By O
using O
this O
bioassay O
- O
oriented O
approach O
five O
proanthocyanindins B
, O
including O
the O
new O
natural O
compounds O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
afzelechin I
( O
1 O
) O
and O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
epiafzelechin I
( O
2 O
) O
and O
the O
known O
geranin B
B I
( O
3 O
) O
, O
proanthocyanidin B
A2 I
( O
4 O
) O
, O
and O

By O
using O
this O
bioassay O
- O
oriented O
approach O
five O
proanthocyanindins B
, O
including O
the O
new O
natural O
compounds O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
afzelechin I
( O
1 O
) O
and O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
epiafzelechin I
( O
2 O
) O
and O
the O
known O
geranin B
B I
( O
3 O
) O
, O
proanthocyanidin B
A2 I
( O
4 O
) O
, O
and O

The O
vasorelaxant O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
did O
not O
depend O
on O
endothelial O
layer O
integrity O
, O
and O
the O
effects O
were O
refractory O
to O
L B
- I
N I
( I
G I
) I
- I
nitroarginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
- O
induced O
nitric B
oxide I
synthase O
inhibition O
. O

Vasorelaxation O
was O
similarly O
resistant O
to O
treatment O
with O
indomethacin B
, O
cis B
- I
N I
- I
( I
2 I
- I
phenylcyclopentyl I
) I
- I
azacyclotridec I
- I
1 I
- I
en I
- I
2 I
- I
amine I
hydrochloride I
( O
MDL B
- I
12330A I
) O
, O
and O
KT5720 B
, O
indicating O
that O
neither O
prostaglandin B
release O
nor O
adenylyl B
cyclase O
activation O
is O
involved O
. O

The O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
were O
reversed O
by O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ B
) O
and O
comparable O
to O
the O
effects O
induced O
by O
sodium B
nitroprusside I
. O

In O
vitro O
, O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
increased O
cyclic B
guanosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cGMP B
) O
levels O
in O
rat O
aortic O
rings O
, O
an O
effect O
also O
reversed O
by O
ODQ B
. O

Nanoscale O
stabilization O
of O
new O
phases O
in O
the O
PbTe B
- O
Sb2Te3 B
system O
: O
Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
. O

A O
series O
of O
novel O
rock O
- O
salt O
- O
type O
Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
( O
m O
= O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
and O
10 O
; O
n O
= O
1 O
and O
2 O
) O
were O
successfully O
prepared O
using O
a O
colloidal O
synthesis O
route O
. O

Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
behave O
as O
metastable O
homogeneous O
solid O
solutions O
at O
room O
temperature O
and O
tend O
to O
phase O
separate O
into O
the O
respective O
binary O
PbTe B
+ O
Sb B
( I
2 I
) I
Te I
( I
3 I
) I
at O
300 O
degrees O
C O
. O

Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
behave O
as O
metastable O
homogeneous O
solid O
solutions O
at O
room O
temperature O
and O
tend O
to O
phase O
separate O
into O
the O
respective O
binary O
PbTe B
+ O
Sb B
( I
2 I
) I
Te I
( I
3 I
) I
at O
300 O
degrees O
C O
. O

Furthermore O
, O
pair O
distribution O
function O
( O
PDF O
) O
analysis O
suggests O
that O
the O
local O
structure O
of O
these O
Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
is O
distorted O
with O
respect O
to O
the O
rock O
- O
salt O
structure O
. O

Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N B
' I
- I
2 I
- I
( I
4 I
- I
benzylpiperidin I
- I
/ I
piperazin I
- I
1 I
- I
yl I
) I
acylhydrazone I
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
A O
beta O
aggregation O
. O

To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer O
' O
s O
disease O
, O
a O
group O
of O
N B
' I
- I
2 I
- I
( I
4 I
- I
Benzylpiperidin I
- I
/ I
piperazin I
- I
1 I
- I
yl I
) I
acylhydrazones I
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesteras O
and O
aggregation O
of O
amyloid O
beta O
peptides O
( O
1 O
- O
40 O
, O
1 O
- O
42 O
and O
1 O
- O
40 O
_ O
1 O
- O
42 O
) O
. O

Recently O
, O
the O
first O
microorganism O
with O
a O
chemically O
different O
genome O
was O
reported O
; O
the O
selected O
Escherichia O
coli O
strain O
relies O
on O
the O
four O
building O
blocks O
5 B
- I
chloro I
- I
2 I
' I
- I
deoxyuridine I
( O
ClU B
) O
, O
A O
, O
C O
and O
G O
instead O
of O
the O
standard O
T O
, O
A O
, O
C O
, O
G O
alphabet O
[ O
Marli O
e O
re O
, O
P O
. O
, O
Patrouix O
, O
J O
. O
, O
D O
o O
ring O
, O
V O
. O
, O
Herdewijn O
, O
P O
. O
, O
Tricot O
, O
S O
. O
, O
Cruveiller O
, O
S O
. O
, O
Bouzon O
, O
M O
. O
and O
Mutzel O
, O

Importantly O
, O
3 B
- I
aminopyridine I
- I
2 I
- I
carboxaldehyde I
thiosemicarbazone I
( O
3 B
- I
AP I
) O
has O
been O
investigated O
in O
> O
20 O
phase O
I O
and O
II O
clinical O
trials O
. O

Here O
we O
show O
that O
morin B
( O
3 B
, I
5 I
, I
7 I
, I
2 I
' I
, I
4 I
' I
- I
pentahydroxyflavone I
) O
has O
potential O
against O
cancer O
cells O
through O
suppression O
of O
the O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
STAT3 O
) O
pathway O
, O
which O
is O
closely O
linked O
to O
the O
transformation O
, O
survival O
, O
proliferation O
, O
and O
metastasis O
of O
cancer O
. O

In O
this O
work O
, O
we O
fabricated O
a O
series O
of O
mixed O
shell O
micelles O
( O
MSMs O
) O
with O
approximately O
the O
same O
size O
, O
charge O
and O
core O
composition O
but O
with O
varied O
hydrophilic O
/ O
hydrophobic O
ratios O
in O
the O
shell O
through O
spontaneously O
self O
- O
assembly O
of O
block O
copolymers O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
l I
- I
lysine I
) I
( O
PEG B
- I
b I
- I
PLys I
) O
and O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- I
block I
- I
poly I
( I
aspartic I
acid I
) I
( O
PNIPAM B
- I
b I
- I
PAsp I
) O
in O

In O
this O
work O
, O
we O
fabricated O
a O
series O
of O
mixed O
shell O
micelles O
( O
MSMs O
) O
with O
approximately O
the O
same O
size O
, O
charge O
and O
core O
composition O
but O
with O
varied O
hydrophilic O
/ O
hydrophobic O
ratios O
in O
the O
shell O
through O
spontaneously O
self O
- O
assembly O
of O
block O
copolymers O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
l I
- I
lysine I
) I
( O
PEG B
- I
b I
- I
PLys I
) O
and O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- I
block I
- I
poly I
( I
aspartic I
acid I
) I
( O
PNIPAM B
- I
b I
- I
PAsp I
) O
in O

By O
combining O
decisive O
structural O
features O
of O
CYP11B2 O
and O
CYP19 O
inhibitors O
into O
a O
common O
template O
, O
a O
series O
of O
pyridinylmethyl B
substituted I
1 I
, I
2 I
, I
5 I
, I
6 I
- I
tetrahydro I
- I
pyrrolo I
[ I
3 I
, I
2 I
, I
1 I
- I
ij I
] I
quinolin I
- I
4 I
- I
ones I
were O
designed O
and O
synthesized O
. O

Absolute O
configuration O
and O
conformational O
analysis O
of O
brevipolides B
, O
bioactive O
5 B
, I
6 I
- I
dihydro I
- I
alpha I
- I
pyrones I
from O
Hyptis O
brevipes O
. O

The O
structure O
of O
the O
new O
brevipolide B
J I
( O
10 O
) O
was O
characterized O
through O
NMR O
and O
MS O
data O
as O
having O
the O
same O
6 B
- I
heptyl I
- I
5 I
, I
6 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
one I
framework O
possessing O
the O
cyclopropane B
moiety O
of O
all O
brevipolides B
but O
substituted O
by O
an O
isoferuloyl B
group O
instead O
of O
the O
p B
- I
methoxycinnamoyl I
moiety O
found O
in O
8 O
and O
9 O
. O

Conformational O
analysis O
of O
these O
cytotoxic O
6 B
- I
heptyl I
- I
5 I
, I
6 I
- I
dihydro I
- I
alpha I
- I
pyrones I
was O
carried O
out O
on O
compound O
9 O
by O
application O
of O
a O
protocol O
based O
on O
comparison O
between O
experimental O
and O
DFT O
- O
calculated O
vicinal O
( B
1 I
) I
H I
- I
( I
1 I
) I
H I
NMR O
coupling O
constants O
. O

Conformational O
analysis O
of O
these O
cytotoxic O
6 B
- I
heptyl I
- I
5 I
, I
6 I
- I
dihydro I
- I
alpha I
- I
pyrones I
was O
carried O
out O
on O
compound O
9 O
by O
application O
of O
a O
protocol O
based O
on O
comparison O
between O
experimental O
and O
DFT O
- O
calculated O
vicinal O
( B
1 I
) I
H I
- I
( I
1 I
) I
H I
NMR O
coupling O
constants O
. O

Discovery O
of O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
4 I
, I
5 I
- I
dihydroisoxazoles I
and O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
1 I
, I
4 I
, I
2 I
- I
dioxazoles I
as O
potent O
firefly O
luciferase O
inhibitors O
. O

Discovery O
of O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
4 I
, I
5 I
- I
dihydroisoxazoles I
and O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
1 I
, I
4 I
, I
2 I
- I
dioxazoles I
as O
potent O
firefly O
luciferase O
inhibitors O
. O

Here O
, O
we O
report O
new O
firefly O
luciferase O
( O
FLuc O
) O
inhibitors O
based O
on O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
4 I
, I
5 I
- I
dihydroisoxazoles I
and O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
1 I
, I
4 I
, I
2 I
- I
dioxazoles I
, O
which O
showed O
up O
as O
" O
false O
positives O
" O
in O
a O
luciferase O
reporter O
gene O
- O
based O
assay O
for O
nuclear O
receptor O
antagonists O
. O

Here O
, O
we O
report O
new O
firefly O
luciferase O
( O
FLuc O
) O
inhibitors O
based O
on O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
4 I
, I
5 I
- I
dihydroisoxazoles I
and O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
1 I
, I
4 I
, I
2 I
- I
dioxazoles I
, O
which O
showed O
up O
as O
" O
false O
positives O
" O
in O
a O
luciferase O
reporter O
gene O
- O
based O
assay O
for O
nuclear O
receptor O
antagonists O
. O

Pharmacological O
studies O
suggest O
that O
perampanel B
acts O
with O
a O
new O
mechanism O
of O
action O
via O
non O
- O
competitive O
antagonism O
of O
the O
ionotropic O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazoleproprionic I
acid I
( O
AMPA B
) O
receptor O
of O
glutamate B
, O
the O
main O
mediator O
of O
excitatory O
neurotransmission O
in O
the O
central O
nervous O
system O
. O

In O
this O
Letter O
we O
report O
on O
the O
advances O
in O
our O
NPBWR1 O
antagonist O
program O
aimed O
at O
optimizing O
the O
5 B
- I
chloro I
- I
2 I
- I
( I
3 I
, I
5 I
- I
dimethylphenyl I
) I
- I
4 I
- I
( I
4 I
- I
methoxyphenoxy I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
lead O
molecule O
previously O
obtained O
from O
a O
high O
- O
throughput O
screening O
( O
HTS O
) O
- O
derived O
hit O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
( O
SAR O
) O
studies O
around O
the O
3 B
, I
5 I
- I
dimethylphenyl I
and O
4 B
- I
methoxyphenyl I
regions O
resulted O
in O
the O
identification O
of O
a O
novel O
series O
of O
non O
- O
peptidic O
submicromolar O
NPBWR1 O
antagonists O
based O
on O
a O
5 B
- I
chloro I
- I
4 I
- I
( I
4 I
- I
alkoxyphenoxy I
) I
- I
2 I
- I
( I
benzyl I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
chemotype O
. O

Amongst O
them O
, O
5 B
- I
chloro I
- I
2 I
- I
( I
9H I
- I
fluoren I
- I
9 I
- I
yl I
) I
- I
4 I
- I
( I
4 I
- I
methoxyphenoxy I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
9h O
( O
CYM50769 B
) O
inhibited O
NPW O
activation O
of O
NPBWR1 O
with O
a O
submicromolar O
IC O
( O
50 O
) O
, O
and O
displayed O
high O
selectivity O
against O
a O
broad O
array O
of O
off O
- O
targets O
with O
pharmaceutical O
relevance O
. O

Inhibition O
of O
matrix O
metalloproteinase O
- O
9 O
expression O
by O
docosahexaenoic B
acid I
mediated O
by O
heme B
oxygenase O
1 O
in O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
- O
induced O
MCF O
- O
7 O
human O
breast O
cancer O
cells O
. O

We O
studied O
the O
anti O
- O
metastasis O
potential O
of O
DHA B
and O
LA O
in O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
( O
TPA B
) O
- O
induced O
MCF O
- O
7 O
cells O
. O

In O
this O
study O
, O
Raman O
, O
infrared O
, O
UV O
/ O
vis O
, O
NMR O
, O
and O
single O
crystal O
X O
- O
ray O
diffraction O
spectroscopies O
are O
used O
to O
elucidate O
the O
tautomeric O
equilibrium O
of O
azo B
dyes O
derived O
from O
1 B
- I
phenyl I
- I
azo I
- I
2 I
- I
naphthol I
( O
Sudan B
I I
) O
. O

Using O
the O
phosphonate B
moiety O
as O
an O
efficient O
trans O
- O
directing O
group O
, O
the O
first O
catalytic O
asymmetric O
route O
to O
diacceptor O
cycloprop B
( I
en I
) I
ylphosphonates I
was O
developed O
by O
employing O
an O
alpha B
- I
cyano I
diazophosphonate I
and O
Rh B
( I
2 I
) I
( I
S I
- I
IBAZ I
) I
( I
4 I
) I
as O
chiral O
catalyst O
. O

The O
isosteric O
character O
of O
phosphonic B
and I
carboxylic I
acid I
derivatives O
allowed O
the O
alternative O
use O
of O
an O
alpha B
- I
cyano I
diazo I
ester I
in O
the O
process O
, O
leading O
to O
alpha B
- I
cyano I
cycloprop I
( I
en I
) I
ylcarboxylates I
in O
high O
yields O
and O
stereoselectivities O
. O

The O
anti O
- O
inflammatory O
effect O
of O
1 B
- I
trifluoromethoxyphen I
- I
3 I
- I
( I
1 I
- I
propionylpiperidin I
- I
4 I
- I
yl I
) I
urea I
( O
TPPU B
) O
, O
the O
most O
promising O
inhibitor O
among O
the O
five O
sEHIs O
tested O
, O
was O
investigated O
in O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
challenged O
murine O
model O
. O

The O
earlier O
broadly O
- O
used O
adamantyl B
- O
containing O
sEHI O
, O
trans B
- I
4 I
- I
[ I
4 I
- I
( I
3 I
- I
adamantan I
- I
1 I
- I
yl I
- I
ureido I
) I
- I
cyclohexyloxy I
] I
- I
benzoic I
acid I
( O
t B
- I
AUCB I
) O
, O
was O
used O
for O
comparison O
. O

Antioxidant O
activities O
of O
thiosemicarbazones B
from O
substituted O
benzaldehydes B
and O
N B
- I
( I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
D I
- I
galactopyranosyl I
) I
thiosemicarbazide I
. O

Reaction O
of O
N B
- I
( I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
d I
- I
galactopyranosyl I
) I
thiosemicarbazide I
and O
different O
substituted O
benzaldehydes B
gave O
some O
new O
substituted O
benzaldehyde B
N I
- I
( I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
d I
- I
galactopyranosyl I
) I
thiosemicarbazones I
. O

Reaction O
of O
N B
- I
( I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
d I
- I
galactopyranosyl I
) I
thiosemicarbazide I
and O
different O
substituted O
benzaldehydes B
gave O
some O
new O
substituted O
benzaldehyde B
N I
- I
( I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
d I
- I
galactopyranosyl I
) I
thiosemicarbazones I
. O

This O
work O
reports O
the O
first O
synthesis O
of O
selenophenolate B
- O
protected O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
. O

The O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
were O
obtained O
via O
a O
controlled O
reaction O
of O
Au B
( I
25 I
) I
( I
SCH I
( I
2 I
) I
CH I
( I
2 I
) I
Ph I
) I
( I
18 I
) I
with O
selenophenol B
. O

The O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
were O
obtained O
via O
a O
controlled O
reaction O
of O
Au B
( I
25 I
) I
( I
SCH I
( I
2 I
) I
CH I
( I
2 I
) I
Ph I
) I
( I
18 I
) I
with O
selenophenol B
. O

Electrospray O
ionization O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
ESI O
- O
TOF O
- O
MS O
) O
revealed O
the O
crude O
product O
to O
contain O
predominantly O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
, O
and O
side O
products O
include O
Au B
( I
15 I
) I
( I
SePh I
) I
( I
13 I
) I
, O
Au B
( I
19 I
) I
( I
SePh I
) I
( I
15 I
) I
and O
Au B
( I
20 I
) I
( I
SePh I
) I
( I
16 I
) I
. O

Electrospray O
ionization O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
ESI O
- O
TOF O
- O
MS O
) O
revealed O
the O
crude O
product O
to O
contain O
predominantly O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
, O
and O
side O
products O
include O
Au B
( I
15 I
) I
( I
SePh I
) I
( I
13 I
) I
, O
Au B
( I
19 I
) I
( I
SePh I
) I
( I
15 I
) I
and O
Au B
( I
20 I
) I
( I
SePh I
) I
( I
16 I
) I
. O

Electrospray O
ionization O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
ESI O
- O
TOF O
- O
MS O
) O
revealed O
the O
crude O
product O
to O
contain O
predominantly O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
, O
and O
side O
products O
include O
Au B
( I
15 I
) I
( I
SePh I
) I
( I
13 I
) I
, O
Au B
( I
19 I
) I
( I
SePh I
) I
( I
15 I
) I
and O
Au B
( I
20 I
) I
( I
SePh I
) I
( I
16 I
) I
. O

Electrospray O
ionization O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
ESI O
- O
TOF O
- O
MS O
) O
revealed O
the O
crude O
product O
to O
contain O
predominantly O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
, O
and O
side O
products O
include O
Au B
( I
15 I
) I
( I
SePh I
) I
( I
13 I
) I
, O
Au B
( I
19 I
) I
( I
SePh I
) I
( I
15 I
) I
and O
Au B
( I
20 I
) I
( I
SePh I
) I
( I
16 I
) I
. O

High O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
was O
employed O
to O
isolate O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
. O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

benzo B
[ I
c I
] I
[ I
1 I
, I
2 I
, I
5 I
] I
thiadiazole I
( O
8 O
) O
fragments O
are O
expected O
to O
be O
promising O
candidates O
for O
luminescent O
materials O
for O
OLEDs O
, O
particularly O
for O
5 O
and O
7 O
. O

Fragment O
- O
based O
discovery O
of O
new O
highly O
substituted O
1H B
- I
pyrrolo I
[ I
2 I
, I
3 I
- I
b I
] I
- I
and I
3H I
- I
imidazolo I
[ I
4 I
, I
5 I
- I
b I
] I
- I
pyridines I
as O
focal O
adhesion O
kinase O
inhibitors O
. O

In O
a O
surface O
plasmon O
resonance O
( O
SPR O
) O
- O
mediated O
fragment O
screening O
campaign O
, O
we O
discovered O
bicyclic O
scaffolds O
like O
1H B
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
d I
] I
pyrimidines I
binding O
to O
the O
hinge O
region O
of O
FAK O
. O

The O
establishment O
of O
highly O
substituted O
unprecedented O
1H B
- I
pyrrolo I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatizations O
provided O
compounds O
with O
submicromolar O
cellular O
FAK O
inhibition O
potential O
. O

Structural O
analysis O
revealed O
that O
the O
appropriately O
substituted O
pyrrolo B
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
induced O
a O
rare O
helical O
DFG O
- O
loop O
conformation O
. O

The O
cOATPs O
were O
stably O
transfected O
in O
human O
embryonic O
kidney O
cells O
and O
were O
functionally O
similar O
to O
the O
corresponding O
human O
OATPs O
( O
hOATPs O
) O
, O
as O
evident O
from O
the O
similar O
uptake O
rate O
of O
typical O
substrates O
( O
estradiol B
- I
17 I
beta I
- I
d I
- I
glucuronide I
, O
cholecystokinin O
octapeptide O
, O
and O
estrone B
- I
3 I
- I
sulfate I
) O
. O

Design O
and O
synthesis O
of O
potent O
inhibitor O
of O
apoptosis O
( O
IAP O
) O
proteins O
antagonists O
bearing O
an O
octahydropyrrolo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
scaffold O
as O
a O
novel O
proline B
mimetic O
. O

To O
develop O
novel O
inhibitor O
of O
apoptosis O
( O
IAP O
) O
proteins O
antagonists O
, O
we O
designed O
a O
bicyclic B
octahydropyrrolo I
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
scaffold O
as O
a O
novel O
proline B
bioisostere O
. O

A O
novel O
polymer O
coating O
consisting O
of O
poly B
( I
lactic I
- I
co I
- I
glycolic I
) I
acid I
( O
PLGA B
) O
microsphere O
dispersed O
in O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
hydrogels O
was O
evaluated O
in O
combination O
with O
dummy O
sensors O
as O
a O
" O
smart O
" O
drug O
eluting O
biocompatible O
coating O
for O
implantable O
biosensors O
to O
prevent O
the O
foreign O
body O
response O
, O
and O
thus O
enhance O
sensor O
performance O
in O
vivo O
. O

Claisen O
- O
Schmidt O
condensation O
reaction O
of O
4 B
- I
acetamidoacetophenon I
with O
aromatic B
aldehydes I
under O
ultrasonic O
irradiation O
affords O
acetylaminochalcones B
( O
yields O
: O
71 O
- O
90 O
% O
) O
which O
also O
under O
ultrasonic O
irradiation O
and O
in O
the O
presence O
of O
sodium B
acetate I
and O
acetic B
acid I
aqueous O
undergo O
facile O
and O
clean O
cyclocondensation O
with O
hydrazine B
to O
afford O
3 B
- I
( I
4 I
- I
acetamidophenyl I
) I
- I
5 I
- I
( I
aryl I
) I
- I
1 I
- I
H I
- I
pyrazolines I
. O

6 B
- I
Ethyl I
- I
N I
- I
[ I
1 I
- I
( I
hydroxyacetyl I
) I
piperidin I
- I
4 I
- I
yl I
] I
- I
1 I
- I
methyl I
- I
4 I
- I
oxo I
- I
5 I
- I
( I
2 I
- I
oxo I
- I
2 I
- I
phenylethyl I
) I
- I
3 I
- I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
- I
4 I
, I
5 I
- I
dihydro I
- I
1H I
- I
pyrrolo I
[ I
3 I
, I
2 I
- I
c I
] I
pyridine I
- I
2 I
- I
carboxamide I
( O
TAK B
- I
441 I
) O
is O
a O
potent O
, O
selective O
hedgehog O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

For O
microscopic O
localization O
of O
arabinogalactan O
- O
proteins O
, O
synthetic O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
that O
specifically O
binds O
to O
most O
plant O
arabinogalactan O
- O
proteins O
was O
used O
to O
label O
arabinogalactan O
- O
proteins O
in O
fresh O
cut O
sections O
of O
stems O
and O
petioles O
of O
Echinacea O
purpurea O
. O

Polyclonal O
antibodies O
against O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
were O
used O
to O
detect O
the O
arabinogalactan O
- O
protein O
- O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
complex O
. O

Polyclonal O
antibodies O
against O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
were O
used O
to O
detect O
the O
arabinogalactan O
- O
protein O
- O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
complex O
. O

Precision O
- O
cut O
liver O
slices O
( O
PCLS O
) O
from O
human O
livers O
were O
incubated O
in O
culture O
, O
and O
hepatic O
function O
was O
determined O
by O
albumin O
production O
, O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
) I
- I
2 I
, I
5 I
- I
diphenyl I
tetrazolium I
bromide I
assay O
, O
glucose B
uptake O
responses O
, O
and O
morphometric O
assessment O
. O

Here O
, O
we O
characterize O
propofol B
binding O
sites O
in O
a O
muscle O
- O
type O
nAChR O
by O
use O
of O
a O
photoreactive O
analog O
of O
propofol B
, O
2 B
- I
isopropyl I
- I
5 I
- I
[ I
3 I
- I
( I
trifluoromethyl I
) I
- I
3H I
- I
diazirin I
- I
3 I
- I
yl I
] I
phenol I
( O
AziPm B
) O
. O

In O
vitro O
evaluation O
of O
( B
99m I
) I
Tc I
- I
EDDA I
/ I
tricine I
- I
HYNIC I
- I
Q I
- I
Litorin I
in O
gastrin O
- O
releasing O
peptide O
receptor O
positive O
tumor O
cell O
lines O
. O

The O
in O
vitro O
cell O
uptake O
of O
( B
99m I
) I
Tc I
- I
EDDA I
- I
HYNIC I
- I
Q I
- I
Litorin I
and O
( B
99m I
) I
Tc I
- I
tricine I
- I
HYNIC I
- I
Q I
- I
Litorin I
were O
evaluated O
on O
pancreatic O
tumor O
and O
control O
cell O
lines O
. O

The O
in O
vitro O
cell O
uptake O
of O
( B
99m I
) I
Tc I
- I
EDDA I
- I
HYNIC I
- I
Q I
- I
Litorin I
and O
( B
99m I
) I
Tc I
- I
tricine I
- I
HYNIC I
- I
Q I
- I
Litorin I
were O
evaluated O
on O
pancreatic O
tumor O
and O
control O
cell O
lines O
. O

Syntheses O
of O
2 B
- I
deoxy I
- I
2 I
, I
3 I
- I
didehydro I
- I
N I
- I
acetylneuraminic I
acid I
analogues O
modified O
by O
alpha B
- I
acylaminoamido I
groups O
at O
the O
C O
- O
4 O
position O
using O
isocyanide B
- O
based O
four O
- O
component O
coupling O
and O
biological O
evaluation O
as O
inhibitors O
of O
human O
parainfluenza O
virus O
type O
1 O
. O

Two O
new O
triterpenoid B
saponins I
, O
named O
platycodon B
A I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I
, I
21 I
beta I
- I
tetrahydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
and O
platycodon B
B I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I

Two O
freshwater O
fish O
, O
Rasbora O
sumatrana O
( O
Cyprinidae O
) O
and O
Poecilia O
reticulata O
( O
guppy O
; O
Poeciliidae O
) O
, O
were O
exposed O
to O
a O
range O
of O
eight O
heavy O
metals O
( O
copper B
( O
Cu B
) O
, O
cadmium B
( O
Cd B
) O
, O
zinc B
( O
Zn B
) O
, O
lead O
( O
Pb B
) O
, O
nickel B
( O
Ni B
) O
, O
iron B
( O
Fe B
) O
, O
aluminium B
( O
Al B
) O
, O
and O
manganese B
( O
Mn B
) O
) O
at O
varied O
concentrations O
for O
96 O
h O
in O
the O
laboratory O
. O

DPA B
- I
713 I
is O
the O
lead O
compound O
of O
a O
recently O
reported O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidineacetamide I
series O
, O
targeting O
the O
translocator O
protein O
( O
TSPO O
18 O
kDa O
) O
, O
and O
as O
such O
, O
this O
structure O
, O
as O
well O
as O
closely O
related O
derivatives O
, O
have O
been O
already O
successfully O
used O
as O
positron O
emission O
tomography O
radioligands O
. O

On O
the O
basis O
of O
the O
pharmacological O
core O
of O
this O
ligands O
series O
, O
a O
new O
magnetic O
resonance O
imaging O
probe O
, O
coded O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
was O
designed O
and O
successfully O
synthesized O
in O
six O
steps O
and O
13 O
% O
overall O
yield O
from O
DPA B
- I
713 I
. O

The O
Gd B
- I
DOTA I
monoamide I
cage O
( O
DOTA B
= O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I
1 I
, I
4 I
, I
7 I
, I
10 I
- I
tetraacetic I
acid I
) O
represents O
the O
magnetic O
resonance O
imaging O
reporter O
, O
which O
is O
spaced O
from O
the O
phenylpyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidineacetamide I
moiety O
( O
DPA B
- I
713 I
motif O
) O
by O
a O
six O
carbon B
- O
atom O
chain O
. O

The O
Gd B
- I
DOTA I
monoamide I
cage O
( O
DOTA B
= O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I
1 I
, I
4 I
, I
7 I
, I
10 I
- I
tetraacetic I
acid I
) O
represents O
the O
magnetic O
resonance O
imaging O
reporter O
, O
which O
is O
spaced O
from O
the O
phenylpyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidineacetamide I
moiety O
( O
DPA B
- I
713 I
motif O
) O
by O
a O
six O
carbon B
- O
atom O
chain O
. O

DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
relaxometric O
characterization O
showed O
the O
typical O
behavior O
of O
a O
small O
- O
sized O
molecule O
( O
relaxivity O
value O
: O
6 O
. O
02 O
mM O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
at O
20 O
MHz O
) O
. O

The O
good O
hydrophilicity O
of O
the O
metal O
chelate O
makes O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
soluble O
in O
water O
, O
affecting O
thus O
its O
biodistribution O
with O
respect O
to O
the O
parent O
lipophilic O
DPA B
- I
713 I
molecule O
. O

Whereas O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
binds O
to O
serum O
albumin O
with O
a O
low O
affinity O
constant O
, O
it O
can O
be O
entrapped O
into O
liposomes O
( O
both O
in O
the O
membrane O
and O
in O
the O
inner O
aqueous O
cavity O
) O
. O

2 B
- I
Carbaborane I
- I
3 I
- I
phenyl I
- I
1H I
- I
indoles I
- O
- O
synthesis O
via O
McMurry O
reaction O
and O
cyclooxygenase O
( O
COX O
) O
inhibition O
activity O
. O

Despite O
the O
lability O
of O
carbaboranes B
under O
reducing O
conditions O
, O
2 B
- I
carbaborane I
- I
3 I
- I
phenyl I
- I
1H I
- I
indoles I
could O
be O
synthesized O
by O
McMurry O
cyclization O
of O
the O
corresponding O
amides B
. O

Photophysical O
and O
electrochemical O
investigations O
of O
the O
fluorescent O
probe O
, O
4 B
, I
4 I
' I
- I
bis I
( I
2 I
- I
benzoxazolyl I
) I
stilbene I
. O

In O
solution O
, O
4 B
, I
4 I
' I
- I
bis I
( I
2 I
- I
benzoxazolyl I
) I
stilbene I
( O
BBS B
) O
was O
found O
to O
exhibit O
consistently O
high O
absolute O
fluorescence O
quantum O
yields O
( O
Phi O
( O
fl O
) O
> O
= O
0 O
. O
88 O
) O
and O
a O
monoexponential O
lifetime O
, O
both O
independent O
of O
BBS B
concentration O
. O

The O
resulting O
photoproduct O
was O
an O
aldehyde B
that O
was O
oxidized O
under O
ambient O
conditions O
to O
its O
corresponding O
carboxylic B
acid I
, O
i O
. O
e O
. O
, O
4 B
- I
( I
1 I
, I
3 I
- I
benzoxazol I
- I
2 I
- I
yl I
) I
benzoic I
acid I
. O

The O
colon O
carcinogen O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
is O
actively O
secreted O
in O
the O
distal O
colon O
of O
the O
rat O
: O
an O
integrated O
view O
on O
the O
role O
of O
PhIP B
transport O
and O
metabolism O
in O
PhIP B
- O
induced O
colon O
carcinogenesis O
. O

In O
a O
previous O
study O
, O
we O
have O
shown O
that O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
, O
the O
most O
abundantly O
formed O
HCA B
in O
the O
above O
- O
mentioned O
food O
items O
, O
is O
mainly O
absorbed O
in O
the O
small O
intestine O
( O
i O
. O
e O
. O
proximal O
jejunum O
) O
of O
the O
rat O
. O

Among O
the O
various O
analogues O
, O
trans B
- I
( I
4 I
- I
guanidino I
) I
cyclohexylmethylamid I
( O
GCMA B
) O
was O
identified O
as O
the O
most O
suitable O
P1 O
residue O
. O

A O
crystal O
structure O
in O
complex O
with O
the O
WNV O
protease O
was O
determined O
for O
one O
of O
the O
most O
potent O
inhibitors O
, O
3 B
, I
4 I
- I
dichlorophenylacetyl I
- I
Lys I
- I
Lys I
- I
GCMA I
( O
K O
( O
i O
) O
= O
0 O
. O
13 O
mu O
M O
) O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
- O
induced O
hypertension O
: O
The O
beneficial O
effects O
of O
melatonin B
. O

Objective O
: O
The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
effects O
of O
melatonin B
on O
biochemical O
and O
cardiovascular O
changes O
resulting O
from O
exposure O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
a O
polychlorinated B
dibenzo I
- I
para I
- I
dioxin I
. O
Methods O
: O
A O
total O
of O
24 O
Sprague O
- O
Dawley O
rats O
were O
divided O
equally O
into O
the O
following O
four O
groups O
: O
( O
1 O
) O
control O
group O
was O
administered O
with O
0 O
. O
5 O
mL O
corn O
oil O
by O
gavage O
and O
0 O
. O
5 O
cc O
vehicle O
of O

Poly B
( I
ferrocenyl I
( I
3 I
- I
bromopropyl I
) I
methylsilane I
) I
and O
poly B
( I
ethylene I
imine I
) I
are O
employed O
in O
a O
layer O
- O
by O
- O
layer O
deposition O
process O
to O
form O
covalently O
connected O
, O
redox O
- O
active O
multilayer O
thin O
films O
by O
means O
of O
an O
amine B
alkylation O
reaction O
. O

Highly O
selective O
2 B
, I
4 I
- I
diaminopyrimidine I
- I
5 I
- I
carboxamide I
inhibitors O
of O
Sky O
kinase O
. O

We O
report O
the O
SAR O
around O
a O
series O
of O
2 B
, I
4 I
- I
diaminopyrimidine I
- I
5 I
- I
carboxamide I
inhibitors O
of O
Sky O
kinase O
. O

Different O
from O
3 B
, I
4 I
- I
DHPEA I
, O
all O
thio O
derivatives O
of O
hydroxytyrosol B
induced O
apoptosis O
by O
a O
mechanism O
not O
involving O
the O
release O
of O
H B
( I
2 I
) I
O I
( I
2 I
) I
in O
the O
culture O
medium O
. O

By O
means O
of O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
, O
the O
main O
flavonoids B
in O
D O
. O
boryanum O
were O
tentatively O
identified O
as O
3 B
- I
hydroxyphloretin I
6 I
' I
- I
O I
- I
hexoside I
, O
quercetin B
- I
7 I
- I
hexoside I
, O
apigenin7 B
- I
O I
- I
glucoside I
, O
luteolin B
7 I
- I
O I
- I
glucoside I
, O
apigenin B
7 I
- I
O I
- I
galactoside I
, O
acacetin B
7 I
- I
O I
- I
( I
alpha I
- I
D I
- I
apio I
- I
furanosyl I
) I
( I
1 I
- I
- I
> I
6 I

) I
- I
beta I
- I
d I
- I
glucoside I
, O
3 B
- I
hydroxy I
phloretin I
6 I
- I
O I
- I
hexoside I
, O
luteolin B
- I
6 I
- I
C I
- I
glucoside I
. O

Importantly O
, O
significantly O
different O
optical O
rotations O
( O
[ O
alpha O
] O
D O
) O
compared O
to O
previous O
reports O
were O
found O
for O
suffruticosols B
A I
( I
+ I
95 I
vs I
- I
34 I
) I
and I
B I
( O
+ O
136 O
vs O
+ O
13 O
) O
. O

Antimicrobial O
activity O
of O
various O
4 B
- I
and I
5 I
- I
substituted I
1 I
- I
phenylnaphthalenes I
. O

1 B
- I
and I
12 I
- I
Aryl I
substituted I
benzo I
[ I
c I
] I
phenanthridines I
have O
been O
identified O
as O
antibacterial O
agents O
that O
could O
exert O
their O
activity O
by O
disruption O
of O
Z O
- O
ring O
formation O
. O

Substituted O
4 B
- I
and I
5 I
- I
amino I
- I
1 I
- I
phenylnaphthalenes I
represent O
substructures O
within O
the O
pharmacophore O
of O
these O
benzo B
[ I
c I
] I
phenanthridines I
. O

Several O
4 B
- I
and I
5 I
- I
substituted I
1 I
- I
phenylnaphthalenes I
were O
synthesized O
and O
evaluated O
for O
antibacterial O
activity O
against O
Staphylococcus O
aureus O
and O
Enterococcus O
faecalis O
. O

Fragment O
- O
based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
N B
- I
substituted I
- I
5 I
- I
( I
4 I
- I
isopropylthiophenol I
) I
- I
2 I
- I
hydroxynicotinamide I
derivatives O
as O
novel O
Mcl O
- O
1 O
inhibitors O
. O

We O
have O
previously O
reported O
a O
nanomolar O
inhibitor O
of O
antiapoptotic O
Mcl O
- O
1 O
protein O
, O
3 B
- I
thiomorpholin I
- I
8 I
- I
oxo I
- I
8H I
- I
acenaphtho I
[ I
1 I
, I
2 I
- I
b I
] I
pyrrole I
- I
9 I
- I
carbonitrile I
( O
S1 O
) O
. O

A O
novel O
potent O
compound O
, O
N B
- I
benzyl I
- I
5 I
- I
( I
4 I
- I
isopropylthiophenol I
) I
- I
2 I
- I
hydroxyl I
nicotinamide I
( O
12c O
) O
, O
which O
binds O
Mcl O
- O
1 O
with O
an O
IC O
( O
50 O
) O
value O
of O
54 O
nM O
was O
obtained O
. O

The O
current O
U O
. O
S O
. O
military O
and O
civilian O
oxime B
countermeasure O
, O
2 B
- I
[ I
( I
hydroxyimino I
) I
methyl I
] I
- I
1 I
- I
methylpyridin I
- I
1 I
- I
ium I
chloride I
( O
2 B
- I
PAM I
) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase O
reactivator O
, O
1 B
, I
1 I
' I
- I
methylenebis I
{ I
4 I
- I
hydroxyiminomethyl I
} I
pyridinium I
dimethanesulfonate I
( O
MMB B
- I
4 I
) O
. O

The O
current O
U O
. O
S O
. O
military O
and O
civilian O
oxime B
countermeasure O
, O
2 B
- I
[ I
( I
hydroxyimino I
) I
methyl I
] I
- I
1 I
- I
methylpyridin I
- I
1 I
- I
ium I
chloride I
( O
2 B
- I
PAM I
) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase O
reactivator O
, O
1 B
, I
1 I
' I
- I
methylenebis I
{ I
4 I
- I
hydroxyiminomethyl I
} I
pyridinium I
dimethanesulfonate I
( O
MMB B
- I
4 I
) O
. O

Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB B
- I
4 I
are O
limited O
; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
( O
PBPK O
) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime B
, O
1 B
, I
1 I
' I
- I
trimethylenebis I
{ I
4 I
- I
hydroximinomethyl I
} I
pyridinium I
dibromide I
. O

Study O
of O
intracellular O
delivery O
of O
doxorubicin B
from O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
nanoparticles O
by O
means O
of O
fluorescence O
lifetime O
imaging O
and O
confocal O
Raman O
microscopy O
. O

The O
intracellular O
delivery O
of O
Doxorubicin B
( O
Dox B
) O
from O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
nanoparticles O
stabilised O
with O
bovine O
serum O
albumin O
, O
in O
HepG2 O
cells O
, O
is O
studied O
via O
flow O
cytometry O
, O
fluorescence O
lifetime O
imaging O
microscopy O
( O
FLIM O
) O
, O
confocal O
Raman O
microscopy O
( O
CRM O
) O
and O
cell O
viability O
studies O
. O

We O
report O
a O
facile O
" O
one O
- O
pot O
" O
method O
for O
the O
synthesis O
of O
Sn B
- O
embedded O
carbon B
- O
silica B
( O
CS O
) O
mesostructured O
( O
nanostructured O
) O
composites O
through O
the O
selective O
interaction O
of O
resol O
( O
carbon B
precursor O
) O
, O
tetraethylorthosilic B
( O
TEOS B
) O
, O
and O
tributylphenyltin B
( O
Sn B
precursor O
) O
with O
an O
amphiphilic O
diblock O
copolymer O
, O
poly B
( I
ethylene I
oxide I
- I
b I
- I
styrene I
) I
, O
PEO B
- I
b I
- I
PS I
. O

Pharmacokinetics O
and O
metabolism O
of O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
methoxyphenyl I
) I
methane I
( O
C O
- O
DIM5 O
) O
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
phenyl I
) I
methane I
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
hydroxyphenyl I
) I
methane I
( O
C O
- O
DIM8 O
) O
, O
and O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I

Pharmacokinetics O
and O
metabolism O
of O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
methoxyphenyl I
) I
methane I
( O
C O
- O
DIM5 O
) O
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
phenyl I
) I
methane I
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
hydroxyphenyl I
) I
methane I
( O
C O
- O
DIM8 O
) O
, O
and O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I

Pharmacokinetics O
and O
metabolism O
of O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
methoxyphenyl I
) I
methane I
( O
C O
- O
DIM5 O
) O
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
phenyl I
) I
methane I
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
hydroxyphenyl I
) I
methane I
( O
C O
- O
DIM8 O
) O
, O
and O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I

After O
pharmacokinetic O
studies O
, O
the O
neuroprotective O
efficacy O
of O
C O
- O
DIM5 O
, O
C O
- O
DIM8 O
, O
and O
C O
- O
DIM12 O
( O
50 O
mg O
/ O
Kg O
per O
oral O
) O
was O
examined O
in O
mice O
exposed O
to O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
and O
probenecid B
for O
14 O
days O
, O
a O
model O
of O
progressive O
neurodegeneration O
with O
a O
strong O
neuroinflammatory O
component O
. O

None O
of O
the O
metabolites O
cotinine B
, O
cotinine B
- I
N I
- I
oxide I
, O
nicotine B
- I
1 I
' I
- I
N I
- I
oxide I
or O
trans B
- I
3 I
' I
- I
hydroxycotinine I
( O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
affected O
platelet O
aggregation O
or O
P O
- O
selectin O
expression O
. O

Nicotine B
( O
10 O
mu O
M O
) O
weakly O
increased O
platelet O
aggregation O
, O
whereas O
trans B
- I
3 I
' I
- I
hydroxycotinine I
( O
0 O
. O
1 O
mu O
M O
) O
and O
nicotine B
- I
1 I
' I
- I
N I
- I
oxide I
( O
1 O
- O
10 O
mu O
M O
) O
weakly O
inhibited O
adhesion O
to O
fibrinogen O
. O

ICA B
- I
105574 I
( O
ICA B
, O
or O
3 B
- I
nitro I
- I
N I
- I
[ I
4 I
- I
phenoxyphenyl I
] I
- I
benzamide I
) O
has O
opposite O
effects O
on O
inactivation O
of O
these O
two O
channel O
types O
. O

To O
establish O
proof O
of O
concept O
, O
microparticles O
were O
prepared O
with O
PLGA B
[ O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
50 O
: O
50 O
, O
MW O
. O
7000 O
- O
17000 O
] O
, O
hydroxypropyl B
methyl I
cellulose O
( O
HPMC O
) O
, O
and O
DXM B
by O
oil O
- O
in O
- O
water O
emulsion O
/ O
solvent O
evaporation O
technique O
. O

The O
newly O
synthesized O
cationic O
polymer O
, O
named O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
, O
could O
be O
cleaved O
efficiently O
, O
and O
FA O
was O
readily O
released O
under O
reductive O
condition O
similar O
to O
intracellular O
environment O
. O

The O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
polymer O
was O
well O
- O
characterized O
and O
studied O
in O
terms O
of O
its O
gene O
delivery O
properties O
in O
FR O
- O
positive O
KB O
cells O
and O
FR O
- O
negative O
A549 O
cells O
under O
various O
conditions O
, O
in O
comparison O
with O
cationic O
polymers O
such O
as O
high O
molecular O
weight O
branched O
polyethylenimine B
( O
PEI B
) O
, O
gamma B
- I
CD I
- I
OEI I
star O
- O
shaped O
cationic O
polymer O
, O
gamma B
- I
CD I
- I
OEI I
- I
FA I
polymer O
where O
FA O
was O
directed O
linked O
to O
the O
star O
polymer O
without O
disulfide B
linker O
. O

Our O
data O
have O
demonstrated O
that O
the O
new O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
gene O
carrier O
had O
low O
cytotoxicity O
and O
possessed O
capacity O
to O
target O
and O
deliver O
DNA O
to O
specific O
tumor O
cells O
that O
overexpress O
FRs O
, O
as O
well O
as O
functions O
to O
recover O
and O
recycle O
FRs O
onto O
cellular O
membranes O
to O
facilitate O
continuous O
FR O
- O
mediated O
endocytosis O
to O
achieve O
very O
high O
levels O
of O
gene O
expression O
. O

A O
new O
2 B
, I
5 I
- I
diketopiperazine I
, O
( B
R I
) I
- I
2 I
- I
( I
2 I
- I
( I
furan I
- I
2 I
- I
yl I
) I
- I
oxoethyl I
) I
- I
octahydropyrrolo I
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
- I
1 I
, I
4 I
- I
dione I
, O
and O
seven O
known O
compounds O
were O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
liquid O
fermentation O
broth O
of O
Armillaria O
mellea O
. O

A O
new O
di B
- I
O I
- I
prenylated I
flavone I
, O
named O
7 B
, I
3 I
' I
- I
di I
- I
( I
gamma I
, I
gamma I
- I
dimethylallyloxy I
) I
- I
5 I
- I
hydroxy I
- I
4 I
' I
- I
methoxyflavone I
( O
1 O
) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
the O
endophytic O
actinomycete O
Streptomyces O
sp O
. O

Evolution O
of O
novel O
tricyclic O
CRTh2 O
receptor O
antagonists O
from O
a O
( B
E I
) I
- I
2 I
- I
cyano I
- I
3 I
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
acrylamide I
scaffold O
. O

( B
E I
) I
- I
2 I
- I
( I
3 I
- I
( I
3 I
- I
( I
( I
3 I
- I
Bromophenyl I
) I
amino I
) I
- I
2 I
- I
cyano I
- I
3 I
- I
oxoprop I
- I
1 I
- I
en I
- I
1 I
- I
yl I
) I
- I
1H I
- I
indol I
- I
1 I
- I
yl I
) I
acetic I
acid I
( O
1 O
) O
was O
discovered O
in O
a O
HTS O
campaign O
for O
CRTh2 O
receptor O
antagonists O
. O

Ring O
closing O
tactics O
to O
convert O
this O
hit O
series O
into O
a O
novel O
2 B
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
pyrido I
[ I
4 I
, I
3 I
- I
b I
] I
indole I
based O
CRTh2 O
receptor O
antagonist O
series O
is O
presented O
. O

Design O
and O
synthesis O
of O
some O
new O
quinazolin B
- I
4 I
- I
( I
3H I
) I
- I
ones I
as O
anticonvulsant O
and O
antidepressant O
agents O
. O

A O
series O
of O
3 B
- I
[ I
( I
4 I
- I
substituted I
- I
benzylidene I
) I
- I
amino I
] I
- I
2 I
- I
phenyl I
- I
3H I
- I
quinazolin I
- I
4 I
- I
ones I
( O
5a O
- O
k O
) O
were O
synthesized O
by O
reacting O
3 B
- I
amino I
- I
2 I
- I
phenyl I
- I
1H I
- I
quinazolin I
- I
4 I
- I
one I
with O
p B
- I
hydroxybenzaldehyde I
, O
and O
then O
further O
with O
various O
alkyl B
/ I
benzyl I
halides I
or O
substituted O
phenacyl B
bromides I
. O

A O
series O
of O
3 B
- I
[ I
( I
4 I
- I
substituted I
- I
benzylidene I
) I
- I
amino I
] I
- I
2 I
- I
phenyl I
- I
3H I
- I
quinazolin I
- I
4 I
- I
ones I
( O
5a O
- O
k O
) O
were O
synthesized O
by O
reacting O
3 B
- I
amino I
- I
2 I
- I
phenyl I
- I
1H I
- I
quinazolin I
- I
4 I
- I
one I
with O
p B
- I
hydroxybenzaldehyde I
, O
and O
then O
further O
with O
various O
alkyl B
/ I
benzyl I
halides I
or O
substituted O
phenacyl B
bromides I
. O

Compound O
3 B
- I
[ I
( I
4 I
- I
butoxy I
- I
benzylidene I
) I
- I
amino I
] I
- I
2 I
- I
phenyl I
- I
3H I
- I
quinazolin I
- I
4 I
- I
one I
was O
emerged O
as O
the O
most O
promising O
anticonvulsant O
agent O
without O
any O
motor O
impairment O
effect O
. O

Quasiclassical O
Trajectory O
Study O
of O
CH B
( I
3 I
) I
NO I
( I
2 I
) I
Decomposition O
via O
Roaming O
Mediated O
Isomerization O
Using O
a O
Global O
Potential O
Energy O
Surface O
. O

We O
report O
a O
global O
potential O
energy O
surface O
( O
PES O
) O
for O
CH B
( I
3 I
) I
NO I
( I
2 I
) I
based O
on O
fitting O
roughly O
114 O
000 O
density O
functional O
theory O
( O
UB3LYP O
/ O
6 O
- O
311 O
+ O
g O
( O
d O
, O
p O
) O
) O
electronic O
energies O
. O

We O
showed O
previously O
, O
using O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
4 I
- I
propyl I
- I
9 I
- I
hydroxynaphthoxazine I
( O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
) O
autoradiography O
, O
that O
several O
antipsychotic O
drugs O
do O
not O
occupy O
dopamine B
D3 O
receptors O
at O
clinically O
- O
relevant O
doses O
in O
rat O
. O

We O
showed O
previously O
, O
using O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
4 I
- I
propyl I
- I
9 I
- I
hydroxynaphthoxazine I
( O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
) O
autoradiography O
, O
that O
several O
antipsychotic O
drugs O
do O
not O
occupy O
dopamine B
D3 O
receptors O
at O
clinically O
- O
relevant O
doses O
in O
rat O
. O

The O
purpose O
of O
the O
current O
study O
was O
to O
address O
two O
possible O
methodological O
limitations O
of O
our O
previous O
report O
, O
namely O
that O
( O
1 O
) O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
may O
have O
been O
administered O
at O
non O
- O
tracer O
dose O
, O
potentially O
causing O
underestimate O
of O
D3 O
receptor O
occupancy O
, O
and O
( O
2 O
) O
antipsychotic O
drugs O
were O
administered O
chronically O
, O
potentially O
causing O
increased O
D3 O
receptor O
expression O
not O
accounted O
for O
in O
the O
vehicle O
- O
treated O
control O
group O
. O

We O
found O
that O
decreasing O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
dose O
from O
5 O
. O
6nmol O
/ O
kg O
( O
our O
previous O
dose O
) O
to O
0 O
. O
6nmol O
/ O
kg O
caused O
a O
> O
60 O
% O
increase O
in O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
binding O
to O
D3 O
receptors O
in O
cerebellar O
lobes O
9 O
and O
10 O
, O
indicating O
that O
our O
previous O
study O
was O
indeed O
conducted O
under O
non O
- O
tracer O
dose O
conditions O
. O

We O
found O
that O
decreasing O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
dose O
from O
5 O
. O
6nmol O
/ O
kg O
( O
our O
previous O
dose O
) O
to O
0 O
. O
6nmol O
/ O
kg O
caused O
a O
> O
60 O
% O
increase O
in O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
binding O
to O
D3 O
receptors O
in O
cerebellar O
lobes O
9 O
and O
10 O
, O
indicating O
that O
our O
previous O
study O
was O
indeed O
conducted O
under O
non O
- O
tracer O
dose O
conditions O
. O

However O
, O
neither O
reducing O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
dose O
further O
to O
0 O
. O
3nmol O
/ O
kg O
( O
a O
tracer O
dose O
) O
, O
nor O
administering O
antipsychotics O
acutely O
affected O
antipsychotic O
receptor O
occupancy O
. O

Potential O
energy O
surfaces O
of O
anionic O
B B
( I
6 I
) I
H I
( I
y I
) I
clusters O
were O
sampled O
using O
the O
coalescence O
kick O
method O
. O

This O
is O
an O
important O
discovery O
because O
this O
transition O
suggests O
a O
major O
structural O
change O
as O
a O
function O
of O
dehydrogenation O
for O
the O
stoichiometric O
B B
( I
n I
) I
H I
( I
n I
) I
( I
- I
) I
polyhedral B
boranes I
. O

We O
also O
found O
that O
the O
B B
( I
6 I
) I
H I
( I
3 I
) I
( I
- I
) I
global O
minimum O
structure O
has O
an O
optical O
isomer O
. O

From O
our O
chemical O
bonding O
analysis O
, O
we O
concluded O
that O
the O
2D O
- O
3D O
transition O
occurs O
at O
B B
( I
6 I
) I
H I
( I
4 I
) I
( I
- I
) I
because O
the O
addition O
of O
one O
extra O
hydrogen B
atom O
further O
destroys O
the O
network O
of O
the O
peripheral O
2c O
- O
2e O
B B
- I
B I
sigma O
- O
bonding O
, O
making O
planar O
structures O
less O
stable O
, O
and O
because O
the O
distorted O
octahedral O
structure O
provides O
some O
occupation O
of O
all O
s O
- O
and O
p O
- O
AOs O
of O
boron B
, O
avoiding O
the O
presence O
of O
any O
empty O
atomic O
orbitals O
. O

The O
surface O
oxidation O
and O
hydrophobicity O
of O
natural O
enargite B
( O
Cu B
( I
3 I
) I
AsS I
( I
4 I
) I
) O
and O
the O
formation O
of O
oxidation O
species O
at O
the O
mineral O
surface O
have O
been O
examined O
by O
a O
novel O
experimental O
approach O
that O
combines O
electrochemical O
techniques O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

A O
new O
pyroxene B
compound O
, O
NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
, O
has O
been O
synthesized O
at O
3 O
GPa O
and O
800 O
degrees O
C O
and O
fully O
characterized O
by O
X O
- O
ray O
single O
- O
crystal O
diffraction O
, O
neutron O
powder O
diffraction O
, O
and O
measurements O
of O
magnetization O
and O
specific O
heat O
. O

NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
crystallizes O
into O
a O
monoclinic O
C2 O
/ O
c O
structure O
with O
unit O
- O
cell O
parameters O
a O
= O
9 O
. O
859 O
( O
2 O
) O
A O
, O
b O
= O
8 O
. O
7507 O
( O
18 O
) O
A O
, O
c O
= O
5 O
. O
5724 O
( O
11 O
) O
A O
, O
and O
beta O
= O
105 O
. O
64 O
( O
3 O
) O
degrees O
at O
153 O
K O
. O

This O
feature O
distinguishes O
NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
from O
other O
pyroxene B
compounds O
without O
Jahn O
- O
Teller O
active O
cations O
and O
suggests O
that O
the O
Jahn O
- O
Teller O
distortion O
competes O
with O
the O
intrinsic O
local O
distortion O
in O
the O
pyroxene B
structure O
. O

Like O
other O
alkali O
- O
metal O
pyroxenes B
with O
S O
> O
( O
1 O
) O
/ O
( O
2 O
) O
, O
NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
( O
S O
= O
2 O
) O
was O
found O
to O
undergo O
a O
long O
- O
range O
antiferromagnetic O
( O
AF O
) O
ordering O
at O
T O
( O
N O
) O
= O
7 O
K O
due O
to O
intrachain O
and O
interchain O
exchange O
interactions O
. O

By O
using O
whole O
- O
cell O
patch O
clamp O
recordings O
in O
brain O
slices O
, O
we O
investigated O
the O
ability O
of O
( B
RS I
) I
- I
3 I
, I
5 I
- I
dihydroxyphenylglyci I
( O
DHPG B
) O
, O
a O
group O
I O
metabotropic O
glutamate B
receptor O
( O
mGluR O
) O
agonist O
, O
to O
evoke O
K B
- O
ATP B
currents O
. O

DHPG B
outward O
current O
was O
also O
blocked O
by O
ryanodine B
and O
2 B
- I
aminoethoxydiphenylb I
, O
suggesting O
mediation O
by O
ryanodine B
- O
and O
inositol B
1 I
, I
4 I
, I
5 I
- I
triphosphate I
- O
sensitive O
Ca B
( I
2 I
+ I
) I
release O
. O

The O
nitric B
oxide I
synthase O
inhibitor O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
and O
inhibitors O
of O
protein O
kinase O
G O
activity O
also O
suppressed O
DHPG B
- O
induced O
outward O
current O
. O

Dimolybdenum B
quadruply O
bonded O
compounds O
containing O
a O
pendant O
lactam B
functional O
group O
form O
self O
- O
complementary O
hydrogen B
bonded O
' O
dimers O
of O
dimers O
' O
in O
the O
solid O
- O
state O
and O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solutions O
. O

Electrochemical O
studies O
in O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
show O
two O
consecutive O
one O
- O
electron O
redox O
processes O
corresponding O
to O
oxidation O
of O
the O
Mo B
( I
2 I
) I
( I
4 I
+ I
) I
cores O
. O

Electrochemical O
studies O
in O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
show O
two O
consecutive O
one O
- O
electron O
redox O
processes O
corresponding O
to O
oxidation O
of O
the O
Mo B
( I
2 I
) I
( I
4 I
+ I
) I
cores O
. O

Photoinduced O
formation O
mechanism O
of O
the O
thymine B
- I
thymine I
( I
6 I
- I
4 I
) I
adduct O
. O

The O
photoinduced O
mechanism O
leading O
to O
the O
formation O
of O
the O
thymine B
- I
thymine I
( I
6 I
- I
4 I
) I
photolesion O
has O
been O
studied O
by O
using O
the O
CASPT2 O
/ O
/ O
CASSCF O
approach O
over O
a O
dinucleotide B
model O
in O
vacuo O
. O

The O
requirement O
of O
localized O
excitation O
on O
just O
one O
thymine B
, O
whose O
main O
decay O
channel O
( O
by O
radiationless O
repopulation O
of O
its O
ground O
state O
) O
is O
nonphotochemical O
, O
can O
rationalize O
the O
experimentally O
observed O
low O
quantum O
yield O
of O
formation O
for O
the O
thymine B
- I
thymine I
( I
6 I
- I
4 I
) I
adduct O
. O

OATP O
/ O
Oatp O
substrates O
include O
drugs O
that O
are O
efficacious O
in O
treatment O
of O
pain O
and O
/ O
or O
cerebral O
hypoxia O
( O
i O
. O
e O
. O
, O
opioid O
analgesic O
peptides O
, O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
inhibitors O
) O
. O

A O
donor O
- O
acceptor O
type O
organic O
dye O
connected O
with O
a O
quinoidal B
thiophene I
as O
a O
pi O
- O
conjugated O
chain O
, O
cyano B
- I
[ I
5 I
' I
- I
( I
4 I
' I
' I
- I
( I
N I
, I
N I
- I
dimethylamino I
) I
benzylidene I
) I
- I
5H I
- I
thiophen I
- I
2 I
' I
- I
ylidene I
] I
acetic I
acid I
, O
was O
synthesized O
and O
applied O
to O
dye O
- O
sensitized O
solar O
cells O
( O
DSSCs O
) O
. O

In O
GK O
islets O
, O
both O
H B
( I
2 I
) I
O I
( I
2 I
) I
and O
superoxide B
were O
sufficiently O
reduced O
and O
glucose B
- O
induced O
IS O
and O
ATP B
elevation O
were O
improved O
by O
TE O
- O
treatment O
. O

These O
results O
, O
which O
are O
not O
intuitively O
explained O
by O
electrostatics O
arguments O
, O
have O
been O
obtained O
by O
combining O
in O
situ O
real O
time O
structural O
and O
electrical O
characterization O
together O
with O
ex O
situ O
AFM O
measurements O
, O
on O
thin O
films O
of O
a O
relevant O
n O
- O
type O
organic O
semiconductor O
, O
N B
, I
N I
' I
- I
bis I
( I
n I
- I
octyl I
) I
- I
dicyanoperylene I
- I
3 I
, I
4 I
: I
9 I
, I
10 I
- I
bis I
dicarboximide I
grown O
by O
sublimation O
in O
a O
quasi O
- O
layer O
- O
by O
- O
layer O
mode O
at O
different O
substrate O
temperatures O
. O

Pharmacokinetics O
, O
tissue O
distribution O
and O
excretion O
study O
of O
resveratrol B
and O
its O
prodrug O
3 B
, I
5 I
, I
4 I
' I
- I
tri I
- I
O I
- I
acetylresveratrol I
in O
rats O
. O

3 B
, I
5 I
, I
4 I
' I
- I
Tri I
- I
O I
- I
acetylresveratrol I
( O
TARES B
) O
synthesized O
by O
acetylating O
three O
hydroxyl B
groups O
of O
resveratrol B
( O
RES B
) O
is O
a O
prodrug O
of O
RES B
. O

Syntheses O
and O
anti O
- O
allergic O
activity O
of O
2 B
- I
( I
( I
bis I
( I
trimethylsilyl I
) I
methylthio I
/ I
methylsulfonyl I
) I
methyl I
) I
- I
5 I
- I
aryl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
. O

A O
new O
class O
of O
sila B
- I
substituted I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
was O
synthesized O
by O
a O
convenient O
synthetic O
method O
. O

Both O
silathio B
/ I
silasulfonyl I
acetic I
acids I
were O
efficiently O
condensed O
with O
benzohydrazides B
in O
the O
presence O
of O
phosphorus B
oxychloride I
to O
give O
sila B
- I
substituted I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
in O
high O
yields O
. O

Compounds O
having O
sulfonyl B
moiety O
with O
bis B
( I
trimethylsilyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
( O
5a O
- O
c O
) O
, O
exhibited O
better O
anti O
- O
allergic O
activities O
than O
those O
of O
compounds O
having O
sulphur B
moiety O
with O
bis B
( I
trimethylsilyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
( O
4a O
- O
c O
) O
. O

Compounds O
having O
sulfonyl B
moiety O
with O
bis B
( I
trimethylsilyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
( O
5a O
- O
c O
) O
, O
exhibited O
better O
anti O
- O
allergic O
activities O
than O
those O
of O
compounds O
having O
sulphur B
moiety O
with O
bis B
( I
trimethylsilyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
( O
4a O
- O
c O
) O
. O

( B
E I
) I
- I
4 I
- I
Aryl I
- I
4 I
- I
oxo I
- I
2 I
- I
butenoic I
acid I
amides I
, O
chalcone B
- I
aroylacrylic I
acid I
chimeras O
: O
Design O
, O
antiproliferative O
activity O
and O
inhibition O
of O
tubulin O
polymerization O
. O

Antiproliferative O
activity O
of O
twenty O
- O
nine O
( B
E I
) I
- I
4 I
- I
aryl I
- I
4 I
- I
oxo I
- I
2 I
- I
butenoic I
acid I
amides I
against O
three O
human O
tumor O
cell O
lines O
( O
HeLa O
, O
FemX O
, O
and O
K562 O
) O
is O
reported O
. O

A O
new O
iridoid B
glycoside I
, O
rotunduside B
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid B
glycosides I
, O
10 B
- I
O I
- I
p I
- I
hydroxybenzoylthevir I
( O
2 O
) O
, O
10 B
- I
O I
- I
vanilloyltheviridosi I
( O
3 O
) O
, O
6 B
' I
' I
- I
O I
- I
( I
trans I
- I
p I
- I
coumaroyl I
) I
- I
procumbide I
( O
4 O
) O
and O
loganic B
acid I
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

Two O
new O
glycosides O
, O
2 B
- I
methyl I
pyromeconic I
acid I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
- I
6 I
' I
- I
( I
O I
- I
4 I
' I
' I
- I
hydroxybenzoate I
) I
( O
1 O
) O
, O
6 B
' I
- I
O I
- I
p I
- I
hydroxybenzoyl I
- I
gardoside I
( O
2 O
) O
and O
four O
known O
iridoid B
glycosides I
( O
3 O
- O
6 O
) O
were O
isolated O
from O
the O
whole O
plant O
of O
Vitex O
negundo O
. O

Two O
new O
glycosides O
, O
2 B
- I
methyl I
pyromeconic I
acid I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
- I
6 I
' I
- I
( I
O I
- I
4 I
' I
' I
- I
hydroxybenzoate I
) I
( O
1 O
) O
, O
6 B
' I
- I
O I
- I
p I
- I
hydroxybenzoyl I
- I
gardoside I
( O
2 O
) O
and O
four O
known O
iridoid B
glycosides I
( O
3 O
- O
6 O
) O
were O
isolated O
from O
the O
whole O
plant O
of O
Vitex O
negundo O
. O

Its O
head O
- O
space O
aroma O
displayed O
new O
volatile O
phytomolecules O
and O
also O
had O
higher O
levels O
of O
green O
volatiles O
from O
the O
lipoxygenase O
( O
LOX O
) O
- O
pathway O
( O
one O
having O
as O
precursors O
the O
polyunsaturated B
fatty I
acids I
containing O
a O
cis B
- I
cis I
- I
1 I
, I
4 I
- I
pentadiene I
system O
) O
. O

glycolide I
) I
acid I
( O
PLGA B
- I
PEO I
) O
nanoparticles O
( O
NPs O
) O
with O
metabolically O
active O
rat O
hepatocytes O
for O
4 O
and O
24 O
- O
h O
periods O
. O

Synthesis O
and O
Structure O
- O
Activity O
Relationships O
of O
N B
- I
Methyl I
- I
5 I
, I
6 I
, I
7 I
- I
trimethoxylindoles I
as O
Novel O
Antimitotic O
and O
Vascular O
Disrupting O
Agents O
. O

N B
- I
Methyl I
- I
5 I
, I
6 I
, I
7 I
- I
trimethoxylindoles I
21 O
and O
31 O
displayed O
the O
highest O
antiproliferative O
activities O
, O
with O
IC O
( O
50 O
) O
values O
ranging O
from O
22 O
to O
125 O
nM O
in O
four O
human O
cancer O
cell O
lines O
and O
activated O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
. O

Identification O
of O
a O
small O
- O
molecule O
inhibitor O
of O
HIV O
- O
1 O
assembly O
that O
targets O
the O
phosphatidylinositol B
( I
4 I
, I
5 I
) I
- I
bisphosphate I
binding O
site O
of O
the O
HIV O
- O
1 O
matrix O
protein O
. O

We O
previously O
reported O
on O
a O
novel O
anti O
- O
HIV O
- O
1 O
compound O
, O
N B
( I
2 I
) I
- I
( I
phenoxyacetyl I
) I
- I
N I
- I
[ I
4 I
- I
( I
1 I
- I
piperidinylcarbonyl I
) I
benzyl I
] I
glycinamide I
( O
14 O
) O
, O
that O
binds O
to O
the O
highly O
conserved O
phosphatidylinositol B
( I
4 I
, I
5 I
) I
- I
bisphosphate I
( O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
) O
binding O
pocket O
of O
the O
HIV O
- O
1 O
matrix O
( O
MA O
) O
protein O
. O

We O
previously O
reported O
on O
a O
novel O
anti O
- O
HIV O
- O
1 O
compound O
, O
N B
( I
2 I
) I
- I
( I
phenoxyacetyl I
) I
- I
N I
- I
[ I
4 I
- I
( I
1 I
- I
piperidinylcarbonyl I
) I
benzyl I
] I
glycinamide I
( O
14 O
) O
, O
that O
binds O
to O
the O
highly O
conserved O
phosphatidylinositol B
( I
4 I
, I
5 I
) I
- I
bisphosphate I
( O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
) O
binding O
pocket O
of O
the O
HIV O
- O
1 O
matrix O
( O
MA O
) O
protein O
. O

We O
previously O
reported O
on O
a O
novel O
anti O
- O
HIV O
- O
1 O
compound O
, O
N B
( I
2 I
) I
- I
( I
phenoxyacetyl I
) I
- I
N I
- I
[ I
4 I
- I
( I
1 I
- I
piperidinylcarbonyl I
) I
benzyl I
] I
glycinamide I
( O
14 O
) O
, O
that O
binds O
to O
the O
highly O
conserved O
phosphatidylinositol B
( I
4 I
, I
5 I
) I
- I
bisphosphate I
( O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
) O
binding O
pocket O
of O
the O
HIV O
- O
1 O
matrix O
( O
MA O
) O
protein O
. O

This O
study O
resulted O
in O
the O
identification O
of O
three O
new O
compounds O
with O
antiviral O
activity O
; O
2 B
- I
( I
4 I
- I
{ I
[ I
3 I
- I
( I
4 I
- I
fluorophenyl I
) I
- I
1 I
, I
2 I
, I
4 I
- I
oxadiazol I
- I
5 I
- I
yl I
] I
methyl I
} I
) I
- I
1 I
- I
piperazinyl I
) I
- I
N I
- I
( I
4 I
- I
methylphenyl I
) I
acetamide I
( O
7 O
) O
, O
3 B
- I
( I
2 I
- I
ethoxyphenyl I
) I
- I
5 I
- I
[ I
[ I
4 I
- I
( I
4 I
- I
nitrophenyl I
) I
piperazin I
- I
1 I
- I
yl I
] I
methyl I
] I
- I
1 I
, I

2 I
, I
4 I
- I
oxadiazole I
( O
17 O
) O
, O
and O
N B
- I
[ I
4 I
- I
ethoxy I
- I
3 I
- I
( I
1 I
- I
piperidinylsulfonyl I
) I
phenyl I
] I
- I
2 I
- I
( I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
[ I
1 I
, I
3 I
] I
thiazol I
- I
6 I
- I
yl I
) I
acetamide I
( O
18 O
) O
, O
with O
compound O
7 O
being O
the O
most O
potent O
of O
these O
hits O
. O

In O
accordance O
with O
our O
drug O
target O
, O
compound O
7 O
competes O
with O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
for O
MA O
binding O
and O
, O
as O
a O
result O
, O
diminishes O
the O
production O
of O
new O
virus O
. O

Mutation O
of O
residues O
within O
the O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
binding O
site O
of O
MA O
decreased O
the O
antiviral O
effect O
of O
compound O
7 O
. O

The O
purpose O
of O
this O
work O
is O
to O
prepare O
a O
nanoparticulate O
drug O
delivery O
system O
of O
donepezil B
using O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
for O
sustained O
release O
and O
efficient O
brain O
targeting O
. O

Our O
in O
vitro O
studies O
showed O
that O
cyclic B
adenosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cAMP B
) O
accumulation O
was O
not O
a O
primary O
cause O
of O
the O
ritodrine B
- O
induced O
SAA O
increase O
. O

A O
variety O
of O
other O
drugs O
, O
such O
as O
topiramate B
, O
TG41 B
, O
( B
+ I
) I
- I
and I
( I
- I
) I
- I
borneol I
, O
apigenin B
, O
and O
6 B
- I
methylflavone I
could O
also O
have O
modulatory O
effects O
on O
the O
GABA B
A O
receptors O
. O

There O
are O
many O
human O
extra O
- O
renal O
tissues O
and O
cells O
that O
biosynthesize O
1 B
alpha I
, I
25 I
- I
dihydroxyvitamin I
D I
( O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
) O
by O
the O
action O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
. O

Their O
in O
vitro O
differentiation O
to O
osteoblasts O
is O
stimulated O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
, O
and O
recent O
evidence O
indicates O
that O
they O
have O
the O
capacity O
to O
metabolize O
vitamin B
D I
in O
a O
regulated O
manner O
. O

The O
finding O
that O
hMSCs O
are O
a O
both O
a O
producer O
and O
target O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
suggests O
a O
potential O
autocrine O
/ O
paracrine O
role O
of O
vitamin B
D I
metabolism O
in O
osteoblast O
differentiation O
. O

Expression O
and O
enzyme O
activity O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
are O
upregulated O
by O
substrate O
25 B
( I
OH I
) I
D I
and O
Parathyroid O
Hormone O
( O
PTH O
) O
and O
are O
downregulated O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

With O
subject O
age O
, O
there O
are O
decreases O
in O
basal O
osteoblast O
potential O
and O
in O
stimulation O
of O
osteoblastogenesis O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
, O
25 B
( I
OH I
) I
D I
, O
and O
PTH O
. O

These O
studies O
suggest O
that O
osteoblastogenesis O
may O
not O
be O
optimal O
unless O
there O
is O
sufficient O
serum O
25 B
( I
OH I
) I
D I
substrate O
for O
hMSCs O
to O
synthesize O
and O
respond O
to O
local O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

PCA O
- O
derived O
factors O
with O
levels O
that O
differed O
the O
most O
between O
MW O
and O
MUW O
groups O
were O
factors O
4 O
( O
branched O
chain O
amino B
acids I
[ O
BCAA O
] O
) O
[ O
p O
< O
. O
0001 O
] O
, O
8 O
( O
various O
metabolites O
) O
[ O
p O
< O
. O
0001 O
] O
, O
9 O
( O
C4 B
/ I
Ci4 I
, I
C3 I
, I
C5 I
acylcarnitines I
) O
[ O
p O
< O
. O
0001 O
] O
and O
10 O
( O
amino B
acids I
) O
[ O
p O
< O
. O
0002 O
] O
. O

Their O
inhibitory O
activity O
, O
along O
with O
previously O
synthesized O
analogues O
( O
C35 B
- I
fluoro I
, I
C35 I
- I
difluoro I
, I
and I
C35 I
- I
trifluorosolamins I
) O
, O
against O
bovine O
mitochondrial O
NADH B
- O
ubiquinone B
oxidoreductase O
( O
complex O
I O
) O
was O
determined O
. O

We O
report O
a O
series O
of O
new O
9 B
- I
oxime I
ether B
non O
- O
ketolides B
, O
including O
3 B
- I
hydroxyl I
, I
3 I
- I
O I
- I
acyl I
and I
3 I
- I
O I
- I
alkyl I
clarithromycin I
derivatives O
, O
and O
thiophene B
- O
containing O
ketolides B
1b O
- O
1d O
. O

Antioxidative O
enzyme O
or O
compounds O
such O
as O
catalase O
, O
acteoside B
, O
and O
( B
E I
) I
- I
1 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenethyl I
) I
- I
3 I
- I
( I
4 I
- I
hydroxystyryl I
) I
urea I
suppressed O
the O
ZEN B
metabolite O
- O
mediated O
reduction O
of O
cell O
viability O
. O

Arsenite B
- O
induced O
ROS O
generation O
and O
COX O
- O
2 O
expression O
were O
significantly O
attenuated O
by O
treatment O
with O
melatonin B
( O
a O
ROS O
scavenger O
) O
, O
but O
enhanced O
by O
DL B
- I
buthionine I
- I
( I
S I
, I
R I
) I
- I
sulfoximine I
( O
BSO B
, O
an O
inhibitor O
of O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
resulting O
in O
lower O
GSH B
and O
increased O
ROS O
levels O
) O
. O

Compound O
5 O
showed O
, O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
and O
beta B
- I
carotene I
systems O
, O
similar O
antioxidant O
activity O
when O
compared O
to O
compound O
( O
1 O
) O
. O

The O
method O
involves O
wet O
- O
spinning O
of O
poly B
( I
3 I
, I
4 I
- I
ethylenedioxythiophe I
) I
poly B
( I
styrenesulfonate I
) I
( O
PEDOT B
: O
PSS B
) O
fibre O
, O
which O
served O
as O
the O
inner O
core O
to O
the O
electropolymerised O
outer O
shell O
layer O
of O
polypyrrole B
( O
Ppy B
) O
. O

The O
mixed O
- O
valence O
diiron B
hydrido B
complex O
( B
mu I
- I
H I
) I
Fe2 I
( I
pdt I
) I
( I
CO I
) I
2 I
( I
dppv I
) I
2 I
( O
[ O
H1 B
] O
( O
0 O
) O
, O
where O
pdt B
= O
1 B
, I
3 I
- I
propanedithiolate I
and O
dppv B
= O
cis B
- I
1 I
, I
2 I
- I
C2H2 I
( I
PPh2 I
) I
2 I
) O
, O
was O
generated O
by O
reduction O
of O
the O
differous O
hydride B
[ B
H1 I
] I
( I
+ I
) I
using O
decamethylcobaltocen B
. O

The O
mixed O
- O
valence O
diiron B
hydrido B
complex O
( B
mu I
- I
H I
) I
Fe2 I
( I
pdt I
) I
( I
CO I
) I
2 I
( I
dppv I
) I
2 I
( O
[ O
H1 B
] O
( O
0 O
) O
, O
where O
pdt B
= O
1 B
, I
3 I
- I
propanedithiolate I
and O
dppv B
= O
cis B
- I
1 I
, I
2 I
- I
C2H2 I
( I
PPh2 I
) I
2 I
) O
, O
was O
generated O
by O
reduction O
of O
the O
differous O
hydride B
[ B
H1 I
] I
( I
+ I
) I
using O
decamethylcobaltocen B
. O

Incubations O
of O
12 B
- I
OH I
- I
NVP I
with O
the O
soluble O
fraction O
from O
a O
9 O
, O
000g O
centrifugation O
( O
S9 O
) O
of O
rat O
or O
human O
skin O
homogenate O
in O
the O
presence O
of O
3 B
' I
- I
phosphoadenosine I
- I
5 I
' I
- I
phosphosulfate I
( O
PAPS B
) O
produced O
extensive O
covalent O
binding O
, O
but O
no O
covalent O
binding O
was O
detected O
with O
mouse O
skin O
S9 O
, O
which O
suggests O
that O
the O
reason O
mice O
do O
not O
develop O
a O
rash O
is O
that O
they O
lack O
the O
required O
sulfotransferase O
. O

Oxidative O
Stress O
and O
DNA O
Damage O
in O
Human O
Gastric O
Carcinoma O
: O
8 B
- I
Oxo I
- I
7 I
' I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dG I
) O
as O
a O
Possible O
Tumor O
Marker O
. O

We O
characterized O
the O
oxidative O
stress O
( O
OS O
) O
status O
by O
the O
levels O
of O
reduced B
/ I
oxidized I
glutathione I
( O
GSH B
/ O
GSSG B
) O
, O
malondialdehyde B
( O
MDA B
) O
and O
the O
mutagenic O
base O
8 B
- I
oxo I
- I
7 I
' I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dG I
) O
in O
human O
gastric O
carcinoma O
( O
HGC O
) O
samples O
and O
compared O
the O
results O
with O
normal O
tissue O
from O
the O
same O
patients O
. O

The O
spontaneous O
one O
- O
step O
synthesis O
of O
hollow O
nanocages O
and O
nanotubes O
from O
spherical O
and O
cylindrical O
micelles O
based O
on O
poly B
( I
acrylic I
acid I
) I
- I
b I
- I
polylactide I
( O
P B
( I
AA I
) I
- I
b I
- I
P I
( I
LA I
) I
) O
block O
copolymers O
( O
BCPs O
) O
has O
been O
achieved O
. O

The O
spontaneous O
one O
- O
step O
synthesis O
of O
hollow O
nanocages O
and O
nanotubes O
from O
spherical O
and O
cylindrical O
micelles O
based O
on O
poly B
( I
acrylic I
acid I
) I
- I
b I
- I
polylactide I
( O
P B
( I
AA I
) I
- I
b I
- I
P I
( I
LA I
) I
) O
block O
copolymers O
( O
BCPs O
) O
has O
been O
achieved O
. O

Additionally O
, O
the O
internal O
topology O
of O
the O
P B
( I
AA I
) I
- I
b I
- I
P I
( I
LA I
) I
particles O
could O
be O
tuned O
by O
manipulating O
the O
drying O
conditions O
to O
give O
solid O
or O
compartmentalized O
structures O
. O

3 B
- I
( I
4 I
, I
5 I
- I
Dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT B
) O
assay O
was O
used O
to O
evaluate O
carrier O
cytotoxicity O
. O

Discovery O
of O
4 B
- I
{ I
4 I
- I
[ I
( I
3R I
) I
- I
3 I
- I
Methylmorpholin I
- I
4 I
- I
yl I
] I
- I
6 I
- I
[ I
1 I
- I
( I
methylsulfonyl I
) I
cyclopropyl I
] I
pyrimidin I
- I
2 I
- I
yl I
} I
- I
1H I
- I
indole I
( O
AZ20 B
) O
: O
a O
potent O
and O
selective O
inhibitor O
of O
ATR O
protein O
kinase O
with O
monotherapy O
in O
vivo O
antitumor O
activity O
. O

The O
objective O
of O
this O
study O
was O
to O
clarify O
the O
mechanism O
underlying O
hepatic O
uptake O
of O
dioscin B
( O
diosgenyl B
2 I
, I
4 I
- I
di I
- I
O I
- I
a I
- I
L I
- I
rhamnopyranosyl I
- I
p I
- I
D I
- I
glucopyranoside I
) O
, O
an O
herbal O
ingredient O
with O
antihepatitis O
activity O
, O
in O
rats O
and O
humans O
. O

Adenosine B
and O
N B
( I
6 I
) I
- I
cyclopentyl I
- I
adenosine I
( O
CPA B
, O
A1R O
agonist O
) O
constricted O
MVs O
but O
not O
MAs O
. O

The O
expression O
levels O
of O
10 O
of O
these O
genes O
( O
ID2 O
, O
ID3 O
, O
CCL2 O
, O
TBX3 O
, O
TGOLN2 O
, O
C1orf71 O
, O
ZNF676 O
, O
GULP1 O
, O
KLF9 O
, O
and O
ITGB5 O
) O
were O
altered O
by O
deiodinase O
- O
disrupting O
chemicals O
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
, O
polychlorinated B
biphenyls I
, O
propylthiouracil B
, O
iodoacetic B
acid I
, O
methylmercury B
, O
beta B
- I
estradiol I

A O
series O
of O
2 B
, I
9 I
- I
substituted I
6 I
- I
guanidinopurines I
, O
structurally O
related O
to O
the O
cyclin O
- O
dependent O
kinase O
( O
CDK O
) O
inhibitors O
olomoucine B
and O
roscovitine B
, O
has O
been O
synthesized O
and O
characterized O
. O

A O
new O
copper B
- O
catalyzed O
method O
for O
the O
synthesis O
of O
2 B
- I
substituted I
6 I
- I
guanidino I
- I
9 I
- I
isopropylpurines I
under O
mild O
reaction O
conditions O
has O
been O
developed O
. O

Synchrotron O
XPS O
was O
used O
to O
investigate O
a O
series O
of O
chemically O
- O
synthesised O
, O
atomically O
- O
precise O
gold O
clusters O
Au B
( I
n I
) I
( I
PPh I
( I
3 I
) I
) I
( I
y I
) I
( O
n O
= O
8 O
, O
9 O
, O
11 O
and O
101 O
, O
with O
y O
depending O
on O
cluster O
size O
) O
immobilized O
on O
titania B
nanoparticles O
. O

The O
authors O
conducted O
an O
aquatic O
mesocosm O
experiment O
to O
assess O
the O
behavior O
of O
three O
NBFRs O
: O
bis B
( I
tribromophenoxy I
) I
ethane I
( O
BTBPE B
) O
, O
tetrabromobisphenol B
A I
bis I
( I
2 I
, I
3 I
- I
dibromopropyl I
ether I
; O
TBBPA B
- O
DBPE B
) O
, O
and O
Firemaster B
BZ I
- I
54 I
, O
a O
commercial O
mixture O
containing O
bis B
( I
2 I
- I
ethylhexyl I
) I
tetrabromophthalate I
( O
BEHTBP B
) O
and O
2 B
- I
ethylhexyl I
- I
2 I
, I
3 I
, I
4 I

, I
5 I
- I
tetrabromobenzoate I
( O
EHTeBB B
) O
in O
a O
ratio O
of O
1 O
: O
4 O
. O

3H I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
3 I
- I
one I
) O
, O
a O
novel O
sodium B
channel O
inhibitor O
, O
in O
rats O
, O
dogs O
, O
and O
monkeys O
. O

Nitroaromatic B
compounds O
, O
including O
1 B
, I
3 I
- I
benzothiazin I
- I
4 I
- I
ones I
( O
BTZs B
) O
and O
related O
agents O
, O
are O
a O
promising O
new O
class O
for O
the O
treatment O
of O
TB O
. O

However O
, O
its O
energy O
efficiency O
is O
greatly O
undermined O
by O
the O
large O
overpotentials O
of O
the O
discharge O
( O
formation O
of O
Li B
( I
2 I
) I
O I
( I
2 I
) I
) O
and O
charge O
( O
oxidation O
of O
Li B
( I
2 I
) I
O I
( I
2 I
) I
) O
reactions O
. O

However O
, O
its O
energy O
efficiency O
is O
greatly O
undermined O
by O
the O
large O
overpotentials O
of O
the O
discharge O
( O
formation O
of O
Li B
( I
2 I
) I
O I
( I
2 I
) I
) O
and O
charge O
( O
oxidation O
of O
Li B
( I
2 I
) I
O I
( I
2 I
) I
) O
reactions O
. O

In O
vitro O
MRP2 O
activity O
was O
determined O
by O
measuring O
the O
ATP B
- O
dependent O
uptake O
of O
5 B
( I
6 I
) I
- I
carboxy I
- I
2 I
' I
, I
7 I
' I
- I
dichlorofluorescein I
( O
CDCF B
) O
in O
inside O
- O
out O
membrane O
vesicles O
isolated O
from O
MDCK O
- O
ABCC2 O
cells O
. O

Efficient O
preparation O
of O
both O
secondary B
and I
tertiary I
linker I
amides I
as O
judged O
by O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
and O
water O
droplet O
contact O
angle O
was O
achieved O
with O
an O
improved O
amide B
bond O
formation O
on O
gold O
quartz B
crystal O
microbalance O
( O
QCM O
) O
sensors O
using O
2 B
- I
( I
1H I
- I
7 I
- I
azabenzotriazol I
- I
1 I
- I
yl I
) I
- I
1 I
, I
1 I
, I
3 I
, I
3 I
- I
tetramethyl I
hexafluorophosphate I
methanaminium I
uronium I
( O
HATU B
) O
. O

In O
a O
previous O
study O
, O
a O
disulfide B
constrained O
cyclic O
peptide O
cyclo B
S I
( I
1 I
) I
, I
S I
( I
9 I
) I
Cys I
- I
Glu I
- I
Thr I
- I
Gly I
- I
Ala I
- I
Lys I
- I
Pro I
- I
His I
- I
Cys I
( O
S O
( O
1 O
) O
, O
S O
( O
9 O
) O
- O
cyclo O
- O
CETGAKPHC O
) O
was O
isolated O
from O
a O
phage O
displayed O
cyclic O
peptide O
library O
using O
an O
affinity O
selection O
method O
against O
HBV O
surface O
antigen O
( O
HBsAg O
) O
. O

Vitamin B
E I
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
have O
well O
- O
known O
lipid O
- O
lowering O
and O
antioxidative O
activities O
. O

The O
present O
study O
evaluates O
the O
protective O
role O
of O
vitamin B
E I
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
on O
the O
testis O
in O
atherosclerosis O
and O
detects O
the O
most O
effective O
choice O
for O
protection O
against O
atherosclerosis O
; O
vitamin B
E I
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
a O
combination O
of O
both O
. O

The O
present O
study O
evaluates O
the O
protective O
role O
of O
vitamin B
E I
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
on O
the O
testis O
in O
atherosclerosis O
and O
detects O
the O
most O
effective O
choice O
for O
protection O
against O
atherosclerosis O
; O
vitamin B
E I
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
a O
combination O
of O
both O
. O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton B
( O
G O
( O
2 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
3 O
) O
) O
, O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
4 O
) O
) O
, O
vitamin B
E I
( O
G O
( O
5 O
) O
) O
, O
triton B
+ O
vitamin B
E I
( O
G O
( O
6 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton B
( O
G O
( O
2 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
3 O
) O
) O
, O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
4 O
) O
) O
, O
vitamin B
E I
( O
G O
( O
5 O
) O
) O
, O
triton B
+ O
vitamin B
E I
( O
G O
( O
6 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton B
( O
G O
( O
2 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
3 O
) O
) O
, O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
4 O
) O
) O
, O
vitamin B
E I
( O
G O
( O
5 O
) O
) O
, O
triton B
+ O
vitamin B
E I
( O
G O
( O
6 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O

( O
7 O
) O
) O
and O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O
( O
8 O
) O
) O
. O

Treatment O
with O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
/ O
and O
vitamin B
E I
helps O
in O
improving O
the O
adverse O
effect O
of O
triton B
; O
also O
the O
histological O
changes O
confirm O
this O
finding O
. O

So O
the O
present O
study O
recommends O
all O
people O
to O
include O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
and O
vitamin B
E I
in O
their O
diet O
to O
be O
protected O
against O
atherosclerosis O
. O

Here O
, O
we O
evaluated O
the O
melanogenesis O
stimulatory O
effects O
of O
leaf O
extracts O
of O
Erica O
multiflora O
, O
a O
medicinal O
plant O
from O
the O
Mediterranean O
region O
, O
and O
its O
active O
component O
, O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
, O
as O
possible O
therapeutic O
agents O
to O
address O
hypopigmentation O
disorders O
. O

Preparative O
TLC O
of O
ethyl B
acetate I
fraction O
2 O
revealed O
the O
presence O
of O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
as O
the O
major O
bioactive O
component O
. O

B16 O
cells O
treated O
with O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
increased O
melanin O
content O
without O
cytotoxicity O
. O

To O
determine O
the O
mechanism O
for O
the O
observed O
effects O
of O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
, O
the O
tyrosinase O
enzyme O
activity O
, O
the O
tyrosinase O
protein O
expression O
, O
and O
the O
activation O
of O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
were O
determined O
. O

Results O
showed O
that O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
has O
no O
effect O
on O
the O
tyrosinase O
enzyme O
activity O
but O
can O
increase O
tyrosinase O
expression O
at O
both O
the O
transcriptional O
and O
translational O
levels O
. O

We O
report O
for O
the O
first O
time O
that O
E O
. O
multiflora O
ethyl B
acetate I
extract O
and O
its O
active O
compound O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
stimulate O
melanogenesis O
by O
increasing O
the O
tyrosinase O
enzyme O
expression O
via O
mitogen O
- O
activated O
protein O
kinase O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
phosphorylation O
inhibition O
, O
making O
it O
a O
possible O
treatment O
for O
hypopigmentation O
diseases O
. O

Photothermal O
tautomerization O
of O
a O
UV O
sunscreen O
( O
4 B
- I
tert I
- I
butyl I
- I
4 I
' I
- I
methoxydibenzoylmeth I
) O
in O
acetonitrile B
studied O
by O
steady O
- O
state O
and O
laser O
flash O
photolysis O
. O

The O
photothermal O
tautomerization O
processes O
between O
enol B
and O
keto B
forms O
of O
4 B
- I
tert I
- I
butyl I
- I
4 I
' I
- I
methoxydibenzoylmeth I
( O
trade O
name O
, O
Avobenzone B
) O
in O
acetonitrile B
have O
been O
studied O
by O
steady O
- O
state O
and O
laser O
flash O
photolysis O
. O

Spiro O
heterocycles O
as O
potential O
inhibitors O
of O
SIRT1 O
: O
Pd B
/ O
C B
- O
mediated O
synthesis O
of O
novel O
N B
- I
indolylmethyl I
spiroindoline I
- I
3 I
, I
2 I
' I
- I
quinazolines I
. O

Novel O
N B
- I
indolylmethyl I
substituted I
spiroindoline I
- I
3 I
, I
2 I
' I
- I
quinazolines I
were O
designed O
as O
potential O
inhibitiors O
of O
SIRT1 O
. O

These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd B
/ O
C B
- I
Cu I
mediated O
coupling O
- O
cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O
1 B
- I
( I
prop I
- I
2 I
- I
ynyl I
) I
- I
1 I
' I
H I
- I
spiro I
[ I
indoline I
- I
3 I
, I
2 I
' I
- I
quinazoline I
] I
- I
2 I
, I
4 I
' I
( I
3 I
' I
H I
) I
- I
dione I
with O
2 B
- I
iodoanilides I
. O

The O
docking O
results O
suggested O
that O
the O
benzene B
ring O
of O
1 B
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydroquinazolin I
ring O
system O
of O
these O
molecules O
occupied O
the O
deep O
hydrophobic O
pocket O
of O
the O
protein O
and O
one O
of O
the O
NH B
along O
with O
the O
sulfonyl B
group O
participated O
in O
strong O
H B
- O
bonding O
interaction O
with O
the O
amino B
acid I
residues O
. O

Cytotoxic O
effects O
of O
salinomycin B
were O
monitored O
by O
the O
[ O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyl I
tetrazolium I
bromide I
] O
( O
MTT B
) O
assay O
. O

ETU B
was O
extracted O
by O
alkaline O
acetonitrile B
( O
containing O
1 O
% O
NH B
( I
3 I
) I
. I
H I
( I
2 I
) I
0 I
) O
, O
separated O
on O
a O
ZIC O
- O
pHILIC O
column O
, O
confirmed O
by O
multiple O
reaction O
monitoring O
( O
MRM O
) O
mode O
with O
electrospray O
ionisation O
source O
. O

Vitexin B
- I
2 I
- I
O I
- I
xyloside I
, O
raphasatin B
and O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
synergistically O
affect O
cell O
growth O
and O
apoptosis O
of O
colon O
cancer O
cells O
. O

Cytotoxic O
effects O
of O
the O
combination O
of O
the O
food O
components O
vitexin B
- I
2 I
- I
O I
- I
xyloside I
( O
X O
) O
, O
raphasatin B
( O
4 B
- I
methylsulphanyl I
- I
3 I
- I
butenyl I
isothiocyanates I
; O
G O
) O
and O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
( O
E O
) O
were O
investigated O
in O
colon O
( O
LoVo O
and O
CaCo O
- O
2 O
) O
and O
breast O
( O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
) O
cancer O
cells O
. O

Cytotoxic O
effects O
of O
the O
combination O
of O
the O
food O
components O
vitexin B
- I
2 I
- I
O I
- I
xyloside I
( O
X O
) O
, O
raphasatin B
( O
4 B
- I
methylsulphanyl I
- I
3 I
- I
butenyl I
isothiocyanates I
; O
G O
) O
and O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
( O
E O
) O
were O
investigated O
in O
colon O
( O
LoVo O
and O
CaCo O
- O
2 O
) O
and O
breast O
( O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
) O
cancer O
cells O
. O

Protein O
derived O
from O
blue O
mussel O
( O
Mytilus O
edulis O
) O
was O
hydrolysed O
using O
four O
kinds O
of O
proteases O
( O
pepsin O
, O
papain O
, O
neutrase O
and O
alcalase O
) O
, O
and O
the O
neutrase O
hydrolysate O
( O
BNH O
) O
obtained O
by O
3 O
- O
h O
hydrolysis O
exhibited O
the O
highest O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
) O
radical O
scavenging O
activity O
compared O
to O
other O
hydrolysates O
. O

By O
using O
ultrafiltration O
, O
gel O
filtration O
chromatography O
and O
reversed O
phase O
high O
performance O
liquid O
chromatography O
( O
RP O
- O
HPLC O
) O
, O
a O
novel O
antioxidant O
peptide O
( O
BNH O
- O
P7 O
) O
was O
isolated O
from O
BNH O
, O
and O
its O
amino B
acid I
sequence O
was O
identified O
as O
YPPAK O
( O
Tyr B
- I
Pro I
- I
Pro I
- I
Ala I
- I
Lys I
) O
with O
molecular O
weight O
of O
574 O
Da O
. O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

Polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and I
dibenzofurans I
( O
PCDD B
/ I
Fs I
) O
, O
dioxin B
- I
like I
polychlorinated I
biphenyls I
( O
DL B
- I
PCBs I
) O
, O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
and O
hexachlorobenzene B
( O
HCB B
) O
concentrations O
were O
determined O
in O
abdominal O
fat O
samples O
from O
30 O
cattle O
. O

Treatment O
of O
yeast O
with O
other O
bifunctional O
electrophiles O
, O
including O
diethyl B
acetylenedicarboxyla I
( O
DAD B
) O
, O
mechlorethamine B
( O
HN2 B
) O
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
- I
diepoxybutane I
( O
DEB B
) O
, O
resulted O
in O
the O
formation O
of O
similar O
cross O
- O
linked O
complexes O
. O

Optimization O
of O
an O
HTS O
hit O
( O
1 O
) O
led O
to O
4 B
- I
phenyl I
- I
1 I
- I
( I
quinuclidin I
- I
3 I
- I
ylmethyl I
) I
quinolin I
- I
2 I
( I
1H I
) I
- I
one I
, O
which O
was O
found O
to O
be O
potent O
and O
selective O
. O

11 B
beta I
- I
Hydroxysteroid I
dehydrogenase O
type O
1 O
contributes O
to O
the O
balance O
between O
7 B
- I
keto I
- I
and I
7 I
- I
hydroxy I
- I
oxysterols I
in O
vivo O
. O

However O
, O
it O
can O
also O
metabolize O
alternative O
substrates O
, O
including O
7 B
beta I
- I
hydroxy I
- I
and I
7 I
- I
keto I
- I
cholesterol I
( O
7 B
beta I
OHC I
, O
7KC B
) O
. O

Angiotensin B
IV I
( O
Val B
( I
1 I
) I
- I
Tyr I
( I
2 I
) I
- I
Ile I
( I
3 I
) I
- I
His I
( I
4 I
) I
- I
Pro I
( I
5 I
) I
- I
Phe I
( I
6 I
) I
) O
has O
demonstrated O
potential O
cognitive O
- O
enhancing O
effects O
. O

Two O
new O
triterpenoids B
, O
3 B
beta I
- I
( I
2 I
- I
methoxy I
- I
oxalyloxy I
) I
- I
24 I
- I
methylene I
- I
lanost I
- I
8 I
- I
en I
- I
21 I
- I
oic I
acid I
( O
1 O
) O
and O
3 B
beta I
- I
( I
2 I
- I
methoxy I
- I
oxalyloxy I
) I
- I
15 I
alpha I
- I
hydroxy I
- I
24 I
- I
methylene I
- I
lanost I
- I
8 I
- I
en I
- I
21 I
- I
oic I
acid I
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Perenniporia O
maackiae O
, O
together O
with O
two O
previously O
known O
triterpenoids B
( O
3 O
and O
4 O
) O

Two O
new O
triterpenoids B
, O
3 B
beta I
- I
( I
2 I
- I
methoxy I
- I
oxalyloxy I
) I
- I
24 I
- I
methylene I
- I
lanost I
- I
8 I
- I
en I
- I
21 I
- I
oic I
acid I
( O
1 O
) O
and O
3 B
beta I
- I
( I
2 I
- I
methoxy I
- I
oxalyloxy I
) I
- I
15 I
alpha I
- I
hydroxy I
- I
24 I
- I
methylene I
- I
lanost I
- I
8 I
- I
en I
- I
21 I
- I
oic I
acid I
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Perenniporia O
maackiae O
, O
together O
with O
two O
previously O
known O
triterpenoids B
( O
3 O
and O
4 O
) O

Intracellular O
antioxidant O
assays O
showed O
that O
compounds O
1 O
- O
4 O
displayed O
significant O
protective O
effects O
on O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
induced O
cardiac O
cell O
injury O
. O

We O
have O
previously O
reported O
that O
a O
chemically O
synthesized O
kavalactone B
derivative O
, O
2 B
' I
, I
6 I
' I
- I
dichloro I
- I
5 I
- I
methoxymethyl I
- I
5 I
, I
6 I
- I
dehydrokawain I
( O
compound O
1 O
) O
protects O
against O
oxidative O
stress O
- O
induced O
neuronal O
cell O
death O
through O
activation O
of O
Nrf2 O
signaling O
. O

Treatment O
with O
hemin B
, O
a O
HO O
- O
1 O
inducer O
, O
and O
with O
[ B
Ru I
( I
CO I
) I
3Cl2 I
] I
2 I
, O
a O
CO B
donor O
, O
decreased O
LPS O
- O
stimulated O
iNOS O
induction O
and O
NO B
production O
. O

The O
molecular O
orientation O
and O
dynamics O
of O
di B
- I
t I
- I
butylnitroxide I
( O
DTBN B
) O
and O
4 B
- I
oxo I
- I
2 I
, I
2 I
, I
6 I
, I
6 I
- I
tetramethyl I
- I
1 I
- I
piperidinyl I
- I
1 I
- I
oxyl I
( O
TEMPONE B
) O
radicals O
in O
the O
organic O
1D O
nanochannels O
of O
tris B
( I
o I
- I
phenylenedioxy I
) I
cyclotriphosphazene I
( O
TPP B
) O
were O
investigated O
by O
examining O
inclusion O
compounds O
( O
ICs O
) O
diluted O
by O
the O
co O
- O
inclusion O
of O
nonradicals O
using O
electron O
spin O
resonance O
( O

The O
rotation O
axes O
for O
both O
DTBN B
and O
TEMPONE B
were O
determined O
to O
be O
almost O
parallel O
to O
the O
principal O
y O
- O
axis O
of O
the O
g O
tensor O
, O
which O
agrees O
with O
the O
result O
reported O
for O
2 B
, I
2 I
, I
6 I
, I
6 I
- I
tetramethyl I
- I
1 I
- I
piperidinyl I
- I
1 I
- I
oxyl I
( O
TEMPO B
) O
in O
TPP B
nanochannels O
, O
which O
has O
the O
activation O
energy O
of O
5 O
kJ O
mol O
( O
- O
1 O
) O
. O

For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V B
( I
5 I
+ I
) I
( O
5 O
mg O
/ O
kg O
) O
in O
the O
absence O
and O
presence O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
( O
15 O
mu O
g O
/ O
kg O
) O
for O
6 O
and O
24 O
h O
. O

Tetraarylmethane B
compounds O
consisting O
of O
two O
pyrogallol B
and O
two O
aniline B
units O
, O
namely O
, O
Ar2CAr B
' I
2 I
{ O
Ar O
= O
3 B
, I
4 I
, I
5 I
- I
C6H2 I
( I
OH I
) I
3 I
and O
Ar O
' O
= O
3 B
, I
5 I
- I
R2 I
- I
4 I
- I
C6H2NH2 I
[ O
R O
= O
Me O
( O
1 O
) O
, O
iPr B
( O
2 O
) O
] O
} O
exhibit O
excellent O
self O
- O
assembly O
behavior O
. O

Tetraarylmethane B
compounds O
consisting O
of O
two O
pyrogallol B
and O
two O
aniline B
units O
, O
namely O
, O
Ar2CAr B
' I
2 I
{ O
Ar O
= O
3 B
, I
4 I
, I
5 I
- I
C6H2 I
( I
OH I
) I
3 I
and O
Ar O
' O
= O
3 B
, I
5 I
- I
R2 I
- I
4 I
- I
C6H2NH2 I
[ O
R O
= O
Me O
( O
1 O
) O
, O
iPr B
( O
2 O
) O
] O
} O
exhibit O
excellent O
self O
- O
assembly O
behavior O
. O

Statins O
inhibit O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
and O
block O
the O
synthesis O
of O
isoprenoid B
lipids O
with O
inhibition O
of O
Rheb O
farnesylation O
and O
RhoA O
geranylgeranylation O
. O

PtCl2 B
- O
Catalyzed O
Tandem O
Enyne B
Cyclization O
/ O
1 B
, I
2 I
Ester I
Migration O
Reaction O
Controlled O
by O
Substituent O
Effects O
of O
All B
- I
Carbon I
1 I
, I
6 I
- I
Enynyl I
Esters I
. O

Physical O
Properties O
and O
Erosion O
Behavior O
of O
Poly B
( I
trimethylene I
carbonate I
- I
co I
- I
epsilon I
- I
caprolactone I
) I
Networks O
. O

Decompression O
- O
induced O
crystal O
polymorphism O
in O
a O
room O
- O
temperature O
ionic O
liquid O
, O
N B
, I
N I
- I
diethyl I
- I
N I
- I
methyl I
- I
N I
- I
( I
2 I
- I
methoxyethyl I
) I
ammonium I
tetrafluoroborate I
. O

Here O
, O
we O
show O
that O
N B
, I
N I
- I
diethyl I
- I
N I
- I
methyl I
- I
N I
- I
( I
2 I
- I
methoxyethyl I
) I
ammonium I
tetrafluoroborate I
( O
[ B
DEME I
] I
[ I
BF4 I
] I
) O
could O
be O
crystallized O
upon O
compression O
, O
but O
it O
usually O
formed O
a O
superpressed O
liquid O
. O

Statins O
are O
inhibitors O
of O
the O
enzyme O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
, O
the O
rate O
- O
limiting O
step O
in O
cholesterol B
biosynthesis O
. O

The O
direct O
involvement O
of O
mu O
- O
opioid O
receptor O
functions O
in O
the O
activation O
of O
G O
- O
proteins O
and O
changes O
in O
protein O
levels O
in O
the O
lower O
midbrain O
of O
mice O
after O
chronic O
treatment O
with O
ethanol B
were O
investigated O
by O
a O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
assay O
and O
Western O
blotting O
, O
respectively O
. O

RESULTS O
: O
The O
function O
of O
mu O
- O
opioid O
receptor O
was O
increased O
by O
treatment O
with O
ethanol B
in O
the O
lower O
midbrain O
using O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
assay O
. O

ABT B
- I
384 I
[ O
1 B
- I
piperazineacetamide I
, I
N I
- I
[ I
5 I
- I
( I
aminocarbonyl I
) I
tricyclo I
[ I
3 I
. I
3 I
. I
1 I
. I
13 I
, I
7 I
] I
dec I
- I
2 I
- I
yl I
] I
- I
alpha I
, I
alpha I
- I
dimethyl I
- I
4 I
- I
[ I
5 I
- I
( I
trifluoromethyl I
) I
- I
2 I
- I
pyridinyl I
] I
- O
, O
stereoisomer O
] O
is O
a O
potent O
and O
selective O
inhibitor O
of O
11 B
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
( O
HSD O
- O
1 O
) O
. O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

Coumarin B
7 O
- O
hydroxylation O
, O
catalyzed O
by O
P450 O
2A13 O
, O
was O
strongly O
inhibited O
by O
2 B
' I
- I
methoxy I
- I
5 I
, I
7 I
- I
dihydroxyflavone I
, O
2 B
- I
ethynylnaphthalene I
, O
2 B
' I
- I
methoxyflavone I
, O
2 B
- I
naphththalene I
propargyl I
ether I
, O
acenaphthene B
, O
acenaphthylene B
, O
naphthalene B
, O
1 B
- I
acetylpyrene I
, O
flavanone B
, O
chrysin B
, O
3 B
- I
ethynylphenanthrene I
, O

Here O
we O
demonstrated O
that O
Rad9 O
was O
involved O
in O
nucleotide B
excision O
repair O
and O
loss O
of O
Rad9 O
led O
to O
defective O
removal O
of O
the O
UV O
- O
derived O
photoproduct O
6 B
- I
4PP I
( O
6 B
, I
4 I
pyrimidine I
- I
pyrimidone I
) O
and O
the O
BPDE B
( O
anti O
- O
benzo B
( I
a I
) I
pyrene I
- I
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
- I
9 I
, I
10 I
- I
epoxide I
) O
- O
DNA O
adducts O
in O
mammalian O
cells O
. O

Development O
of O
SAR O
in O
a O
5 B
- I
aryl I
- I
3 I
- I
acylpyridinyl I
- I
pyrazoles I
and O
1 B
- I
aryl I
- I
4 I
- I
acylpyridinyl I
imidazoles I
series O
of O
mGlu5 O
receptor O
negative O
allosteric O
modulators O
( O
mGluR5 O
NAMs O
) O
using O
a O
functional O
cell O
- O
based O
assay O
is O
described O
in O
this O
Letter O
. O

Development O
of O
SAR O
in O
a O
5 B
- I
aryl I
- I
3 I
- I
acylpyridinyl I
- I
pyrazoles I
and O
1 B
- I
aryl I
- I
4 I
- I
acylpyridinyl I
imidazoles I
series O
of O
mGlu5 O
receptor O
negative O
allosteric O
modulators O
( O
mGluR5 O
NAMs O
) O
using O
a O
functional O
cell O
- O
based O
assay O
is O
described O
in O
this O
Letter O
. O

Microwave O
assisted O
nano O
( O
ZnO B
- O
TiO2 B
) O
catalyzed O
synthesis O
of O
some O
new O
4 B
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
( I
( I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
methyl I
) I
thieno I
[ I
2 I
, I
3 I
- I
c I
] I
pyridine I
as O
antimicrobial O
agents O
. O

Combined O
nano O
zinc B
oxide I
and O
titanium B
dioxide I
[ O
nano O
( O
ZnO B
- O
TiO B
( I
2 I
) I
) O
] O
has O
been O
reported O
first O
time O
for O
the O
synthesis O
of O
novel O
series O
of O
4 B
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
( I
( I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
methyl I
) I
thieno I
[ I
2 I
, I
3 I
- I
c I
] I
pyridine I
. O

We O
performed O
fluorescence O
( O
FL O
) O
and O
fluorescence O
excitation O
( O
FLE O
) O
spectroscopy O
on O
the O
model O
molecule O
perylene B
- I
3 I
, I
4 I
, I
9 I
, I
10 I
- I
tetracarboxyl I
acid I
dianhydride I
( O
PTCDA B
) O
for O
very O
low O
coverages O
( O
below O
1 O
% O
of O
a O
monolayer O
) O
on O
thin O
( O
100 O
) O
oriented O
KCl B
films O
. O

MDV3100 B
, O
however O
, O
shares O
its O
4 B
- I
cyano I
- I
3 I
- I
( I
trifluoromethyl I
) I
phenyl I
group O
with O
bicalutamide B
and O
hydroxyflutamide B
required O
for O
binding O
to O
the O
AR O
. O

In O
this O
work O
, O
we O
used O
a O
combined O
strategy O
to O
find O
new O
antagonist O
structures O
distinct O
from O
the O
4 B
- I
cyano I
- I
3 I
- I
( I
trifluoromethyl I
) I
phenyl I
group O
to O
avoid O
cross O
- O
resistance O
for O
these O
compounds O
and O
to O
find O
structures O
without O
agonist O
activity O
on O
mutant O
ARs O
( O
AR O
W741C O
and O
AR O
T877A O
) O
. O

A O
series O
of O
3 B
, I
4 I
- I
diarylpyrazoles I
were O
concisely O
synthesized O
, O
one O
of O
which O
, O
3 B
- I
methoxy I
- I
6 I
- I
[ I
4 I
- I
( I
3 I
, I
4 I
, I
5 I
- I
trimethoxyphenyl I
) I
- I
1H I
- I
pyrazol I
- I
3 I
- I
yl I
] I
benzene I
- I
1 I
, I
2 I
- I
diol I
( O
27 O
) O
, O
proved O
to O
be O
a O
cytotoxic O
anti O
- O
tubulin O
agent O
with O
low O
nanomolar O
potency O
. O

Here O
, O
we O
report O
that O
Kawazulite B
, O
a O
mineral O
with O
the O
approximate O
composition O
Bi2 B
( I
Te I
, I
Se I
) I
2 I
( I
Se I
, I
S I
) I
, O
represents O
a O
naturally O
occurring O
topological O
insulator O
whose O
electronic O
properties O
compete O
well O
with O
those O
of O
its O
synthetic O
counterparts O
. O

( B
S I
) I
- I
3 I
- I
( I
Aminomethyl I
) I
- I
7 I
- I
( I
3 I
- I
hydroxypropoxy I
) I
- I
1 I
- I
hydroxy I
- I
1 I
, I
3 I
- I
dihydro I
- I
2 I
, I
1 I
- I
benzoxaborole I
( O
GSK2251052 B
) O
is O
a O
novel O
boron B
- O
containing O
antibiotic O
that O
inhibits O
bacterial O
leucyl B
tRNA O
synthetase O
, O
and O
that O
has O
been O
in O
development O
for O
the O
treatment O
of O
serious O
Gram O
- O
negative O
infections O
. O

Novel O
mutations O
within O
the O
transmembrane O
domain O
( O
TM O
) O
regions O
were O
identified O
that O
had O
differential O
effects O
on O
acetylene B
PAMs O
versus O
2 B
- I
methyl I
- I
6 I
- I
( I
phenylethynyl I
) I
- I
pyridine I
, O
a O
prototypical O
NAM O
. O

The O
internal O
transport O
and O
recombination O
parameters O
of O
solid O
- O
state O
dye O
- O
sensitized O
solar O
cells O
( O
ssDSCs O
) O
using O
the O
amorphous O
organic O
semiconductor O
2 B
, I
2 I
' I
, I
7 I
, I
7 I
' I
- I
tetrakis I
( I
N I
, I
N I
- I
di I
- I
p I
- I
methoxyphenylamine I
) I
- I
9 I
, I
9 I
' I
- I
spirobifluorene I
( O
spiro B
- I
MeOTAD I
) O
as O
a O
hole O
transport O
material O
( O
HTM O
) O
are O
investigated O
using O
electrical O
impedance O
spectroscopy O
. O

Synthesis O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyrimidin I
- I
5 I
- I
ones I
as O
potential O
antimicrobial O
agents O
. O

Synthesis O
of O
new O
derivatives O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyrimidin I
- I
5 I
- I
one I
via O
reaction O
of O
7 B
- I
( I
4 I
- I
bromophenyl I
) I
- I
1 I
, I
2 I
- I
dihydro I
- I
5 I
- I
( I
4 I
- I
fluorophenyl I
) I
- I
2 I
- I
thioxopyrido I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
4 I
( I
3H I
) I
- I
one I
with O
hydrazonoyl B
chlorides I
or O
reaction O
of O
2 B
- I
hydrazino I
- I

Synthesis O
of O
new O
derivatives O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyrimidin I
- I
5 I
- I
one I
via O
reaction O
of O
7 B
- I
( I
4 I
- I
bromophenyl I
) I
- I
1 I
, I
2 I
- I
dihydro I
- I
5 I
- I
( I
4 I
- I
fluorophenyl I
) I
- I
2 I
- I
thioxopyrido I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
4 I
( I
3H I
) I
- I
one I
with O
hydrazonoyl B
chlorides I
or O
reaction O
of O
2 B
- I
hydrazino I
- I

{ B
[ I
( I
2 I
- I
[ I
( I
Guanine I
- I
9H I
- I
yl I
) I
methyl I
] I
propane I
- I
1 I
, I
3 I
- I
diyl I
) I
bis I
( I
oxy I
) I
] I
bis I
( I
methylene I
) I
} I
diphosphonic I
acid I
( O
compound O
17 O
) O
exhibited O
a O
Ki O
value O
of O
30 O
nM O
for O
human O
HGPRT O
and O
70 O
nM O
for O
Pf O
HGXPRT O
. O

Three O
pharmaceutical O
compounds O
, O
acetaminophen B
, O
indomethacin B
, O
and O
tri B
- I
O I
- I
methyl I
- I
beta I
- I
cyclodextrin I
were O
used O
as O
model O
compounds O
. O

On O
day O
8 O
colitis O
was O
induced O
by O
intracolonic O
instillation O
of O
2 B
, I
4 I
, I
6 I
- I
trinitrobenzenesulfo I
acid I
, O
when O
overt O
signs O
of O
lesions O
develop O
within O
the O
next O
3 O
days O
. O

Synthesis O
of O
novel O
2 B
- I
amino I
- I
4 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
6 I
- I
aryl I
- I
4H I
- I
pyran I
- I
3 I
- I
carbonitrile I
derivatives O
as O
antimicrobial O
and O
antioxidant O
agents O
. O

As O
a O
part O
of O
systematic O
investigation O
of O
synthesis O
and O
biological O
activities O
of O
indole B
analogues O
linked O
to O
various O
heterocyclic O
systems O
, O
we O
have O
synthesized O
new O
compounds O
viz O
. O
, O
2 B
- I
amino I
- I
4 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
6 I
- I
aryl I
- I
4H I
- I
pyran I
- I
3 I
- I
carbonitriles I
( O
2a O
- O
i O
) O
, O
4 B
, I
5 I
- I
diamino I
- I
6 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I

yl I
) I
- I
8 I
- I
aryl I
- I
2 I
- I
oxo I
- I
2 I
, I
6 I
- I
dihydrodipyrano I
[ I
2 I
, I
3 I
- I
b I
: I
3 I
, I
2 I
- I
e I
] I
pyridine I
- I
3 I
- I
carbonitriles I
( O
3a O
- O
i O
) O
, O
4 B
- I
amino I
- I
5 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
7 I
- I
aryl I
- I
1H I
- I
pyrano I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
2 I
( I
5H I
) I
- I
ones I
( O
4a O
- O
i O
) O
, O

4 B
- I
amino I
- I
5 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
7 I
- I
aryl I
- I
1H I
- I
pyrano I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
2 I
( I
5H I
) I
- I
thiones I
( O
5a O
- O
i O
) O
, O
4 B
- I
( I
5 I
' I
- I
subtituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
6 I
- I
aryl I
- I
1 I
, I
4 I
- I
dihydropyrano I
[ I
2 I
, I
3 I
- I
c I
] I

pyrazol I
- I
3 I
- I
amines I
( O
6a O
- O
i O
) O
and O
5 B
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
7 I
- I
aryl I
- I
3H I
- I
pyrano I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
4 I
( I
5H I
) I
- I
ones I
( O
7a O
- O
i O
) O
. O

We O
have O
developed O
a O
new O
series O
of O
anti O
- O
inflammatory O
agents O
( O
1 B
, I
5 I
- I
diarylpyrrole I
- I
3 I
- I
alkoxyethyl I
esters I
and I
ethers I
) O
. O

To O
evaluate O
the O
effect O
of O
two O
1 B
, I
5 I
- I
diarylpyrrole I
- I
3 I
- I
alkoxyethyl I
ethers I
, O
VA441 B
and O
VA428 B
( O
up O
to O
100 O
mu O
M O
) O
, O
respectively O
, O
in O
comparison O
with O
two O
well O
known O
COXib O
, O
celecoxib B
and O
rofecoxib B
, O
on O
HaCaT O
cell O
( O
keratinocytes O
) O
proliferation O
and O
toxicity O
. O

Among O
three O
compounds O
, O
obovatol B
most O
strongly O
scavenged O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radicals O
and O
inhibited O
the O
elevation O
of O
intracellular O
reactive O
oxygen B
species O
levels O
in O
glutamate B
- O
stressed O
HT22 O
cells O
. O

Among O
the O
synthetic O
analogs O
tested O
, O
DMBT B
, O
6 B
, I
6 I
' I
- I
bis I
( I
2 I
, I
3 I
- I
dimethoxybenzoyl I
) I
- I
a I
, I
a I
- I
d I
- I
trehalose I
, O
was O
found O
to O
be O
the O
most O
potent O
anti O
- O
invasive O
agent O
. O

In O
chemico O
evaluation O
of O
prohapten O
skin O
sensitizers O
: O
behavior O
of O
2 B
- I
methoxy I
- I
4 I
- I
( I
( I
1 I
) I
( I
3 I
) I
C I
) I
methylphenol I
in O
the O
peroxidase O
peptide O
reactivity O
assay O
( O
PPRA O
) O
as O
an O
alternative O
to O
animal O
testing O
. O

Graphene B
oxide I
( O
GO O
) O
was O
functionalized O
covalently O
with O
pH O
- O
sensitive O
poly B
( I
2 I
- I
( I
diethylamino I
) I
ethyl I
methacrylate I
) I
( O
PDEA B
) O
by O
surface O
- O
initiated O
in O
situ O
atom O
transfer O
radical O
polymerization O
. O

Three O
free O
unusual O
amino B
acids I
, O
named O
N B
- I
methyl I
- I
alpha I
- I
alanine I
, O
N B
- I
methyl I
- I
beta I
- I
alanine I
, O
and O
2 B
, I
7 I
- I
diaminooctan I
- I
1 I
, I
8 I
- I
dioic I
acid I
, O
described O
for O
the O
first O
time O
in O
a O
plant O
, O
and O
known O
trigonelline B
were O
also O
isolated O
from O
the O
stem O
bark O
of O
D O
. O
michelsonii O
. O

In O
our O
study O
, O
biocompatible O
Ni B
( I
II I
) I
- I
nitrilo I
( I
triacetic I
acid I
) I
- O
modified O
poly B
( I
ethylene I
imine I
) I
- I
maltose I
( O
Ni B
- I
NTA I
- I
DG I
) O
is O
realized O
and O
evaluated O
as O
complexation O
agent O
against O
His B
- O
tagged O
peptides O
using O
fluorescence O
polarization O
and O
dynamic O
light O
scattering O
. O

Synthesis O
of O
mixed O
ceramic O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
nanofibers O
via O
Mg2 B
+ I
doping O
using O
sol O
- O
gel O
electrospinning O
. O

We O
report O
on O
the O
synthesis O
of O
tuned O
energy O
band O
gap O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
nanofibers O
( O
NFs O
) O
with O
different O
Mg B
( I
2 I
+ I
) I
content O
via O
the O
sol O
- O
gel O
electrospinning O
( O
ES O
) O
technique O
wherein O
the O
addition O
of O
the O
doping O
material O
affects O
not O
only O
the O
morphologies O
of O
as O
- O
spun O
ZnAc B
/ O
PVA B
and O
MgAc B
/ O
ZnAc B
/ O
PVA B
nanofibers O
but O
also O
the O
crystal O
microstructure O
and O
optical O
properties O
of O
calcined O
ZnO B
and O
Mg B
( I
x I
) I
Zn I
( I

Following O
an O
appropriate O
aqueous O
solution O
preparation O
of O
magnesium B
acetate I
( O
MgAc B
) O
and O
zinc B
acetate I
( O
ZnAc B
) O
with O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
, O
electrospinning O
is O
performed O
and O
then O
as O
- O
spun O
nanofibers O
are O
calcined O
in O
an O
air O
atmosphere O
at O
600 O
degrees O
C O
for O
3 O
h O
. O

As O
- O
spun O
and O
calcined O
nanofiber O
diameters O
and O
morphologies O
are O
evaluated O
with O
scanning O
( O
SEM O
) O
and O
transmission O
( O
TEM O
) O
electron O
microscopies O
, O
whereas O
crystalline O
microstructural O
interpretations O
of O
ZnO B
and O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
are O
conducted O
with O
wide O
- O
angle O
X O
- O
ray O
diffraction O
spectra O
( O
XRD O
) O
. O

A O
new O
fengycin B
isoform O
, O
fengycin B
C I
, O
with O
the O
amino B
acid I
sequence O
Glu B
- I
Orn I
- I
Tyr I
- I
Thr I
- I
Glu I
- I
Val I
- I
Pro I
- I
Gln I
- I
Thr I
- I
Ile I
was O
isolated O
. O

A O
new O
halimane B
diterpenoid I
, O
13 B
- I
hydroxy I
- I
5 I
( I
10 I
) I
, I
14 I
- I
halimadien I
- I
6 I
- I
one I
( O
1 O
) O
and O
two O
new O
labdane B
diterpenoids I
, O
6 B
alpha I
, I
7 I
alpha I
- I
diacetoxy I
- I
13 I
- I
hydroxy I
- I
8 I
( I
9 I
) I
, I
14 I
- I
labdadien I
( O
2 O
) O
and O
9 B
- I
hydroxy I
- I
13 I
( I
14 I
) I
- I
labden I
- I
15 I
, I
16 I
- I
olide I
( O
3 O
) O
, O
were O
isolated O
for O
the O
first O
time O
, O
along O
with O
fifteen O
known O
compounds O
, O
from O
the O
hexane B
soluble O
fraction O
of O
methanolic O
extract O
of O

A O
new O
halimane B
diterpenoid I
, O
13 B
- I
hydroxy I
- I
5 I
( I
10 I
) I
, I
14 I
- I
halimadien I
- I
6 I
- I
one I
( O
1 O
) O
and O
two O
new O
labdane B
diterpenoids I
, O
6 B
alpha I
, I
7 I
alpha I
- I
diacetoxy I
- I
13 I
- I
hydroxy I
- I
8 I
( I
9 I
) I
, I
14 I
- I
labdadien I
( O
2 O
) O
and O
9 B
- I
hydroxy I
- I
13 I
( I
14 I
) I
- I
labden I
- I
15 I
, I
16 I
- I
olide I
( O
3 O
) O
, O
were O
isolated O
for O
the O
first O
time O
, O
along O
with O
fifteen O
known O
compounds O
, O
from O
the O
hexane B
soluble O
fraction O
of O
methanolic O
extract O
of O

A O
new O
halimane B
diterpenoid I
, O
13 B
- I
hydroxy I
- I
5 I
( I
10 I
) I
, I
14 I
- I
halimadien I
- I
6 I
- I
one I
( O
1 O
) O
and O
two O
new O
labdane B
diterpenoids I
, O
6 B
alpha I
, I
7 I
alpha I
- I
diacetoxy I
- I
13 I
- I
hydroxy I
- I
8 I
( I
9 I
) I
, I
14 I
- I
labdadien I
( O
2 O
) O
and O
9 B
- I
hydroxy I
- I
13 I
( I
14 I
) I
- I
labden I
- I
15 I
, I
16 I
- I
olide I
( O
3 O
) O
, O
were O
isolated O
for O
the O
first O
time O
, O
along O
with O
fifteen O
known O
compounds O
, O
from O
the O
hexane B
soluble O
fraction O
of O
methanolic O
extract O
of O

We O
demonstrate O
this O
method O
with O
two O
dyes O
, O
6 B
- I
methoxy I
- I
N I
- I
( I
3 I
- I
sulfopropyl I
) I
quinolinium I
( O
SPQ B
) O
and O
10 B
- I
( I
3 I
- I
sulfopropyl I
) I
acridinium I
betaine I
( O
SAB B
) O
. O

We O
demonstrate O
this O
method O
with O
two O
dyes O
, O
6 B
- I
methoxy I
- I
N I
- I
( I
3 I
- I
sulfopropyl I
) I
quinolinium I
( O
SPQ B
) O
and O
10 B
- I
( I
3 I
- I
sulfopropyl I
) I
acridinium I
betaine I
( O
SAB B
) O
. O

Ciliatamide B
D I
( O
1 O
) O
is O
a O
congener O
of O
2 O
, O
in O
which O
N B
- I
Me I
- I
Phe I
is O
replaced O
by O
N B
- I
Me I
- I
Met I
( I
O I
) I
. O

Since O
complexation O
of O
the O
ligated O
ODNs O
with O
hemin B
in O
the O
presence O
of O
K B
( I
+ I
) I
showed O
strong O
soret O
band O
absorption O
and O
also O
catalyzed O
the O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
mediated O
oxidation O
of O
luminol B
, O
it O
appears O
that O
the O
quadruplex O
formed O
from O
ligated O
ODNs O
showed O
a O
function O
similar O
to O
native O
DNA O
quadruplex O
. O

A O
new O
diarylheptanoid B
, O
( B
5S I
) I
- I
hydroxy I
- I
1 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
7 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
hepta I
- I
1E I
- I
en I
- I
3 I
- I
one I
( O
1 O
) O
, O
was O
isolated O
along O
with O
seventeen O
known O
diarylheptanoids B
( O
2 O
- O
18 O
) O
from O
the O
methanol B
extract O
of O
Alnus O
hirsuta O
f O
. O
sibirica O
leaves O
using O
bioactivity O
- O
guided O
fractionation O
. O

Of O
the O
compounds O
active O
in O
the O
present O
assay O
system O
, O
the O
most O
potent O
compound O
7 O
, O
platyphyllonol B
- I
5 I
- I
O I
- I
beta I
- I
d I
- I
xylopyranoside I
, O
significantly O
suppressed O
the O
induction O
of O
peroxisome O
proliferator O
activated O
receptor O
gamma O
( O
PPAR O
gamma O
and O
CCAAT O
/ O
enhancer O
binding O
protein O
alpha O
( O
C O
/ O
EBP O
alpha O
) O
protein O
expression O
, O
and O
inhibited O
adipocyte O
differentiation O
induced O
by O
troglitazone B
, O
a O
PPAR O
gamma O
agonist O
. O

A O
new O
eudesmanolide B
, O
1 B
alpha I
- I
acetoxy I
- I
8 I
alpha I
, I
9 I
beta I
- I
dihydroxy I
- I
2 I
- I
oxo I
- I
eudesman I
- I
3 I
, I
7 I
( I
11 I
) I
- I
dien I
- I
8 I
, I
12 I
- I
olide I
( O
2 O
) O
, O
together O
with O
a O
known O
eudesmanolide B
, O
1 B
alpha I
- I
acetoxy I
- I
8 I
alpha I
- I
hydroxy I
- I
2 I
- I
oxo I
- I
eudesman I
- I
3 I
, I
7 I
( I
11 I
) I
- I
dien I
- I
8 I
, I
12 I
- I
olide I
( O
1 O
) O
, O
and O
a O
known O
flavone B
, O
4 B
' I
, I
5 I
, I
7 I
- I

A O
new O
eudesmanolide B
, O
1 B
alpha I
- I
acetoxy I
- I
8 I
alpha I
, I
9 I
beta I
- I
dihydroxy I
- I
2 I
- I
oxo I
- I
eudesman I
- I
3 I
, I
7 I
( I
11 I
) I
- I
dien I
- I
8 I
, I
12 I
- I
olide I
( O
2 O
) O
, O
together O
with O
a O
known O
eudesmanolide B
, O
1 B
alpha I
- I
acetoxy I
- I
8 I
alpha I
- I
hydroxy I
- I
2 I
- I
oxo I
- I
eudesman I
- I
3 I
, I
7 I
( I
11 I
) I
- I
dien I
- I
8 I
, I
12 I
- I
olide I
( O
1 O
) O
, O
and O
a O
known O
flavone B
, O
4 B
' I
, I
5 I
, I
7 I
- I

Despite O
the O
disappointing O
results O
of O
these O
antagonists O
in O
the O
field O
of O
heart O
failure O
, O
almost O
from O
the O
initial O
animal O
trials O
of O
bosentan B
, O
a O
dual O
endothelin O
receptor O
antagonist O
, O
in O
pulmonary O
arterial O
hypertension O
, O
it O
has O
been O
demonstrated O
that O
the O
drug O
leads O
at O
least O
to O
hemodynamic O
and O
clinical O
improvement O
of O
the O
patients O
, O
thus O
receiving O
official O
approval O
for O
the O
management O
of O
this O
rare O
but O
eventually O
lethal O
disease O
. O

Using O
[ B
( I
1 I
- I
13 I
) I
C I
] I
glutamine I
, O
we O
demonstrated O
in O
vivo O
RC O
activity O
in O
VHL O
- O
deficient O
tumors O
growing O
as O
xenografts O
in O
mice O
. O

The O
activity O
coefficients O
in O
binary O
solutions O
containing O
1 B
- I
butanol I
and O
an O
IL O
were O
determined O
experimentally O
: O
the O
ILs O
studied O
were O
1 B
- I
decyl I
- I
3 I
- I
methyl I
- I
imidazolium I
tetracyanoborate I
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
4 B
- I
decyl I
- I
4 I
- I
methyl I
- I
morpholinium I
tetracyanoborate I
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
1 B
- I
decyl I
- I
3 I
- I
methyl I
- I
imidazolium I
bis I

The O
activity O
coefficients O
in O
binary O
solutions O
containing O
1 B
- I
butanol I
and O
an O
IL O
were O
determined O
experimentally O
: O
the O
ILs O
studied O
were O
1 B
- I
decyl I
- I
3 I
- I
methyl I
- I
imidazolium I
tetracyanoborate I
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
4 B
- I
decyl I
- I
4 I
- I
methyl I
- I
morpholinium I
tetracyanoborate I
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
1 B
- I
decyl I
- I
3 I
- I
methyl I
- I
imidazolium I
bis I

( I
trifluoromethylsulfo I
) I
imide I
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 B
] O
( O
- O
) O
) O
, O
and O
4 B
- I
decyl I
- I
4 I
- I
methyl I
- I
morpholinium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 B
] O
( O
- O
) O
) O
. O

( I
trifluoromethylsulfo I
) I
imide I
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 B
] O
( O
- O
) O
) O
, O
and O
4 B
- I
decyl I
- I
4 I
- I
methyl I
- I
morpholinium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 B
] O
( O
- O
) O
) O
. O

We O
evaluated O
the O
effect O
of O
the O
demethylating O
agent O
5 B
- I
aza I
- I
2 I
' I
- I
deoxycytidine I
( O
5AzadC B
) O
and O
the O
histone O
deacetylase O
inhibitor O
trichostatin B
A I
( O
TSA B
) O
on O
PR O
expression O
in O
human O
astrocytoma O
cell O
lines O
U373 O
( O
grade O
III O
) O
and O
D54 O
( O
grade O
IV O
) O
by O
RT O
- O
PCR O
and O
Western O
blot O
. O

This O
inhibition O
was O
blocked O
when O
mice O
were O
pretreated O
with O
the O
selective O
H3R O
agonist O
R B
- I
( I
alpha I
) I
- I
methyl I
- I
histamine I
( O
10 O
mg O
/ O
kg O
) O
. O

These O
glycosides O
are O
found O
to O
have O
sugar B
moieties O
of O
both O
beta B
- I
l I
- I
and I
beta I
- I
d I
- I
arabinopyranoses I
by O
HPLC O
analysis O
of O
their O
thiocarbamoyl B
- I
thiazolidine I
derivatives O
and O
those O
of O
authentic O
d B
- I
and I
l I
- I
arabinoses I
, O
leading O
to O
the O
structure O
revision O
of O
junceelloside B
C I
( O
1 O
) O
. O

In O
situ O
forming O
reduction O
- O
sensitive O
degradable O
nanogels O
were O
designed O
and O
developed O
based O
on O
poly B
( I
ethylene I
glycol I
) I
- I
b I
- I
poly I
( I
2 I
- I
( I
hydroxyethyl I
) I
methacrylate I
- I
co I
- I
acryloyl I
carbonate I
) I
( O
PEG B
- I
P I
( I
HEMA I
- I
co I
- I
AC I
) I
) O
block O
copolymers O
for O
efficient O
loading O
as O
well O
as O
triggered O
intracellular O
release O
of O
proteins O
. O

In O
situ O
forming O
reduction O
- O
sensitive O
degradable O
nanogels O
were O
designed O
and O
developed O
based O
on O
poly B
( I
ethylene I
glycol I
) I
- I
b I
- I
poly I
( I
2 I
- I
( I
hydroxyethyl I
) I
methacrylate I
- I
co I
- I
acryloyl I
carbonate I
) I
( O
PEG B
- I
P I
( I
HEMA I
- I
co I
- I
AC I
) I
) O
block O
copolymers O
for O
efficient O
loading O
as O
well O
as O
triggered O
intracellular O
release O
of O
proteins O
. O

PEG B
- I
P I
( I
HEMA I
- I
co I
- I
AC I
) I
copolymers O
were O
prepared O
with O
controlled O
Mn O
of O
9 O
. O
1 O
, O
9 O
. O
5 O
, O
and O
9 O
. O
9 O
kg O
/ O
mol O
and O
varying O
numbers O
of O
AC O
units O
per O
molecule O
of O
7 O
, O
9 O
and O
11 O
, O
respectively O
( O
denoted O
as O
copolymer O
1 O
, O
2 O
, O
and O
3 O
) O
by O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
copolymerization O
. O

Acetaminophen B
( O
AAP B
) O
is O
metabolized O
in O
hepatocytes O
by O
these O
CYPs O
to O
the O
reactive O
intermediate O
N B
- I
acetyl I
- I
p I
- I
benzoquinone I
- I
imine I
, O
which O
is O
toxic O
to O
hepatocytes O
at O
high O
doses O
where O
depletion O
of O
glutathione B
occurs O
. O

Human O
milk O
oligosaccharides O
contain O
a O
large O
variety O
of O
oligosaccharides O
, O
of O
which O
lacto B
- I
N I
- I
biose I
I I
( O
Gal B
- I
beta I
1 I
, I
3 I
- I
GlcNAc I
; O
LNB B
) O
predominates O
as O
a O
major O
core O
structure O
. O

Here O
, O
we O
have O
determined O
the O
first O
three O
- O
dimensional O
structures O
of O
lacto O
- O
N B
- O
biosidase O
from O
Bifidobacterium O
bifidum O
JCM1254 O
in O
complex O
with O
LNB B
and O
LNB B
- I
thiazoline I
( O
Gal B
- I
beta I
1 I
, I
3 I
- I
GlcNAc I
- I
thiazoline I
) O
at O
1 O
. O
8 O
- O
A O
resolution O
. O

The O
results O
reveal O
that O
the O
reaction O
of O
the O
unsaturated O
lipid O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
, O
POPC B
, O
with O
ozone B
leads O
to O
the O
rapid O
loss O
of O
the O
terminal O
C9 O
portion O
of O
the O
oleoyl B
strand O
of O
POPC B
from O
the O
air O
- O
water O
interface O
. O

Further O
experiments O
studying O
the O
reaction O
of O
mixed O
monolayers O
composed O
of O
unsaturated O
lipid O
POPC B
and O
saturated O
lipid O
dipalmitoyl B
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
, O
DPPC B
, O
revealed O
that O
no O
loss O
of O
DPPC B
from O
the O
air O
- O
water O
interface O
occurs O
, O
eliminating O
the O
possibility O
that O
a O
reactive O
species O
such O
as O
an O
OH B
radical O
is O
formed O
and O
is O
able O
to O
attack O
nearby O
lipid O
chains O
. O

As O
an O
inhibitor O
of O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
- I
coenzyme I
A I
reductase O
( O
HMG B
- O
CoA B
) O
, O
SIM B
has O
been O
shown O
to O
stimulate O
apoptotic O
cell O
death O
. O

Four O
ruthenium B
( I
ii I
) I
asymmetric O
complexes O
, O
[ B
Ru I
( I
bpy I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
PAIDH B
= O
2 B
- I
pyridyl I
- I
1H I
- I
anthra I
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
, O
) O
, O
[ B
Ru I
( I
phen I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
) O
, O
[ B
Ru I
( I
dmp I
) I
2 I
( I

Four O
ruthenium B
( I
ii I
) I
asymmetric O
complexes O
, O
[ B
Ru I
( I
bpy I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
PAIDH B
= O
2 B
- I
pyridyl I
- I
1H I
- I
anthra I
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
, O
) O
, O
[ B
Ru I
( I
phen I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
) O
, O
[ B
Ru I
( I
dmp I
) I
2 I
( I

Four O
ruthenium B
( I
ii I
) I
asymmetric O
complexes O
, O
[ B
Ru I
( I
bpy I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
PAIDH B
= O
2 B
- I
pyridyl I
- I
1H I
- I
anthra I
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
, O
) O
, O
[ B
Ru I
( I
phen I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
) O
, O
[ B
Ru I
( I
dmp I
) I
2 I
( I

PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dmp B
= O
4 B
, I
7 I
- I
dimethyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
and O
[ B
Ru I
( I
dip I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dip B
= O
4 B
, I
7 I
- I
diphenyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
, O
have O
been O
synthesized O
and O
characterized O
. O

PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dmp B
= O
4 B
, I
7 I
- I
dimethyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
and O
[ B
Ru I
( I
dip I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dip B
= O
4 B
, I
7 I
- I
diphenyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
, O
have O
been O
synthesized O
and O
characterized O
. O

PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dmp B
= O
4 B
, I
7 I
- I
dimethyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
and O
[ B
Ru I
( I
dip I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dip B
= O
4 B
, I
7 I
- I
diphenyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
, O
have O
been O
synthesized O
and O
characterized O
. O

PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dmp B
= O
4 B
, I
7 I
- I
dimethyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
and O
[ B
Ru I
( I
dip I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dip B
= O
4 B
, I
7 I
- I
diphenyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
, O
have O
been O
synthesized O
and O
characterized O
. O

Three O
new O
diarylheptanoids B
, O
( B
3S I
, I
5R I
) I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methoxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
6E I
- I
heptene I
( O
1 O
) O
, O
( B
3S I
, I
5S I
) I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methoxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
6E I
- I
heptene I
( O
2 O
) O
, O
and O
( B
3S I
) I
- I
3 I
- I
hydroxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I

Three O
new O
diarylheptanoids B
, O
( B
3S I
, I
5R I
) I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methoxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
6E I
- I
heptene I
( O
1 O
) O
, O
( B
3S I
, I
5S I
) I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methoxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
6E I
- I
heptene I
( O
2 O
) O
, O
and O
( B
3S I
) I
- I
3 I
- I
hydroxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I

hydroxyphenyl I
) I
- I
6E I
- I
hepten I
- I
5 I
- I
one I
( O
3 O
) O
, O
four O
new O
flavonoid B
glycosides I
, O
3 B
, I
7 I
, I
3 I
' I
- I
tri I
- I
O I
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
4 O
) O
, O
7 B
, I
3 I
' I
- I
di I
- I
O I
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranosyl I
- I
3 I
- I
O I
- I
[ I

hydroxyphenyl I
) I
- I
6E I
- I
hepten I
- I
5 I
- I
one I
( O
3 O
) O
, O
four O
new O
flavonoid B
glycosides I
, O
3 B
, I
7 I
, I
3 I
' I
- I
tri I
- I
O I
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
4 O
) O
, O
7 B
, I
3 I
' I
- I
di I
- I
O I
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranosyl I
- I
3 I
- I
O I
- I
[ I

- I
hydroxy I
- I
3 I
- I
methylglutaroyl I
) I
] I
- I
alpha I
- I
d I
- I
glucopyranoside I
( O
6 O
) O
, O
and O
( B
2S I
) I
- I
5 I
- I
hydroxy I
- I
7 I
, I
3 I
' I
- I
dimethoxyflavanone I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
- I
- I
> I
5 I
) I
- I
O I
- I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
9 O
) O
, O
and O
17 O
known O
compounds O
were O
isolated O
from O
the O
leaves O
and O

The O
geometries O
and O
the O
vibrational O
frequencies O
of O
the O
encounter O
complexes O
[ B
M I
( I
pyridine I
) I
2 I
( I
CH4 I
) I
] I
( I
2 I
+ I
) I
have O
been O
determined O
using O
density O
functional O
theory O
with O
the O
omega O
B97XD O
hybrid O
functional O
and O
triple O
- O
zeta O
basis O
sets O
. O

The O
periodic O
trend O
in O
methane B
binding O
energies O
in O
the O
[ B
M I
( I
pyridine I
) I
2 I
( I
CH4 I
) I
] I
( I
2 I
+ I
) I
complexes O
follows O
the O
trend O
in O
electron O
affinity O
until O
the O
Mn B
complex O
but O
then O
exhibits O
decreasing O
energies O
from O
Fe B
to O
Zn B
. O

For O
the O
most O
stable O
complex O
, O
[ B
Cr I
( I
pyridine I
) I
2 I
( I
CH4 I
) I
] I
( I
2 I
+ I
) I
, O
the O
structures O
, O
energies O
, O
and O
spin O
states O
of O
the O
key O
intermediates O
and O
products O
in O
the O
oxidative O
addition O
/ O
reductive O
elimination O
pathway O
have O
been O
investigated O
. O

In O
this O
study O
, O
we O
report O
the O
synthesis O
and O
application O
of O
a O
FePt B
/ O
CNTs O
nanocomposite O
as O
a O
highly O
sensitive O
sensor O
and O
novel O
amide B
ligand O
( B
9 I
, I
10 I
- I
dihydro I
- I
9 I
, I
10 I
- I
ethanoanthracene I
- I
11 I
, I
12 I
- I
dicarboximido I
) I
- I
4 I
- I
ethylbenzene I
- I
1 I
, I
2 I
- I
diol I
as O
a O
mediator O
for O
the O
determination O
of O
glutathione B
( O
GSH B
) O
, O
nicotinamide B
adenine I
dinucleotide I
( O
NADH B
) O
and O
tryptophan B
( O
Trp B
) O

Anti O
- O
influenza O
active O
and O
low O
toxic O
N B
- I
phenyl I
- I
substituted I
beta I
- I
amidoamidines I
structurally O
related O
to O
natural O
antibiotic O
amidinomycin B
. O

A O
set O
of O
racemic B
N I
- I
phenyl I
- I
substituted I
beta I
- I
amidoamidines I
hydrochlorides I
4 O
, O
which O
are O
structurally O
related O
to O
natural O
antiviral O
agent O
amidinomycin B
( O
1 O
) O
, O
was O
synthesized O
in O
four O
steps O
starting O
from O
methacryloyl B
anilide I
( O
5 O
) O
. O

SK O
- O
N O
- O
SH O
cells O
were O
treated O
with O
two O
distinct O
inhibitors O
of O
glutathione B
metabolism O
: O
L B
- I
buthionine I
- I
( I
S I
, I
R I
) I
- I
sulfoximine I
( O
BSO B
) O
and O
ethacrynic B
acid I
( O
EA O
) O
. O

( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
analysis O
of O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamido I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamide I
derivatives O
. O

( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
analysis O
of O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamido I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamide I
derivatives O
. O

The O
complete O
assignment O
of O
the O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
of O
various O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamide I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamides I
with O
p B
- I
methoxy I
, O
o B
- I
chloro I
and O
m B
- I
chloro I
substituents O
is O
reported O
. O

The O
complete O
assignment O
of O
the O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
of O
various O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamide I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamides I
with O
p B
- I
methoxy I
, O
o B
- I
chloro I
and O
m B
- I
chloro I
substituents O
is O
reported O
. O

Four O
new O
4 B
- I
hydroxy I
- I
2 I
- I
pyridone I
alkaloids I
, O
didymellamides B
A I
- I
D I
( O
1 O
- O
4 O
) O
, O
were O
isolated O
from O
the O
marine O
- O
derived O
fungus O
Stagonosporopsis O
cucurbitacearum O
. O

Increasing O
pH O
, O
as O
in O
some O
aged O
food O
products O
, O
decreases O
the O
solubility O
, O
and O
Ksp O
( O
' O
) O
= O
[ O
Ca B
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
[ I
OH I
( I
- I
) I
] O
is O
found O
constant O
rather O
than O
Ksp O
= O
[ B
Ca I
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
( I
2 I
) I
in O
agreement O
with O
an O
initial O
precipitation O
of O
Ca B
( I
OH I
) I
( I
Pal I
) I
, O
which O
slowly O
may O
convert O
into O
Ca B
( I
Pal I
) I
2 I
. I
Ca I
( I
OH I
) I
( I
Pal I
) I
has O
a O
solubility O
minimum O
at O
physiological O
ionic O
strength O
with O
Ksp O
( O

Increasing O
pH O
, O
as O
in O
some O
aged O
food O
products O
, O
decreases O
the O
solubility O
, O
and O
Ksp O
( O
' O
) O
= O
[ O
Ca B
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
[ I
OH I
( I
- I
) I
] O
is O
found O
constant O
rather O
than O
Ksp O
= O
[ B
Ca I
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
( I
2 I
) I
in O
agreement O
with O
an O
initial O
precipitation O
of O
Ca B
( I
OH I
) I
( I
Pal I
) I
, O
which O
slowly O
may O
convert O
into O
Ca B
( I
Pal I
) I
2 I
. I
Ca I
( I
OH I
) I
( I
Pal I
) I
has O
a O
solubility O
minimum O
at O
physiological O
ionic O
strength O
with O
Ksp O
( O

Increasing O
pH O
, O
as O
in O
some O
aged O
food O
products O
, O
decreases O
the O
solubility O
, O
and O
Ksp O
( O
' O
) O
= O
[ O
Ca B
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
[ I
OH I
( I
- I
) I
] O
is O
found O
constant O
rather O
than O
Ksp O
= O
[ B
Ca I
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
( I
2 I
) I
in O
agreement O
with O
an O
initial O
precipitation O
of O
Ca B
( I
OH I
) I
( I
Pal I
) I
, O
which O
slowly O
may O
convert O
into O
Ca B
( I
Pal I
) I
2 I
. I
Ca I
( I
OH I
) I
( I
Pal I
) I
has O
a O
solubility O
minimum O
at O
physiological O
ionic O
strength O
with O
Ksp O
( O

Identification O
of O
pyrrolo B
[ I
2 I
, I
3 I
- I
g I
] I
indazoles I
as O
new O
Pim O
kinase O
inhibitors O
. O

The O
synthesis O
and O
Pim O
kinase O
inhibition O
potency O
of O
a O
new O
series O
of O
pyrrolo B
[ I
2 I
, I
3 I
- I
g I
] I
indazole I
derivatives O
is O
described O
. O

The O
results O
obtained O
in O
this O
preliminary O
structure O
- O
activity O
relationship O
study O
pointed O
out O
that O
sub O
- O
micromolar O
Pim O
- O
1 O
and O
Pim O
- O
3 O
inhibitory O
potencies O
could O
be O
obtained O
in O
this O
series O
, O
more O
particularly O
for O
compounds O
10 O
and O
20 O
, O
showing O
that O
pyrrolo B
[ I
2 I
, I
3 I
- I
g I
] I
indazole I
scaffold O
could O
be O
used O
for O
the O
development O
of O
new O
potent O
Pim O
kinase O
inhibitors O
. O

Delivery O
of O
definable O
number O
of O
drug O
or O
growth O
factor O
loaded O
poly B
( I
dl I
- I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
microparticles O
within O
human O
embryonic O
stem O
cell O
derived O
aggregates O
. O

Using O
poly B
( I
DL I
- I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
microparticles O
( O
MPs O
) O
with O
an O
average O
diameter O
of O
13 O
mu O
m O
, O
we O
have O
demonstrated O
controllable O
incorporation O
of O
defined O
numbers O
of O
MPs O
within O
human O
ES O
cell O
derived O
EBs O
, O
down O
to O
1 O
MP O
per O
EB O
. O

The O
study O
compared O
the O
effects O
of O
two O
legacy O
and O
two O
emerging O
fish O
pollutants O
( O
Hexabromocyclododeca B
HBCD B
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
ether I
BDE B
- I
47 I
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I
Hexachlorobiphenyl I
PCB B
- I
153 I
; O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
doxin I
TCDD B
) O
in O
juvenile O
female O
mice O
exposed O
through O
a O
salmon O
based O
rodent O
diet O
for O
28days O
( O

The O
study O
compared O
the O
effects O
of O
two O
legacy O
and O
two O
emerging O
fish O
pollutants O
( O
Hexabromocyclododeca B
HBCD B
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
ether I
BDE B
- I
47 I
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I
Hexachlorobiphenyl I
PCB B
- I
153 I
; O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
doxin I
TCDD B
) O
in O
juvenile O
female O
mice O
exposed O
through O
a O
salmon O
based O
rodent O
diet O
for O
28days O
( O

The O
study O
compared O
the O
effects O
of O
two O
legacy O
and O
two O
emerging O
fish O
pollutants O
( O
Hexabromocyclododeca B
HBCD B
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
ether I
BDE B
- I
47 I
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I
Hexachlorobiphenyl I
PCB B
- I
153 I
; O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
doxin I
TCDD B
) O
in O
juvenile O
female O
mice O
exposed O
through O
a O
salmon O
based O
rodent O
diet O
for O
28days O
( O

We O
investigated O
the O
impact O
of O
a O
soluble O
cobalt B
compound O
, O
CoCl B
( I
2 I
) I
. I
6H I
( I
2 I
) I
O I
, O
on O
the O
BEAS O
- O
2B O
lung O
epithelial O
cell O
line O
, O
as O
well O
as O
its O
impact O
on O
metal O
homeostasis O
. O

The O
PEMUs O
were O
built O
layer O
- O
by O
- O
layer O
with O
the O
polycation O
poly B
( I
allylamine I
hydrochloride I
) I
( O
PAH B
) O
and O
a O
polyanion O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
that O
was O
modified O
with O
photoreactive O
4 B
- I
( I
2 I
- I
hydroxyethoxy I
) I
benzophenone I
( O
PAABp O
) O
. O

We O
have O
now O
developed O
an O
isotope O
- O
dilution O
, O
liquid O
chromatography O
- O
coupled O
, O
tandem O
quadrupole O
mass O
spectrometric O
method O
to O
quantify O
representative O
species O
across O
the O
spectrum O
of O
RNA O
damage O
products O
predicted O
to O
arise O
at O
sites O
of O
inflammation O
, O
including O
nucleobase B
deamination O
( O
xanthosine B
and O
inosine B
) O
, O
oxidation O
( O
8 B
- I
oxoguanosine I
) O
, O
and O
alkylation O
( O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenosine I
) O
. O

The O
known O
compounds O
, O
ursolic B
acid I
( O
7 O
) O
and O
5 B
, I
7 I
, I
4 I
' I
- I
trimethoxyflavone I
( O
14 O
) O
, O
exhibited O
weak O
cytotoxic O
activity O
against O
some O
cells O
. O

Acoustics O
as O
a O
Tool O
for O
Better O
Characterization O
of O
Ionic O
Liquids O
: O
A O
Comparative O
Study O
of O
1 B
- I
Alkyl I
- I
3 I
- I
methylimidazolium I
Bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
Room O
- O
Temperature O
Ionic O
Liquids O
. O

Acoustic O
properties O
of O
three O
( O
1 B
- I
ethyl I
- O
, O
1 B
- I
butyl I
- O
, O
and O
1 B
- I
octyl I
- O
) O
1 B
- I
alkyl I
- I
3 I
- I
methylimidazolium I
bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
room O
- O
temperature O
ionic O
liquids O
are O
reported O
and O
discussed O
. O

All O
investigations O
were O
completed O
by O
the O
ultrasound O
absorption O
coefficient O
measurements O
in O
1 B
- I
ethyl I
- I
and I
1 I
- I
octyl I
- I
3 I
- I
methylimidazolium I
bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
as O
a O
function O
of O
frequency O
from O
10 O
to O
300 O
MHz O
at O
temperatures O
293 O
. O
15 O
- O
298 O
. O
15 O
K O
. O

The O
thermodynamically O
more O
stable O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
2 I
( I
mu I
- I
O2H3 I
) I
( I
mu I
- I
OH I
) I
2 I
( I
H2O I
) I
2 I
] I
( O
from O
now O
on O
, O
( B
O2H3 I
) I
Sc I
- O
MOF O
; O
3 B
, I
5 I
- I
DSB I
= O
3 B
, I
5 I
- I
disulfobenzoic I
acid I
) O
was O
obtained O
as O
a O
pure O
and O
stable O
phase O
. O

It O
was O
impossible O
to O
isolate O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
2 I
( I
mu I
- I
OH I
) I
3 I
( I
H2O I
) I
4 I
] I
as O
a O
pure O
phase O
, O
as O
it O
turned O
out O
to O
be O
the O
precursor O
of O
( B
O2H3 I
) I
Sc I
- O
MOF O
. O

Additionally O
, O
a O
third O
compound O
that O
appears O
at O
pH O
between O
3 O
. O
5 O
and O
4 O
, O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
( I
mu I
- I
OH I
) I
6 I
( I
H2O I
) I
] I
and O
a O
fourth O
, O
[ B
Sc I
( I
3 I
, I
5 I
- I
DSB I
) I
( I
Phen I
) I
( I
H2O I
) I
] I
( I
H2O I
) I
, O
in O
whose O
formula O
neither O
OH B
groups O
nor O
H3O2 B
( I
- I
) I
anions O
appear O
, O
are O
reported O
for O
comparative O
purposes O
. O

Additionally O
, O
a O
third O
compound O
that O
appears O
at O
pH O
between O
3 O
. O
5 O
and O
4 O
, O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
( I
mu I
- I
OH I
) I
6 I
( I
H2O I
) I
] I
and O
a O
fourth O
, O
[ B
Sc I
( I
3 I
, I
5 I
- I
DSB I
) I
( I
Phen I
) I
( I
H2O I
) I
] I
( I
H2O I
) I
, O
in O
whose O
formula O
neither O
OH B
groups O
nor O
H3O2 B
( I
- I
) I
anions O
appear O
, O
are O
reported O
for O
comparative O
purposes O
. O

Identification O
of O
benzofurano B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidin I
- I
2 I
- I
ones I
, O
a O
new O
series O
of O
HIV O
- O
1 O
nucleotide B
- O
competing O
reverse O
transcriptase O
inhibitors O
. O

Screening O
of O
our O
sample O
collection O
led O
to O
the O
identification O
of O
a O
set O
of O
benzofurano B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
- I
2 I
- I
one I
hits O
acting O
as O
nucleotide B
- O
competing O
HIV O
- O
1 O
reverse O
transcriptase O
inhibitiors O
( O
NcRTI O
) O
. O

A O
study O
of O
secondary O
metabolites O
from O
the O
bark O
of O
Alnus O
glutinosa O
led O
to O
the O
isolation O
of O
fourteen O
diarylheptanoids B
: O
oregonin B
( O
1 O
) O
, O
platyphylloside B
( O
2 O
) O
, O
rubranoside B
A I
( O
3 O
) O
, O
rubranoside B
B I
( O
4 O
) O
, O
hirsutanonol B
( O
5 O
) O
, O
hirsutenone B
( O
6 O
) O
, O
hirsutanonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
7 O
) O
, O
platyphyllonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
8 O

A O
study O
of O
secondary O
metabolites O
from O
the O
bark O
of O
Alnus O
glutinosa O
led O
to O
the O
isolation O
of O
fourteen O
diarylheptanoids B
: O
oregonin B
( O
1 O
) O
, O
platyphylloside B
( O
2 O
) O
, O
rubranoside B
A I
( O
3 O
) O
, O
rubranoside B
B I
( O
4 O
) O
, O
hirsutanonol B
( O
5 O
) O
, O
hirsutenone B
( O
6 O
) O
, O
hirsutanonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
7 O
) O
, O
platyphyllonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
8 O

) O
, O
aceroside B
VII I
( O
9 O
) O
, O
alnuside B
A I
( O
10 O
) O
, O
alnuside B
B I
( O
11 O
) O
, O
1 B
, I
7 I
- I
bis I
- I
( I
3 I
, I
4 I
- I
dihydoxyphenyl I
) I
- I
5 I
- I
hydroxy I
- I
heptane I
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
12 O
) O
, O
( B
5S I
) I
- I
1 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
7 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I

heptan I
- I
3 I
- I
one I
( O
13 O
) O
, O
and O
( B
5S I
) I
- I
1 I
, I
7 I
- I
bis I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
[ I
6 I
- I
( I
3 I
, I
4 I
- I
dimethoxycinnamoylgl I
) I
] I
- I
heptan I
- I
3 I
- I
one I
( O
14 O
) O
. O

Substituted O
7 B
- I
Amino I
- I
5 I
- I
thio I
- I
thiazolo I
[ I
4 I
, I
5 I
- I
d I
] I
pyrimidines I
as O
Potent O
and O
Selective O
Antagonists O
of O
the O
Fractalkine O
Receptor O
( O
CX3CR1 O
) O
. O

By O
modifying O
the O
substituents O
on O
the O
7 B
- I
amino I
- I
5 I
- I
thio I
- I
thiazolo I
[ I
4 I
, I
5 I
- I
d I
] I
pyrimidine I
core O
structure O
, O
we O
were O
able O
to O
achieve O
compounds O
with O
high O
selectivity O
for O
CX3CR1 O
over O
the O
closely O
related O
CXCR2 O
receptor O
. O

1 B
, I
4 I
, I
2 I
- I
Benzo I
/ I
pyridodithiazine I
1 I
, I
1 I
- I
Dioxides I
Structurally O
Related O
to O
the O
ATP B
- O
Sensitive O
Potassium B
Channel O
Openers O
1 B
, I
2 I
, I
4 I
- I
Benzo I
/ I
pyridothiadiazine I
1 I
, I
1 I
- I
Dioxides I
Exert O
a O
Myorelaxant O
Activity O
Linked O
to O
a O
Distinct O
Mechanism O
of O
Action O
. O

1 B
, I
4 I
, I
2 I
- I
Benzo I
/ I
pyridodithiazine I
1 I
, I
1 I
- I
Dioxides I
Structurally O
Related O
to O
the O
ATP B
- O
Sensitive O
Potassium B
Channel O
Openers O
1 B
, I
2 I
, I
4 I
- I
Benzo I
/ I
pyridothiadiazine I
1 I
, I
1 I
- I
Dioxides I
Exert O
a O
Myorelaxant O
Activity O
Linked O
to O
a O
Distinct O
Mechanism O
of O
Action O
. O

The O
synthesis O
of O
diversely O
substituted O
3 B
- I
alkyl I
/ I
aralkyl I
/ I
arylamino I
- I
1 I
, I
4 I
, I
2 I
- I
benzodithiazine I
1 I
, I
1 I
- I
dioxides I
and O
3 B
- I
alkylaminopyrido I
[ I
4 I
, I
3 I
- I
e I
] I
- I
1 I
, I
4 I
, I
2 I
- I
dithiazine I
1 I
, I
1 I
- I
dioxides I
is O
described O
. O

The O
synthesis O
of O
diversely O
substituted O
3 B
- I
alkyl I
/ I
aralkyl I
/ I
arylamino I
- I
1 I
, I
4 I
, I
2 I
- I
benzodithiazine I
1 I
, I
1 I
- I
dioxides I
and O
3 B
- I
alkylaminopyrido I
[ I
4 I
, I
3 I
- I
e I
] I
- I
1 I
, I
4 I
, I
2 I
- I
dithiazine I
1 I
, I
1 I
- I
dioxides I
is O
described O
. O

Their O
biological O
activities O
on O
pancreatic O
beta O
- O
cells O
and O
on O
smooth O
muscle O
cells O
were O
compared O
to O
those O
of O
the O
reference O
ATP B
- O
sensitive O
potassium B
channel O
( O
KATP O
channel O
) O
openers O
diazoxide B
and O
7 B
- I
chloro I
- I
3 I
- I
isopropylamino I
- I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
benzothiadiazine I
1 I
, I
1 I
- I
dioxide I
. O

Tightly O
related O
3 B
- I
( I
1 I
- I
phenylethyl I
) I
sulfanyl I
- I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
benzothiadiazine I
1 I
, I
1 I
- I
dioxides I
were O
also O
found O
to O
exert O
a O
pronounced O
myorelaxant O
activity O
, O
resulting O
from O
both O
a O
KATP O
channel O
activation O
and O
a O
calcium B
channel O
blocker O
mechanism O
. O

The O
4 B
- I
nitrophenyl I
linked I
3 I
, I
3 I
' I
- I
diindolylmethane I
8g O
was O
found O
to O
be O
the O
most O
potent O
antileishmanial O
analog O
showing O
IC50 O
values O
of O
7 O
. O
88 O
and O
8 O
. O
37 O
mu O
M O
against O
both O
L O
. O
donovani O
promastigotes O
and O
amastigotes O
, O
respectively O
. O

These O
compounds O
also O
exhibited O
promising O
antifungal O
activity O
against O
Cryptococcus O
neoformans O
, O
wherein O
fluorophenyl B
substituted I
3 I
, I
3 I
' I
- I
diindolylmethanes I
were O
found O
to O
be O
most O
potent O
antifungal O
agents O
. O

Synthesis O
and O
selected O
immunological O
properties O
of O
substituted O
quino B
[ I
3 I
, I
2 I
- I
b I
] I
benzo I
[ I
1 I
, I
4 I
] I
thiazines I
. O

A O
new O
type O
of O
azaphenothiazines B
- O
tetracyclic B
quino I
[ I
3 I
, I
2 I
- I
b I
] I
benzo I
[ I
1 I
, I
4 I
] I
thiazines I
, O
possessing O
common O
substituents O
( O
H B
, O
CH3 B
, O
Cl B
, O
Br B
, O
F B
, O
CF3 B
, O
SCH3 B
) O
in O
positions O
8 O
- O
10 O
and O
pharmacophoric O
aminoalkyl B
substituents O
in O
position O
6 O
, O
were O
obtained O
from O
diquinodithiin B
and O
2 B
, I
2 I
' I
- I
dichloro I
- I
3 I
, I
3 I
' I
- I
diquinolinyl I
disulfide I
in O

A O
new O
type O
of O
azaphenothiazines B
- O
tetracyclic B
quino I
[ I
3 I
, I
2 I
- I
b I
] I
benzo I
[ I
1 I
, I
4 I
] I
thiazines I
, O
possessing O
common O
substituents O
( O
H B
, O
CH3 B
, O
Cl B
, O
Br B
, O
F B
, O
CF3 B
, O
SCH3 B
) O
in O
positions O
8 O
- O
10 O
and O
pharmacophoric O
aminoalkyl B
substituents O
in O
position O
6 O
, O
were O
obtained O
from O
diquinodithiin B
and O
2 B
, I
2 I
' I
- I
dichloro I
- I
3 I
, I
3 I
' I
- I
diquinolinyl I
disulfide I
in O

Structural O
elucidation O
of O
possible O
lutein B
oxidation O
products O
mediated O
through O
peroxyl B
radical O
inducer O
2 B
, I
2 I
' I
- I
Azobis I
( I
2 I
- I
methylpropionamidine I
) I
dihydrochloride I
: O
Antioxidant O
and O
cytotoxic O
influence O
of O
oxidized O
lutein B
in O
HeLa O
cells O
. O

Aim O
of O
this O
study O
was O
to O
elucidate O
lutein B
oxidation O
products O
mediated O
through O
peroxyl B
radical O
inducer O
2 B
, I
2 I
' I
- I
Azobis I
( I
2 I
- I
methylpropionamidine I
) I
dihydrochloride I
( O
AAPH B
) O
and O
to O
study O
antioxidant O
and O
cytotoxic O
effects O
of O
oxidized B
lutein I
using O
liposome O
and O
HeLa O
cells O
. O

Two O
structurally O
superimposable O
scaffolds O
- O
4H B
- I
thiochromeno I
[ I
4 I
, I
3 I
- I
d I
] I
thiazol I
- I
2 I
- I
amine I
and O
5 B
, I
6 I
- I
dihydro I
- I
4H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
- I
d I
] I
thiazol I
- I
2 I
- I
amine I
derivatives O
- O
yielded O
low O
- O
micromolar O
inhibitors O
, O
and O
two O
among O
them O
37 O
and O
43 O
also O
exhibited O
antiangiogenic O
activity O
in O
an O
endothelial O
tube O
formation O
assay O
. O

Two O
structurally O
superimposable O
scaffolds O
- O
4H B
- I
thiochromeno I
[ I
4 I
, I
3 I
- I
d I
] I
thiazol I
- I
2 I
- I
amine I
and O
5 B
, I
6 I
- I
dihydro I
- I
4H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
- I
d I
] I
thiazol I
- I
2 I
- I
amine I
derivatives O
- O
yielded O
low O
- O
micromolar O
inhibitors O
, O
and O
two O
among O
them O
37 O
and O
43 O
also O
exhibited O
antiangiogenic O
activity O
in O
an O
endothelial O
tube O
formation O
assay O
. O

We O
investigated O
the O
effects O
of O
6 B
- I
gingerol I
( O
( B
S I
) I
- I
5 I
- I
hydroxy I
- I
1 I
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenyl I
) I
- I
3 I
- I
decanone I
) O
on O
the O
inhibition O
of O
rosiglitazone B
( O
RGZ B
) O
- O
induced O
adipogenesis O
in O
3T3 O
- O
L1 O
cells O
. O

Here O
we O
characterized O
the O
effects O
of O
systemic O
administration O
of O
the O
DAAO O
inhibitor O
4H B
- I
furo I
[ I
3 I
, I
2 I
- I
b I
] I
pyrrole I
- I
5 I
- I
carboxylic I
acid I
( O
SUN B
) O
in O
rat O
models O
of O
neuropathic O
and O
inflammatory O
pain O
. O

Synthesis O
and O
Structure O
- O
Activity O
Relationships O
of O
5 B
, I
6 I
, I
7 I
- I
Substituted I
Pyrazolopyrimidines I
: O
Discovery O
of O
a O
Novel O
TSPO O
PET O
Ligand O
for O
Cancer O
Imaging O
. O

Focused O
library O
synthesis O
and O
structure O
- O
activity O
relationship O
development O
of O
5 B
, I
6 I
, I
7 I
- I
substituted I
pyrazolopyrimidines I
led O
to O
the O
discovery O
of O
2 B
- I
( I
5 I
, I
7 I
- I
diethyl I
- I
2 I
- I
( I
4 I
- I
( I
2 I
- I
fluoroethoxy I
) I
phenyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
- I
N I
, I
N I
- I
diethylacetamide I
( O
6b O
) O
, O
a O
novel O
translocator O
protein O
( O
TSPO O
) O
ligand O
exhibiting O
a O
36 O
- O
fold O
enhancement O
in O
affinity O
compared O
to O
another O

Focused O
library O
synthesis O
and O
structure O
- O
activity O
relationship O
development O
of O
5 B
, I
6 I
, I
7 I
- I
substituted I
pyrazolopyrimidines I
led O
to O
the O
discovery O
of O
2 B
- I
( I
5 I
, I
7 I
- I
diethyl I
- I
2 I
- I
( I
4 I
- I
( I
2 I
- I
fluoroethoxy I
) I
phenyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
- I
N I
, I
N I
- I
diethylacetamide I
( O
6b O
) O
, O
a O
novel O
translocator O
protein O
( O
TSPO O
) O
ligand O
exhibiting O
a O
36 O
- O
fold O
enhancement O
in O
affinity O
compared O
to O
another O

Radiolabeling O
with O
fluorine B
- I
18 I
( O
( B
18 I
) I
F I
) O
facilitated O
production O
of O
2 B
- I
( I
5 I
, I
7 I
- I
diethyl I
- I
2 I
- I
( I
4 I
- I
( I
2 I
- I
[ I
( I
18 I
) I
F I
] I
fluoroethoxy I
) I
phenyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
- I
N I
, I
N I
- I
diethylacetamide I
( O
( B
18 I
) I
F I
- O
6b O
) O
in O
high O
radiochemical O
yield O
and O
specific O
activity O
. O

A O
new O
compound O
1 O
( O
named O
botryosphaerin B
F I
) O
, O
along O
with O
other O
three O
known O
compounds O
2 O
( O
13 B
, I
14 I
, I
15 I
, I
16 I
- I
tetranorlabd I
- I
7 I
- I
ene I
- I
19 I
, I
6b I
: I
12 I
, I
17 I
- I
diolide I
) O
, O
3 O
( O
botryosphaerin B
B I
) O
and O
4 O
( O
LL B
- I
Z1271 I
beta I
) O
, O
has O
been O
isolated O
from O
the O
mangrove O
fungus O
Aspergillus O
terreus O
( O
No O
. O
GX7 O
- O
3B O
) O
. O

A O
phytochemical O
study O
of O
Baeckea O
frutescens O
afforded O
a O
new O
biflavonoid B
named O
as O
baeckein B
E I
( O
1 O
) O
, O
along O
with O
four O
known O
C B
- I
methylated I
flavonols I
, O
baeckeins B
A I
( O
2 O
) O
and O
B O
( O
3 O
) O
, O
6 B
- I
methylquercetin I
( O
6 O
) O
and O
6 B
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
7 O
) O
, O
and O
two O
known O
biflavonoids O
baeckeins B
C I
( O
4 O
) O
and O
D O
( O
5 O
) O
. O

The O
use O
of O
peptide O
( O
Cys B
- I
Ala I
- I
Leu I
- I
Asn I
- I
Asn I
) O
as O
ligands O
to O
stabilize O
and O
functionalize O
gold O
nanoparticles O
provides O
technical O
and O
operational O
convenience O
. O

We O
performed O
a O
study O
on O
the O
effect O
of O
quercetin B
and O
epigallocatechin B
- I
3 I
- I
gallate I
on O
2 B
- I
Dimyristoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
small O
unilamellar O
vesicles O
( O
SUVs O
) O
with O
different O
amounts O
of O
cholesterol B
, O
using O
Laurdan B
as O
a O
fluorescent O
probe O
, O
to O
put O
into O
evidence O
the O
perturbations O
of O
the O
phospholipid O
membrane O
fluidity O
and O
local O
lipid O
order O
in O
an O
attempt O
to O
decipher O
the O
action O
mechanism O
of O
the O
flavonoids B
at O
the O
cell O
membrane O
level O
. O

The O
HPLC O
- O
DAD O
analysis O
allowed O
the O
identification O
and O
quantification O
of O
3 B
- I
O I
- I
caffeoylquinic I
, I
4 I
- I
O I
- I
caffeoylquinic I
, I
5 I
- I
O I
- I
caffeoylquinic I
and I
rosmarinic I
acids I
, O
and O
luteolin B
and O
pinocembrin B
. O

Although O
isorhamnetin B
- I
3 I
- I
O I
- I
rhmanoside I
- I
7 I
, I
4 I
' I
- I
di I
- I
O I
- I
glucoside I
and O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
pentosyl I
) I
hexoside I
are O
the O
main O
metabolites O
in O
both O
aqueous O
and O
hydromethanolic O
extracts O
, O
qualitative O
and O
quantitative O
differences O
were O
found O
between O
them O
. O

Although O
isorhamnetin B
- I
3 I
- I
O I
- I
rhmanoside I
- I
7 I
, I
4 I
' I
- I
di I
- I
O I
- I
glucoside I
and O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
pentosyl I
) I
hexoside I
are O
the O
main O
metabolites O
in O
both O
aqueous O
and O
hydromethanolic O
extracts O
, O
qualitative O
and O
quantitative O
differences O
were O
found O
between O
them O
. O

Lysergic B
acid I
diethylamide I
( O
LSD B
) O
and O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
are O
serotonergic O
hallucinogens O
and O
activation O
of O
5HT2A O
receptors O
likely O
underlies O
their O
hallucinogenic O
effects O
. O

The O
aggregation O
behavior O
of O
cationic O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidac I
with O
chloride B
( O
TTBC B
- I
Cl I
) O
or O
iodide B
counterions O
( O
TTBC B
- I
I I
) O
in O
aqueous O
solution O
is O
investigated O
by O
absorption O
, O
linear O
dichroism O
, O
and O
fluorescence O
spectroscopies O
, O
as O
well O
as O
cryogenic O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

Hoduloside B
XI I
was O
confirmed O
to O
be O
3 B
- I
O I
- I
{ I
beta I
- I
d I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
3 I
) I
- I
[ I
beta I
- I
d I
- I
xylopyranosyl I
( I
1 I
- I
- I
> I
2 I
) I
] I
- I
alpha I
- I
l I
- I
arabinopyranosyl I
} I
- I
20 I
, I
26 I
- I
epoxypseudojujubogen I
. O

Hoduloside B
XII I
was O
identified O
as O
3 B
- I
O I
- I
{ I
beta I
- I
d I
- I
xylopyranose I
( I
1 I
- I
- I
> I
2 I
) I
glucopyranosyl I
( I
1 I
- I
- I
> I
3 I
) I
[ I
rhamnopyranose I
( I
1 I
- I
- I
> I
2 I
) I
] I
beta I
- I
d I
- I
glucopyranosyl I
} I
- I
20 I
, I
26 I
- I
epoxypseudojujubogen I
. O

Antinociceptive O
effect O
and O
gastroprotective O
mechanisms O
of O
3 B
, I
5 I
- I
diprenyl I
- I
4 I
- I
hydroxyacetophenone I
from O
Ageratina O
pichinchensis O
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
antinociceptive O
activity O
( O
in O
inflammatory O
and O
neuropathic O
pain O
models O
) O
and O
gastroprotective O
effect O
of O
the O
3 B
, I
5 I
- I
diprenyl I
- I
4 I
- I
hydroxyacetophenone I
( O
HYDP B
) O
, O
isolated O
from O
Ageratina O
pichinchensis O
. O

This O
gastroprotective O
effect O
was O
attenuated O
by O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
, O
indomethacin B
and O
N B
- I
ethylmaleimide I
, O
indicating O
that O
NO B
, O
prostaglandins B
and O
sulfhydryl B
groups O
are O
involved O
in O
the O
mechanisms O
of O
action O
. O

HISTONE O
DEACETYLASE O
INHIBITION O
AFFECTS O
SODIUM B
IODIDE I
SYMPORTER O
( O
NIS O
) O
EXPRESSION O
AND O
INDUCES O
( B
1 I
) I
( I
3 I
) I
( I
1 I
) I
I I
CYTOTOXICITY O
IN O
ANAPLASTIC O
THYROID O
CANCER O
CELLS O
. O

Objective O
: O
To O
investigate O
astaxanthin B
( O
ATX B
) O
neuroprotection O
, O
and O
its O
mechanism O
, O
on O
a O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
pyridine I
ion O
( O
MPP B
+ I
) O
- O
induced O
cell O
model O
of O
Parkinson O
' O
s O
disease O
. O

Copper B
- O
catalyzed O
diastereoselective O
arylation O
of O
tryptophan B
derivatives O
: O
total O
synthesis O
of O
( B
+ I
) I
- I
naseseazines I
a I
and I
B I
. O

The O
utility O
of O
this O
transformation O
is O
highlighted O
in O
the O
five O
- O
step O
syntheses O
of O
the O
natural O
products O
( B
+ I
) I
- I
naseseazine I
A I
and I
B I
. O

Synthesis O
and O
biological O
evaluation O
of O
prodrugs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
. O

Synthesis O
and O
biological O
evaluation O
of O
prodrugs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
. O

We O
report O
in O
this O
Letter O
the O
synthesis O
of O
prodrugs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyarabinose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
. O

We O
report O
in O
this O
Letter O
the O
synthesis O
of O
prodrugs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyarabinose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
. O

Stability O
studies O
of O
produgs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
in O
acidic O
and O
neutral O
conditions O
were O
conducted O
to O
confirm O
our O
observation O
. O

Stability O
studies O
of O
produgs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
in O
acidic O
and O
neutral O
conditions O
were O
conducted O
to O
confirm O
our O
observation O
. O

Biological O
evaluation O
of O
prodrugs O
of O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
for O
antiviral O
and O
cytotoxic O
activity O
is O
reported O
. O

Biodegradable O
oligo B
( I
poly I
( I
ethylene I
glycol I
) I
fumarate I
) I
( O
OPF B
) O
composite O
hydrogels O
have O
been O
investigated O
for O
the O
delivery O
of O
growth O
factors O
( O
GFs O
) O
with O
the O
aid O
of O
gelatin O
microparticles O
( O
GMPs O
) O
and O
stem O
cell O
populations O
for O
osteochondral O
tissue O
regeneration O
. O

Novel O
4 B
- I
substituted I
- I
2 I
( I
1H I
) I
- I
phthalazinone I
derivatives O
: O
synthesis O
, O
molecular O
modeling O
study O
and O
their O
effects O
on O
alpha O
- O
receptors O
. O

Novel O
4 B
- I
( I
4 I
- I
bromophenyl I
) I
phthalazine I
derivatives O
connected O
via O
an O
alkyl B
spacer O
to O
amine B
or O
N B
- I
substituted I
piperazine I
were O
designed O
and O
synthesized O
as O
promising O
alpha O
- O
adrenoceptor O
antagonists O
. O

Estimates O
of O
CLint O
for O
the O
production O
of O
mono B
( I
2 I
- I
ethyl I
- I
5 I
- I
hydroxyhexyl I
) I
phthalate I
and O
mono B
( I
2 I
- I
ethyl I
- I
5 I
- I
oxohexyl I
) I
phthalate I
by O
human O
CYP2C9 O
( O
* O
) O
1 O
were O
4 O
. O
2 O
- O
and O
2 O
. O
6 O
- O
fold O
greater O
than O
those O
by O
rat O
CYP2C6 O
, O
respectively O
. O

Estimates O
of O
CLint O
for O
the O
production O
of O
mono B
( I
2 I
- I
ethyl I
- I
5 I
- I
hydroxyhexyl I
) I
phthalate I
and O
mono B
( I
2 I
- I
ethyl I
- I
5 I
- I
oxohexyl I
) I
phthalate I
by O
human O
CYP2C9 O
( O
* O
) O
1 O
were O
4 O
. O
2 O
- O
and O
2 O
. O
6 O
- O
fold O
greater O
than O
those O
by O
rat O
CYP2C6 O
, O
respectively O
. O

Design O
, O
Synthesis O
and O
Antiviral O
Activity O
of O
2 B
- I
( I
3 I
- I
Amino I
- I
4 I
- I
piperazinylphenyl I
) I
chromone I
Derivatives O
. O

The O
synthesized O
2 B
- I
( I
3 I
- I
amino I
- I
4 I
- I
piperazinylphenyl I
) I
- I
chromones I
showed O
severe O
acute O
respiratory O
syndrome O
- O
corona O
virus O
( O
SARS O
- O
CoV O
) O
- O
specific O
antiviral O
activity O
. O

To O
study O
the O
glucose B
uptake O
, O
the O
glucose B
fluorescent O
analogue O
2 B
- I
[ I
N I
- I
( I
7 I
- I
nitrobenz I
- I
2 I
- I
oxa I
- I
1 I
, I
3 I
- I
diazol I
- I
4 I
- I
yl I
) I
amino I
] I
- I
2 I
- I
deoxy I
- I
d I
- I
glucose I
was O
used O
. O

Exploration O
of O
adenosine B
analogs O
in O
this O
class O
identified O
1 B
' I
- I
cyano I
- I
2 I
' I
- I
C I
- I
methyl I
4 I
- I
aza I
- I
7 I
, I
9 I
- I
dideaza I
adenosine I
as O
a O
potent O
and O
selective O
inhibitor O
of O
NS5B O
. O

Cytotoxicity O
and O
Modulation O
of O
Cancer O
- O
Related O
Signaling O
by O
( B
Z I
) I
- I
and I
( I
E I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
Tetramethoxystilbene I
Isolated O
from O
Eugenia O
rigida O
. O

Bioassay O
- O
guided O
fractionation O
of O
the O
leaves O
of O
Eugenia O
rigida O
yielded O
three O
stilbenes B
, O
( B
Z I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
1 O
) O
, O
( B
E I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
2 O
) O
, O
and O
( B
E I
) I
- I
3 I
, I
5 I
, I
4 I
' I
- I
trimethoxystilbene I
( O
3 O
) O
. O

Bioassay O
- O
guided O
fractionation O
of O
the O
leaves O
of O
Eugenia O
rigida O
yielded O
three O
stilbenes B
, O
( B
Z I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
1 O
) O
, O
( B
E I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
2 O
) O
, O
and O
( B
E I
) I
- I
3 I
, I
5 I
, I
4 I
' I
- I
trimethoxystilbene I
( O
3 O
) O
. O

Bioassay O
- O
guided O
fractionation O
of O
the O
leaves O
of O
Eugenia O
rigida O
yielded O
three O
stilbenes B
, O
( B
Z I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
1 O
) O
, O
( B
E I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
2 O
) O
, O
and O
( B
E I
) I
- I
3 I
, I
5 I
, I
4 I
' I
- I
trimethoxystilbene I
( O
3 O
) O
. O

The O
sterically O
hindered O
Z O
- O
stereoisomer O
1 O
, O
a O
new O
natural O
product O
, O
was O
prepared O
by O
time O
- O
dependent O
photoisomerization O
of O
the O
E O
- O
isomer O
( O
2 O
) O
under O
UV O
irradiation O
at O
lambda O
254 O
nm O
, O
while O
2 B
, I
3 I
, I
5 I
, I
7 I
- I
tetramethoxyphenanth I
( O
5 O
) O
was O
identified O
at O
lambda O
365 O
nm O
by O
UHPLC O
/ O
APCI O
- O
MS O
and O
NMR O
spectroscopy O
. O

The O
structures O
of O
three O
aromatic O
- O
rich O
isolated O
peptides O
, O
Ac B
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FF O
) O
, O
Ac B
- I
Trp I
- I
Tyr I
- I
NH2 I
( O
WY O
) O
, O
and O
Ac B
- I
Phe I
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FFF O
) O
, O
all O
in O
the O
gas O
phase O
, O
have O
been O
studied O
by O
infrared O
- O
ultraviolet O
( O
IR O
/ O
UV O
) O
double O
resonance O
laser O
spectroscopy O
, O
aided O
by O
dispersion O
- O
corrected O
density O
functional O
theory O
( O
DFT O
- O
D O
) O
calculations O
. O

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP B
( I
7 I

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP B
( I
7 I

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP B
( I
7 I

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP B
( I
7 I

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP B
( I
7 I

The O
photocytotoxicity O
of O
BaP B
, O
3 B
- I
OH I
- I
BaP I
, O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
diol I
- I
anti I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
, O
and O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
in O
the O
HaCaT O
keratinocytes O
was O
examined O
. O

The O
photocytotoxicity O
of O
BaP B
, O
3 B
- I
OH I
- I
BaP I
, O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
diol I
- I
anti I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
, O
and O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
in O
the O
HaCaT O
keratinocytes O
was O
examined O
. O

The O
photocytotoxicity O
of O
BaP B
, O
3 B
- I
OH I
- I
BaP I
, O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
diol I
- I
anti I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
, O
and O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
in O
the O
HaCaT O
keratinocytes O
was O
examined O
. O

When O
photoirradiation O
was O
conducted O
in O
the O
presence O
of O
a O
lipid O
( O
methyl B
linoleate I
) O
, O
BaP B
metabolites O
, O
BPDE B
, O
and O
three O
related O
PAHs B
, O
pyrene B
, O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
7 I
, I
8 I
- I
diol I
, O
and O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
9 I
, I
10 I
- I
diol I
, O
all O
induced O
lipid O
peroxidation O
. O

When O
photoirradiation O
was O
conducted O
in O
the O
presence O
of O
a O
lipid O
( O
methyl B
linoleate I
) O
, O
BaP B
metabolites O
, O
BPDE B
, O
and O
three O
related O
PAHs B
, O
pyrene B
, O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
7 I
, I
8 I
- I
diol I
, O
and O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
9 I
, I
10 I
- I
diol I
, O
all O
induced O
lipid O
peroxidation O
. O

The O
formation O
of O
lipid O
peroxides O
by O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
was O
inhibited O
by O
NaN3 B
and O
enhanced O
by O
deuterated B
methanol I
, O
which O
suggests O
that O
singlet O
oxygen B
may O
be O
involved O
in O
the O
generation O
of O
lipid O
peroxides O
. O

Results O
from O
4 B
' I
- I
6 I
- I
diamidino I
- I
2 I
- I
phenylindole I
and O
annexin O
- O
V O
/ O
PI O
double O
- O
staining O
assay O
showed O
that O
caspase O
- O
3 O
- O
and O
caspase O
- O
8 O
- O
dependent O
, O
and O
dose O
- O
dependent O
apoptoses O
were O
detected O
after O
a O
24 O
- O
h O
dioscin B
treatment O
. O

Chemical O
examination O
of O
a O
South O
China O
Sea O
soft O
coral O
Lobophytum O
sp O
. O
led O
to O
the O
isolation O
of O
three O
new O
alpha B
- I
methylene I
- I
gamma I
- I
lactone I
- O
containing O
cembranoids B
, O
( B
1R I
* I
, I
3R I
* I
, I
4R I
* I
, I
14R I
* I
, I
7E I
, I
11E I
) I
- I
3 I
, I
4 I
- I
epoxycembra I
- I
7 I
, I
11 I
, I
15 I
( I
17 I
) I
- I
trien I
- I
16 I
, I
14 I
- I
olide I
( O
1 O
) O
, O
( B
1R I
* I
, I
7S I
* I
, I
14S I
* I
, I
3E I
, I
11E I
) I
- I
7 I
- I

hydroperoxycembra I
- I
3 I
, I
8 I
( I
19 I
) I
, I
11 I
, I
15 I
( I
17 I
) I
- I
tetraen I
- I
16 I
, I
14 I
- I
olide I
( O
2 O
) O
, O
and O
( B
1R I
* I
, I
7S I
* I
, I
14S I
* I
, I
3E I
, I
11E I
) I
- I
18 I
- I
acetoxy I
- I
7 I
- I
hydroperoxycembra I
- I
3 I
, I
8 I
( I
19 I
) I
, I
11 I
, I
15 I
( I
17 I
) I
- I
tetraen I
- I
16 I
, I
14 I
- I
olide I
( O
3 O
) O
, O
along O
with O
eleven O
known O
analogues O
4 O
- O
14 O
. O

Liposomes O
were O
composed O
of O
phosphatidylcholine B
, O
hydrogenated O
soy O
phosphatidylcholine B
( O
HSPC O
) O
, O
stearylamine B
, O
alpha B
- I
tocopherol I
and O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphoethanolamine I
- I
N I
- I
[ I
amino I
( I
polyethylene I
glycol I
) I
- I
2000 I
] I
( O
PEG B
- I
DSPE I
) O
or O
folate B
- I
polyethylene I
glycol I
- I
cholesteryl I
hemisuccinate I
( O
F B
- I

The O
antioxidant O
capacities O
of O
the O
extract O
were O
evaluated O
using O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
, O
beta B
- I
carotene I
/ O
linoleic B
acid I
and O
reducing O
power O
and O
metal O
chelating O
activity O
assays O
. O

Redox O
- O
responsive O
amphiphilic O
diblock O
copolymers O
, O
poly B
( I
6 I
- I
O I
- I
methacryloyl I
- I
d I
- I
galactopyranose I
- I
co I
- I
2 I
- I
( I
N I
, I
N I
- I
dimethylaminoethyl I
) I
methacrylate I
) I
- I
b I
- I
poly I
( I
pyridyl I
disulfide I
ethyl I
methylacrylate I
) I
( O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
) O
were O
obtained O
by O
deprotection O
of O
poly B
( I
( I
6 I
- I
O I
- I
methacryloyl I

Redox O
- O
responsive O
amphiphilic O
diblock O
copolymers O
, O
poly B
( I
6 I
- I
O I
- I
methacryloyl I
- I
d I
- I
galactopyranose I
- I
co I
- I
2 I
- I
( I
N I
, I
N I
- I
dimethylaminoethyl I
) I
methacrylate I
) I
- I
b I
- I
poly I
( I
pyridyl I
disulfide I
ethyl I
methylacrylate I
) I
( O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
) O
were O
obtained O
by O
deprotection O
of O
poly B
( I
( I
6 I
- I
O I
- I
methacryloyl I

- I
1 I
, I
2 I
: I
3 I
, I
4 I
- I
di I
- I
O I
- I
isopropylidene I
- I
d I
- I
galactopyranose I
) I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
[ O
P B
( I
MAlpGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
] O
, O
which O
were O
prepared O
via O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
PDSMA B
using O
P B
( I
MAlpGP I
- I
co I
- I
DMAEMA I
) I
as O
macro O
- O
RAFT O
agent O
. O

- I
1 I
, I
2 I
: I
3 I
, I
4 I
- I
di I
- I
O I
- I
isopropylidene I
- I
d I
- I
galactopyranose I
) I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
[ O
P B
( I
MAlpGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
] O
, O
which O
were O
prepared O
via O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
PDSMA B
using O
P B
( I
MAlpGP I
- I
co I
- I
DMAEMA I
) I
as O
macro O
- O
RAFT O
agent O
. O

Dynamic O
light O
scattering O
( O
DLS O
) O
and O
transmission O
electron O
microscopy O
( O
TEM O
) O
studies O
showed O
that O
diblock O
copolymers O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
can O
self O
- O
assemble O
into O
micelles O
. O

Doxorubicin B
( O
DOX B
) O
could O
be O
encapsulated O
by O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
upon O
micellization O
and O
released O
upon O
adding O
glutathione B
( O
GSH B
) O
into O
the O
micelle O
solution O
. O

The O
galactose B
functional O
groups O
in O
the O
PMAGP B
block O
had O
specific O
interaction O
with O
HepG2 O
cells O
, O
and O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
can O
act O
as O
gene O
delivery O
vehicle O
. O

1 B
, I
3 I
, I
4 I
- I
Oxadiazol I
- I
2 I
- I
ones I
as O
fatty B
- I
acid I
amide I
hydrolase O
and O
monoacylglycerol B
lipase O
inhibitors O
: O
Synthesis O
, O
in O
vitro O
evaluation O
and O
insight O
into O
potency O
and O
selectivity O
determinants O
by O
molecular O
modelling O
. O

Continuing O
our O
previous O
work O
, O
we O
take O
the O
first O
steps O
of O
structure O
- O
activity O
relationship O
exploration O
and O
show O
that O
1 B
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
ones I
can O
serve O
as O
scaffold O
for O
both O
selective O
FAAH O
and O
MAGL O
inhibitors O
, O
and O
also O
function O
as O
a O
dual O
FAAH O
/ O
MAGL O
inhibitor O
at O
sub O
- O
micromolar O
IC50 O
values O
. O

A O
diarylheptanoid B
phytoestrogen O
from O
Curcuma O
comosa O
, O
1 B
, I
7 I
- I
diphenyl I
- I
4 I
, I
6 I
- I
heptadien I
- I
3 I
- I
ol I
, O
accelerates O
human O
osteoblast O
proliferation O
and O
differentiation O
. O

Previous O
work O
showed O
that O
C O
. O
comosa O
extracts O
protect O
mice O
from O
ovariectomy O
- O
induced O
osteopenia O
with O
minimal O
effects O
on O
reproductive O
organs O
, O
and O
identified O
the O
diarylheptanoid B
( B
3R I
) I
- I
1 I
, I
7 I
- I
diphenyl I
- I
( I
4E I
, I
6E I
) I
- I
4 I
, I
6 I
- I
heptadien I
- I
3 I
- I
ol I
( O
DPHD B
) O
as O
the O
major O
active O
component O
of O
C O
. O
comosa O
rhizomes O
. O

Synthesis O
and O
Cytostatic O
and O
Antiviral O
Activities O
of O
2 B
' I
- I
Deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibo I
- I
and I
2 I
' I
- I
Deoxy I
- I
2 I
' I
- I
fluororibonucleoside I
Derived O
from O
7 B
- I
( I
Het I
) I
aryl I
- I
7 I
- I
deazaadenines I
. O

Synthesis O
and O
Cytostatic O
and O
Antiviral O
Activities O
of O
2 B
' I
- I
Deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibo I
- I
and I
2 I
' I
- I
Deoxy I
- I
2 I
' I
- I
fluororibonucleoside I
Derived O
from O
7 B
- I
( I
Het I
) I
aryl I
- I
7 I
- I
deazaadenines I
. O

A O
series O
of O
sugar B
- O
modified O
derivatives O
of O
cytostatic O
7 B
- I
heteroaryl I
- I
7 I
- I
deazaadenosines I
( O
2 B
' I
- I
deoxy I
- I
2 I
' I
- I
fluororibo I
- I
and I
2 I
' I
- I
deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibonucleosi I
) O
bearing O
an O
aryl B
or O
heteroaryl B
group O
at O
position O
7 O
was O
prepared O
and O
screened O
for O
biological O
activity O
. O

The O
difluororibonucleosi B
were O
prepared O
by O
non O
- O
stereoselective O
glycosidation O
of O
6 B
- I
chloro I
- I
7 I
- I
deazapurine I
with O
benzoyl B
- I
protected I
2 I
- I
deoxy I
- I
2 I
, I
2 I
- I
difluoro I
- I
D I
- I
erythro I
- I
pentofuranosyl I
- I
1 I
- I
mesylate I
, O
followed O
by O
amination O
and O
aqueous O
Suzuki O
cross O
- O
couplings O
with O
( B
het I
) I
arylboronic I
acids I
. O

The O
fluororibo B
derivatives O
were O
prepared O
by O
aqueous O
palladium B
- O
catalyzed O
cross O
- O
coupling O
reactions O
of O
the O
corresponding O
7 B
- I
iodo I
- I
7 I
- I
deazaadenine I
2 I
' I
- I
deoxy I
- I
2 I
' I
- I
fluororibonucleoside I
20 O
with O
( B
het I
) I
arylboronic I
acids I
. O

The O
key O
intermediate O
20 O
was O
prepared O
by O
a O
six O
- O
step O
sequence O
from O
the O
corresponding O
arabinonucleoside B
by O
selective O
protection O
of O
3 B
' I
- I
and I
5 I
' I
- I
hydroxy I
groups O
with O
acid O
- O
labile O
groups O
, O
followed O
by O
stereoselective O
SN O
2 O
fluorination O
and O
deprotection O
. O

The O
corresponding O
2 B
' I
- I
deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibonucleosi I
5 I
' I
- I
O I
- I
triphosphates I
were O
found O
to O
be O
good O
substrates O
for O
bacterial O
DNA O
polymerases O
, O
but O
are O
inhibitors O
of O
human O
polymerase O
alpha O
. O

Synthesis O
and O
Biological O
Evaluation O
of O
a O
New O
Series O
of O
Hexahydro B
- I
2H I
- I
pyrano I
[ I
3 I
, I
2 I
- I
c I
] I
quinolines I
as O
Novel O
Selective O
sigma O
1 O
Receptor O
Ligands O
. O

The O
synthesis O
and O
pharmacological O
activity O
of O
a O
new O
series O
of O
hexahydro B
- I
2H I
- I
pyrano I
[ I
3 I
, I
2 I
- I
c I
] I
quinoline I
derivatives O
as O
potent O
sigma O
1 O
receptor O
( O
sigma O
1R O
) O
ligands O
are O
reported O
. O

The O
organic O
acid O
profiles O
of O
these O
strains O
comprise O
acetic B
, I
citric I
, I
succinic I
and I
malic I
acids I
that O
qualitatively O
and O
quantitatively O
vary O
between O
different O
species O
as O
well O
as O
among O
strains O
from O
the O
same O
species O
. O

The O
production O
from O
glycerol B
of O
succinic B
, I
acetic I
, I
citric I
, I
malic I
and I
oxalic I
acids I
from O
C O
. O
oleophila O
and O
W O
. O
anomalus O
, O
and O
that O
of O
succinic B
, I
oxalic I
and I
acetic I
acids I
by O
P O
. O
fermentans O
is O
reported O
for O
the O
first O
time O
in O
this O
work O
, O
as O
is O
the O
production O
of O
oxalic B
acid I
from O
glycerol B
in O
yeasts O
. O

The O
protective O
effects O
of O
maqui O
berry O
( O
Aristotelia O
chilensis O
) O
extract O
( O
MBE O
) O
and O
its O
major O
anthocyanins B
[ O
delphinidin B
3 I
, I
5 I
- I
O I
- I
diglucoside I
( O
D3G5G B
) O
and O
delphinidin B
3 I
- I
O I
- I
sambubioside I
- I
5 I
- I
O I
- I
glucoside I
( O
D3S5G B
) O
] O
against O
light O
- O
induced O
murine O
photoreceptor O
cells O
( O
661W O
) O
death O
were O
evaluated O
. O

The O
protective O
effects O
of O
maqui O
berry O
( O
Aristotelia O
chilensis O
) O
extract O
( O
MBE O
) O
and O
its O
major O
anthocyanins B
[ O
delphinidin B
3 I
, I
5 I
- I
O I
- I
diglucoside I
( O
D3G5G B
) O
and O
delphinidin B
3 I
- I
O I
- I
sambubioside I
- I
5 I
- I
O I
- I
glucoside I
( O
D3S5G B
) O
] O
against O
light O
- O
induced O
murine O
photoreceptor O
cells O
( O
661W O
) O
death O
were O
evaluated O
. O

Intracellular O
radical O
activation O
in O
661W O
, O
evaluated O
using O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
- O
sensitive O
probe O
5 B
- I
( I
and I
- I
6 I
) I
- I
chloromethyl I
- I
2 I
, I
7 I
- I
dichlorodihydro I
fluorescein I
diacetate I
acetyl I
ester I
( O
CM B
- I
H2DCFDA I
) O
, O
was O
reduced O
by O
MBE O
and O
its O
anthocyanins B
. O

From O
the O
compounds O
identified O
in O
both O
species O
, O
3 B
- I
O I
- I
( I
6 I
' I
' I
- I
O I
- I
galloyl I
) I
- I
hexose I
derivatives O
of O
myricetin B
, O
quercetin B
, O
laricitrin B
and O
isorhamnetin B
are O
reported O
for O
the O
first O
time O
for O
the O
genus O
Luma O
. O

The O
anti O
- O
mutagenic O
properties O
was O
assayed O
with O
the O
following O
HCAs B
: O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
, O
2 B
- I
amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
MeIQ B
) O
, O
2 B
- I
amino I
- I
3 I
, I
8 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoxaline I
( O
MeIQx B
) O
, O
the O
imidazoles B
2 B
- I
amino I
- I
6 I
- I

The O
anti O
- O
mutagenic O
properties O
was O
assayed O
with O
the O
following O
HCAs B
: O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
, O
2 B
- I
amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
MeIQ B
) O
, O
2 B
- I
amino I
- I
3 I
, I
8 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoxaline I
( O
MeIQx B
) O
, O
the O
imidazoles B
2 B
- I
amino I
- I
6 I
- I

The O
anti O
- O
mutagenic O
properties O
was O
assayed O
with O
the O
following O
HCAs B
: O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
, O
2 B
- I
amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
MeIQ B
) O
, O
2 B
- I
amino I
- I
3 I
, I
8 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoxaline I
( O
MeIQx B
) O
, O
the O
imidazoles B
2 B
- I
amino I
- I
6 I
- I

methyldipyrido I
- I
[ I
1 I
, I
2 I
- I
a I
: I
3 I
' I
, I
2 I
' I
- I
d I
] I
imidazole I
( O
Glu B
- I
P I
- I
1 I
) O
and O
2 B
- I
aminodipirydo I
- I
[ I
1 I
, I
2 I
- I
a I
: I
3 I
' I
, I
2 I
' I
- I
d I
] I
imidazole I
( O
Glu B
- I
P I
- I
2 I
) O
. O

methyldipyrido I
- I
[ I
1 I
, I
2 I
- I
a I
: I
3 I
' I
, I
2 I
' I
- I
d I
] I
imidazole I
( O
Glu B
- I
P I
- I
1 I
) O
and O
2 B
- I
aminodipirydo I
- I
[ I
1 I
, I
2 I
- I
a I
: I
3 I
' I
, I
2 I
' I
- I
d I
] I
imidazole I
( O
Glu B
- I
P I
- I
2 I
) O
. O

NMR O
data O
confirmed O
that O
the O
predominant O
non O
- O
polar O
dimer O
formed O
during O
beta B
- I
sitosterol I
oxidative O
degradation O
has O
a O
configuration O
of O
3 B
beta I
, I
3 I
beta I
' I
- I
disitosteryl I
ether I
. O

KY O
had O
the O
highest O
phenolic B
content O
, O
and O
the O
strongest O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
pireyhydrazyl I
radical O
scavenging O
capacity O
and O
hydroxyl B
radical O
scavenging O
activity O
. O

In O
" O
pinking O
" O
of O
onion O
, O
E B
- I
( I
+ I
) I
- I
S I
- I
( I
1 I
- I
propenyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
is O
first O
cleaved O
by O
alliinase O
to O
yield O
colour O
developers O
( O
CDs O
) O
, O
which O
react O
with O
amino B
acids I
, O
such O
as O
valine B
, O
to O
form O
pigment O
precursors O
( O
PPs O
) O
. O

The O
structure O
of O
one O
of O
the O
colourless O
compounds O
was O
established O
as O
2 B
- I
( I
2 I
- I
( I
1 I
- I
( I
1 I
- I
carboxy I
- I
2 I
- I
methylpropyl I
) I
- I
3 I
, I
4 I
- I
dimethyl I
- I
1H I
- I
pyrrol I
- I
2 I
- I
yl I
) I
methyl I
- I
3 I
, I
4 I
- I
dimethyl I
- I
1H I
- I
pyrrol I
- I
1 I
- I
yl I
) I
- I
3 I
- I
methylbutanoic I
acid I
. O

The O
honey O
from O
B O
. O
pilosa O
also O
had O
significantly O
greater O
scavenging O
activities O
for O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
. I
) O
and O
hydroxyl B
radical O
, O
and O
substantially O
more O
reducing O
power O
. O

A O
series O
of O
( B
S I
) I
- I
2 I
- I
( I
2 I
- I
( I
diethylamino I
) I
- I
5 I
- I
( I
N I
- I
alkyl I
- I
N I
- I
sulfonamido I
) I
pyrimidin I
- I
4 I
- I
ylamino I
) I
- I
3 I
- I
( I
4 I
- I
( I
carbamoyloxy I
) I
phenyl I
) I
propanoic I
acid I
is O
discovered O
as O
orally O
available O
VLA O
- O
4 O
antagonists O
. O

Poly B
( I
N I
- I
isopropylacrylamide I
- I
co I
- I
hydroxyethylacrylami I
) I
thermosensitive O
microspheres O
: O
The O
size O
of O
microgels O
dictates O
the O
pulsatile O
release O
mechanism O
. O

Poly B
( I
N I
- I
isopropylacrylamide I
- I
co I
- I
N I
- I
hydroxyethylacrylami I
) I
( O
poly B
( I
NIPAAm I
- I
co I
- I
HEAAm I
) I
) O
was O
prepared O
as O
a O
new O
thermosensitive O
copolymer O
possessing O
a O
sharp O
phase O
transition O
around O
the O
human O
body O
temperature O
. O

Poly B
( I
N I
- I
isopropylacrylamide I
- I
co I
- I
N I
- I
hydroxyethylacrylami I
) I
( O
poly B
( I
NIPAAm I
- I
co I
- I
HEAAm I
) I
) O
was O
prepared O
as O
a O
new O
thermosensitive O
copolymer O
possessing O
a O
sharp O
phase O
transition O
around O
the O
human O
body O
temperature O
. O

The O
synthesized O
compounds O
, O
especially O
tris B
( I
4 I
- I
( I
pyridin I
- I
4 I
- I
yl I
) I
phenyl I
) I
amine I
, O
presented O
pH O
- O
dependent O
absorptions O
and O
emissions O
, O
indicating O
that O
these O
compounds O
might O
be O
used O
as O
pH O
sensors O
. O

Recent O
studies O
indicate O
that O
dietary O
supplements O
of O
antioxidants O
and O
omega B
- I
3 I
and I
omega I
- I
6 I
fatty I
acids I
may O
reduce O
the O
cognitive O
deficits O
in O
AD O
patients O
. O

The O
antioxidative O
activity O
of O
the O
extract O
, O
the O
anthocyanin B
- O
rich O
fraction O
( O
AF O
) O
was O
determined O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
and O
ferric B
- O
reducing O
ability O
of O
plasma O
along O
with O
resveratrol B
as O
a O
reference O
. O

In O
further O
evaluation O
, O
the O
representative O
compound O
N B
, I
N I
- I
diethyl I
- I
N I
- I
( I
2 I
- I
( I
N I
- I
methyltetradecanamid I
) I
ethyl I
) I
prop I
- I
2 I
- I
en I
- I
1 I
- I
aminium I
bromide I
( O
3b O
) O
exhibited O
potent O
pro O
- O
apoptotic O
activity O
, O
through O
RhoB O
activation O
, O
in O
HeLa O
cells O
. O

In O
vivo O
and O
in O
vitro O
anti O
- O
inflammatory O
potential O
of O
pentahydroxy B
- I
pregn I
- I
14 I
- I
ol I
, I
20 I
- I
one I
- I
beta I
- I
d I
- I
thevetopyranoside I
in O
rats O
. O

Ornidazole B
[ O
R B
, I
S I
- I
1 I
- I
chloro I
- I
3 I
- I
( I
2 I
- I
methyl I
- I
5 I
- I
nitro I
- I
1H I
- I
imidazol I
- I
1 I
- I
yl I
) I
propan I
- I
2 I
- I
ol I
] O
is O
a O
chiral O
5 B
- I
nitroimidazole I
class O
antimicrobial O
agent O
. O

The O
in O
vitro O
intrinsic O
clearance O
( O
CLint O
) O
ratios O
of O
S B
- I
and I
R I
- I
ornidazole I
were O
approximately O
4 O
. O
3 O
in O
HLMs O
and O
6 O
. O
5 O
in O
HKMs O
, O
respectively O
. O

In O
the O
present O
study O
, O
a O
chemical O
derivatization O
of O
isomeric O
hydroxylated O
metabolites O
with O
2 B
- I
fluoro I
- I
N I
- I
methyl I
pyridinium I
p I
- I
toluenesulfonate I
was O
found O
to O
confer O
distinct O
theoretical O
CCS O
value O
on O
each O
isomer O
by O
forming O
corresponding O
N B
- I
methyl I
pyridine I
( O
NMP B
) O
derivative O
. O

The O
metallogels O
showed O
different O
fluorescence O
changes O
when O
they O
met O
with O
enantiomeric O
( B
R I
, I
R I
) I
- I
or I
( I
S I
, I
S I
) I
- I
1 I
, I
2 I
- I
diaminocyclohexane I
. O

Interestingly O
, O
the O
Zn B
( I
HQLG I
) I
2 I
gels O
showed O
obviously O
different O
fluorescent O
color O
with O
respect O
to O
( B
R I
, I
R I
) I
- I
and I
( I
S I
, I
S I
) I
- I
1 I
, I
2 I
- I
diaminocyclohexane I
, O
thus O
providing O
visible O
chiral O
recognition O
via O
the O
naked O
eye O
. O

The O
main O
goal O
of O
the O
present O
study O
was O
to O
examine O
the O
neurobehavioral O
changes O
in O
rat O
offspring O
that O
were O
perinatally O
exposed O
to O
one O
of O
the O
most O
prevalent O
PBDEs B
congeners O
found O
in O
humans O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
- I
pentaBDE I
( O
BDE B
- I
99 I
) O
. O

It O
was O
noteworthy O
that O
the O
contents O
of O
two O
major O
constituents O
, O
kaempferol B
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
3 I
) I
- I
alpha I
- I
l I
- I
rhamnopyranosyl I
- I
( I
1 I
- I
- I
> I
6 I
) I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
10 O
) O
and O
kaempferol B
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
3 I
) I
- I
alpha I
- I
l I
- I
rhamnopyranosyl I
- I
( I
1 I
- I
- I
> I
6 I
) I
- I
beta I
- I
d I
- I

A O
new O
flavonol B
glycoside I
, O
chakaflavonoside B
B I
( O
17 O
) O
, O
which O
was O
isolated O
in O
the O
course O
of O
this O
analytical O
study O
, O
was O
found O
to O
show O
oleic B
acid I
- O
albumin O
- O
induced O
lipid O
accumulation O
inhibitory O
activity O
. O

The O
least O
susceptible O
cvs O
, O
above O
all O
Percoca O
Romagnola O
7 O
, O
contained O
the O
higher O
amounts O
of O
hexenyl B
, I
hexyl I
, I
3 I
- I
methylbutyl I
, I
butyl I
and I
2 I
- I
methylpropyl I
esters I
; O
among O
these O
, O
some O
C6 O
derivatives O
detected O
, O
such O
as O
( B
Z I
) I
- I
3 I
- I
hexenyl I
acetate I
, O
are O
known O
to O
act O
as O
priming O
agents O
, O
enhancing O
plant O
defence O
response O
to O
insects O
. O

The O
least O
susceptible O
cvs O
, O
above O
all O
Percoca O
Romagnola O
7 O
, O
contained O
the O
higher O
amounts O
of O
hexenyl B
, I
hexyl I
, I
3 I
- I
methylbutyl I
, I
butyl I
and I
2 I
- I
methylpropyl I
esters I
; O
among O
these O
, O
some O
C6 O
derivatives O
detected O
, O
such O
as O
( B
Z I
) I
- I
3 I
- I
hexenyl I
acetate I
, O
are O
known O
to O
act O
as O
priming O
agents O
, O
enhancing O
plant O
defence O
response O
to O
insects O
. O

A O
new O
isobenzofuranone B
, O
4 B
- I
( I
methoxymethyl I
) I
- I
7 I
- I
methoxy I
- I
6 I
- I
methyl I
- I
1 I
( I
3H I
) I
- I
isobenzofuranone I
( O
1 O
) O
, O
together O
with O
seven O
known O
compounds O
, O
dilation B
( O
2 O
) O
, O
lumichrome B
( O
3 O
) O
, O
curvulari B
( O
4 O
) O
, O
5 B
, I
5 I
' I
- I
oxy I
- I
dimethylene I
- I
bis I
( I
2 I
- I
furaldehyde I
) I
( O
5 O
) O
, O
chromone B
( O
6 O
) O
, O
harman B
( I
1 I
- I
methyl I
- I
beta I
- I
carboline I
) I

A O
new O
isobenzofuranone B
, O
4 B
- I
( I
methoxymethyl I
) I
- I
7 I
- I
methoxy I
- I
6 I
- I
methyl I
- I
1 I
( I
3H I
) I
- I
isobenzofuranone I
( O
1 O
) O
, O
together O
with O
seven O
known O
compounds O
, O
dilation B
( O
2 O
) O
, O
lumichrome B
( O
3 O
) O
, O
curvulari B
( O
4 O
) O
, O
5 B
, I
5 I
' I
- I
oxy I
- I
dimethylene I
- I
bis I
( I
2 I
- I
furaldehyde I
) I
( O
5 O
) O
, O
chromone B
( O
6 O
) O
, O
harman B
( I
1 I
- I
methyl I
- I
beta I
- I
carboline I
) I

( O
7 O
) O
, O
N9 B
- I
methyl I
- I
1methyl I
- I
beta I
- I
carboline I
( O
8 O
) O
, O
was O
isolated O
from O
the O
mangrove O
endophytic O
fungus O
, O
Penicillium O
sp O
. O

Metabolism O
of O
2 B
, I
2 I
' I
, I
3 I
, I
3 I
' I
, I
6 I
, I
6 I
' I
- I
hexachlorobiphenyl I
( O
PCB B
136 I
) O
atropisomers O
in O
tissue O
slices O
from O
phenobarbital B
or O
dexamethasone B
- O
induced O
rats O
is O
sex O
- O
dependent O
. O

The O
thermoregulatory O
circuitry O
of O
" O
endogenous O
pyrogen O
( O
EP O
) O
^ O
- O
hypothalamus O
Na B
( I
+ I
) I
/ I
Ca I
( I
2 I
+ I
) I
- I
cAMP I
^ O
" O
was O
partially O
confirmed O
in O
this O
study O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
- O
induced O
inflammatory O
activation O
is O
mediated O
by O
intracellular O
free O
calcium B
in O
microglial O
cells O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
has O
been O
known O
to O
induce O
inflammatory O
signaling O
in O
a O
number O
of O
cell O
types O
and O
tissues O
. O

These O
pro O
- O
inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca B
( I
2 I
+ I
) I
blockers O
, O
bis B
- I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetra I
- I
acetic I
acid I
acetoxymethyl I
ester I
( O
BAPTA B
- I
AM I
) O
and O
nifedipine B
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca B
( I
2 I
+ I
) I
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

MATERIAL O
AND O
METHODS O
: O
The O
antioxidant O
activity O
of O
MPG O
leaf O
hydromethanolic O
extract O
was O
determined O
by O
using O
both O
the O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
scavenging O
and O
the O
oxygen B
radical O
absorbance O
capacity O
in O
vitro O
assays O
. O

Antibacterial O
oxazolidinone B
analogues O
having O
a O
N B
- I
hydroxyacetyl I
- O
substituted O
seven O
- O
membered O
[ B
1 I
, I
2 I
, I
5 I
] I
triazepane I
or O
[ B
1 I
, I
2 I
, I
5 I
] I
oxadiazepane I
C B
- O
ring O
unit O
. O

Antibacterial O
oxazolidinone B
analogues O
having O
a O
N B
- I
hydroxyacetyl I
- O
substituted O
seven O
- O
membered O
[ B
1 I
, I
2 I
, I
5 I
] I
triazepane I
or O
[ B
1 I
, I
2 I
, I
5 I
] I
oxadiazepane I
C B
- O
ring O
unit O
. O

We O
synthesized O
a O
series O
of O
oxazolidinone B
analogues O
bearing O
a O
N B
- I
hydroxyacetyl I
- I
substituted I
[ I
1 I
, I
2 I
, I
5 I
] I
triazepane I
or I
[ I
1 I
, I
2 I
, I
5 I
] I
oxadiazepane I
C B
- O
ring O
unit O
as O
homologues O
of O
an O
earlier O
drug O
candidate O
, O
eperezolid B
. O

Hemin B
, O
iron B
( I
III I
) I
protoporphyrin I
chloride I
( I
IX I
) I
, O
as O
a O
stable O
form O
of O
heme B
iron B
, O
has O
been O
used O
in O
iron B
absorption O
studies O
. O

Both O
enzyme O
variants O
outperformed O
the O
wild O
- O
type O
enzyme O
in O
the O
cyanolysis O
of O
ethyl B
( I
S I
) I
- I
3 I
, I
4 I
- I
epoxybutyrate I
, O
a O
conversion O
yielding O
ethyl B
( I
R I
) I
- I
4 I
- I
cyano I
- I
3 I
- I
hydroxybutyrate I
, O
an O
important O
chiral O
building O
block O
for O
statin O
synthesis O
. O

Both O
enzyme O
variants O
outperformed O
the O
wild O
- O
type O
enzyme O
in O
the O
cyanolysis O
of O
ethyl B
( I
S I
) I
- I
3 I
, I
4 I
- I
epoxybutyrate I
, O
a O
conversion O
yielding O
ethyl B
( I
R I
) I
- I
4 I
- I
cyano I
- I
3 I
- I
hydroxybutyrate I
, O
an O
important O
chiral O
building O
block O
for O
statin O
synthesis O
. O

Crystal O
structures O
of O
this O
enzyme O
were O
elucidated O
with O
chloride B
and O
ethyl B
( I
S I
) I
- I
3 I
, I
4 I
- I
epoxybutyrate I
or O
with O
ethyl B
( I
R I
) I
- I
4 I
- I
cyano I
- I
3 I
- I
hydroxybutyrate I
bound O
in O
the O
active O
site O
. O

Crystal O
structures O
of O
this O
enzyme O
were O
elucidated O
with O
chloride B
and O
ethyl B
( I
S I
) I
- I
3 I
, I
4 I
- I
epoxybutyrate I
or O
with O
ethyl B
( I
R I
) I
- I
4 I
- I
cyano I
- I
3 I
- I
hydroxybutyrate I
bound O
in O
the O
active O
site O
. O

PURPOSE O
: O
Paraquat B
( O
PQ O
; O
1 B
, I
1 I
' I
dimethyl I
- I
bipyridilium I
4 I
, I
4 I
' I
- I
dichloride I
) O
, O
which O
is O
used O
extensively O
throughout O
the O
world O
, O
is O
highly O
toxic O
to O
humans O
. O

As O
a O
model O
system O
we O
have O
chosen O
a O
rigid O
molecular O
module O
, O
1 B
, I
3 I
, I
5 I
- I
tris I
( I
pyridine I
- I
4 I
- I
ylethynyl I
) I
benzene I
, O
which O
can O
undergo O
self O
- O
association O
via O
hydrogen B
bonding O
( O
H B
- O
bonding O
) O
to O
form O
ordered O
2D O
nanostructures O
. O

A O
novel O
series O
of O
10 B
- I
hydroxyl I
ketolide I
derivatives O
were O
synthesized O
, O
during O
which O
a O
distinctive O
intermediate O
, O
3 B
- I
O I
- I
descladinosyl I
- I
3 I
- I
oxo I
- I
11 I
- I
deoxy I
- I
10 I
, I
11 I
- I
epoxy I
- I
6 I
- I
O I
- I
methylerythromycin I
A I
, O
was O
obtained O
from O
6 B
- I
O I
- I
methylerythromycin I
A I
. O

ESI O
- O
MS O
revealed O
that O
the O
most O
abundant O
A O
. O
bestiarum O
LPS O
glycoforms O
have O
a O
hexa O
- O
acylated O
or O
tetra O
- O
acylated O
lipid O
A O
with O
conserved O
architecture O
of O
the O
backbone O
, O
consisting O
of O
a O
1 B
, I
4 I
' I
- I
bisphosphorylated I
beta I
- I
( I
1 I
- I
- I
> I
6 I
) I
- I
linked I
d I
- I
GlcN I
disaccharide I
with O
an O
AraN B
residue O
as O
a O
non O
- O
stoichiometric O
substituent O
and O
a O
core O
oligosaccharide O
composed O
of O
Kdo1Hep6Hex1HexN1P1 O

1 B
, I
1 I
- I
Difluoroethyl I
- I
substituted I
triazolothienopyrimi I
as O
inhibitors O
of O
a O
human O
urea B
transport O
protein O
( O
UT O
- O
B O
) O
: O
New O
analogs O
and O
binding O
model O
. O

Poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
) I
changes O
in O
conformation O
with O
altered O
temperature O
and O
pH O
. O

Their O
structures O
were O
elucidated O
as O
3 B
beta I
- I
[ I
( I
2 I
- I
O I
- I
sulfo I
- I
beta I
- I
d I
- I
xylopyranosyl I
) I
oxy I
] I
urs I
- I
12 I
, I
19 I
( I
29 I
) I
- I
diene I
- I
28 I
- I
oic I
acid I
28 I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
3 B
beta I
- I
[ I
( I
2 I
- I
O I
- I
sulfo I
- I
beta I
- I
d I
- I
xylopyranosyl I
) I
oxy I
] I
urs I
- I
12 I
, I
19 I
- I
diene I
- I
28 I
- I
oic I
acid I
28 I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
2 O
) O
, O
and O
3 B

Their O
structures O
were O
elucidated O
as O
3 B
beta I
- I
[ I
( I
2 I
- I
O I
- I
sulfo I
- I
beta I
- I
d I
- I
xylopyranosyl I
) I
oxy I
] I
urs I
- I
12 I
, I
19 I
( I
29 I
) I
- I
diene I
- I
28 I
- I
oic I
acid I
28 I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
3 B
beta I
- I
[ I
( I
2 I
- I
O I
- I
sulfo I
- I
beta I
- I
d I
- I
xylopyranosyl I
) I
oxy I
] I
urs I
- I
12 I
, I
19 I
- I
diene I
- I
28 I
- I
oic I
acid I
28 I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
2 O
) O
, O
and O
3 B

In O
- O
vivo O
studies O
were O
carried O
out O
for O
( B
99m I
) I
Tc I
- I
EDTA I
- I
bis I
( I
tyramide I
) I
included O
blood O
kinetics O
showed O
a O
quick O
wash O
out O
from O
the O
circulation O
via O
renal O
route O
and O
biodistribution O
revealed O
that O
maximum O
% O
ID O
/ O
g O
was O
found O
in O
kidney O
at O
1h O
and O
its O
scintigraphy O
image O
shows O
3 O
. O
96 O
% O
brain O
uptake O
with O
respect O
to O
whole O
body O
. O

We O
analysed O
FA O
and O
( B
6S I
) I
- I
5 I
- I
methyltetrahydrofoli I
acid I
( O
( B
6S I
) I
- I
5 I
- I
CH3 I
- I
H4PteGlu I
) O
content O
in O
ready O
- O
to O
- O
eat O
cereals O
( O
RTEC O
) O
( O
n O
= O
68 O
) O
and O
cow O
' O
s O
milk O
( O
n O
= O
25 O
) O
by O
a O
previously O
validated O
affinity O
chromatography O
- O
HPLC O
method O
. O

We O
analysed O
FA O
and O
( B
6S I
) I
- I
5 I
- I
methyltetrahydrofoli I
acid I
( O
( B
6S I
) I
- I
5 I
- I
CH3 I
- I
H4PteGlu I
) O
content O
in O
ready O
- O
to O
- O
eat O
cereals O
( O
RTEC O
) O
( O
n O
= O
68 O
) O
and O
cow O
' O
s O
milk O
( O
n O
= O
25 O
) O
by O
a O
previously O
validated O
affinity O
chromatography O
- O
HPLC O
method O
. O

Results O
showed O
that O
at O
all O
food O
fortification O
levels O
obtained O
, O
fortified O
products O
provided O
more O
than O
tenfold O
FA O
than O
( B
6S I
) I
- I
5 I
- I
CH3 I
- I
H4PteGlu I
. O

2 B
- I
( I
1H I
- I
Pyrazol I
- I
4 I
- I
yl I
) I
acetic I
acids I
as O
CRTh2 O
antagonists O
. O

The O
synthetic O
approach O
used O
for O
preparation O
of O
isomeric O
amidino B
substituted I
- I
phenylene I
- I
bis I
- I
benzothyazoles I
3a O
- O
3f O
was O
achieved O
by O
condensation O
reaction O
of O
isophthaloyl B
dichloride I
1a O
and O
terephthaloyl B
dichloride I
1b O
or O
with O
phthalic B
acid I
1c O
with O
5 B
- I
amidinium I
- I
2 I
- I
aminobenzothiolate I
2a O
and O
5 B
- I
( I
imidazolinium I
- I
2 I
- I
yl I
) I
- I
2 I
- I
aminobenzothiolate I
2b O
in O
good O
yields O
. O

The O
synthetic O
approach O
used O
for O
preparation O
of O
isomeric O
amidino B
substituted I
- I
phenylene I
- I
bis I
- I
benzothyazoles I
3a O
- O
3f O
was O
achieved O
by O
condensation O
reaction O
of O
isophthaloyl B
dichloride I
1a O
and O
terephthaloyl B
dichloride I
1b O
or O
with O
phthalic B
acid I
1c O
with O
5 B
- I
amidinium I
- I
2 I
- I
aminobenzothiolate I
2a O
and O
5 B
- I
( I
imidazolinium I
- I
2 I
- I
yl I
) I
- I
2 I
- I
aminobenzothiolate I
2b O
in O
good O
yields O
. O

Adding O
ethylene B
glycol I
( O
EG O
) O
to O
poly B
( I
3 I
, I
4 I
- I
ethylenedioxythiophe I
) I
: O
poly B
( I
styrenesulfonate I
) I
( O
PEDOT B
: O
PSS B
) O
solution O
improves O
the O
crystallinity O
of O
the O
PEDOT B
and O
the O
ordering O
of O
the O
PEDOT B
nanocrystals O
in O
solid O
films O
. O

The O
O B
- I
methyl I
free O
derivatives O
used O
in O
the O
study O
were O
fully O
trimethylated O
( O
100 O
% O
) O
N B
, I
N I
, I
N I
- I
trimethyl I
chitosan O
( O
TMC O
) O
and O
N B
- I
propyl I
- I
( I
QuatPropyl I
) I
, O
N B
- I
butyl I
- I
( I
QuatButyl I
) I
and O
N B
- I
hexyl I
( I
QuatHexyl I
) I
- I
N I
, I
N I
- I
dimethyl I
chitosan O
, O
with O
85 O
- O
91 O
% O
degree O
of O
quaternization O
. O

METHODS O
: O
Effects O
of O
chronic O
venlafaxine B
were O
evaluated O
at O
different O
levels O
of O
5 O
- O
HT1B O
receptor O
by O
using O
receptor O
autoradiography O
, O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
, O
and O
the O
regulation O
of O
body O
temperature O
induced O
by O
selective O
5 O
- O
HT1B O
agonist O
. O

Ultrasensitive O
Polarized O
Up O
- O
Conversion O
of O
Tm B
( I
3 I
+ I
) I
- I
Yb I
( I
3 I
+ I
) I
Doped I
beta I
- I
NaYF4 I
Single O
Nanorod O
. O

Their O
structures O
including O
the O
absolute O
configurations O
were O
determined O
by O
spectroscopic O
and O
chemical O
methods O
as O
( B
- I
) I
- I
2 I
- I
hydroxy I
- I
5 I
- I
methoxybenzoic I
acid I
2 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
- I
O I
- I
benzoyl I
) I
- I
glucopyranoside I
( O
1 O
) O
, O
( B
- I
) I
- I
4 I
- I
hydroxy I
- I
3 I
, I
5 I
- I
dimethoxybenzoic I
acid I
4 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
- I
O I
- I
benzoyl I
) I
- I
glucopyranoside I
( O
2 O
) O
, O
( B
- I
) I
- I
( I
E I
) I
- I
3 I
, I
5 I
- I

Their O
structures O
including O
the O
absolute O
configurations O
were O
determined O
by O
spectroscopic O
and O
chemical O
methods O
as O
( B
- I
) I
- I
2 I
- I
hydroxy I
- I
5 I
- I
methoxybenzoic I
acid I
2 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
- I
O I
- I
benzoyl I
) I
- I
glucopyranoside I
( O
1 O
) O
, O
( B
- I
) I
- I
4 I
- I
hydroxy I
- I
3 I
, I
5 I
- I
dimethoxybenzoic I
acid I
4 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
- I
O I
- I
benzoyl I
) I
- I
glucopyranoside I
( O
2 O
) O
, O
( B
- I
) I
- I
( I
E I
) I
- I
3 I
, I
5 I
- I

dimethoxyphenylprope I
acid I
4 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
- I
O I
- I
benzoyl I
) I
- I
glucopyranoside I
( O
3 O
) O
, O
( B
- I
) I
- I
( I
7S I
, I
8R I
) I
- I
( I
4 I
- I
hydroxyphenylglycero I
9 I
- I
O I
- I
beta I
- I
d I
- I
[ I
6 I
- I
O I
- I
( I
E I
) I
- I
4 I
- I
hydroxy I
- I
3 I
, I
5 I
- I
dimethoxyphenylprope I
] I
- I
glucopyranoside I
( O
4 O
) O
, O
( B
- I
) I
- I
( I
7S I
, I
8R I
) I
- I
( I
4 I
- I

This O
report O
describes O
a O
bioaffinity O
matrix O
of O
viruses O
integrated O
into O
PEDOT B
films O
for O
electrochemical O
sensing O
of O
prostate O
specific O
membrane O
antigen O
( O
PSMA O
) O
, O
a O
prostate O
cancer O
biomarker O
. O

One O
day O
following O
VOCs O
exposure O
, O
oxidative O
stress O
markers O
in O
lung O
, O
8 B
- I
hydroxy I
- I
2 I
' I
- I
deoxyguanosine I
in O
bronchoalveolar O
lavage O
fluid O
and O
genotoxicity O
( O
DNA O
damage O
) O
in O
liver O
were O
examined O
. O

Hybrid O
Molecule O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
Dinitrophenyl I
) I
diazeniumdiolate I
and O
Oleanolic B
Acid I
: O
a O
GST O
pi O
Activated O
Nitric B
Oxide I
Prodrug O
with O
Selective O
Anti O
- O
human O
Hepatocellular O
Carcinoma O
Activity O
and O
Improved O
Stability O
. O

A O
series O
of O
hybrids O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
diazeniumdiolate I
and O
oleanolic B
acid I
( O
OA O
) O
were O
designed O
, O
synthesized O
, O
and O
biologically O
evaluated O
as O
novel O
nitric B
oxide I
( O
NO B
) O
releasing O
prodrugs O
which O
could O
be O
activated O
by O
glutathione B
S O
- O
transferase O
pi O
( O
GST O
pi O
) O
overexpressed O
in O
a O
number O
of O
cancer O
cells O
. O

n B
- I
3 I
/ I
n I
- I
6 I
polyunsaturated I
, I
saturated I
, I
and I
monounsaturated I
FAs I
in O
maternal O
plasma O
and O
in O
liver O
of O
wild O
- O
type O
offspring O
, O
and O
representative O
enzymes O
for O
FA O
desaturation O
and O
elongation O
in O
maternal O
liver O
, O
were O
measured O
. O

The O
synthesis O
of O
new O
ribo B
and I
2 I
' I
- I
beta I
- I
C I
- I
methyl I
ribo I
Janus I
type I
nucleosides I
J O
- O
AA O
, O
J O
- O
AG O
and O
J O
- O
AU O
is O
reported O
along O
with O
their O
ability O
to O
block O
HCV O
and O
HIV O
replication O
. O

One O
new O
compound O
, O
ethyl B
13 I
( I
2 I
) I
( I
S I
) I
- I
hydroxy I
- I
chlorophyllide I
a I
( O
1 O
) O
, O
along O
with O
10 O
known O
compounds O
, O
i O
. O
e O
. O
2 B
- I
methyl I
- I
3 I
- I
methoxyanthraquinone I
( O
2 O
) O
, O
2 B
- I
hydroxymethylanthraq I
( O
3 O
) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
( O
4 O
) O
, O
2 B
- I
hydroxymethy I
- I
1 I
- I
hydroxyanthraquinone I
( O
5 O
) O
, O
1 B
- I
methoxy I
- I
2 I
- I
hydroxyanthraquinone I
( O
6 O

) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
methoxyanthraquinone I
( O
7 O
) O
, O
oleanolic B
acid I
( O
8 O
) O
, O
ursolic B
acid I
( O
9 O
) O
, O
stigmasterol B
( O
10 O
) O
and O
docosanoic B
acid I
( O
11 O
) O
, O
were O
isolated O
and O
identified O
. O

1 B
, I
1 I
- I
Diphenyl I
, I
2 I
- I
picrylhydrazyl I
free O
radical O
scavenging O
, O
bactericidal O
, O
fungicidal O
and O
leishmanicidal O
properties O
of O
Teucrium O
stocksianum O
. O

The O
crude O
extract O
of O
T O
. O
stocksianum O
( O
Ts O
. O
Cr O
) O
and O
its O
subsequent O
organic O
fractions O
: O
n B
- I
hexane I
( O
Ts O
. O
Hex B
) O
, O
chloroform B
( O
Ts O
. O
CHCl3 B
) O
and O
ethyl B
acetate I
( O
Ts O
. O
EtAc B
) O
exhibited O
1 B
, I
1 I
- I
diphenyl I
, I
2 I
- I
picrylhydrazyl I
free O
radical O
scavenging O
activity O
with O
different O
potencies O
. O

It O
is O
humbling O
to O
think O
that O
30 O
years O
have O
passed O
since O
the O
paper O
by O
Collingridge O
, O
Kehl O
and O
McLennan O
showing O
that O
one O
of O
Jeff O
Watkins O
most O
interesting O
compounds O
, O
R B
- I
2 I
- I
amino I
- I
5 I
- I
phosphonopentanoate I
( O
d B
- I
AP5 I
) O
, O
blocked O
the O
induction O
of O
long O
- O
term O
potentiation O
in O
vitro O
at O
synapses O
from O
area O
CA3 O
of O
the O
hippocampus O
to O
CA1 O
without O
apparent O
effect O
on O
baseline O
synaptic O
transmission O
( O
Collingridge O
et O
al O
. O
, O
1983 O
) O
. O

In O
this O
study O
, O
a O
copolymer O
of O
MPC B
and O
vinylferrocene B
[ O
VF O
; O
poly B
( I
MPC I
- I
co I
- I
VF I
) I
] O
( O
PMF B
) O
is O
synthesized O
. O

The O
most O
potent O
compound O
, O
3 B
alpha I
- I
2 I
' I
, I
2 I
' I
- I
dimethylsuccinic I
acyl I
epi I
- I
aleuritolic I
acid I
( O
11 O
) O
, O
displayed O
significant O
anti O
- O
HIV O
activity O
with O
an O
EC50 O
value O
of O
5 O
. O
80 O
mu O
M O
. O

Four O
new O
glycosylated B
flavonoids I
were O
isolated O
and O
their O
structures O
were O
elucidated O
on O
the O
basis O
of O
1D O
, O
2D O
NMR O
and O
MS O
spectra O
as O
3 B
' I
, I
5 I
' I
- I
dimethoxymyricetin I
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
xylopyranosyl I
- I
7 I
- I
O I
- I
fucopyranosyl I
- I
( I
1 I
- I
- I
> I
3 I
) I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
3 B
' I
- I
methoxyquercetin I
- I
7 I
- I
O I
- I
beta I
- I
d I
- I
fucopyranosyl I
- I
( I
1 I
- I
- I

> I
3 I
) I
- I
beta I
- I
d I
- I
glucopyranosyl I
- I
3 I
- I
O I
- I
beta I
- I
xylopyranosyl I
- I
( I
1 I
- I
- I
> I
4 I
) I
- I
beta I
- I
xylopyranoside I
( O
2 O
) O
, O
3 B
' I
- I
methoxyquercetin I
- I
7 I
- I
O I
- I
alpha I
- I
l I
- I
rhamnopyranosyl I
- I
3 I
- I
O I
- I
alpha I
- I
arabinofuranosyl I
- I
( I
1 I
- I
- I
> I
6 I
) I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
3 O
) O
and O
3 B
' I
, I
5 I
' I
- I
dimethoxymyricetin I
- I
7 I
- I
O I
- I

LC O
- O
MS O
( O
n O
) O
analysis O
on O
the O
extract O
revealed O
the O
presence O
of O
other O
myricetin B
, O
quercetin B
, O
isorhamnetin B
glycosides I
, O
simple O
phenolic B
acids I
and O
esters B
. O

Glucose B
uptake O
and O
mitochondrial O
activity O
were O
measured O
using O
2 B
- I
deoxy I
- I
[ I
( I
3 I
) I
H I
] I
- I
d I
- I
glucose I
, O
MTT B
and O
ATP B
assays O
, O
respectively O
. O

GRE O
contained O
higher O
levels O
of O
all O
compounds O
, O
except O
the O
enolic O
phenylpyruvic B
acid I
- I
2 I
- I
O I
- I
glucoside I
and O
luteolin B
- I
7 I
- I
O I
- I
glucoside I
. O

Cyperi O
Rhizoma O
inhibits O
the O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
- O
induced O
reduction O
in O
nigrostriatal O
dopaminergenic O
neurons O
in O
estrogen B
- O
deprived O
mice O
. O

To O
evaluate O
the O
neuroprotective O
effect O
of O
CRE O
, O
we O
measured O
striatal O
dopamine B
, O
movement O
ability O
, O
tyrosine B
hydroxylase O
( O
TH O
) O
immunoreactivity O
, O
and O
apoptosis O
- O
related O
protein O
expression O
levels O
after O
treatment O
of O
CRE O
either O
with O
or O
without O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
in O
ovariectomized O
female O
mice O
. O

Here O
we O
report O
the O
development O
of O
a O
biodegradable O
localized O
delivery O
system O
using O
poly B
( I
D I
, I
L I
- I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
for O
the O
combinatorial O
release O
of O
fusidic B
acid I
( O
FA O
) O
( O
or O
its O
sodium B
salt O
; O
SF O
) O
and O
rifampicin B
( O
RIF B
) O
using O
electrospinning O
. O

Synthesis O
, O
spectral O
and O
antimicrobial O
evaluation O
of O
some O
novel O
1 B
- I
methyl I
- I
3 I
- I
alkyl I
- I
2 I
, I
6 I
- I
diphenylpiperidin I
- I
4 I
- I
one I
oxime I
carbonates I
. O

Synthesis O
of O
some O
novel O
biologically O
active O
piperidin B
- I
4 I
- I
one I
oxime I
carbonates I
from O
1 B
- I
methyl I
- I
3alkyl I
- I
2 I
, I
6 I
- I
diphenylpiperidin I
- I
4 I
- I
one I
oximes I
and O
substituted O
chloroformates B
was O
carried O
out O
in O
the O
presence O
of O
potassium B
carbonate I
as O
base O
and O
tetrabutylammonium B
bromide I
( O
TBAB B
) O
as O
catalyst O
. O

Previous O
quantitative O
proteomic O
studies O
on O
the O
actions O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
in O
5L O
rat O
hepatoma O
cells O
, O
a O
cell O
model O
frequently O
used O
for O
investigating O
the O
mechanisms O
of O
TCDD B
toxicity O
, O
had O
indicated O
that O
dioxin B
exposure O
reduced O
the O
abundance O
of O
numerous O
proteins O
which O
are O
regulated O
at O
the O
level O
of O
protein O
synthesis O
initiation O
. O

Here O
, O
we O
describe O
the O
synthesis O
and O
structure O
- O
activity O
relationships O
of O
potent O
inhibitors O
of O
platelet O
aggregation O
based O
on O
the O
1 B
, I
5 I
- I
diarylpyrazol I
- I
3 I
- I
carboxamide I
scaffold O
. O

1 B
, I
5 I
- I
Diarylpyrazole I
- I
3 I
- I
carboxamides I
obtained O
with O
small O
- O
basic O
amines B
( O
7 O
, O
8 O
, O
50 O
, O
51 O
, O
61 O
, O
62 O
) O
displayed O
the O
strongest O
activity O
with O
IC50 O
values O
in O
low O
nanomolar O
range O
( O
5 O
. O
7 O
- O
83 O
nM O
) O
. O

Here O
we O
show O
that O
the O
compound O
CID16020046 B
( O
( B
4 I
- I
[ I
4 I
- I
( I
3 I
- I
hydroxyphenyl I
) I
- I
3 I
- I
( I
4 I
- I
methylphenyl I
) I
- I
6 I
- I
oxo I
- I
1H I
, I
4H I
, I
5H I
, I
6H I
- I
pyrrolo I
[ I
3 I
, I
4 I
- I
c I
] I
pyrazol I
- I
5 I
- I
yl I
] I
benzoic I
acid I
) O
is O
a O
selective O
GPR55 O
antagonist O
. O

Copolymerization O
of O
2 B
- I
methylene I
- I
1 I
, I
3 I
- I
dioxepane I
and O
glycidyl B
methacrylate I
, O
a O
well O
- O
defined O
and O
efficient O
process O
for O
achieving O
functionalized O
polyesters B
for O
covalent O
binding O
of O
bioactive O
molecules O
. O

We O
have O
in O
a O
one O
- O
pot O
reaction O
synthesized O
a O
series O
of O
amorphous O
and O
degradable O
polyester B
- O
based O
copolymers O
with O
active O
functional O
groups O
by O
copolymerization O
of O
2 B
- I
methylene I
- I
1 I
, I
3 I
- I
dioxepane I
and O
glycidyl B
methacrylate I
. O

Statistical O
and O
diblock O
copolymers O
of O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
, O
oligolysine O
, O
and O
oligohistidine O
were O
synthesized O
via O
reversible O
- O
addition O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
, O
and O
tested O
for O
in O
vitro O
transfection O
efficiency O
, O
buffering O
ability O
, O
and O
polyplex O
uptake O
mechanism O
via O
the O
use O
of O
chemical O
endocytic O
inhibitors O
. O

Dodecanitrile B
and O
2 B
, I
2 I
, I
3 I
- I
trimethylcyclopent I
- I
3 I
- I
enylacetonitrile I
were O
negative O
in O
the O
in O
- O
vitro O
chromosome O
aberration O
test O
and O
in O
- O
vitro O
micronucleus O
test O
, O
respectively O
. O

While O
citronellyl B
nitrile I
, O
3 B
- I
methyl I
- I
5 I
- I
phenylpentanenitrile I
, O
cinnamyl B
nitrile I
, O
and O
3 B
- I
methyl I
- I
5 I
- I
phenylpent I
- I
2 I
- I
enenitrile I
revealed O
positive O
results O
in O
the O
in O
- O
vitro O
tests O
, O
but O
confirmatory O
in O
- O
vivo O
tests O
determined O
these O
nitriles B
to O
be O
negative O
in O
the O
in O
- O
vivo O
micronucleus O
assay O
. O

Reduction O
of O
the O
carbonyl B
groups O
lead O
to O
the O
20 B
- I
epi I
- I
12 I
, I
23 I
- I
dihydroxy I
- I
22 I
- I
oxo I
system O
11a O
- O
b O
. O

Designing O
, O
structural O
elucidation O
, O
comparison O
of O
DNA O
binding O
, O
cleavage O
, O
radical O
scavenging O
activity O
and O
anticancer O
activity O
of O
copper B
( I
I I
) I
complex O
with O
5 B
- I
dimethyl I
- I
2 I
- I
phenyl I
- I
4 I
- I
[ I
( I
pyridin I
- I
2 I
- I
ylmethylene I
) I
- I
amino I
] I
- I
1 I
, I
2 I
- I
dihydro I
- I
pyrazol I
- I
3 I
- I
one I
Schiff B
base I
ligand O
. O

Synthesis O
and O
biological O
evaluation O
of O
novel O
phosphatidylinositol B
3 O
- O
kinase O
inhibitors O
: O
Solubilized O
4 B
- I
substituted I
benzimidazole I
analogs O
of O
2 B
- I
( I
difluoromethyl I
) I
- I
1 I
- I
[ I
4 I
, I
6 I
- I
di I
( I
4 I
- I
morpholinyl I
) I
- I
1 I
, I
3 I
, I
5 I
- I
triazin I
- I
2 I
- I
yl I
] I
- I
1H I
- I
benzimidazole I
( O
ZSTK474 B
) O
. O

A O
range O
of O
4 O
- O
substituted O
derivatives O
of O
the O
pan O
class O
I O
PI O
3 O
- O
kinase O
inhibitor O
2 B
- I
( I
difluoromethyl I
) I
- I
1 I
- I
[ I
4 I
, I
6 I
- I
di I
- I
( I
4 I
- I
morpholinyl I
) I
- I
1 I
, I
3 I
, I
5 I
- I
triazin I
- I
2 I
- I
yl I
] I
- I
1H I
- I
benzimidazole I
( O
ZSTK474 B
) O
were O
prepared O
in O
a O
search O
for O
more O
soluble O
analogs O
. O

Two O
series O
of O
compounds O
with O
hydrazone B
derivatives O
( O
HZ1 O
- O
HZl2 O
, O
series O
1 O
) O
and O
oxadiazoline B
derivatives O
( O
OZ1 O
- O
OZ12 O
, O
series O
2 O
) O
of O
the O
2 B
- I
methyl I
- I
5 I
- I
nitro I
- I
1H I
- I
imidazole I
scaffold O
were O
designed O
and O
synthesized O
. O

